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Abstract 
Antibiotics have been described as a ‘wonder drug’ that have transformed 
medicine since their discovery at the beginning of the 20th century and are used 
globally in safeguarding human and animal health. Environmental risk 
assessment (ERA) aims to ensure their environmental safety by setting 
protection limits that seek to prevent adverse effects upon populations and 
ecosystem function. In the case of antibiotics however, there is concern that 
ERA may not be fully protective of bacterial populations.  
This thesis examines the ERA of antibiotics and highlights that protection limits 
may in some cases be under-protective or over-protective for bacteria 
populations (including cyanobacteria), depending on the antibiotic mode of 
action and the species on which the protection limit is based.  The first section 
of the thesis contains a systematic review including a meta-analysis of all 
publically available aquatic ecotoxicity data. The results illustrate that generally 
bacteria are the most sensitive taxa to antibiotics compared with eukaryotes but 
that interspecies variability in sensitivity among bacteria can range by up to five 
orders of magnitude. This far exceeds the assessment factor of 10 used to 
account for such uncertainty in protection limits. It also shows that the costly 
testing on fish may not be required and in accordance with the principle of the 
3Rs could be excluded from the ERA of antibiotics, as they are not likely to 
drive the protection limit. Further, it demonstrates that protection limits 
established for antimicrobial resistance (AMR) may not always be protective of 
environmental health and that both protection limits should be determined in 
ERA. 
Next, the thesis reports on the development and validation of a microplate 
assay for the rapid screening of chemical effects (here antibiotics) on 
cyanobacteria.  The microplate assay is optimised to allow for the direct 
comparison of species sensitivity, ensuring consistent test conditions and thus 
limiting differences in antibiotic behaviour between assays. Reference toxicity 
testing with potassium dichromate demonstrates reproducibility over time and 
comparability with the standard shake flask test used in ERA. 
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The microplate assay is then used to experimentally confirm the findings of the 
meta-analysis. In this work, interspecies sensitivity across eight cyanobacteria 
species was demonstrated to vary by up to 70 fold following exposure to β-
lactam antibiotics but only by an order of magnitude for macrolides.  
Cyanobacteria were not sensitive to sulfonamides and thus are not likely to be 
suitable for the setting of protection limits for this antibiotic class.  
Finally in this thesis, species sensitivity distributions were created to examine 
how effective the protection limit currently derived in ERA is for antibiotics. For 
cephalosporins, there was a higher probability of under-protection whilst the 
protection limits were over-protective for classes of antibiotics with less 
interspecies differences in sensitivity, such as macrolides. Further, a 
probabilistic ecological risk assessment suggested that 60 to 100% of 
cyanobacteria species might be adversely affected at the higher measured 
environmental concentrations in the literature, while no significant risk was 
found at average concentrations. 
The findings from this thesis illustrate that protection limits, as currently 
determined in ERA for antibiotics, may not be suitable for the adequate 
protection of cyanobacteria populations and most likely other bacterial taxa. The 
thesis proposes several approaches for improving ERA, including incorporating 
greater bacterial diversity in ecotoxicity testing, the inclusion of functional and/or 
community testing and the use of probabilistic methods to derive protection 
limits. 
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Chapter 1  
General Introduction  
General background 
Microorganism communities in the environment 
Microorganisms and their communities are vital components of all ecosystems, 
performing many services on which the normal functioning of the ecosystem 
relies. These functions include, but are not restricted to, biomass production, 
primary productivity, regulation of nutrient cycles and the biodegradation of 
pollutants. Furthermore, recent genomic and bioinformatic analyses have 
started to demonstrate the importance of microorganism abundance, 
metabolism and community structure in a multitude of ecological relationships 
related to animal health. For example, the interrelationships between the 
microbiota of a gut and the digestive, immune and mental well being of the 
animal host (Knip and Siljander 2016; Rieder et al. 2017; Rogers et al. 2016; 
Rooks and Garrett 2016), and for ecosystem health, from the creation of soils 
that suppress pathogens and disease outbreaks (Bardgett and van der Putten 
2014; Panke-Buisse et al. 2014; Wagg et al. 2014) to biofilms that play vital 
roles in water purification (Besemer 2015) and wastewater treatment systems 
(Shu et al. 2015). Indeed, the importance of healthy, diverse and balanced 
microorganism communities to the functioning of all life on the planet is 
becoming ever more apparent as more research has been directed to this field 
of study. 
Ecosystem services in freshwater and the functional role of bacteria 
Freshwater microbial communities can be broadly categorised into three 
groups: i) free-moving planktonic cells, ii) biofilms upon the surface of 
substrates, plants and animals and iii) below the surface/benthic sediment 
communities. All three communities perform a wide range of ecosystem 




Primary productivity, biomass production and supporting the food web 
Microorganisms in aquatic ecosystems are an essential component in the food 
webs of aquatic ecosystems. Some are autotrophs, for example cyanobacteria, 
which photosynthesise to produce energy that supports the ecosystem. Other 
bacteria, archaea and fungi found in biofilms and sediments, and to a lesser 
extent in the water column, constitute a large biomass that incorporate nutrients 
harnessed from the decomposition of organic material which are then released 
following their death (Fischer and Pusch 2001; Hoppe et al. 2002; Lee and 
Bong 2008). Cole et al. (1988) estimated that bacterial production constituted 
30% of primary production in the water column (data largely based upon lakes 
and coastal waters) and that the levels of production in the sediments of lakes 
depended on whether the lake was eutrophic or oligotrophic.  
Nitrogen cycle 
Microorganisms are vital in the biogeochemical cycle of nitrogen, which is 
required for primary productivity and involves a diverse range of bacteria, 
including cyanobacteria (Falkowski 1997; Kuypers et al. 2003). Briefly, nitrogen 
fixing bacteria convert nitrogen into ammonium, which is then converted to 
nitrite and then nitrate by nitrifying bacteria. Bacteria are also responsible for 
denitrification, the reduction of nitrate ions to nitrogen gas (N2), which prevents 
the build up of nitrates in the environment that may otherwise lead to 
acidification of aquatic environments, eutrophication and have direct toxicity on 
wildlife (Camargo and Alonso 2006). 
Decomposition of organic material 
Heterotrophic bacteria decompose organic matter and release dissolved 
organic matter into the water reincorporating it into the food web (Bertilsson and 
Jones 2003; Griffiths et al. 2009). The decomposition of organic material 
involves many different and diverse bacterial groups. For example, 
decomposition of sea grass in estuarine system was shown to be dominated 
initially by heterotrophic bacteria, with those attached to the substrate having a 
greater role than free bacteria, these were then succeeded by flagellates 
(Anesio et al. 2003). Bacteria are thus are vital for the decomposition of organic 




Microorganisms have long been used in the treatment of waste water (Wagner 
et al. 2002) and they play key roles in the purification of freshwaters (Edwards 
and Kjellerup 2013; Sabater et al. 2002). Indeed, considerable effort has 
recently gone into understanding the roles that biofilms in particular play in this 
regard and how to maximise their water purification and ecosystem remediation 
potential. It has been shown that microorganisms are responsible for the 
degradation of pharmaceuticals in polluted waters (Cai et al. 2016; Zuehlke et 
al. 2007) and that pharmaceutical pollution in freshwater systems may influence 
the spatial variation in biofilm community structure in rivers (Cai et al. 2016). 
The full extent of the relationship between microbial diversity and function are 
still unclear (Antwis et al. 2017; Burgin et al. 2011). The functions microbial 
communities provide can be affected by a range of environmental, chemical 
and biological factors such as light, temperature, substrate composition and 
topography, water current, nutrient availability, competition and predation 
(Ponsatí et al. 2016; Sabater et al. 2002). How anthropogenic stressors, 
including chemical contaminates such as antibiotics, interact with these 
processes as well as the diversity and function relationship is generally poorly 
understood. 
Cyanobacteria 
Cyanobacteria are a phylum of bacteria that produce their own energy through 
photosynthesis and are considered to have originated at least 2.6 billion years 
ago playing a major role in the formation of oxygen on the planet and reduction 
of atmospheric carbon dioxide (Altermann and Kazmierczak 2003; Graham et 
al. 2009; Mulkidjanian et al. 2006; Riding 2006). Cyanobacteria have evolved 
into a wide range of morphological forms (unicellular, multicellular to colonial) 
and became highly diversified more than 2 billion years ago and before green 
algae even existed, towards the end of the proterozoic era (Knoll 2008). They 
are ubiquitous in both aquatic and terrestrial environments and have adapted to 
perform a range of ecological functions that are crucial for the regulation of our 
aquatic ecosystems, of which nitrogen fixation and primary production are of 





Antibiotics kick started the age of “wonder drugs” in the early 20th century 
following the discovery of penicillin by Alexander Fleming in 1929, although 
arsphenamine, a sulphonamide, was in fact discovered earlier in 1910 (Zaffiri et 
al. 2012). In the following 100 years many classes of antibiotics with several 
modes of action have been discovered to treat a wide range of diseases, but 
this progress has stalled in the last 10 to 15 years with very few new antibiotics 
being clinically trialled (Review on Antimicrobial Resistance 2015). 
Antibiotics have been transformative in modern medicine and are essential for 
the treatment of bacterial infection and in surgical interventions in humans. They 
are also vital for animal welfare in the farming of livestock as well as in 
veterinary medicine. Additionally, they are also used as growth promoters in 
some livestock farming and in the fish farming industry, although in the light of 
concerns relating to the development of antimicrobial resistance (AMR) this 
practice is in decline or has been stopped in some countries (Cully 2014). 
Antibiotics are a specific class of antimicrobials that target bacteria (and fungi) 
in humans and animals, although they are also used as anticancer drugs, 
growth promoters in aquaculture and as pesticides (Grenni et al. 2018). 
Current use and sales of antibiotics 
Several investigators have attempted to assess the sales and distribution of 
antibiotics globally in an attempt to help identify trends and associated potential 
risks (Klein et al. 2018; Kümmerer 2009; Van Boeckel et al. 2015; Van Boeckel 
et al. 2014). These studies are limited generally due to the fact that different 
methods apply for the reporting such information across the globe as well as, in 
many instances, the lack of any records at all. Additionally, there is limited 
scope to combine the sales and distribution of antibiotics across industries (e.g. 
for human and veterinary health). Moreover, the trends in antibiotic use appear 
to change over the space of several years, meaning that the data collected 
soon becomes out of date. This is something that might be expected to occur 
more rapidly in the future as policy to address AMR drives changes in their use 
even more quickly. However, most investigations conclude that macrolides, 
floroquinolones and sulfonamides are of relatively high risk to bacterial 
populations (Kümmerer 2009; Välitalo et al. 2017) and due to their persistent 
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nature may remain so for the foreseeable future. Indeed, the macrolides, 
clarithromycin, erythromycin and azithromycin are all included in the European 
Unions watch list of priority substances and the US Environmental protection 
agencies (Carvalho et al. 2015; US EPA 2009). 
There was an estimated 36% increase in global antibiotic consumption for 
human healthcare between the years 2000 and 2010 (Van Boeckel et al. 2014) 
and an increase of 65% between 2000 and 2015 (based on defined daily 
doses), much of which was driven by use in the low- to middle- income 
countries (Klein et al. 2018). Currently, broad-spectrum penicillin’s are the most 
widely used class of antibiotics (39% increase in defined daily doses between 
2000 and 2015), followed by cephalosporins, macrolides and fluoroquinolones; 
with cephalosporins seeing the greatest rise in global sales (Hamad 2010; Klein 
et al. 2018). Contrasting with this the macrolide class of antibiotics has seen a 
decrease in the sales (5% in 5 years) due to patent expiry. 
There is a clear overlap between the antibiotics most commonly used for human 
medicine with those favoured for veterinary usage, with Charuaud et al. (2019) 
reporting that tetracyclines, sulfonamides, penicillins and macrolides are the 
most frequently used antibiotics worldwide for veterinary purposes, although 
many sulfonamides are not used in the treatment of human medicine 
(sulfamethoxazole is used in treatment of human health). Van Boeckel et al. 
(2015) estimated that 63,151 tonnes of antibiotics were used in the treatment of 
livestock in 2010 and predicted it would increase by 67% by 2030, most of 
which will be in the BRICS countries (Brazil, Russia, India, China, and South 
Africa; countries where there was a predicted doubling in antibiotic use for 
livestock). 
In total, the antibiotic industry is valued at 40 billion USD a year. Most of this 
(88%) coming from off-patent molecules (Review on Antimicrobial Resistance 
2016) reflecting the limited development of new antibiotics and the likely 
continued use and release of legacy antibiotics into the environment. 
Antibiotics therefore have a clear and large social and economic importance. 
However, the release of antibiotics into the environment can pose a significant 
risk to; 1) bacterial communities and the ecosystem functions that they provide 
and on which the normal functioning and resilience of whole ecosystems rely 
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upon; and 2) human health through the development of AMR in human (or 
animal) pathogens. 
How antibiotics work – the modes of action and susceptible taxonomic 
groups 
For an antibiotic to be deemed suitable for effective use against pathogenic 
bacteria they need to be able to kill or selectively inhibit their growth whilst also 
having limited or no detrimental effects upon humans (or in the case of 
veterinary medicine; fish, reptiles, birds and other mammals). As such, antibiotic 
drug targets are those that are generally specific to bacteria and can be 
grouped into three broad modes of action (MoA); i) those that target the cell wall 
and/or its synthesis, ii) those that target nucleic acid synthesis, and iii) those 
that target the ribosome and/or protein synthesis. Some investigators split 
nucleic acid synthesis inhibitors into two groups, RNA synthesis inhibitors and 
DNA synthesis inhibitors but for the purposes of this thesis these are 
categorised jointly as nucleic acid synthesis inhibitors. 
Cell wall synthesis inhibitors 
The bacterial cell envelope is an antibiotic target that, for the most part, enables 
the discrimination between bacteria and eukaryotic cells. This is because 
eukaryotes have a phospholipid plasma membrane rather than the 
lipopolysaccharide and/or peptidoglycan membranes found in bacteria. 
The cell envelopes of bacteria can be quite variable in structure but they are 
broadly divided into one of two types; i) the first, found in Gram-negative 
bacteria, is where there is an outer membrane made of lipopolysaccharide, a 
peptidoglycan layer and an inner/cytoplasmic membrane and ii) in the second, 
found in Gram-positive bacteria, the outer membrane is composed of a much 
thicker peptidoglycan layer but has no lipopolysaccharide layer (Silhavy et al. 
2010). There are variations on these cell envelope structures in the different 
taxonomic classes of bacteria. For example, cyanobacteria have a cell envelope 
that is structured like that of the Gram-negative bacteria with three layers but 
the peptidoglycan layer in cyanobacteria is much thicker, resembling the 
envelope of Gram-positive cells (Hoiczyk and Hansel 2000). Other bacterial 
classes that do not necessarily follow the normal Gram-negative or Gram-
positive cell envelope structure are the spirochaetes that have a fluid outer 
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membrane and a flagella in the periplasm (Haake 2000) and the 
planctomycetes that have a similar cell envelope structure to Gram-negative 
bacteria but with an enlarged periplasm forming cavities into the cytoplasm 
(Boedeker et al. 2017). 
The vast majority of antibiotics that inhibit the synthesis of the bacterial cell wall 
target the synthesis of the peptidoglycan layer, which maintains structural 
integrity and the shape of the bacterial cell. Some inhibit the synthesis of 
peptidoglycan, for example fosfomycin (Silver 2017), whilst glycopeptides (e.g. 
vancomycin) prevent the polymerisation of the peptidoglycan chain (Allen and 
Nicas 2003). Most cell wall synthesis inhibitors however are -lactams and 
these target the penicillin binding proteins that are responsible for the formation 
of the side-chains between peptidoglycan polymers. 
Protein synthesis inhibitors 
The bacterial ribosome is the main target for antibiotics that inhibit protein 
synthesis. The bacterial ribosome (70S, 2300 kd) is smaller than that of the 
eukaryotic ribosome (80S, 4300 kd) and is made up of a 30S and 50S subunits 
compared with the eukaryotic ribosome that is comprised of 60S and 40S 
subunits (Melnikov et al. 2012). The bacterial and eukaryotic ribosomes are 
thus sufficiently different from each other such that antibiotics can be used to 
selectively target the bacterial ribosome whilst having less affinity for that of the 
eukaryotes. 
Antibiotics can be divided into those that target the 30S subunit of the ribosome 
(aminoglycosides and tetracyclines) and those that target the 50S subunit 
(oxazolidinones, amphenicols, pleuromutilins and the MLS antibiotics; namely 
macrolides, lincosamides and streptogramins grouped together based on their 
similar MoA). The smaller, 30S subunit is where the mRNA enters the ribosome 
and pairs with tRNA. Aminoglycosides target this subunit to cause 
mistranslation of the mRNA and tetracyclines target it to prevent the tRNA 
associating with the ribosome (Chopra and Roberts 2001; Kotra et al. 2000; 
Melnikov et al. 2012). The surface side of the 50S subunit which constitutes the 
interface between 30S and 50S subunits is where the peptide bonds are 
catalysed and sent through an exit tunnel in the 50S subunit (Melnikov et al. 
2012). Antibiotics target and bind to various parts of the ribosome and in doing 
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so prevent it functioning properly and/or inhibit the correct translation of mRNA 
into a peptide sequence. 
Although the ribosome is evolutionarily well conserved, there is variability in 
composition and structure between species in each domain (bacterial and 
eukaryotic), which may lead to differences in species sensitivity to the effects of 
antibiotics. Some off-target effects are sometimes observed in mitochondria and 
chloroplasts due to their endosymbiotic origin from -proteobacteria and 
cyanobacteria respectively and this in turn can lead to affects in eukaryotes 
(Chopra and Roberts 2001; Wang et al. 2015). 
Nucleic acid synthesis inhibitors 
There are several drug targets in bacteria through which the synthesis of 
nucleic acids can be inhibited. The first are the bacterial type II topoisomerases, 
DNA gyrase and topoisomerase IV, which are enzymes required in the 
management of DNA cleavage and ligation (re-joining DNA strands) and are 
essential for DNA replication, transcription and recombination. These enzymes 
are specifically targeted by quinolones which bind to them and inhibit their 
function causing permanent DNA breakages and initiation of the SOS response 
(Aldred et al. 2014; Hooper 1999). DNA gyrase is evolutionarily well conserved 
across bacteria and is even found in some archea, into which they were likely 
introduced from bacteria via horizontal gene transfer (Forterre et al. 2007; Sioud 
et al. 1988). Additionally, gyrase has been identified in the mitochondria and 
chloroplasts of plants and algae and is phylogenetically closely linked with 
cyanobacteria, likely due to their endosymbiotic origin (Falcon et al. 2010; 
Forterre et al. 2007; Moriyama and Sato 2014; Wall et al. 2004). Indeed, toxic 
effects of DNA gyrase inhibitors have been observed in plants (Brain et al. 
2008a; Brain et al. 2004; Ebert et al. 2011; Evans-Roberts et al. 2016) 
A second target for antibiotics that inhibit the synthesis of nucleic acids is RNA 
polymerase. This is targeted by the antibiotic class rifamycins. Rifamycins 
inhibit the initiation of RNA synthesis and show similar comparative affinity for 
both Gram-positive and Gram-negative bacterial enzymes, although it is thought 
that the more protective cell envelope of the Gram-negative bacteria explains 
their lower sensitivity overall (Floss and Yu 2005). Rifamycins are also able to 
inhibit eukaryotic RNA polymerase but they have a much higher affinity for 
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prokaryotic RNA polymerase (prokaryotes are between 1000 to 100000 time 
more sensitive) (Floss and Yu 2005). 
Both DNA and RNA synthesis can also be inhibited by antifolates that prevent 
the synthesis of folic acid, which is required in the production of nucleic acids. 
The folic acid synthesis pathway includes specific catalysing enzymes that are 
the target for some antibiotics. Examples of these include sulfonamides that 
target dihydropteroate synthase and trimethoprim that targets dihydrofolate 
reductase. As observed for DNA gyrase, plants and algae have been shown to 
possess the same folate synthesis pathway as bacteria and therefore they also 
show sensitivity to these antibiotics (Basset et al. 2005; Brain et al. 2008b; 
Zhang et al. 2012). Some bacteria, including cyanobacteria, are not sensitive to 
sulphonamides, likely due to the presence of a folate transporter protein in the 
membrane that allows them to survive on environmental folates thus avoiding 
the dependence on the folate synthesis pathway on which these antibiotics 
target (de Crécy-Lagard et al. 2007). 
In chapters 5 and 6 of this thesis the effects of three classes of antibiotics upon 
cyanobacteria are experimentally considered; -lactam (cell wall synthesis 
inhibitors); macrolides (protein synthesis inhibitors); and sulphonamides (DNA 
synthesis inhibitors). The sections below give a brief outline of the MoA of these 
classes of antibiotics. 
-lactams 
-lactam antibiotics largely consist of the classes of penicillin, cephalosporin 
and carbapenem, with a few other smaller classes including penems and 
monobactams. These antibiotics are bactericidal, working by targeting the 
penicillin binding proteins and preventing the synthesis peptide cross chains in 






Figure 1: How -lactam antibiotics inhibit the synthesis of the bacterial cell wall. This diagram 
depicts the structure of a cyanobacteria or Gram-negative bacteria with an outer membrane and 
periplasm (not present in a Gram-positive bacteria). It also shows the presence of -lactamase 
enzymes that hydrolyse the -lactam antibiotics as a resistance mechanism. 
 
Macrolides 
Macrolides are antibiotics that prevent the synthesis of proteins by binding to 
the exit tunnel of the 50S subunit of the ribosome. Once bound, the macrolide 
prevents the ribosome from catalysing the bonding between amino acid when a 
specific sequence of codons in the mRNA, called an macrolide arresting motif, 





Figure 2: How macrolide antibiotics inhibit protein synthesis. 
 
Sulfonamides 
Sulfonamide antibiotics inhibit the production of folic acid, which is a precursor 
in the DNA synthesis pathway. Specifically, they competitively inhibit 
dihydropteroate synthase, an enzyme that catalyses the reaction between para-
aminobenzoic acid (of which sulfonamides are structural analogues) and 
dihydropteroate diphosphate to create dihydropteroic acid (Figure 3) 
(Bermingham and Derrick 2002). 
 
Figure 3: How sulphonamide antibiotics inhibit the synthesis of DNA. 
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Release of antibiotics into the environment 
There are several ways that antibiotics may enter aquatic and terrestrial 
environments due to their use in both human and animal healthcare. They may 
be discharged into aquatic systems via waste/contamination from antibiotic 
manufacturing plants, effluent from WWTPs and STPs, hospital effluents, as 
leachate from landfill into groundwater or from use in aquaculture. Terrestrial 
soils may be contaminated directly from livestock urine/faeces, from the 
spreading of sewage sludge/biosolids on agricultural land as fertiliser and 
leaching from land fill into surrounding soils, all of which may leach out and run-
off into the groundwater and surface waters (Batt et al. 2007; Brown et al. 2006; 
Carvalho and Santos 2016; Kümmerer 2009; Larsson 2014; Larsson et al. 
2007; Michael et al. 2013). Antibiotics are also found in the marine environment 
(Gaw et al. 2014) and in sediments (Lalumera et al. 2004; Pei et al. 2006). 
Following human use, antibiotics and their transformation products are 
generally excreted unmetabolised and processed in WWTPs where, depending 
on the type of treatment facilities, they are broken down in to transformation 
products or passed into the environment (He et al. 2015; Watkinson et al. 2007; 
Xu et al. 2015). Investigators have found that removal efficiencies are highly 
dependent on the antibiotic (He et al. 2015; Gulkowska et al. 2008; Xu et al. 
2007). For example, one study found this was 49% for olfloxacin, 64% for 
molifloxacin and 74% for ciprofloxacin in WWTPs in USA (He et al. 2015). 
Removal efficiencies are also dependent on the type of treatment technology 
implemented; such as conventional activated sludge sewage plants compared 
to more advanced microfiltration/reverse osmosis plants (Batt et al. 2007; 
Watkinson et al. 2007). Furthermore, since the removal efficiency is highly 
associated with the type of sewage treatment process, there tends to be a 
disparity between countries based on their wealth, with lower income countries 
having less advanced waste water treatment (if any) and less stringent 
regulations (if any) which results generally in higher concentrations of antibiotics 
entering the environment compared to higher income countries (Kookana et al. 
2014; Review on Antimicrobial Resistance 2016; Segura et al. 2009; Segura et 
al. 2015). It is important to recognise however, that robust data sets that can 
reliably inform upon global patterns of the occurrence of antibiotics in the 
environment (and antibiotic resistance) are skewed, with large data sets 
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available for regions that are better funded for research (e.g. Europe, USA, east 
China) and often, little or no information is available for other countries 
(Kookana et al. 2014; Schafhauser et al. 2018; Segura et al. 2009). 
As for other contaminants, antibiotics that are not easily transformed or 
degraded can persist in the environment. Persistent antibiotics, such as the 
macrolide erythromycin, may not be effectively broken down in the WWTP into 
‘safe’ (i.e. non-active) transformation products and may therefore reach the 
environment as the parent compound where they can accumulate and cause 
adverse effects on the microbiota. Some antibiotics are pseudo-persistent, such 
as occurs for some β-lactams, where partial degradation occurs in WWTPs but 
because of a constant discharge (e.g. from urban centres, hospital effluents, 
manufacturing discharges) levels persist or can even accumulate in the 
receiving environment. These environments can sometime be hotspots for the 
accumulation of antibiotics and AMR. 
Antibiotics are regularly found in the ng/L range in the effluents of WWTPs, 
although some antibiotics have been recorded at levels reaching into the μg/L 
range (Batt et al. 2007; Brown et al. 2006; Monteiro and Boxall 2010; Watkinson 
et al. 2007; Watkinson et al. 2009). Hospital effluents however, have been 
identified as a particularly important source of antibiotics where concentrations 
can reach high μg/L or even mg/L levels (Brown et al. 2006; Kümmerer 2001). 
Rodriguez-Mozaz et al. (2015) found that of nine antibiotics they measured 
(notably ciprofloxacin, ofloxacin, cefazolin, cefotaxime, azythromycin, 
clarithromycin, sulfamethoxazole, trimethoprim and metronidazole) eight were 
recorded at higher concentrations in the hospital effluent than in the WWTP 
effluent. Of particular concern were the fluoroquinolones, ciprofloxacin and 
ofloxacin, which were regularly found in hospital effluents at concentrations of 
8.3 to 13.8, and 4.8 to 14.4 μg/L, respectively. Downstream of the WWTP the 
highest recorded concentrations of ciprofloxacin and ofloxacin were 0.72 and 
0.138 μg/L, respectively. Antibiotic manufacturing plant effluents have also been 
identified as a particular concern in the release of antibiotics into the aquatic 
environment with recorded levels also in the mg/L range (Larsson 2014; 
Larsson et al. 2007). Worryingly, there are currently no regulations that govern 
the safe discharge of antibiotics from manufacturing plants but attempts have 
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been made to address this via the AMR industry alliance (AMR Industry alliance 
2018). 
Effects observed upon bacteria and resistance selection in aquatic 
environments are generally observed in the low μg/L concentrations (see 
chapter 2) and therefore where environmental concentrations reach these 
levels there is clearly a potential risk to the bacterial communities and the 
functions that they perform. For example, in China, the production and 
consumption of antibiotics are some of the highest globally and some of the 
highest recorded environmental concentrations are found there. Indeed, in a 
review of antibiotics in the lakes of China (Liu et al. 2018) found 12 antibiotics 
occurring at concentrations at levels giving a risk quotient (RQ) of ≥1 and 4 with 
RQs of ≥10, indicating a high risk to the environment. 
The spreading of biosolids on agricultural land is another important source of 
antibiotic contamination in the environment (Kinney et al. 2006; Walters et al. 
2010). This thesis work is focused on the effects and environmental risk 
assessment (ERA) of antibiotics in aquatic ecosystems however and the effects 
of antibiotics on the terrestrial environment are therefore not explored further 
here. 
Antimicrobial resistance 
Ever since the discovery of penicillin, the first antibiotic used in the treatment of 
human infection, the emergence of resistance to every newly introduced 
antibiotic has quickly followed, reducing their efficacy (Davies and Davies 
2010). If antibiotics are rendered ineffective in the control and treatment of 
pathogenic bacteria, medical advances in treating infectious diseases, surgical 
interventions and cancer treatment will be affected hugely (Review on 
Antimicrobial Resistance 2016). This is in addition to the potential damage it 
would do to food security. AMR is a crisis that the World Health Organisation 
has identified as “a major threat to public health” (World Health Organization 
2014). Indeed, a series of reports (Review on Antimicrobial Resistance 2016) 
has predicted that AMR will be responsible for 10 million deaths a year by 2050 
(currently estimated to be approximately 700,000) and cost up to $40 billion 
over the next ten years to address. 
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AMR genes are selected for where the benefit of possessing and expressing 
the resistance gene outweighs the fitness costs of carriage. Thus when 
antibiotic contaminants are present in the environment resistance genes in the 
bacterial populations/communities could be selected for and enriched, 
potentially leading to their transfer into human pathogens (Ashbolt et al., 2013). 
There are four broad resistance mechanisms employed by bacteria: i) 
modification of the drug target to reduce or eliminate the binding affinity of the 
antibiotic; ii) reducing the bioavailable concentration of the antibiotic in the cell 
by reducing the permeability of the membrane or increasing efflux of the 
antibiotic; iii) production of cellular molecules (e.g. enzymes) to metabolise or 
degrade the antibiotic molecules; and iv) use of an alternative biochemical 
pathway to bypass the antibiotic mode of action (Fernandes et al. 2013; Walsh 
2000). 
The role cyanobacteria have in harbouring AMR genes and if they are able to 
transfer these genes to other bacteria, including pathogenic bacteria, is poorly 
understood. But recent evidence suggests that they may have the potential to 
hold and transfer resistance genes. Microcystis aeruginosa was found to 
possess the gene for thymidylate synthase (an alternate enzyme in the folic 
synthesis pathway that reduced susceptibility to trimethoprim), some β-lactum 
resistance genes, the mfd gene, which is involved in quinolone resistance and 
also some tetracycline resistance genes (Barata 2017). Although transference 
of AMR genes in cyanobacteria has not yet been observed directly, 
cyanobacteria have been demonstrated to undergo horizontal gene transfer 
(Humbert et al. 2013; Shi and Falkowski 2008) with some species 
demonstrating the ability to transfer large DNA sequences. As an example 
Humbert et al. (2013) found that Microcystis aeruginosa was able to transfer 
gene clusters of up to 19kb. 
One of the many key questions being addressed by researchers regarding AMR 
is what role does the environmental compartment play in the harbouring and 
selection of AMR genes and how does it contribute to the potential transfer of 
these resistance determinants into pathogens. Furthermore, since the 
environmental compartment has been identified as a potential source for the 
harbouring, selection and dissemination of AMR determinants (Laxminarayan et 
al. 2013; Martínez 2008; Segawa et al. 2013; Taylor et al. 2011), there is an 
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urgent need to better understand the risk posed from the release of antibiotics 
into the environment. As such, it has been suggested that AMR could be 
considered within human and environmental risk assessment frameworks and a 
protection limit established to mitigate the risk posed from antibiotics in the 
environment to the selection of AMR (Agerstrand et al. 2015; Ashbolt et al. 
2013). However, further research is required to identify the most appropriate 
methodologies for investigating AMR and what should be measured (e.g. 
population growth or AMR gene abundance) to obtain endpoints from which to 
base protection limits. Figure 4 illustrates the number of publications relating to 
AMR and highlights that environmental AMR risk assessment has received 
relatively little study compared with AMR research more generally, (only 2.5% of 
academic publications on AMR include “risk assessment”, and when the term 
“environment” is included this decreases to 1.6%). 
 
 
Figure 4: Google Scholar search for publications relating to AMR, using key words relating to 
antimicrobial resistance, environment and risk assessment. Search’s were conducted on 19 
September 2018 and exclude citations and patents. 
 
The minimum inhibitory concentration (MIC), which is the concentration at which 
there is complete inhibition of growth in the strain of bacteria being tested, is 
commonly used in microbiology when determining the effects of an antibiotic on 
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bacteria. MICs are monitored and collected for clinically relevant bacteria to 
ensure clinical efficacy and are recorded in the European Committee on 
Antimicrobial Susceptibility Testing database (http:// www.eucast.org). However, 
it has been established that resistance determinants are selected for at sub-
lethal concentrations, well below the MIC and in some cases by up to two 
orders of magnitude below sub-lethal concentrations (Gullberg et al. 2011; 
Hughes and Andersson 2012; Lundström et al. 2016). The minimum selective 
concentration (MSC) is the concentration at which there is a net fitness 
advantage for the cells that carry and express the resistance gene compared to 
those in the same species/strain that do not (Gullberg et al. 2011). This may, 
however, still be somewhat too simplistic, as it does not take into account the 
added complexities added by the horizontal gene transfer of resistance genes, 
community interactions, the presence of extracellular resistance molecules (e.g 
β-lactams) that benefit non-resistance carrying cells, nor does it consider the 
biological and/or exposure effects due to growth in biofilms (Greenfield et al. 
2017; Murray et al. 2018). 
Nonetheless, the experimental determination of the MSC for use in risk 
assessment is an approach several investigators are exploring. Greenfield et al. 
(2017) propose a theoretical method using the parameters of modelled dose 
response relationships of susceptible and resistant bacterial strains. A recent 
experimental approach has been proposed using a complex community (raw 
untreated wastewater) and measuring the selection coefficients of resistance 
genes by qPCR (Murray et al. 2018). Using this method they identified positive 
selection for the resistance gene bla-CTX-M (and others) at 0.4 μg/L in the 
presence of cefotaxime and a significant change in community structure, 
increasing the abundance of some pathogenic bacteria, although in reality this 
may occur at lower than 0.4 μg/L due to degradation. Another more theoretical 
approach to establish a protection limit for AMR was proposed by Bengtsson-
Palme and Larsson (2016) using the MIC data in the EUCAST database to 
predict the upper boundaries for resistance. 
This thesis primarily considers the ecotoxicity of antibiotics in the environment 
and with a primary focus on cyanobacteria as the prokaryotic representative in 
ERA. However, AMR is intrinsically involved within the debate on antibiotics in 
the environment and it is impossible to fully consider the ecotoxicological effects 
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of antibiotics and their risk assessment without its consideration. As such, 
although this thesis does not provide an in depth discussion of AMR nor its 
threat to human health, chapters 2, 3, 6 and 7 do reflect on the relationship 
between protection limits for ecotoxicity and AMR and the implications for ERA. 
Environmental risk assessment of antibiotics 
Current EU regulations 
In the European Union pharmaceuticals are regulated according to Directive 
2001/83/EC and Regulation (EC) No 726/2004. To comply with these, an ERA 
is required performed according to the guideline EMEA/CHMP/SWP/4447/00 
corr 2 (European Medicenes Agency (EMA) 2006), which consists of a two 
phases. Phase I requires the estimation of the environmental exposure, termed 
a predicted environmental concentration (PEC). If the PEC is greater than a 
threshold of 0.01μg/L a second phase of testing is required. This is split into two 
tiers. Phase II Tier A requires a base set of ecotoxicity studies upon a green 
algae, invertebrate and fish species and the performance of an activated sludge 
respiration inhibition test (ASRIT). In the case of antibiotics the green algae is 
replaced with a test on a cyanobacteria species. From these studies a no 
observed effect concentration (NOEC) is determined and an assessment factor 
of 10 applied (NOEC/10) to the most sensitive NOEC to establish a predicted 
no effect concentration (PNEC). Depending on the ratio between the PEC and 
the PNECs further testing may be required to refine the risk assessment. Table 
1 summarises the phase II ecotoxicity testing according to (EMA 2006). There is 
currently no legislation or guidance to cover/include the risk assessment of 
AMR. 
Data on the ecotoxicological effects of some pharmaceuticals, including 
antibiotics, upon the environment is scarce, partly due to the lack of regulatory 
requirement previous to 2006 before which the vast majority of antibiotics were 
registered (Le Page et al. 2017; Välitalo et al. 2017). Indeed, following our 
systematic review of data for the meta-analysis in chapter 2, we found data for a 
complete phase II, ERA dataset for only 7 out of 79 antibiotics (9%). Many 
antibiotics were patented before the introduction of environmental regulation 
and because pharmaceuticals have a maximum patent period of 20 years 
starting from when an active pharmaceutical ingredient (API) is discovered, any 
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manufacturer can now generically produce many antibiotics. These antibiotics 
are therefore sometimes termed as ‘legacy compounds’ and are of concern 
because they are untested (environmentally speaking) and there is no longer 
any responsibility over their environmental profile given that anyone is able to 
manufacture them. There have thus been calls for approaches to prioritise 
legacy compounds in the environment in order to identify important substances 
that may pose a risk and require additional research (Brooks et al. 2009; Burns 
et al. 2018; Roos et al. 2012). In support of this, chapter 4 details the 
development and validation of a microplate assay that establishes the effects of 
antibiotics (or any other soluble compound) on the growth inhibition of eight 
species of cyanobacteria. 
There is a high dropout of potential APIs in the process of bringing a new drug 
to market and thus ERA, which is expensive to perform, is not carried out until 
just before the submission of a regulatory dossier in order to prevent the 
wasting of investment if the molecule fails late stage clinical trials. This results in 
the environmental profile of a molecule only being discovered at the end of the 
process of bringing a new drug to market and the need to implement 
environmental management for any higher risk APIs. Since many hundreds of 
molecules may be developed at the very beginning of drug discovery, it is 
possible that more ‘green’ (and thus lower risk) molecules were excluded in the 
discovery process that may have the same or similar clinical efficacy. It has 
therefore been suggested that obtaining environmental data earlier on in the 
drug discovery process could help support decision making, lead to greener 
drug design and inform ERA when it is carried out. The micro plate assay 
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Table 1: European Medicines Agency environmental risk assessment ecotoxicity Phase II testing. Phase I, the estimation of exposure, is not included. 
PEC = Predicted environmental concentration; PNEC = Predicted no effect concentration; PNECW = PNEC in water (based on most sensitive NOEC of 
algae/cyanobacteria, invertebrate and fish test); PECSW = refined PEC in surface water; PNECM = PNEC of microorganisms (from ASRIT); PECAT = 
PEC in aeration tank; PECGR = PEC in groundwater; PNECGR = PNEC in groundwater; KOW = n-octanol/water partition coefficient; KOC = adsorption 
coefficient; API = active pharmaceutical ingredient 
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Current methodologies for the testing of antibiotics in ERA 1 
For antibiotics, the ERA framework includes just two ecotoxicity tests upon 2 
prokaryotic organisms, the ASRIT and a growth inhibition test upon a single 3 
species of cyanobacteria. The ASRIT has been demonstrated to not be 4 
sensitive to antibiotics and is thus not suitable for establishing protection limits 5 
that are protective of bacteria populations (Kümmerer et al. 2004; Le Page et al. 6 
2017). Furthermore, since antibiotics are designed or selected to have MoAs 7 
that are bactericidal or bacteriostatic whilst having limited effects upon humans 8 
(or other mammals in the case of veterinary medicine), there is unlikely to be 9 
affects upon fish or invertebrates as they don’t possess the drug targets (Le 10 
Page et al. 2017). Although, as discussed previously, some effects have been 11 
observed in some algae, macrophytes and terrestrial plants due to the 12 
prokaryotic origin of the chloroplasts and mitochondria. 13 
Thus, out of four ecotoxicity tests in ERA, all prokaryotic diversity is effectively 14 
represented by a single species cyanobacteria growth inhibition study. This bias 15 
towards tests that are inherently not sensitive to antibiotic MoAs has been 16 
identified by several investigators, whom have raised concerns regarding the 17 
capability of ERA to establish suitable protection limits for the protection of 18 
bacteria populations, communities and the ecosystem functions that they 19 
perform (Agerstrand et al. 2015; Brandt et al. 2015; Le Page et al. 2017). 20 
Furthermore, within species that possess the drug target, interspecies 21 
sensitivity differences can still be highly variable, as demonstrated by species 22 
sensitivity distributions of clinically relevant bacteria exposed to ciprofloxacin, 23 
erythromycin and tetracycline that each have sensitivity ranges of up to or more 24 
than two orders of magnitudes (Tello et al. 2012). Indeed, a single bacterial 25 
species is highly unlikely to be representative of the whole assemblage. This 26 
has also been shown for algae exposed to herbicides (Nagai et al. 2016; Van 27 
den Brink et al. 2006) and accordingly, the relevant ERA regulations require 28 
multiple algae species to be tested in ERA (EFSA 2013; US EPA 2017). 29 
There is a clear need for a critical assessment of antibiotic ERA to establish 30 
more suitable protection limits that are protective of bacterial diversity and 31 
ecosystem function. There are however, only limited experimental data 32 
available for MoA relevant species for the majority of antibiotics on which to 33 
base a critical assessment (Le Page et al. 2017). Thus a test method that 34 
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allows the rapid assessment of the effects of antibiotics to several bacterial 35 
species and allows for the direct comparison of sensitivity would be valuable in 36 
order to determine if testing upon a single species of cyanobacteria can be 37 
protective of a cyanobacteria diversity more broadly. Furthermore, it is vital to 38 
ascertain whether cyanobacteria are a suitable representative of all other 39 
bacterial clades and if not, identify what other bacteria should be represented. 40 
Shake flask for the growth inhibition of cyanobacteria 41 
Traditionally the shake flask growth inhibition test has been used to determine 42 
the growth inhibition of green algae and cyanobacteria following chemical 43 
exposure and there are several internationally recognised test guidelines, 44 
including (ISO 2004; OECD 2011; US EPA 1996). 45 
Briefly, the test consists of exposing an anexic culture of cells in balanced 46 
(exponential) growth to a range of test chemical concentrations and measuring 47 
the cell density at the beginning of the test and every 24 hours for 3 to 4 days. 48 
The exposures are generally performed in 100mL of culture medium in 250mL 49 
conical flasks, being shaken and under continuous lighting and temperature 50 
conditions. The cell density at each concentration at the start and end of the 51 
test is used to calculate the growth rate, yield and occasionally the area-under- 52 
the-curve to determine the inhibitory effects of the chemical on growth. There 53 
are several benefits to this test methodology including limited experimental error 54 
due to the large volumes, stable growing conditions (due to large volumes) and 55 
large historical use and thus published data for comparison, analysis and 56 
validation. 57 
There are however also several drawbacks to this methodology, mainly based 58 
around the large size, resource requirement and cost. The shake flask test 59 
requires several litres of test media and enough API, which may be expensive 60 
(especially if early on in drug design process), to make up the test concentration 61 
range. It also takes up considerable space and requires a lot of operator time, 62 
all restricting the throughput. Finally, there is little scope for automation of this 63 





Miniaturised assays and surrogates for cell density determination 67 
The use of miniaturised assays, often performed in 24 or 96 well microplates, 68 
have been frequently proposed to address the limitations associated with the 69 
shake flask test design (Eisentraeger et al. 2003; Nagai et al. 2013; Skjelbred et 70 
al. 2012) and are employed in the Environment Canada testing guidelines 71 
(Environment Canada 2007). A microplate test design has the advantages over 72 
the shake flask test in that it requires fewer resources in terms of consumables 73 
and operator time, requires less space allowing many tests to be performed in 74 
the same space as a single shake flask test, more easily allows for the rapid 75 
assessment of fluorescence/optical density (OD) in plate readers (as surrogates 76 
for cell density) and has higher potential for automation. Thus, the use of 77 
microplate assays enables screening of several test compounds at the same 78 
time, several species to the same test compound or indeed both. Given the 79 
current limitations in ERA previously identified, a microplate test that allows the 80 
rapid screening of several species of cyanobacteria would be of great value in 81 
both early drug discovery and prioritising legacy compounds. Indeed, similar 82 
assays have been developed for the screening of chemical toxicity and produce 83 
comparable results to the shake flask test, although the vast majority focus on 84 
green algae rather than cyanobacteria (Eisentraeger et al. 2003; Guo et al. 85 
2016; Nagai et al. 2013; Nagai et al. 2016; Paixão et al. 2008; Skjelbred et al. 86 
2012). There are however, several drawbacks from the use of microplate 87 
assays that need consideration in test design, such as the potential for higher 88 
variability in growth rates due to the smaller volumes used and potential 89 
underestimation of toxicity for volatile or hydrophobic compounds (Riedl and 90 
Altenburger 2007); although, these can be mitigated with a suitable analytical 91 
testing regime and the use of glass-coated microplates. 92 
In order to maximise the throughput of microplate assays and minimise the 93 
operator time required, most studies use an automated surrogate for cell 94 
density determination. Various surrogates have been proposed including 95 
fluorescence and OD that is also known as absorbance. In addition to the ability 96 
for precise, rapid and automated measurement, fluorescence and OD have the 97 
additional benefit that they are non-destructive sampling techniques and allow 98 
for repeated measurement of the same replicate without risk of contamination or 99 
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the reduction in replicate volume (Berden-Zrimec et al. 2007; MacIntyre and 100 
Cullen 2005). 101 
Two types of fluorescence have been used as a surrogate for biomass in algae 102 
toxicity studies; prompt fluorescence (often simply termed fluorescence) and 103 
delayed fluorescence. Prompt fluorescence is the emission of light from pigment 104 
molecules (e.g. in chlorophyll), excited by a specific wavelength and which 105 
occurs rapidly before charge separation in photosynthesis (the transfer of an 106 
electron from the primary election donor (Cardona et al. 2012)). Delayed 107 
fluorescence however, is a longer lasting but weaker emission of light that 108 
occurs following charge separation (Berden-Zrimec et al. 2010). Delayed 109 
fluorescence has the advantage of only occurring from actively 110 
photosynthesising cells and thus reflects living cells only, whilst prompt 111 
fluorescence may also occur from excited pigments in dead cells. Delayed 112 
fluorescence has been successfully used for algae toxicity testing (Berden- 113 
Zrimec et al. 2007; Katsumata et al. 2006) but since its measurement was not 114 
possible in the experimental work of this thesis it will not be discussed further. 115 
Prompt fluorescence (just referred to as fluorescence from herein), is more 116 
regularly used than delayed fluorescence. Many studies use fluorescence in 117 
situ for monitoring cell density of phytoplankton communities in the field, 118 
especially in regards to harmful algal blooms (Bowling et al. 2016; Zamyadi et 119 
al. 2016), but most laboratory studies have focused on green algae and thus 120 
use chlorophyll fluorescence with excitations and emissions at approximately 121 
420-430nm and 670-685 respectively. For example, Eisentraeger et al. (2003) 122 
demonstrated that for the growth inhibition of the green algae, Raphidocelis 123 
subcapitata, both a 96 well and 24 well microplate test using chlorophyll 124 
fluorescence were equally as sensitive as a shake flask test. 125 
Cyanobacteria have phycobiliproteins in addition to chlorophyll that most algae 126 
do not possess. Phycobiliproteins include phycocyanin, allophycocyanin and 127 
phycoerythrin and they absorb light at different wavelengths than for 128 
chlorophyll, passing the energy harvested from one to the other and finally to 129 
chlorophyll. Because they are at higher levels than chlorophyll in cyanobacteria 130 
cells they have been suggested to be a better surrogate for cell density. Nagai 131 
et al. (2013) used phycocyanin fluorescence to measure the growth inhibition in 132 
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the cyanobacteria Pseudanabaena galeata obtaining comparable results to a 133 
shake flask test design that used direct counting to determine cell density. 134 
OD is the absorbance of a specific wavelength of light in a suspension of the 135 
cells. Paixão et al. (2008) tested five compounds and six wastewater effluents 136 
on the growth of R. subcapitata in a microplate using OD at 450nm as a 137 
surrogate for cell density and found the results comparable to the shake flask 138 
test. The selection of a wavelength for OD is of particular importance in order to 139 
reduce error in biomass determination because cellular pigment concentration 140 
may vary considerably both under different conditions and in different parts of 141 
the growth curve (Griffiths et al. 2011; Hecht et al. 2016). An OD wavelength of 142 
>700nm, which outside of the range absorbed by cellular pigments (e.g. 143 
chlorophyll) or fluorescent proteins has thus been shown to be most suitable 144 
(Griffiths et al. 2011; Hecht et al. 2016). 145 
Using precise techniques such as OD and fluorescence also has the 146 
advantages of allowing the detection of low cell numbers with less experimental 147 
error compared with other techniques such as coulter counting or direct 148 
counting with a haemocytometer. Low cell densities provide higher 149 
environmental relevance, assay reproducibility and don’t affect the physio- 150 
chemical properties in the test (e.g. pH) nor bioavailability as greatly as higher 151 
cell densities (Berden-Zrimec et al. 2007; Franklin et al. 2002). Fluorescence 152 
has however, been shown to be more sensitive at lower cell densities than OD 153 
(Eisentraeger et al. 2003) and this has been confirmed in cyanobacteria in 154 
chapter 4 of this thesis. 155 
Which surrogate, fluorescence or OD, is best for determining cell density 156 
depends on several factors in the test design, but generally fluorescence 157 
appears to have more advantages. Firstly, fluorescence is preferable for lower 158 
cell densities than OD, providing several benefits as described above, but if the 159 
assay intends or requires testing at higher cell densities neither technique 160 
outperforms the other. Additionally, OD will likely be affected if the sample has 161 
other particulate matter other than the cells to be measured, whereas 162 
fluorescence is targeted to a fluorescent pigment with specific excitation and 163 
emission wavelengths making interference less likely. Finally, OD is also 164 
affected more than fluorescence by changes in cell morphology that change the 165 
optical properties of the suspension (Griffiths et al. 2011), although this is 166 
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unlikely to have severe detrimental affects in its application for single species 167 
assays given that cells are generally uniform in nature, unless the toxicity of the 168 
test compound changes the morphology of the cells. 169 
One key consideration in all algae and cyanobacteria growth inhibition assays is 170 
to ensure that, as best as possible, the test is run when the population is in 171 
balanced growth. Balanced growth, sometimes called exponential growth, is 172 
where a population is replicating at the maximum growth rate possible under the 173 
specific environmental conditions they are in and without nutrient limitations. 174 
Thus, reproducing cells are equally distributed across all stages of the cell cycle 175 
and at any given time interval the cell density increases at the same rate as well 176 
as the cellular components (ribosomes, proteins etc) (Campbell 1957; 177 
Schaechter 2015). Populations in other phases of the growth cycle (e.g. lag and 178 
stationary phases) have cells that vary in metabolic states and replication rates, 179 
leading to variability in cellular component ratios (Chang et al. 2012). This is of 180 
particular importance for obtaining reproducible results over time in growth 181 
inhibition studies (Schaechter 2015) and especially when measuring cell density 182 
with a surrogate such as phycocyanin fluorescence. For example, cells in the 183 
lag phase are preparing themselves for exponential growth by synthesising all 184 
the cellular components required (RNA, proteins, light harvesting complex’s, 185 
enzymes etc) (Rolfe et al. 2012). The lag phase will thus differ depending on 186 
the previous environmental conditions and their metabolic state on inoculation, 187 
as well as the amount of light harvesting pigments such as phycocyanin, which 188 
will in turn affect the fluorescence, growth rates and therefore the reproducibility 189 
of the assay (Chang et al. 2012; MacIntyre and Cullen 2005; Van Wagenen et 190 
al. 2014). Furthermore, Chang et al. (2012) show that phycocyanin levels per 191 
cell change throughout a populations growth curve and that that there is 192 
considerable interspecies variability in this respect. 193 
In order to develop a test method that could provide data in early drug discovery 194 
and/or for the prioritising of legacy antibiotics, a microplate-based assay that 195 
allows for the testing of several cyanobacteria could be of great value. It will 196 
however need to ensure, as best as possible, that the test is performed on 197 
populations that are in balanced growth and careful consideration of the 198 
individual growth conditions for each species will thus be required. In addition, 199 
for a fair comparison of cyanobacteria sensitivity and for the data to be 200 
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environmentally relevant, the exposure conditions should be the same across 201 
species to ensure the behaviour of the antibiotic is controlled (e.g. differences in 202 
light intensity and temperature may affect antibiotic degradation across assays). 203 
Chapter 4 sets out to develop, optimise and validate such an assay for eight 204 
species of cyanobacteria. Chapters 5 and 6 in turn use this assay in order to 205 
consider cyanobacteria sensitivity to antibiotics and the implications this may 206 
have for protection limits derived in ERA. 207 
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Aims of the thesis 
There are growing concerns regarding the suitability of current ERA to identify 
the risk antibiotics pose to bacterial communities and the essential ecosystem 
functions that they provide. Furthermore, ERA does not address for the 
selection of AMR in the environment. The primary aim of this thesis was 
therefore to determine if ERA is able to establish adequate limits for the 
protection of environmental bacteria populations. I have addressed this issue by 
performing both meta-analytical and experimental techniques whilst ensuring 
that the methods, taxa and focus remain relevant to traditional ERA. 
Specifically, the aims of this thesis were: 
 Evaluate current antibiotic ERA through the collation and analysis of 
publically available data on organisms regularly used in ecotoxicology 
testing (Chapter 2) 
 Compare the protection limits established traditionally for the 
environment in ERA with those proposed for the protection of human 
health via AMR selection (Chapter 2) 
 Provide a considered response to a series of criticisms made by 
Bengtsson-Palme and Larsson (2018) on the work I conducted and 
subsequently published in chapter 2 (Chapter 3) 
 To develop and validate a microplate assay suitable for a range of 
cyanobacteria species to determine growth inhibition following chemical 
exposure (Chapter 4) 
 Using the microplate assay developed in chapter 4, establish differences 
in cyanobacteria species sensitivity across a range of antibiotics 
(Chapter 5) 
 To compare current protection limits derived for ERA with the 
probabilistic species sensitivity distribution approach using data obtained 
from the microplate assays conducted in chapter 5 (Chapter 6) 
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 To establish the expected total risk antibiotics may pose to freshwater 
cyanobacteria based upon species sensitivity distributions and measured 
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This is a systematic review and meta-analysis of the publically available aquatic 
ecotoxicity data and minimum inhibitory concentrations of clinically relevant 
bacteria.  It includes a comparative analysis of species sensitivity and the 
protection goals derived for environmental health and for human health (in 
regards to antimicrobial resistance).   
I performed all data collection, analysis and first drafting of the paper. All 
authors were actively involved in discussions on the work and in the preparation 
of the manuscript for submission.  This paper is included in the thesis appendix 
in its published format.  The data tables referred to in the text as supplemental 
material table 1 and 2 are too large to be included within this thesis, but can be 
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Integrating human and 
environmental health in antibiotic 
risk assessment: a critical 
analysis of protection goals, 
species sensitivity and 
antimicrobial resistance 
Abstract  
Antibiotics are vital in the treatment of bacterial infectious diseases but when 
released into the environment they may impact non-target organisms that 
perform vital ecosystem services and enhance antimicrobial resistance 
development with significant consequences for human health. We evaluate 
whether the current environmental risk assessment regulatory guidance is 
protective of antibiotic impacts on the environment, protective of antimicrobial 
resistance, and propose science-based protection goals for antibiotic 
manufacturing discharges. A review and meta-analysis was conducted of 
aquatic ecotoxicity data for antibiotics and for minimum selective concentration 
data derived from clinically relevant bacteria. Relative species sensitivity was 
investigated applying general linear models, and predicted no effect 
concentrations were generated for toxicity to aquatic organisms and compared 
with predicted no effect concentrations for resistance development. Prokaryotes 
were most sensitive to antibiotics but the range of sensitivities spanned up to 
several orders of magnitude. We show reliance on one species of 
(cyano)bacteria and the ‘activated sludge respiration inhibition test’ is not 
sufficient to set protection levels for the environment. Individually, neither 
traditional aquatic predicted no effect concentrations nor predicted no effect 
concentrations suggested to safeguard for antimicrobial resistance, protect 
against environmental or human health effects (via antimicrobial resistance 
development). Including data from clinically relevant bacteria and also more 
species of environmentally relevant bacteria in the regulatory framework would 
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help in defining safe protection limits for the protection of environmental and 
human health 
Introduction: 
Antibiotics are crucial in human healthcare.  They are used in the treatment of 
bacterial infectious diseases, supporting surgical interventions, and in cancer 
and prophylactic treatment.  Antibiotics are also used widely in livestock and 
domestic animal veterinary treatments and as growth promoters in aquaculture.  
Global production of antibiotics for human use is valued at $40 billion a year 
(O’Neill 2015) illustrating their societal and economic importance. Antibiotic 
consumption is on the rise and between the years 2000 and 2010 there was an 
estimated 36% increase in use globally for human healthcare (Van Boeckel et 
al. 2014).  
Antibiotics, as other pharmaceuticals, enter the environment via patient and 
animal use, through manufacturing plants and/or improper disposal. Common 
points of entry into the environment from human therapeutic use are via 
effluents from hospitals, domestic sewerage treatment plants, as well as via 
leachates from landfill sites. Antibiotics can enter into surface waters from 
sewerage treatment plants directly or they can be transferred via surface run 
off. Ground waters can be exposed from agricultural land treated with sewage 
sludge biosolids as a source of fertiliser (Kümmerer 2009). Veterinary antibiotics 
enter the aquatic environment either directly, and may leach into or run off 
surface water or via groundwater from the manure of treated livestock (Davies 
2012; Kümmerer 2009; Sarmah et al. 2006). Antibiotics in surface waters and 
sewerage treatment plant effluents/wastewaters are generally measured at 
concentrations ranging between 0.01 and 1.0 μg/L (Batt et al. 2007; Miao et al. 
2004; Monteiro and Boxall 2010; Watkinson et al. 2009).  The highest levels of 
antibiotic residues in effluents - in the milligram per litre range, with records in 
excess of 1000 mg/L - are reported from manufacturing plants in China and 
India (Larsson 2014; Larsson et al. 2007; Li et al. 2008; O'Neill 2015). Hospital 
effluents too can contain antibiotic residues in the mg/L concentration range 
(Brown et al. 2006; Watkinson et al. 2009). 
Antibiotics affect prokaryotic cells via a number of distinct mechanisms of 
action, including the inhibition of cell envelope synthesis, inhibition of protein 
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synthesis or inhibition of nucleic acid (DNA/RNA) synthesis.  Antibiotics are 
designed for use in the treatment of bacterial infection in humans and livestock 
and are thus developed to avoid, or limit, effects on mammalian cells. It is, 
therefore, reasonable to assume that environmental bacteria are more likely to 
be adversely affected as a result of non-therapeutic exposure compared with 
aquatic vertebrates, such as fish. 
Within Europe, an environmental risk assessment (ERA) is required for a 
medicine if the predicted environmental concentration exceeds 0.01 μg/l (EMA 
2006).  In the USA effect studies are triggered if the expected environmental 
concentration exceeds 0.1 μg/L (US Food and Drug Administration 1998). The 
ERA aims to establish the safe concentrations for the protection of wildlife 
populations, ecosystem structure and function and includes the calculation of 
three predicted no effect concentrations (PNEC) for aquatic organisms, namely 
PNECsurfacewater (PNECSW), PNECmicroorganism, and PNECgroundwater (EMA 2006).  
These are determined by establishing a no observed effect concentration 
(NOEC, the test concentration at which there is no statistically significant effect 
in the response being tested, such as on growth rate or reproduction) for a 
range of aquatic taxa and applying an assessment factor of ten to account for 
variability in species sensitivity and extrapolation from laboratory data to the 
field. PNECmicroorganism is based on the ‘activated sludge respiration inhibition 
test’ (ASRIT, (OECD 2010)) and is primarily used to establish risk to 
microorganisms in (and the function of) sewerage treatment plants. The 
PNECgroundwater is based on a chronic test with Daphnia magna (e.g. OECD 211 
test guideline, (OECD 2012) and PNECSW is calculated from the toxicity to three 
eukaryotic species – a green algae, invertebrate and fish.  For antibiotics, in 
Europe the ERA guidance encourages ecotoxicity testing with prokaryotes 
rather than a green algae “as they are [a] more sensitive indicator organisms 
than green algae” (EMA 2006), and this is conducted in one species of 
cyanobacteria only. 
There is concern that the ERA for antibiotics is biased towards testing on 
metazoan species (invertebrates and fish in this instance), and does not 
consider fully the possible impacts of antibiotics on microbial community 
structure, function and resilience (Agerstrand et al. 2015; Brandt et al. 2015). 
This is a major shortfall considering the fundamental ecosystem services 
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microbial communities provide (e.g. primary production, nutrient cycling, 
metabolism and degradation of organic, inorganic and synthetic compounds). A 
major aim of this meta-analysis therefore was to test if current ERA is protective 
of vulnerable populations in the environment.  
Microorganisms exposed to antibiotics at low, sub-lethal or sub-inhibitory 
exposure concentrations can develop, or acquire, antimicrobial resistance 
(AMR) and this has been identified as a major threat to public health (Smith and 
Coast 2002; World Health Organization 2014). AMR is likely to persist and 
disseminate in diverse environments, including in aquatic ecosystems 
(Laxminarayan et al. 2013; Taylor et al. 2011).  Where the benefit of possessing 
and expressing the resistance gene outweighs the fitness costs of carriage, 
antibiotics in the environment may select for and enrich resistance genes in 
bacterial populations/communities which can then harbour these resistance 
determinants and transfer them to human pathogens (Ashbolt et al. 2013). 
To ensure clinical efficacy and protection of human health, minimum inhibitory 
(growth) concentrations (MICs, the lowest concentration at which there is no 
observable growth) are monitored in clinically relevant bacteria (CRB) and 
recorded in the European Committee on Antimicrobial Susceptibility Testing 
database (http://www.eucast.org).  In addition to monitoring MICs in clinically 
relevant species, studies with clinical isolates have also identified the lowest 
concentration that will select for AMR, called minimum selective concentrations 
(MSCs).  MSCs are the minimum concentration at which the presence and 
expression of resistance gene(s) give bacteria a fitness advantage over non-
resistant cells of the same species/strain. This can occur at concentrations 
considerably below the MIC of the non-resistant cells (Gullberg et al. 2011). 
Indeed, selection may occur at exposures up to two orders of magnitude lower 
than the MIC for growth (Gullberg et al. 2011; Hughes and Andersson 2012; 
Lundström et al. 2016).   
From both human and environmental health perspectives, it is important that 
risk assessment frameworks incorporate the risk of AMR selection.  An 
approach to establish a surrogate PNEC for AMR (PNECR) has been suggested 
adopting MICs from CRB, which are available through the European Committee 
on Antimicrobial Susceptibility Testing database (Bengtsson-Palme and 
Larsson 2016). This is the most comprehensive dataset available where 
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theoretical PNECs (PNECR(T)) have been calculated for 111 antibiotics. This 
approach uses growth (via the MIC) to predict upper boundaries for resistance, 
although there has been no verification of an increase in resistance 
determinants.  The approach also assumes that the CRB are representative of 
the diversity of bacteria in nature.  Furthermore, whilst AMR maybe enriched at 
concentrations well below the MIC of clinical bacteria, the AMR enrichment 
could potentially occur at concentrations below the effects determined in 
traditional ERA ecotoxicity growth tests on cyanobacteria.  This meta-analysis 
therefore also sought to determine the relationship between protection goals 
proposed to protect against resistance development and the traditional aquatic 
protection goals; i.e. establish if the proposed methods used to derive a PNEC 
for AMR development (PNECR) are protective of those currently used for 
aquatic ecosystem function (PNECsw) and vice versa.    
Recognising that antibiotic releases from drug production and formulation 
facilities represent ‘hot spots’ for the development of AMR it is critical that these 
discharges are minimised and managed effectively across the whole supply 
chain. To address this concern, the pharmaceutical industry recently 
established an AMR Road map which included a commitment to “establish 
science-driven, risk-based targets for discharge concentrations for antibiotics 
and good practice methods to reduce environmental impact of manufacturing 
discharges, by 2020” (IFPMA 2016).  
To improve the testing paradigm for antibiotics for use in prospective regulatory 
frameworks and to establish safe discharge concentrations for antibiotic 
production, we conducted a meta-analysis based on a systematic review of the 
publically available aquatic ecotoxicity data and clinically relevant MICs for 
antibiotics. Specifically we; 1) assess the relative sensitivity of commonly used 
taxa in aquatic ecotoxicity, with a MOA perspective, to evaluate the reliability of 
the current ERA of antibiotics to identify risk to vulnerable populations; 2) 
assess the value of extending the toxicity testing for bacteria through an 
assessment on the relative sensitivity of several cyanobacterial species, the 
marine bacteria Vibrio fischeri and the CRB MICs; 3) critically evaluate the 
current proposed approaches for determining the risk of AMR and its 
incorporation into risk assessment for the protection of human health; i.e. 
whether a PNECR is more or less protective than PNECSW calculated using 
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traditional ecotoxicity testing; 4) test the assumption that CRB adequately 
represent environmental bacteria and evaluate the use of pre-clinical MIC data 
for the protection of other bacterial species through a comparison of the NOECs 
for cyanobacteria with the adjusted MIC, calculated by Bengtsson-Palme and 
Larsson (2016) from CRB and; 5) use the empirical data collected in these 
analysis to help establish science-driven, risk-based targets for manufacturing 
discharge concentrations for antibiotics. 
Methods 
Data search strategy 
A comprehensive literature search was carried out to identify studies reporting 
toxicological effects of antibiotics on aquatic taxa commonly used in ERA.  
These taxa included cyanobacteria, green algae, macrophytes (the latter 
currently used in ERA for agrochemicals, but not pharmaceuticals), 
invertebrates and fish.  Data were also collected for the effects of antibiotics on 
Vibro fischeri, for the ASRIT test and Pseudomonas putida (where available).  
Data were used in our analyses only if they met the following criteria: 1) the 
endpoint calculated was a NOEC, 50% effective concentration (EC50) or 50% 
inhibition concentration (IC50), the concentration at which 50% of the population 
are effected or inhibited respectively; 2) the methodology adopted was 
according to (or with minor deviations from) currently accepted regulatory 
protocols (e.g. Organisation for Economic Co-operation and Development 
(OECD) or International Organisation for Standardisation (ISO) test guidelines); 
3) the aquatic species belong to the taxa described above; 4) exposures were 
for single species not multiple species/community exposures (with exception of 
the ASRIT which is a community based exposure) and; 5) organisms were 
exposed to a single  antibiotic (not a chemical mixture).  
The aim of this paper was to conduct a meta-analysis of available data in the 
context of current regulatory guidance that uses population-relevant endpoints 
to establish PNECs. Therefore NOECs and EC/IC50s for growth, reproduction 
or mortality only (or accepted surrogates e.g luminescence in V. fischeri or 
respiration in the ASRIT) were collected and analysed. Moreover, interpretation 
of biomarker endpoints in relation to population-based NOECs and EC/IC50s 




Searches and data collections were conducted for the following public 
databases and literature: 
 Environmental data on antibiotics from the trade organisation for the 
research-based pharmaceutical industry in Sweden (LIF), obtained from 
the Swedish fass.se database (www.fass.se accessed Jan 2016). 
 Environmental data for antibiotics from the ‘European public assessment 
report’ database (www.ema.europa.eu, accessed Jan 2016). 
 All published data in the Wikipharma database 
(http://www.wikipharma.org, accessed Jan 2016).  
 All relevant data in the study by Vestel et al. (2015) which included the 
antibiotics azithromycin, bedaquiline, ceftobiprole, doripenem, linezolid, 
meropenem, sulfamethoxazole and trimethoprim. 
 Data for sulfadiazine, neomycin and gentamycin, kindly provided by 
Merck Sharp & Dohme (MSD) through the ‘Innovative Medicines 
Initiative’ iPIE project (https://www.imi.europa.eu/content/ipie). 
 A GoogleScholar search focused on cyanobacteria with the following 
search criteria for the 111 antibiotics listed in the paper by (Bengtsson-
Palme and Larsson 2016): Antibiotic cyanobacteria "OECD 201" OR 
"ISO8962" OR "ISO 8962" OR "850.4500" OR "E1440-91" 
 The theoretical PNECR (PNECR(T)) and the size-adjusted MIC (MICaj) for 
antibiotics were collected from Bengtsson-Palme and Larsson (2016). 
For antibiotics where less than 40 species have been tested in the 
European Committee on Antimicrobial Susceptibility Testing database, 
Bengtsson-Palme and Larsson (2016) calculated a size-adjusted MIC. 
This is a theoretical adjustment to the MIC to include 99% of CRB. The 
number derived from that calculation was rounded down to the nearest 
concentration in the range operated in the European Committee on 
Antimicrobial Susceptibility Testing protocol. PNECR(T)s were calculated 
by applying an assessment factor of 10 to account for differences 
between inhibitory concentrations and selective concentrations of the 
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antibiotics. Experimentally derived MSCs were identified from literature 
following a GoogleScholar search with search criteria: “Minimum 
selective concentration” MSC AND “antibiotic resistance”. We highlight 
here that currently there is no internationally standardised test method for 
MSC and that extrapolation to the environment is poorly understood due 
to the complex nature of resistance enrichment, the complex nature of 
communities and a range of environmental factors that may influence the 
MSC (Khan et al. 2017; Quinlan et al. 2011). 
 Antifungal and antiviral drugs obtained through our search criteria were 
excluded from this assessment. 
All data derived from these searches are provided in the supplemental material, 
Table S1 and a flowchart to illustrate the data collection and statistical 
processes for these analyses is provided in figure S1. 
Assessment of data reliability 
Assessments on data reliability were undertaken using the ‘Criteria for reporting 
and evaluating ecotoxicity data’ (CRED) system that is specifically designed for 
the evaluation of ecotoxicity data for regulatory use (Moermond et al. 2016).  In 
this system reliability is defined as “the inherent quality of a test report or 
publication relating to (preferably) standardized methodology and the way the 
experimental procedure and results are described to give evidence of the clarity 
and plausibility of the findings”.  The CRED system categorises the reliability of 
studies into one of four scores: R1 (reliable without constraints), R2 (reliable 
with constraints), R3 (unreliable) or R4 (not assignable).  Studies identified as 
R3 are considered unsuitable for use in regulatory decision-making; whereas 
caution needs to be applied on a study-by-study basis for studies categorised 
as R2 or R4.  The CRED evaluation method also provides guidance on the 
evaluation of the relevance of data (Moermond et al. 2016). This, however, was 
not applied as the data were considered relevant for this meta-analysis having 
fulfilled the selection criteria outlined in section 2.1.  The CRED reliability score 





Relative taxa sensitivity data 
The lowest ‘reliable’ NOEC and EC50 for each taxa were identified for each 
antibiotic. Data from studies that had CRED reliability scores of R1 and R2 were 
prioritised, without bias between R1 and R2, over those in the categories of R3 
or R4.  R4 data were selected over R3 data as the majority of R4 studies were 
assigned R4 due to unpublished/missing information in an otherwise 
(apparently) reliable study compared with R3, which were assigned unreliable 
for defined reason.  The lowest ‘reliable’ NOEC and EC50 were applied in the 
analysis of relative taxa sensitivity and are presented in the Table S2.  This 
conservative approach was deemed more appropriate rather than taking an 
average of all available data that has imbalanced taxa representation and 
varying data reliability.   
An analysis of the relative sensitivity of cyanobacterial species adopted the 
same CRED criteria as described above to establish the lowest ‘reliable’ EC50.  
EC50s were used rather than NOECs as there was a larger dataset for 
cyanobacterial EC50s.  These data are presented in Table S3. 
Censored data 
For some antibiotics the data was either left or right censored, meaning that the 
value was not a precise number and was given as greater than (>) or less than 
(<) the value reported (i.e. no effect at the highest test concentration or an 
observed effect at the lowest tested concentration, respectively). Censored data 
values were used when no other data were available (< than numbers would 
represent conservative values and > numbers were included only when they 
represented the lowest ‘reliable’ data value). Where data were censored, this is 
indicated in Table S1. 
Establishing relative taxa sensitivity to antibiotics 
A sensitivity ratio (SR) was calculated between the different taxa and 
cyanobacteria for each antibiotic, where data were available.  The SR was 
calculated using the lowest NOEC (or NOEC and MICaj in the case of CRB) or 
EC50 using the following equation:  
Log10SR = logEcyanobacteria - logEtaxa 
where E is the endpoint (NOEC, EC50 or MICaj).   
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A SR >0 indicates that the cyanobacteria are more sensitive than the other taxa 
and less sensitive when SR <0.  Each unit of SR is equivalent to an order of 
magnitude difference in sensitivity. 
The difference between a SR calculated from NOECs compared with those 
calculated from EC50s was examined to identify how the endpoint used might 
impact the sensitivity ratio. Briefly, a generalised linear model (GLM) (Gaussian 
error family with identity link function) was constructed using the ‘lmer’ package 
with the restricted maximum likelihood method (Bates et al. 2015) in R (version 
3.3.0; R Project for Statistical Computing, Vienna, Austria). The model residuals 
were normally distributed and significant differences identified using the 
“lmerTest” package in R (Kuznetsova et al. 2013).  SRs were used only where a 
NOEC and EC50 were from the same species and publication in order to 
exclude effects of different methodologies.  The SRs calculated from EC50s 
were significantly higher by 0.5 (p = 0.05) than those calculated from NOECs 
i.e. cyanobacteria were less sensitive as measured by EC50s.  As such, SRs 
calculated from EC50s were only included in subsequent analyses comparing 
taxa sensitivities where NOEC SRs were not available.  We acknowledge that 
this will have a small effect on the output of the models. However, because of 
the sparse dataset and the relatively small difference in SR between EC50s and 
NOECs compared with the differences between taxa, the inclusion of the EC50 
SRs where NOEC SRs are not available increases the number of SRs for 
comparison and robustness of the models.   
We established a GLM in R (version 3.3.0; R Project for Statistical Computing, 
Vienna, Austria) to determine the effects of exposure duration on the EC50 for 
V. fischeri, as EC50 are often reported for 5, 15 and 30 minutes and for 24 
hours.  Censored data were removed and the remaining EC50s were log10 
transformed before use in the GLM (Gaussian error family with inverse link 
function) that was constructed as described for comparing NOEC and EC50 SRs 
above. Significant differences were identified by applying a TukeyHSD post hoc 
test. Twenty four hour EC50s were significantly lower (p = <0.001) than those 
following shorter exposure periods and data for this time point only were 
therefore used in subsequent analyses on relative taxa sensitivities. 
Differences in SR across all taxa for all antibiotics were analysed using a GLM.  
The aim of the analysis was to compare the sensitivity of all taxa to 
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cyanobacteria.  Cyanobacteria were chosen as the comparator because they 
are assumed to be the most mode-of-action relevant taxa (therefore, most 
sensitive species) in current ERA, and thus expected to drive the PNECSW.  
Briefly, to assess for statistical differences in SR the GLM was constructed 
forcing the intercept through 0 (the SR value of cyanobacteria). Therefore, the 
statistical differences identified by “lmerTest” (Bates et al. 2015) represent the 
statistical difference from 0 and thus the statistical difference between the taxa 
and cyanobacteria.  This allowed for the exclusion of cyanobacterial SRs in the 
GLM as the sensitivity of cyanobacteria were already accounted for in the 
calculation of the SRs. TukeyHSD post hoc tests were applied to identify any 
further differences between the taxa groups.  Details on model construction and 
validation are provided in the Supplemental Material. Adopting the same 
process and validation steps, further GLMs were established for analyses of 
antibiotics with different mechanisms of actions and, where sufficient data were 
available, for antibiotic classes (a more detailed methodology for this is 
presented in Supplementary Material). 
Antibiotics were classified into three groups based on their broad mode of 
action, specifically, cell envelope inhibitors (Anatomical Therapeutic Chemical 
(ATC) classification system codes J01C and J01D), Nucleic acid synthesis 
inhibitors (ATC codes J01E and J01M) and protein synthesis inhibitors (ATC 
codes J01A, J01B, J01F, J01G, J01XC, J01XX08, J01XX11 and QJ01XQ).   
It is important to note that in addition to comparing different endpoints and 
methodologies, representation of antibiotics - in both potency and number of 
antibiotics with data - varied between and within taxa and antibiotic classes. We 
acknowledge this may introduce some uncertainty and potential bias in our 
analysis and have thus avoided the use of more complex model designs that 
might otherwise have introduced random factors and interactions. However, the 
biases mentioned above are unlikely to have an impact on the overall 
conclusions drawn from these analyses. 
Calculation of PNECs 
Where a full set of ecotoxicity data for an European Medicines Agency Phase 2 
ERA was available (cyanobacteria, invertebrate and fish tests) a PNECSW was 
calculated by taking the lowest NOEC of the three studies and applying an 
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assessment factor of 10, as described in the regulatory guidance (EMA 2006).  
A theoretical PNECR (PNECR(T)) was taken directly from Bengtsson-Palme and 
Larsson (2016).  An experimental PNECR (PNECR(Exp)) was calculated from the 
lowest experimental selective concentration and applying an assessment factor 
of 10.  
There was not enough data to conduct species sensitivity distribution analysis 
and calculate 95% percentile protective limits, as this requires a minimum of 10 
species and preferably more than 15 (ECHA 2008). 
5th percentile determination 
The calculated 5th percentiles for the NOEC and MIC data subsets were not 
normally distributed or fitting to other known distributions (e.g. gamma and 
weibull) before or following transformations (log, log10 or boxcox). The 5th 
percentile therefore was established using the non-parametric Harrell-Davis 
quantile estimator method.  Analysis was conducted in R (version 3.3.0; R 
Project for Statistical Computing, Vienna, Austria) using the hdquantile function 
in the ‘Hmisc’ package (Harrell Jr 2016).   
Results 
Ecotoxicity data were collected for 79 antibiotics (Table S1) representing 48% of 
the 164 approved antibiotics identified in www.drugbank.ca and (Santos et al. 
2017). Information on the ecotoxicity in cyanobacteria was available for 41 of 
these 79 antibiotics, but with NOECs for only 27 (16%).  Antibiotics with NOECs 
for cyanobacteria were well distributed across all ATC sub-classes under J01, 
with exception of J01XX (‘other antibacterials’; Figure S2).   
 A complete Phase 2, ERA dataset that included the full range of taxa for 
calculating a PNECSW (EMA 2006) was available for only seven of these 
antibiotics. This may reflect the lack of pharmaceutical ERA datasets placed in 
the public domain and/or that few antibiotics have been approved since the 
existing European Medicines Agency guideline came into force in 2006 
requiring full chronic toxicity testing on cyanobacteria/microalgae, invertebrates 




Relative species sensitivities 
 
Figure 1. Boxplots of Log10 sensitivity ratio (SR) between cyanobacteria and other species/phyla 
for A) all antibiotics (n=37), B) cell envelope inhibitors (n=8), C) Nucleic acid synthesis inhibitors 
(n=12) and D) protein synthesis inhibitors (n=16). Log10SR calculated based on 
log10cyanobacteria NOEC or EC50 – log10taxa NOEC or EC50.  Where SR = 0 the sensitivity of 
the taxa is equal to cyanobacteria, represented by horizontal line, where SR >0 taxa had a 
lower sensitivity and <0 indicates higher comparative taxa sensitivity. Significant differences of 
SR from cyanobacteria in the generalised linear mixed models are indicated by: * p<0.05; ** 
p<0.01; *** p<0.001.  Statistical tests were not performed on macrophytes in cell envelope 







Overall, cyanobacteria were the most sensitive taxa of those currently 
recommended in the ERA of human pharmaceuticals (EMA 2006; US Food and 
Drug Administration 1998) (p = <0.001, Figure 1A) and they were equally 
sensitive as other bacteria (CRB and V. fischeri) and more sensitive than 
macrophytes (that are not currently required in ERA of pharmaceuticals; 
p = <0.001).   
 
 
Figure 2. Chronic exposure effects of antibiotics on A) environmental bacteria and clinically 
relevant bacteria (no observed effect concentrations (NOEC) and adjusted minimum inhibitory 
concentrations respectively) and B) environmental bacteria EC50s.   
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The sensitivity of cyanobacteria and CRB were not significantly different for any 
of the three broad antibiotic mechanisms of actions (Figures 1B-D); NOECs in 
cyanobacteria were lower than CRB MICaj for half (12 out of 24 antibiotics; 
Figure 2A). If we were to adopt the lowest MIC, instead of the modelled MICaj, in 
this meta-analysis there would be more cases (18, rather than 12, out of 24) 
where the cyanobacteria were the most sensitive.  Although there was no clear 
relationship between the CRB MICaj and cyanobacterial NOECs the difference 
in sensitivity was up to two orders of magnitude for specific individual antibiotics 
(Figure 2A and 6C).  
There were no significant differences in sensitivity to DNA or protein synthesis 
inhibiting antibiotics between V. fischeri and cyanobacteria (Figure 1; there were 
no data for cell-envelope inhibiting antibiotics). Of the seven antibiotics where 
SRs could be determined five were for quinolones giving an antibiotic class bias 
for the V. fischeri data. EC50s for V. fischeri were lower than those for the 
cyanobacteria on six occasions (Figure 2B), three of these were almost an 
order of magnitude lower (flumequine, lomefloxacin and oxolinic acid).  V. 
fischeri was also the most sensitive organism to olfoxacin, with a NOEC one 
order of magnitude lower than the CRB MICaj (Figure 2A) and an EC50 half that 
for the cyanobacteria (Figure S3).  
Pseudomonas putida, a model (soil) Gram-negative bacteria used in standard 
growth inhibition test guideline (ISO 1995) was more sensitive than 
cyanobacteria for one out of five antibiotics (meropenem; Figure 2A and B). 
The ASRIT (OECD 2010) was consistently between two and four orders of 
magnitude less sensitive than cyanobacteria, with the exception of trimethoprim 





Figure 3. Chronic exposure effects (EC50s) of antibiotics on different cyanobacteria species.  
There were large differences in sensitivity between cyanobacterial genera and 
species, with between two and three orders of magnitude difference in EC50s for 
10 out of the 16 antibiotics, and approximately five orders of magnitude 
difference in response to the β-lactams amoxicillin and ampicillin (Figure 3).  
Overall, Microcystis aeruginosa was the most sensitive species (in half of the 16 
antibiotics). Anabaena cylindrical, Synechococcus leopoliensis and Microcystis 
wesenbergii were each the most sensitive cyanobacterium for 2 of 16 antibiotics 
for which there were data on multiple species.  A. flos-aquae, one of the 
cyanobacterial species recommended for testing in the OECD 201 test 
guideline, was the most sensitive species for only 1 of the 13 antibiotics in 
which it was tested. When considering antibiotic sensitivity based on their 
mechanisms of action, Microcystis species appeared to be more sensitive to 
nucleic acid synthesis inhibitors (7 out of 9 antibiotics). Microcystis and 
Synechococcus species were the most sensitive to cell envelope inhibiting 
antibiotics. Anabaena genera were the most sensitive to the protein synthesis 
inhibitors (3 out of 6) and in two cases by more than an order of magnitude.   
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Overall, macrophytes were generally less sensitive to antibiotics compared with 
cyanobacteria with a wide range of SRs (Figure 1, p = <0.001).  However, they 
showed equal sensitivity with cyanobacteria to nucleic acid synthesis inhibitors 
(average SR = 0.42; p = 0.3). The NOECs for trimethoprim and 
sulfadimethoxine were lower for macrophytes than for cyanobacteria (Figure 
4A).  A comparison of macrophyte and environmental bacteria EC50s is 
provided in Figure S3. 
Microalgae were also generally less sensitive to antibiotics than cyanobacteria 
(Figure 1, p = <0.001). However, for sulfadiazine and sulfadimethoxine the 
NOECs in microalgae (0.135 and 0.529 mg/L, respectively) were over an order 
of magnitude lower than for the lowest in the cyanobacteria (Figure 4A).  We 
interpret these data with caution, however, as the results for the cyanobacteria 
were derived from a study based on nominal (i.e. not measured) test exposure 
concentrations (Ando et al. 2007). A comparison of the EC50s for microalgae 





Figure 4. Chronic exposure effects of antibiotics on cyanobacteria and clinically relevant 
bacteria (no observed effect concentrations (NOEC) and adjusted minimum inhibitory 
concentrations respectively) compared with A) NOECs for microalgae and macrophytes and B) 





Metazoans (fish and invertebrates) were significantly less sensitive across all 
antibiotics compared with cyanobacteria and often by between two and four 
orders of magnitude (with exception of tedlizolid phosphate, Figure 1 and 4, 
p = < 0.001, for both fish and invertebrates).  There was substantial variation in 
SR between cyanobacteria and the metazoan taxa (as illustrated by the 
standard errors in the data; Figure 1). In the case of tedlizoid phosphate, a pro-
drug, fish appeared more sensitive than cyanobacteria (NOECs of 0.032 versus 
0.063 mg/L, respectively; Figure 4B). A MICaj for tedozolid (the active 
pharmaceutical ingredient) was not available from the (Bengtsson-Palme and 
Larsson 2016))  study, but a MIC of 0.016 mg/L (based on 12 species), 
corresponding to a MICaj <0.008 mg/L was recently (January 2017) reported the 
European Committee on Antimicrobial Susceptibility Testing database. This 
suggests that CRB are substantially more sensitive to tedozolid compared with 
fish and cyanobacteria. The fact that tedizolid phosphate (pro-drug) requires 
activation by phosphatases in the blood to convert it into the active ingredient 
(tedizolid), and the ecotoxicity assessments in cyanobacteria appear to be 
based on the pro-drug only, may explain why cyanobacteria were relatively 
insensitive.  In no cases were the chronic NOECs for invertebrates lower than 
the NOECs for cyanobacteria (Figure 4).  The daphnid EC50 for the antifolate 
trimethoprim, however, was lower than the EC50 for cyanobacteria (8.21 and 
91.68 mg/L, respectively. Figure S3). This was not the case for the NOECs for 
the same compound, indicating differences in the shape of the dose-response 







Figure 5. Comparisons of predicted no effect concentrations (PNEC) for antimicrobial resistance 
and ecotoxicity for aquatic taxa in surface water.  A) Comparison of theoretically derived PNEC 
for resistance development (PNECR(T)) based on clinically relevant bacteria (Bengtsson-Palme 
and Larsson 2016) and PNEC for ecotoxicity in surface water (PNECSW). (B) Comparison of 
PNECR(T),PNECR based on experimentally derived minimum selective concentrations 
(PNECR(EXP)) and  PNECSW. In A) data are presented for antibiotics only where a full data set 
including cyanobacteria, invertebrate and fish tests were available and calculated from no 
observed effect concentrations as described in (EMA 2006).  PNECSW in B) are calculated from 
cyanobacteria NOECs regardless of a complete ecotoxicity data set where a PNECR(EXP) was 
available.  PNECR(EXP) is a less than (<) value in erythromycin and trimethoprim. PNECR(EXP) 
based on strain specific MSC in ciprofloxacin, erythromycin, streptomycin and trimethoprim. 
PNECR(EXP) based on community based MSC in tetracycline.  EC50 for cyanobacteria was used 
because NOEC were not available for PNECSW in streptomycin and tetracycline therefore 
NOEC may be up to an order of magnitude lower. 
 
For the limited number of antibiotics where a definitive PNECSW could be 
calculated (n=7) an analysis of the relationship between traditional ERA PNECs 
and those for AMR was conducted.  Within this meta-analysis the theoretically 
determined PNEC for resistance development PNECR(T)) obtained from 
Bengtsson-Palme and Larsson (2016) for the different antibiotics was not 
always protective of (lower than) the PNECSW (Figure 5A).  The PNECR(T) was 
lower than PNECSW for ceftaroline, ciprofloxacin and tobramycin.  However, the 
PNECSW was approximately ten-fold lower than PNECR(T) for ceftobiprole, 




Where experimentally derived MSCs existed, the PNECR(Exp) was lower than 
PNECR(T) for three out of five antibiotics with available data (Figure 5B).  
However, PNECR(T) overestimated the risk of resistance development for 
streptomycin by an order of magnitude. PNECR(T) and PNECR(Exp) were similar 
for trimethoprim (Figure 5B; trimethoprim PNECR(Exp) was <0.2 μg/L). The 
PNECSW for erythromycin and streptomycin were lower than their PNECR(T) and 
PNECR(Exp) (Figure 5B).  The PNECR(Exp) for erythromycin however, did not have 
a  definitive value, (i.e. <0.2mg/L) and as such we assign caution to this 
comparison. 
We determined the 5th percentile for growth inhibition data for cyanobacteria 
and environmental bacteria and MICs for CRB (See table S4). The rationale for 
this was to establish an environmental protection goal for antibiotic production 
discharges that would be protective of bacterial NOECs with 95% confidence. 
The 5th percentiles ranged from 225 to 2028 ng/L, depending on the bacteria 
and endpoints used.  The lowest NOECs for environmentally relevant bacteria 
(cyanobacteria, P. putida and V. fischeri) gave the lowest value (225 ± 71 ng/L, 




Establishing 5th percentiles 
 
Figure 6.  A) Cumulative density plot of the NOECs for environmental bacteria for 27 antibiotics, 
showing the 5th percentile. B) Cumulative density plot of PNECs for AMR for 103 antibiotics, as 
calculated by Bengtsson-Palme and Larsson (2016). The vertical solid line represents the 5th 
percentile of the bacteria NOECs, dashed lines represent the standard error and dotted line 
indicates the proposed discharge limit.  Note each point can represent up to 17 antibiotics. C) 





In our evaluation of the current regulatory ERA guidance we show that of the 
taxa tested, as expected based on the mechanisms of action, prokaryotes were 
most sensitive to antibiotics. However, we also show that reliance on one 
species of cyanobacteria to set protection levels (e.g. PNECs), as operates 
currently, is unlikely to be protective of environmental and human health 
(through AMR). Individually, neither traditional aquatic PNECs nor the AMR 
based PNECs protect fully against the effects of antibiotics. We thus 
recommend the inclusion of both clinically important bacteria and a wider range 
of species of environmentally relevant bacteria to improve the prospective 
regulatory framework for human and ERA. This approach will help also in 
defining more appropriate safe discharge concentrations for antibiotic 
production, and help to exclude unnecessary ERA testing on metazoan species.   
Species relative sensitivity: the need for more bacteria  
During their development, the efficacy and safety of new antibiotics are 
assessed in preclinical and clinical studies before market approval. It is 
therefore unlikely that toxic effects will occur in an aquatic vertebrate (such as 
fish) at water concentrations lower than those affecting prokaryotic species 
(target or non-target).  As expected, in our analyses, those species 
evolutionarily more distant to pathogenic bacteria were generally less sensitive 
to antibiotics compared with clinically relevant and environmental bacteria. Our 
results also indicate that neither cyanobacteria, CRB nor other environmental 
bacteria (V. fischeri and P. putida) provide a single organism/test that is fully 
protective of the diversity of bacteria in the environment. Thus, a PNECSW 
determined according to the current ERA guidance (EMA 2006; US Food and 
Drug Administration 1998) will not always be protective of the environment.  
Sensitivity to any one antibiotic differed by up to five orders of magnitude across 
different species of cyanobacteria. Patterns of sensitivity for the different genera 
were observed across the different antibiotic mechanisms of actions, but no one 
species was consistently the most sensitive. Cyanobacteria are one of the most 
diverse phyla on the planet (Shih et al. 2013; Whitton 2012) and this large range 
in sensitivity to antibiotics might therefore be expected. In ERA A. flos-aquae is 
the most regularly used of the two OECD test guideline recommended 
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cyanobacterial species (the other being S. leopoliensis; (OECD 2011)) but 
A. flos-aquae was the most sensitive cyanobacteria for only one of the 13 
antibiotics for which data were available for multiple genera and species. In the 
cases of ampicillin, erythromycin, norfloxacin, oxytetracycline, sulfdiazine and 
trimethoprim (35% of antibiotics with multiple cyanobacterial EC50s) the 
difference in sensitivity between A. flos-aquae and the most sensitive taxon was 
greater than the assessment factor (x10) used to generate a PNEC for the risk 
assessment. For ampicillin, reliance on A. flos-aquae could underestimate the 
PNECSW by more than three orders of magnitude. This questions the current 
over reliance on a single cyanobacteria test species within ERA frameworks 
and we propose at least three cyanobacteria genera should be included within 
these risk assessment frameworks.  The case above for ampicillin highlights a 
further important issue relating to the relevance of high sensitivity for some 
cyanobacteria. Ampicillin is not persistent in the environment and undergoes 
partial degradation by bacteria; indeed, primary degradation is the resistance 
mechanism.  If degradation were factored in, from an ecotoxicological point of 
view, exposure and environmental effects would be low, although community 
structure changes could impact resilience.  Furthermore, since the resistance 
mechanism partially degrades the antibiotic resulting in a lower concentration of 
ampicillin in the environment care needs to be taken not to assume a low 
measured concentration of ampicillin necessarily equates with an absence of 
selection for AMR development and human health risk. 
The cyanobacteria adopted for toxicity testing has been based largely on 
experimental convenience (e.g. the ability to grow them and measure cell 
density in the laboratory) with little knowledge on how representative they are of 
other cyanobacteria.  No consideration has been given to how they grow and 
function in non-pelagic habitats, e.g. biofilms. From our analyses, M. aeruginosa 
would potentially provide a relatively high sensitivity to most antibiotics. This 
species however, has a slower growth rate and the current test with this species 
may therefore have to be extended to make the test comparable in terms of the 
growth and replication dynamics with that for A. flos-aquae and S. leopoliensis. 
We highlight that the requirement for optimised conditions for culturing a 
species and variation in life history components across species (e.g. growth 
rates and lag time) create further challenges for interspecies substance effects 
analyses. For example, exposure time can have a direct impact on the 
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perceived sensitivity.  In this meta-analysis we have used data that are based 
on regulatory approved guidelines in which exposure time and exposure 
conditions have been optimized for the different organisms to ensure that 
growth in the controls do not reach the plateau phase, thus maximizing the 
ability to detect for any effects against treatment groups. Longer exposure 
periods could potentially result in lower effective exposure concentrations, as 
we demonstrate for the EC50 in V. fischeri (for a 24 hour exposure compared 
with shorter test periods) and as has been shown for the ASRIT (Kümmerer et 
al. 2004). Extending exposure periods in growth tests however needs to ensure 
that this does not compromise the ability to distinguish for effects i.e. additional 
time does not result in the controls being limited in their growth dynamics by the 
available resources and thus affect the comparison with the treated groups. It 
needs to be recognized, however, that differences between test conditions 
optimized for different species (e.g. chemical constituents of the culture media, 
pH, temperature, light intensity and test length, to name just a few) could all 
impact the fate and behavior of the antibiotic and its bioavailability, distribution, 
metabolism and excretion in test organisms, which in turn may influence the 
perceived relative sensitivity. Distinction needs to be made on whether the 
exposure adopted is optimized for assessment of effects relative to controls (as 
is the case in the OECD 201 test guideline for green algae and cyanobacteria) 
or focused more on environmental relevance (for example in the ASRIT 
analyzing for impacts within hydraulic residence time in sewerage treatment 
works). Species sensitivity analyses and /or functional impacts are arguably 
better addressed under context specific conditions that consider the microbial 
community structure(s) and physicochemical conditions that occur in those 
natural systems.  
Available study information was not sufficiently comprehensive to allow for 
consideration of these variables within our meta-analysis and we were thus 
restricted to endpoint data (EC50 and NOEC) that we derived from reliable 
studies.  Further investigation is warranted into the physiological basis for the 
differences in sensitivity to antibiotics to help identify species, or groups of 
species, that best represent the phylum for their protection and the critical 
ecosystem services (e.g. primary productivity and food source) they provide. 
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V. fischeri and Pseudomonads were more sensitive than cyanobacteria to some 
antibiotics and may potentially provide valuable additional species for inclusion 
within the ERA. Furthermore, they already have internationally recognised test 
guidelines (ISO 1995; 2007).  V. fischeri, is a marine bacterium that would not 
normally be considered in ERA for freshwaters, but  is sometimes used in whole 
effluent assessments (ECETOC 2004). It is, nevertheless, a prokaryotic species 
and antibiotics and antibiotic resistant bacteria have been detected in estuaries 
and marine environments emanating from sewerage treatment plant discharges 
and manufacturing effluents (Schaefer et al. 2009; Webster et al. 2004; Zheng 
et al. 2011; Zou et al. 2011). The compiled data show that V. fischeri was more 
sensitive than cyanobacteria for six antibiotics, and for half of these by nearly an 
order of magnitude (flumequine, lomefloxacin and oxolinic acid).  The inclusion 
of this test could therefore be of value to ERA if performed with an exposure 
time of 24 hours (results based on exposure lengths of less than 24 hours 
showed significantly less sensitivity). Pseudomonads have been shown to be 
less sensitive than the other soil bacteria to tetracycline, chlortetracycline, and 
oxytetracycline and in some instances by over an order of magnitude (Halling-
Sørensen et al. 2002). The low sensitivity observed in Pseudomonas species 
has been attributed to their apparent high natural resistance to some antibiotics 
(Halling-Sørensen et al. 2002; Kittinger et al. 2016).  Thus, our findings suggest 
that additional testing with P. putida could be of value to the ERA, but it may still 
not be protective of other soil bacteria. Any consideration to incorporate the test 
with P. putida in antibiotic ERA would need to first characterise the strain in 
terms of its chromosomal and plasmid resistance to help prevent biasing any 
function or growth based assessment (Brandt et al. 2015).  
The ASRIT (OECD 2010) was several orders of magnitude less sensitive to 
antibiotics than cyanobacteria and other bacterial species, confirming reports 
that this test is largely insensitive to antibiotics (Kümmerer et al. 2004).  As 
such, the ASRIT would not influence the outcome of the ERA.  This lack of 
sensitivity may be due to several factors, including the short exposure time (3 
hour) of the test (Kümmerer et al. 2004), the lack of antibiotic bioavailability due 
to adsorption to the sludge solids (Golet et al. 2002) or that the microbial 
community in the activated sludge has an innate resistance having been 
exposed previously to the antibiotic (Davies 2012). It was not possible to assess 
the effect of extending the ASRIT test duration due to a lack of available data 
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and because most ASRIT results are reported as censored data of >100 mg/L. 
Furthermore, the endpoint of respiration, may not be suitable for all 
mechanisms of actions (Brandt et al. 2015) and it does not equate with changes 
in bacterial diversity or community structure.  We thus support the need to 
replace and/or complement the ASRIT with other assays (Brandt et al. 2015), 
which are relevant for all pharmaceuticals. 
In order to build greater confidence in the ERA for antibiotics we sought to gain 
a better understanding on the differences observed in sensitivity between the 
species and to establish both how often and for which antibiotic classes these 
differences exceed the assessment factor of 10.  Overall, across all the 
antibiotics assessed, cyanobacteria and CRB were equally sensitive to 
antibiotics (figure 1). Thus, neither CRB nor cyanobacteria were consistently 
more sensitive than the other. In this meta-analysis, the inclusion of CRB in 
ERA would drive the PNEC in 40% of cases further supporting a more holistic 
‘one health’ approach that uses clinical and environmental data.  There were, 
however, substantial differences in sensitivity to antifolates observed between 
the cyanobacterial species and CRB. The folate synthesis pathway that 
antifolates inhibit is present in cyanobacteria and so the reason for the apparent 
lack of sensitivity in some cyanobacteria is unknown.  However, de Crécy-
Lagard et al. (2007) reported that cyanobacteria possess a protein that may act 
as a folate transporter allowing the bypassing of some of the folate synthesis 
pathway.  Our analysis suggests therefore that cyanobacteria may not always 
be a suitable representative for bacteria for full protection against antifolate 
antibiotics.  
Macrophytes appear especially sensitive to antifolates and quinolones. The 
folate synthesis pathway in bacteria, algae and plants is fundamentally the 
same (Basset et al. 2005) and they are, therefore, all potentially susceptible to 
antifolates.  Indeed, sulfamethoxazole has been reported to act as a competitive 
agonist to p-aminobenzoic acid in both Lemna gibba (Brain et al. 2008b) and 
Arabidopsis thaliana (Zhang et al. 2012).  Macrophytes were also more 
sensitive than cyanobacteria to five quinolones. Quinolones cause toxicity by 
forming complexes with DNA gyrase or topoisomerase IV resulting in the 
inhibition of DNA replication and transcription (Aldred et al. 2014).  Chloroplasts 
are descended from cyanobacteria (Falcon et al. 2010) and some plants and 
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red algae have been shown to contain DNA gyrases in their plastids (including 
chloroplasts) and mitochondria (Moriyama and Sato 2014; Wall et al. 2004).  
Quinolone antibiotics are reported to have anti-chloroplastic activity (Brain et al. 
2008a; Brain et al. 2004; Ebert et al. 2011) which can affect photosynthesis in 
plants (Brain et al. 2008a).  Indeed, organellar DNA gyrase has been shown to 
be the primary target of ciprofloxacin in Arabidopsis thaliana (Evans-Roberts et 
al. 2016). Thus, our findings indicate that for some antibiotics in these classes, 
macrophytes could potentially drive the protection goal.  Consequently, these 
species should be considered for inclusion within risk assessment frameworks 
for antibiotics. 
The metazoan taxa were never found to be the most sensitive compared with all 
bacterial taxa. This questions the necessity of resource intensive metazoan 
testing of antibiotics, as required by European Medicines Agency and Food and 
Drugs Administration guidance (EMA 2006). Inclusion of appropriate (and 
additional) bacterial testing in the ERA for antibiotics would potentially allow for 
the exclusion of some unnecessary testing on metazoan species, 
acknowledging the principles of the 3R’s to replace, reduce and refine studies 
that use ‘protected’ animals, such as fish (Hutchinson et al. 2016; Scholz et al. 
2013).  
We performed this meta-analysis based on data that was deemed most reliable 
according to the CRED system (Moermond et al. 2016).  The conclusions 
however, are still drawn upon data that were conducted in different labs, with 
different procedures and of varying quantity (in terms of test performance and 
meta-data) and quality of reporting.  We strongly emphasise the need to collect 
and report suitable control data, chemical analysis and meta-data in order to 
assist in reliable comparisons of studies.  
An analysis of appropriate additional bacterial species for inclusion in the ERA 
needs to consider potential differences in sensitivity due to pharmacokinetic 
considerations including bioavailability, charge, uptake, elimination, metabolism, 
degradation rates or binding affinities, or a combination of them. Differences in 
bacterial morphologies and innate resistance may also account for some of the 
differences in sensitivity between species.  Some bacteria have several different 
growth forms depending on the environmental conditions. As an example, 
increased temperature and light intensity causes aggregation of Synechococcus 
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elongates cells (Koblížek et al. 2000) and this aggregation may have an impact 
on the sensitivity of the cells to antibiotic exposure.  Several studies have 
demonstrated that cells in biofilms are less sensitive/more protected from 
chemical exposure (Balcázar et al. 2015).  A better understanding of how 
physiological and morphological differences in cells and community structure 
affect the toxicity of chemicals to bacteria is required to fully understand the risk 
posed by antibiotics in the environment. 
Bacteria are fundamental to many vital ecosystem services, but little is 
understood regarding species loss and functional redundancy and thus, the 
resilience of ecosystem function.  Some investigators, however, have begun to 
address this.  For example, Lundström et al. (2016) found no change in the 
overall taxonomic diversity when biofilms were exposed to tetracycline, 
however, the community composition  was  altered and the functional diversity, 
as measured by utilization of carbon sources, decreased with increasing 
tetracycline concentrations.  Ciprofloxacin exposure altered the bacterial 
community structure in marine sediments at 0.2 mg/L), resulting in a decrease 
in the community ability to degrade pyrene (Näslund et al. 2008). It was also 
found to increase overall biomass in salt marsh microbial communities, 
favouring gram negative and sulfate-reducing bacteria (Cordova-Kreylos and 
Scow 2007). Several studies have shown that bacterial diversity has a positive 
relationship with ecosystem function (Bell et al. 2005; Langenheder et al. 2010). 
(Delgado-Baquerizo et al. 2016) demonstrated that loss of diversity in aquatic 
bacterial communities caused a decrease in both broad (microbial respiration) 
and specialized (toxin degradation; of mycrocystin-LR and triclosan 
degradation) endpoints and the communities showed little or no functional 
redundancy. These studies indicate that a small drop in bacterial diversity may 
potentially impact negatively on the ecosystem services they provide.  
From this, we conclude that the ERA framework for antibiotics needs to be 
based upon a suitable range of bacteria. This should include CRB and capture 
a wider range of ecologically important functional groups.  Previous 
investigators have identified standard studies that may fulfill some of these data 
gaps e.g. nitrifying bacteria, methanogens and sulfate-reducing bacteria (Brandt 
et al. 2015) although more research is required to identify if these tests will be 
protective of all functional bacterial groups or if further standard tests will need 
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to be developed.  The effect of antibiotics on these functional groups is currently 
outside risk assessment frameworks and environmental and non-therapeutic 
human impacts are considered in isolation. Furthermore, a measure of the 
change in community structure would add value, especially looking at diversity 
in terms of clinical and environmental relevance, and understanding to changes 
in functional endpoints in bacterial multispecies/community tests to determine 
whether ecological resilience is being compromised. 
PNECs for AMR verses traditional ecotoxicological effects  
AMR is a serious risk to human health globally and currently sits outside the 
ERA regulations. Both theoretical methodologies and empirical data available 
for assessing AMR selection and transfer in the environment are limited. 
Consequentially, evidence is lacking to assess the best approach for the risk of 
AMR development, how resistance in the environment may lead to enrichment 
of resistance in human pathogens and how the risk posed by antibiotics by 
AMR development compares to their effects upon ecosystem function and 
services. Previous investigators have explored resistance selection using a 
variety of approaches, for example, comparing predicted environmental 
concentrations with MICs (Kümmerer and Henninger 2003), using MICs to 
calculate potentially affected fractions of communities (Singer et al. 2011) and 
using growth and competition experiments to demonstrate resistance selection 
(Negri et al. 2000) and calculate MSCs (Gullberg et al. 2011).  The theoretical 
approach proposed by (Bengtsson-Palme and Larsson 2016) is a recent 
contribution and provides a good basis for this discussion, using MIC data to 
assess reduction in antibiotic efficacy due to erosion by resistance.  However, it 
is important to note that this approach assumes growth can be used to predict 
resistance and is not verified through direct testing of resistance markers and as 
such any conclusions drawn from this analysis must therefore be considered 
with this in mind.   
Our findings suggest that the PNECRT) defined by Bengtsson-Palme and 
Larsson (2016) is not always lower than the PNECSW; for 7 antibiotics PNECSW 
was lower in four cases (figure 5). This may be due to either the PNECR(T) 
underestimating the risk or cyanobacteria being more sensitive to some 
antibiotics compared with the CRB. Experimentally determined MSCs were 
derived largely from laboratory strain competition experiments (four of the five 
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cases; Figure 5B), where strains that differ in only the presence/absence of the 
resistance genes under investigation are compared (Gullberg et al. 2014; 
Gullberg et al. 2011).  These strain competition experiments have limitations in 
scaling up to more complex microbial communities (Bengtsson-Palme et al. 
2014).  There are very few cases where analyses have been conducted for 
more complex communities but it is hypothesised that the combined effects of 
changes in community structure (due to loss of the most sensitive species), 
protective morphological forms (e.g. bacteria maybe less susceptible in biofilms 
compared to those within the water column (Balcázar et al. 2015)), difficulty in 
defining the ‘true’ antibiotic exposure concentration, and alternative selection 
pressures (e.g. nutrient limitation, predation and other chemical/physical 
stressors) may negate the fitness benefit of the resistance (Bengtsson-Palme 
and Larsson 2016; Brosche and Backhaus 2010; Day et al. 2015; Gullberg et al. 
2014; Lundström et al. 2016; Quinlan et al. 2011). Most studies that have 
considered effects of antibiotics on complex communities have been taxon 
independent, assessing AMR gene copy number relative to 16SrRNA, rather 
than providing species specific information. Investigations into AMR following 
tetracycline exposure, however, have found that resistance was increased in 
periphyton at the lowest test concentration of 0.5 μg/L (Quinlan et al. 2011), 
horizontal gene transfer (HGT) was promoted at 10 μg/L (Jutkina et al. 2016) 
and resistant bacteria and resistance genes was increased in biofilms at 
concentrations below 1 μg/L (Lundström et al , 2016). Assuming an assessment 
factor of 10, from this data a PNECR(Exp) would be 0.05 μg/L, which is 20 times 
lower than PNECR(T) of 1 μg/L (Bengtsson-Palme and Larsson 2016).  There is 
no NOEC data for tetracycline in cyanobacteria, but in Microcystis aeruginosa a 
EC50 is reported at 90 μg/L (Halling-Sørensen, 2000) and in Anabaena sp an 
EC10 of 2.5 mg/L (González-Pleiter et al. 2013), suggesting that resistance for 
tetracycline may occur at concentrations nearly 100-fold lower than effects on 
growth inhibition in cyanobacteria.  This again emphasizes the need for a more 
holistic approach to the setting of protection goals for antibiotics and the 
development of validated assays to assess MSCs in complex and simple 
systems, as well as generating toxicity data for cyanobacteria and other 
environmental and/or clinical bacteria.  
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It should be recognized that although studies that are used to guide regulatory 
decision-making require standardized test methodologies to help ensure reliable 
and repeatable results, the link between these single species studies and those 
operating in the complex systems in the field is largely unknown and, as 
mentioned previously, the link to ecosystem services is not made. The 
application of mesocosm studies that enable community response and effects 
upon ecosystem functions to be assessed have good utility here to help provide 
insights into the development of AMR in environmentally realistic scenarios 
(Knapp et al., 2008; Knapp et al., 2010; Quinlan et al., 2011).   In addition to 
living in complex communities in the environment, it is important to note that 
organisms are also likely to be exposed to antibiotic mixtures and the 
relationship between single exposure laboratory testing and mixtures toxicity is 
unknown and requires further research (Backhaus et al. 2000; Brosche and 
Backhaus 2010; González-Pleiter et al. 2013; Liu et al. 2014).   
In the context of current regulatory guidance, MSCs derived from experimental 
data, albeit they are limited, in some cases supported the theoretically derived 
PNECR(T).  There were cases also where PNECR(T) was not necessarily 
appropriate (optimal) for risk assessment for AMR.  Nevertheless, until there is 
an internationally accepted method for the experimental determination of 
PNECR - which may require further knowledge on resistance mechanisms, 
model variability and the application to mixed communities that vary over time 
and space - the theoretical approach advocated by Bengtsson-Palme and 
Larsson (2016), based on MIC data in the European Committee on 
Antimicrobial Susceptibility Testing database, provides a valuable alternative as 
part of a broader evidence-based approach to ERA.  Moreover, it provides an 
efficient and cost effective method to address concerns and prioritise legacy 
antibiotics that have already been registered and are present in the 
environment.  It should be noted, however, that there are clear limitations to this 
approach (as identified by the paper’s authors).  These include the test 
conditions for determining the MIC in CRB, that are largely environmentally 
irrelevant, the assumptions that growth inhibition can be used to predict 
selection for resistance.  There is also an assumption that an assessment factor 
of 10 will provide a suitable safety margin to account for selection below the 
MIC and conversely that adjusting the MIC down to account for species 
numbers and then applying a further assessment factor of 10 isn’t 
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overprotective. Finally, MIC-derived protection goals will change over time, as 
MICs are determined for more species with variable sensitivity and as a 
consequence periodic updates will be required.     
Our analysis suggests that the susceptibility of species in European Committee 
on Antimicrobial Susceptibility Testing is not always protective of environmental 
bacteria, such as cyanobacteria and therefore a PNECR(T) using CRB MIC data 
as a surrogate for resistance may not be protective of the risk of AMR 
development in environmental bacteria. Furthermore, we show that a PNECR(T) 
may not be protective of ecosystem function traditionally determined using the 
growth inhibition test with cyanobacteria. From this we conclude that despite 
evidence that resistance will occur at lower concentrations than the effects on 
population density (Gullberg et al. 2011; Hughes and Andersson 2012), both a 
PNECR and a PNECSW are needed to establish safe concentrations for the 
protection of ecosystem function and against the development of resistance. 
It is noteworthy that from an environmental health perspective (rather than 
human health), AMR can provide an ecosystem service or benefit. For example, 
bacteria expressing beta-lactamase enzyme activity degrade and reduce the 
environmental burden of beta-lactam antibiotics and this in turn could contribute 
positively in sewerage treatment plants where high antibiotic concentration 
might otherwise compromise functional efficiency.  
Production discharge limits 
In addressing the impact of antibiotic pollution on ecosystem function, AMR 
development and human health, safe discharge limits for antibiotic production 
facilities need to be established (Agerstrand et al. 2015; Larsson 2014; Pruden 
et al. 2013).  However, there are few data available in the public domain to 
support the development of such limits and this is especially so for experimental 
data on AMR development. Most data that are available are based on growth 
inhibition tests and we have therefore identified the lowest NOEC values for 27 
antibiotics representing sensitive phyla (cyanobacteria, V. fischeri and P. putida) 
and using these data we estimate the 5th percentile to be 225 ± 71 ng/L. Thus, a 
conservative limit of 154 ng/L would account for uncertainty. Provided that these 
27 antibiotics are representative of all antibiotics, the cyanobacterial NOECs 
are, with 95% confidence, likely to be higher than 154 ng/L.  
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The lowest MSC reported in the literature is 100 ng/L with many others between 
10-1000 times higher (Brosche and Backhaus 2010; Gullberg et al. 2014; 
Gullberg et al. 2011; Lundström et al. 2016).  Setting a threshold limit of 
100 ng/L for antibiotic discharges would, therefore, appear to be protective of 
environmental bacterial populations (with 95% confidence) and match the 
lowest empirical evidence of AMR development. However, it would not be 
protective for 16% of the theoretical PNECR(T)s, described by Bengtsson-Palme 
and Larsson (2016) (Figure 6B) highlighting that safe discharge limits may need 
to be lower than this for some antibiotics in order to consider the potential to 
select for resistance in clinical and environmental isolates. It should be noted, 
however, that the PNECR(T) incorporates a correction factor that adjusts the MIC 
according to the number of species it is based upon and a further assessment 
factor of 10 to account for AMR.  In turn, the corrections could cause the 
PNECR(T) to be over protective (as shown for some antibiotics in Figure 5B).  
A single, protective threshold limit that could be applied as an interim measure 
in the absence of other reliable empirical clinical and or environmental data (and 
standardised methodologies for AMR), which is based on empirical data would 
be of great value.  Based on the antibiotic compounds for which we were able to 
obtain NOECs from environmentally relevant bacteria and from the available 
MSCs in the literature, we suggest a production discharge limit of 100 ng/L for 
each antibiotic, applied in the mixing zone downstream of the point source 
discharge for protection of ecosystem function and the risk of AMR 
development. The use of a single protection goal rather than a range, for 
production facilities offers pragmatic benefits to industry and suppliers.  
Compliance with a single protection value provides simplicity and ease of 
implementation compared with the 111 values advocated for the different 
antibiotics suggested by Bengtsson-Palme and Larsson (2016), of which some 
would not be protective of the environment or the MSC.  Consideration is 
required for how this limit would apply in the case of antibiotic mixtures, 
although this falls out of scope of this meta-analysis.   
This approach could also help prevent the use of conflicting values for a single 
antibiotic.  However, it is important to ensure that this value proves to be 
protective. So where other data are available (e.g. empirical or PNECR(T)) that 
suggest a lower limit is required to be protective, the 100 ng/L should be 
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adjusted accordingly to provide the required protection. Equally, a higher limit 
may be applicable where there are substantive data to support its increase.  We 
advocate this as an interim measure only until more data are obtained to 
support the risk analysis for antibiotics. Furthermore, as methodologies for the 
assessment of AMR are developed these values should also be incorporated 
and protection goals updated.   
Concluding remarks and considerations for ERA 
Our analysis shows that frameworks for ERA and human health protection 
(through protection for the risk of AMR) for antibiotics need to consider the 
impact of antibiotics on relevant vulnerable species and the essential 
ecosystem services they provide. The current framework for ERA based on just 
one cyanobacterial species is, in many cases, inadequate and it does not 
address risk to critical ecosystem services. There is also an urgent need to 
better establish the effects of antibiotics on bacterial diversity, community 
structure, ecosystem function and resilience in order to better understand the 
effects of antibiotics in the environment. 
We emphasise that the presence of antibiotics in the environment does not 
necessarily lead to the development of AMR in bacterial communities and 
studies are required that better establish the toxic effects of antibiotics, AMR 
and the relationship between them in environmentally relevant contexts.  In the 
environment other selection pressures (e.g. nutrient availability and predation) 
may be more significant than that posed by exposure to low levels of antibiotics. 
As a consequence AMR may not be observed at the same concentrations as in 
the laboratory studies.  However, it is also the case that the fitness cost of 
carrying some resistance genes may be very low or even neutral and therefore 
the genes coding for resistance could remain in the bacterial communities after 
only a short exposure. Understanding these complexities in AMR development 
in the environment is crucial for establishing interrelationships with human 
pathogens and in turn managing and mitigating the risk of antibiotics in the 
environment for the protection of human health. 
From our analyses on relative species sensitivity we highlight the following as 
key considerations for the use, and development of human and ERA 
frameworks for antibiotics. 
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1. The need for inclusion of a larger selection of bacterial species for testing 
to account for the variability in sensitivity between species and for greater 
confidence in the protection of bacterial communities and the ecosystem 
services they provide.   
a. Brandt et al. (2015) have identified a number of suitable 
established standard tests for other bacteria (including P. putida) 
and for ecosystem services (e.g. nitrification and carbon 
transformation) and these should be considered as additional 
tests in the ERA of antibiotics.   
b. We show that pre-clinical MIC data of CRB could be used to 
increase the diversity of bacterial species represented in ERA at 
little cost. The use of pre-clinical and clinical data is often 
advocated to identify environmental risk (Boxall et al. 2012) but 
the realisation of this is limited with ‘bridging’ studies and methods 
still being developed. 
c. We reaffirm that the only required community test, the ASRIT, is 
not sensitive to antibiotics and thus its suitability for determining 
the effect of antibiotics to environmental bacteria and sewerage 
treatment plant microorganism communities is questionable. 
Consideration for its replacement by tests to assess the effects on 
bacterial community function or impacts on population growth are 
warranted.   
2. Testing of antibiotics on metazoans may not be required.  
a. Metazoans were generally 2 to 4 orders of magnitude less 
sensitive to antibiotics than cyanobacteria. Further investigation is 
required to assess and confirm these results on a wider series of 
empirical in vivo exposures, however this meta-analysis provides 
a starting point for this discussion and the possible reduction in 
the use of metazoans in antibiotic testing. 
3. Our meta-analysis highlights that the relative high sensitivity of 
microalgae and macrophytes to some antifolate and quinolone antibiotics 
(compared with cyanobacteria) supporting their inclusion in risk 
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assessment frameworks for these compound classes. Further research 
into the relative sensitivity of macrophytes and microalgae to these 
classes of antibiotics is warranted. 
4. Test systems to determine PNEC or MSC for AMR development are 
urgently required for clinical and environmental species. Our analysis, 
suggests that the CRB in the European Committee on Antimicrobial 
Susceptibility Testing database are not always representative of the 
diversity of sensitive bacteria in nature. This illustrates that ERA needs to 
incorporate both PNECSW and PNECR.  There is a need to develop a 
standardised method to experimentally determine an MSC in 
environmental and clinical bacteria, exemplified by three out of five 
experimental values being lower than the theoretical value. 
5. A discharge limit of 100 ng/L maybe a protective and pragmatic approach 
to address environmental concerns around antibiotic production in the 
absence of sufficient reliable clinical and environmental data, whilst 
urgently needed methodologies and empirical data are obtained to draw 
firmer conclusions.  Where data exists that suggest a higher or lower 
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Figure S2. Number of regularly approved antibiotics by anatomical therapeutic chemical (ATC) 
classification system codes, identified in www.fass.se and (Santos et al. 2017), and number of 
antibiotics that have cyanobacteria no observed effect concentration data in this meta analysis.  
This figure also includes data for tedizolid phosphate, enrofloxacin and tiamulin that were not 









API EC50 (mg/L) Species 
Amoxcillin 
0.0022 Synechococcus leopoldensis 
0.0037 Microcystis aeruginosa 
56.3 Anabaena CPB4337 
Ampicillin 
0.14 Anabaena cylindrica 
3.3 Anabaena flos-aquae 
2.2 Anabaena variabilis 
0.002 Microcystis aeruginosa 
0.013 Microcystis wesenbergii 
>200 Nostoc sp. 
0.083 Synechococcus leopoldensis 
0.0069 Synechococcus sp. 
Ciprofloxacin 
0.005 Microcystis aeruginosa 
0.0102 Anabaena flos-aquae 
Enrofloxacin 
0.049 Microcystis aeruginosa 
0.173 Anabaena flos-aquae 
Erythromycin 
0.022 Anabaena CPB4337 
0.0035 Anabaena cylindrica 
0.27 Anabaena flos-aquae 
0.43 Anabaena variabilis 
0.023 Microcystis aeruginosa 
0.023 Microcystis wesenbergii 
0.2 Nostoc sp. 
0.16 Synechococcus leopoldensis 
0.23 Synechococcus sp. 
Gentamycin 
0.069 Synechococcus leopoldensis 
0.0047 Anabaena flos-aquae 
Levofloxacin 
4.8 Anabaena CPB4337 
0.0079 Microcystis aeruginosa 
Lincomycin 
0.053 Anabaena flos-aquae 
0.039 Synechococcus leopoldensis 
Norfloxacin 
5.6 Anabaena CPB4337 
0.053 Anabaena cylindrica 
0.29 Anabaena flos-aquae 
0.19 Anabaena variabilis 
0.062 Microcystis aeruginosa 
0.038 Microcystis wesenbergii 
1.7 Nostoc sp. 
0.63 Synechococcus leopoldensis 
0.63 Synechococcus sp. 
Oxytetracycline 
0.21 Microcystis aeruginosa 
0.032 Anabaena cylindrica 
0.39 Anabaena flos-aquae 
0.36 Anabaena variabilis 
0.23 Microcystis aeruginosa 
0.35 Microcystis wesenbergii 
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API EC50 (mg/L) Species 
7 Nostoc sp. 
1.1 Synechococcus leopoldensis 
2 Synechococcus sp. 
Sulfadiazine 
0.14 Microcystis aeruginosa 
7.2 Anabaena flos-aquae 
Sulfadimethoxine 
480 Anabaena cylindrica 
>2000 Anabaena flos-aquae 
1500 Anabaena variabilis 
500 Microcystis aeruginosa 
470 Microcystis wesenbergii 
>2000 Nostoc sp. 
1100 Synechococcus leopoldensis 
760 Synechococcus sp. 
Tetracycline 
6.2 Anabaena CPB4337 
0.09 Microcystis aeruginosa 
Thiamphenicol 
1.3 Anabaena cylindrica 
13 Anabaena flos-aquae 
14 Anabaena variabilis 
0.32 Microcystis aeruginosa 
0.43 Microcystis wesenbergii 
3.5 Nostoc sp. 
0.36 Synechococcus leopoldensis 
0.67 Synechococcus sp. 
Trimethoprim 
112 Microcystis aeruginosa 
253 Anabaena flos-aquae 
>200 Anabaena cylindrica 
>200 Anabaena flos-aquae 
11 Anabaena variabilis 
150 Microcystis aeruginosa 
>200 Microcystis wesenbergii 
53 Nostoc sp. 
>200 Synechococcus leopoldensis 
>200 Synechococcus sp. 
91.677 Anabaena flos-aquae 
>100 Synechococcus leopoldensis 
Tylosin 
0.034 Microcystis aeruginosa 
0.0842812 Anabaena flos-aquae 
0.082449 Synechococcus leopoldensis 
Ofloxacin 
0.016 Synechococcus leopoldensis 
0.021 Microcystis aeruginosa 









5th percentile (μg/L) Standard error (μg/L) 
Lowest CRB MIC (LOEC) 103 2.028 0.087 
Lowest CRB MIC rounded down to next concentration in concentration range (NOEC) 103 1.014 0.043 
Adjusted MIC as calculated in Bengtsson-Palme and Larsson (2016) (NOEC) 103 0.457 0.059 
All environmental bacteria and CRB (NOEC and lowest MICs rounded down) 107 0.703 0.253 
Environmental bacteria (NOECs) 27 0.225 0.071 
Cyanobacteria only (NOECs) 27 0.225 0.072 
Table S4.  5th percentiles and standard error of different bacteria no observed effect concentration (NOEC) and/or minimum inhibitory concentration 
(MIC) datasets.  Clinically relevant bacteria (CRB) MICs were obtained from Bengtsson-Palme and Larsson (2016).  The lowest MIC is broadly 
equivalent to a traditional lowest observed concentration (LOEC) the MIC rounded down to the next test concentration is broadly equivalent to a 
traditional NOEC.  The adjusted MIC has been statistically adjusted down to account for antibiotics with fewer CRB MIC data.  5th percentiles and 
standard error were calculated using Harrell-Davis quantile estimator method that accounts for the non-normal distribution of the data.  Analysis was 




Extended method and results for the analysis of sensitivity ratios 
Sensitivity ratios (SRs) were analysed using a general linear model (GLM).  
GLMs were constructed using the ‘lmer’ package with the restricted maximum 
likelihood method (Bates et al. 2015) in R (version 3.3.0; R Project for Statistical 
Computing, Vienna, Austria).  Model residuals were checked to assess the 
validity of the GLM and significant differences from 0 (value of cyanobacteria 
SR) were identified using the “lmerTest” package in R (Kuznetsova et al. 2013).  
Further statistical differences between taxa were identified using TukeyHSD 
procedure.  A more detailed method is provided below: 
1. A GLM was constructed for all antibiotics, followed by further GLMs 
based upon mode of action groups and individual antibiotic classes.  
GLM were only constructed where there were SRs for 3 or more 
antibiotics.  Where a taxa group had only one SR in any antibiotic class 
these were removed from the GLM analysis. Cyanobacteria SRs (which 
were 0) were removed from the data before constructing the GLMs and 
the intercept of the model was forced through 0. Identifying significant 
differences from the intercept (0) and removing the cyanobacteria SRs 
prevented 1) the over-representation of cyanobacteria SRs in the model 
that caused the standardised residuals to be non-normal and 2) the 
cyanobacteria being accounted for twice in the analysis (once in the ratio 
calculation and secondly in the statistical analysis of the GLM).  
2. The SRs used to construct each model were checked for normality using 
a histogram, QQ-plot, and the Shapiro-Wilk normality test and equal 
variances were checked using Levene test in the Lawstat package in R 
(Gastwirth J L et al. 2015). 
3. A GLM was constructed in the 'lmer’ package using the following basic 
model outline: 
Model <- glm(SR ~ Taxa -1, 
                 family = gaussian (link ="inverse" or “identity”),  
                 na.action = na.exclude, 
                 data = data) 
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4. The error family was Gaussian and link function (identity or inverse) was 
chosen using the GLM with the lowest akaile information criterion. 
5. Model validation was conducted to assess  
a. Normal distribution of standardised residuals  
b. Homoscedasticity of residuals 
c. Collinearity 
d. Auto-correlation 
e. Leverage of data 
Boxplots and statistical results from the GLM analysis are provided for all 









Supplemental material, part 1 Figures 1A-K.  Boxplots of Log10 sensitivity ratio (SR) between 
cyanobacteria and other species/phyla for A) cephalosporins (n=3), B) penicillins (n=4), 
C) antifolates (n=4), D) sulfonamides (n=3), E) quinolones (n=9), F) fluoroquinolones (n=4), 
G) 30S ribosome inhibitors (n=7), H) 50S ribosome inhibitors (n=10), I) aminoglycosides (n=4), 
J) tetracyclines (n=3) and K) macrolides (n=5).  SR calculated by log10cyanobacteria NOEC or 
EC50 – log10taxa NOEC or EC50.  Where SR = 0 the sensitivity of the taxa is equal to 
cyanobacteria, represented by horizontal line, where SR >0 a lower sensitivity and <0 indicates 
higher comparative sensitivity. Significant differences of SR from 0 (cyanobacteria SR = 0) in 
the generalised linear mixed models are indicated by: * p<0.05; ** p<0.01; *** p<0.001.  
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Antibiotic risk assessment needs to protect both 
environmental and human health 
 
Gareth Le Page, Lina Gunnarsson, Jason Snape, Charles R. Tyler;  
published in Environmental International (2018) 115: 397-399. 
 
This article is a published response to a commentary article by Bengtsson-
Palme and Larsson (2018) published in Environment International 111: 352-353 
that has a series of criticisms on the previous published chapter. We discuss 
the consequences of comparing a no observed effect concentration with a 
minimum inhibitory concentration and the limited impact that it likely has upon 
our conclusions in chapter 2.  We also address questions raised by Bengtsson-
Palme and Larsson regarding the setting of protection limits for manufacturing 
discharges. 
I carried out the first drafting of the paper. All authors were actively involved in 
later discussions on the work and in the preparation of the manuscript for 






Antibiotic risk assessment needs 
to protect both environmental and 
human health  
 
In our recent meta-analysis on antibiotic ecotoxicity data published in 
Environment International (Le Page et al. 2017)  we suggest that because of 
the great diversity in species sensitivity, environmental risk assessment (ERA) 
would be improved by testing a more diverse range of bacteria (including both 
environmental bacteria and clinically relevant bacteria (CRB)). We also 
conclude that tests on antibiotics should consider endpoints of relevance to 
ecosystem function. Comparing the protection goals for environmental heath 
with those for human health (protection against antimicrobial resistance (AMR) 
development) we, furthermore, identify that neither protection goal is always 
protective of the other whilst using current methodologies (with surrogate 
endpoints for each goal and very limited bacterial biodiversity tested); 
supporting the need for both in any comprehensive health protection system for 
antibiotics. 
In a correspondence to our paper Bengtsson-Palme and Larsson (2018) point 
out a bias in our sensitivity analysis favouring environmental bacteria  (including 
cyanobacteria). We acknowledge this, but equally in this correspondence we 
challenge some of their points made on how this impacts on the significance of 
our data. We also address points relating to the lack of clarity on protection 
goals for antibiotics in the discussion of our paper and discuss what data are 
most suitable for establishing those protection goals.  We emphasise that the 
main conclusion drawn from our original paper has not changed and we 
maintain that a holistic approach including both environmental health and 
resistance selection is required to drive an effective overall protection limit for 
antibiotics. 
Sensitivity analyses skews 
Bengtsson-Palme and Larsson (2018) rightfully point out that our analysis 
skews the apparent sensitivity in favour of the environmental bacteria because 
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the endpoints compared for CRB (minimum inhibitory concentrations, MIC) and 
environmental bacteria (no observed effect concentrations, NOEC) for growth 
inhibition are derived from different ends of the dose response curve; MICs are 
derived from the top of the dose-response curve (full inhibitory effect on growth) 
and the NOECs for environmental bacteria from the bottom of the response 
curve (concentration with no inhibition). In some cases therefore CRB may be 
more sensitive than environmental bacteria than our analysis suggests. 
However, it should be highlighted that this doesn’t necessarily mean that 
environmental bacteria will not represent the most sensitive taxa for individual 
antibiotics. This is because, in the first instance, in the cases where 
environmental bacteria were more sensitive by an order of magnitude or more 
compared with CRB in our analysis, environmental bacteria are likely to be 
comparable, if not more sensitive to those antibiotics. In our meta analysis this 
would be the case for 6 out of 24 antibiotics (including azithromycin and 
ampicillin).  Secondly, very large differences in sensitivity can occur between 
different species of bacteria (our meta analysis showed sensitivity spanned five 
orders of magnitude in 8 species cyanobacteria exposed to ampicillin) and 
because of the far greater species number and diversity tested in CRB 
compared with environmental bacteria there is likely to be a sensitivity bias in 
favour of CRB. The size-adjusted MIC value used as our comparative endpoint 
for CRB was calculated from the MICs of up to 70 species in up to 5 families 
(Bengtsson-Palme and Larsson 2016). In stark contrast to CRB, cyanobacteria 
antibiotic test data were generally derived from only one or two species giving 
far greater uncertainty in the sensitivity calculation for this group.  
Uncertainty in protection targets. 
ERA for antibiotics in the European Union is legislated by the Medicinal 
Products for Human Use directive (EC 2001) where the protection goal is to 
prevent “any risk of undesirable effects on the environment”. Current practice is 
to calculate a PNEC using chronic growth and/or reproduction data on single 
species, which for antibiotics is normally based on the PNECSW driven by a 
cyanobacterium. The relationship however, between individual species 
sensitivity, ecosystem function and functional redundancy is not well 
understood (Antwis et al. 2017) and what constitutes an “undesirable effect” is 
unclear.  As Bengtsson-Palme and Larsson (2018) point out, clarity is, 
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therefore, required in the definition and objectives of these protection goals.  
The issue of functional redundancy, and to what extent it is possible to 
eradicate or lose a microbial species without compromising that ecosystem 
function is a hugely important consideration for environmental protection. There 
is some evidence that microbial communities may be less functionally 
redundant than macroorganism communities (Delgado-Baquerizo et al. 
2016).  Thus, although we re-iterate our support of the inclusion of ecosystem 
function based tests, given the uncertainties relating to functional redundancy, 
at this time ecosystem level protection may be best served by a conservative 
protection goal based upon bacterial biodiversity (and therefore inherently 
ecosystem function). 
Bengtsson-Palme and Larsson (2018), highlight that the risk of AMR and 
human health concerns are generally the main driving force for antibiotic 
protection goals but they also agree with our conclusions that a holistic 
approach that considers both environmental health and AMR should be taken. 
The meta analysis shows that for some antibiotics the environmental protection 
limits may be lower than the protection limits predicted for AMR (using current 
methodologies and surrogate endpoints for biodiversity and AMR). To illustrate 
this, here (Fig 1) we compare the PNECr determined using the size-adjusted 
MIC data (Bengtsson-Palme and Larsson 2016) and PNECsw calculated from 
the lowest NOEC in our meta analysis with the PNECfw (PNEC in freshwater) 
determined for the 5 antibiotics in the European commission environmental 
quality standards watch list (Carvalho et al. 2015).  In each case the PNECr 
represents the highest PNEC for each antibiotic (i.e. is least protective as a 
whole). 
As Bengtsson-Palme and Larsson (2018) point out, protection against antibiotic 
pollution for environmental health is more of a localised impact, whereas AMR 
has a wider and more pervasive global significance, directing stakeholders 
towards the need for two different protection targets determined from 
appropriate data and methodologies.  We still maintain however, that an overall 
protection limit should protect both environmental and human health. 
Environmental protection and associated legislation differs across countries, but 
equally there is a social responsibility to ensure that product provenance is 




Fig 1.  Predicted no effect concentrations (PNEC) for the antibiotics in the European 
commission watch list under the environmental quality standards directive (Carvalho et al. 
2015).  PNECfw is the PNEC that is determined for freshwater in the European commission 
directive (Note that the assessment factor for PNECfw may be up to 50 rather than 10 in these 
examples due to the lack of a full phase II base set of data – algae/cyanobacteria, invertebrates 
and fish (EMA 2006). The PNECfw for ciprofloxacin is thus most likely overprotective); PNECr is 
the PNEC calculated from minimum inhibitory concentrations (Bengtsson-Palme and Larsson 
2016); PNECsw is the PNEC determined from the lowest, publically available, environmental 
bacteria no observed effect concentration (Le Page et al. 2017). PNECsw uses an assessment 
factor of 10 for each antibiotic. 
 
Discharge limit 
In response to stakeholder calls to address the risk of antibiotics released from 
manufacturing operations, which currently sits outside of the regulatory ERA 
framework, in our original paper we proposed an interim production discharge 
limit of 100 ng/L for each antibiotic, to be applied in the mixing zone to both 
protect environmental bacteria populations and reduce the risk of AMR 
development.  This interim limit recognised that (i) because most antibiotics 
were authorised before the current guidelines came into force, many either lack 
or have very limited ecotoxicology data, and (ii) the need to establish science-
based limits in the absence of such data.  We were explicit in our paper to point 
out, however, that as sufficient data become available for mode of action 
relevant species we support the use of higher or lower protection limits based 
on these empirical data. Bengtsson-Palme and Larsson (2018) questioned this 
conservative limit for antibiotics because it may incur higher manufacturing 
costs through the need for infrastructure investment to reduce discharges and 
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based on the fact that some antibiotics have relatively low toxicity and do not 
exert a strong selection pressure for antibiotic resistance.  These are important 
points to debate.  A single interim value helps the pharmaceutical industry, 
many of whom are currently reviewing their antibiotic manufacturing operations, 
to prioritise interventions and actions.  These interventions may include 
generating relevant environmental toxicology data where empirical data does 
not exist or when a possible risk is identified at a site. A single value will also 
enable the pharmaceutical industry to benchmark existing suppliers more 
effectively to identify best practice in waste management.  The requirement for 
infrastructure investments, as highlighted by Bengtsson-Palme and Larsson 
(2018), represents a last resort and these would only be required where risks 
could not be refined and managed through other interventions.  Where 
infrastructure upgrades are required to meet scientifically robust limits, then the 
costs of these upgrades will need to be evaluated and justified as part of a 
wider socio-economic assessment into the stewardship of antimicrobial 
chemotherapy.  In most cases, however, these interventions are not likely to 
incur excessive costs; the manual wipe down of equipment prior to cleaning 
washes, separation and incineration of the wastewater from the first wash of 
equipment, or the installation of inline filters to remove undissolved material can 
all significantly reduce environmental concentrations of APIs, in most cases by 
>90% (Hargreaves et al. 2017).  The logistics for antibiotic supply can be 
extremely complex with many suppliers manufacturing a whole range of 
antibiotics for numerous contractors and there can be language barriers and 
many suppliers lack the expertise to determine safe concentrations for 
themselves. In this case the use of a single interim limit has practical as well as 
scientific value.  It may help remove conflicting limits (e.g. where two 
contractors provide different safe values or no level of protection), and minimise 
confusion amongst the pharmaceutical industry and their suppliers in the 
absence of data.   
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Development and application of a 
microplate assay for toxicity 
testing on aquatic cyanobacteria 
 
Abstract 
Environmental risk assessment (ERA) relies on a growth inhibition test 
performed upon a single species of cyanobacteria and conducted in a 
cumbersome shake flask assay, to represent all bacterial diversity when 
establishing a protection limit. Recently, the ability of this approach to account 
for the wide range of interspecies differences in sensitivity has been questioned 
and there is therefore a requirement for empirical data for additional species to 
further investigate the effectiveness of ERA. To this end, we present the 
development and validation of a microplate assay that is able to obtain growth 
rate inhibition data for eight cyanobacteria and which is comparable to the 
traditional shake flask test, whilst also being cost effective and time efficient. We 
use phycocyanin fluorescence as a surrogate for cell density and optimise the 
assay to ensure a comparison of cyanobacteria sensitivity under exponential 
growth in the same experimental conditions. Finally the test is validated using 
the reference compound potassium dichromate to show reproducible results 
across assays over time and comparable results with the OECD 201 shake 
flask test design. This assay is also suitable for the screening of ecotoxicology 






Bacteria, including cyanobacteria, play key functional roles in our aquatic 
ecosystem including primary production, biogeochemical cycles and processing 
pollutants (Díaz 2004; Falkowski et al. 2008; Finlay et al. 1997). In particular, 
cyanobacteria are autotrophs (although many are additionally able to produce 
energy through other mechanisms) that are ubiquitous across all habitats 
having evolved to perform many ecological functions essential to supporting life, 
such as, among others, nitrogen fixation, oxygen generation and 
photosynthesis-mediated calcification (Falkowski et al. 2008; Zhu and Dittrich 
2016). 
There is concern however, that in the environmental risk assessment (ERA) of 
antibiotics, microorganisms are underrepresented and that the protection limits 
determined may not be fully protective of bacteria populations nor of the 
ecological functions that they provide (Agerstrand et al. 2015; Brandt et al. 
2015; Le Page et al. 2017). Additionally, the vast majority of antibiotics were 
registered before new EU regulations were introduced in 2006 when effects 
upon the bacterial compartment were not considered in ERA. Thus there is only 
limited data in the published literature regarding the environmental effects of 
antibiotics from which to establish their potential risk. 
Regulatory studies supporting ERA that are responsible for representing all 
global bacterial diversity, currently rely upon the activated sludge respiration 
inhibition test (which is not considered to be sensitive to antibiotics (Kümmerer 
et al. 2004; Le Page et al. 2017)) and a cyanobacteria growth inhibition test 
based upon just one species, normally Anabaena flos-aquae. Since antibiotics 
are selected to inhibit growth or kill pathogenic bacteria without affecting 
mammals, cyanobacteria are likely to have the antibiotic drug targets which are 
unlikely to be evolutionally well conserved in the other eukaryotic species 
normally required for regulatory testing (green algae, daphnid and fish). 
Ideally, testing on bacterial should consider different bacteria phyla and 
determine effects upon communities and the ecological functions that they 
perform (Brandt et al. 2015; Le Page et al. 2017). However, the requirement for 
standardised test methodologies and robust results that are consistent across 
laboratories in both space and time has favoured more simplistic single species 
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testing on growth rate and/or reproduction endpoints. As with green algae in the 
regulatory testing of other chemicals, the endpoint determined to establish the 
effects of antibiotics on cyanobacteria is population growth inhibition based 
upon cell density. In a recent meta-analysis we demonstrate that there can be 
considerable differences in sensitivity to the effects of antibiotics between 
cyanobacteria species and in that work it was concluded that testing on a more 
diverse species selection would provide greater confidence in the protection 
goal derived (Le Page et al. 2017). In support of this, a low-cost and medium 
throughput screening assay suitable for testing a range of cyanobacteria 
species would be of great value for use in both i) assessing the toxicity of new 
antibiotics to inform regulatory testing and ii) in considering the toxicity of legacy 
antibiotics that were registered previous to 2006 so that the risk to the 
environment from antibiotics with limited environmental data can be evaluated. 
Furthermore, the screening of such antibiotics would allow for the prioritisation 
of antibiotics that pose the greatest potential risk for further testing. 
The internationally accepted shake flask test is traditionally used for determining 
the growth inhibition of chemicals to green algae and cyanobacteria, especially 
for studies that support regulatory dossiers (ISO 2004; OECD 2011). However, 
considerable work has gone into the development, validation and adoption of 
miniaturised microplate versions of the shake flask test in 24, 48 and 96 well 
microplates (Eisentraeger et al. 2003; Paixão et al. 2008; Pavlic et al. 2006; 
Rojíčková et al. 1998; Schrader et al. 1997; Wells et al. 1997). A microplate 
assay has considerable benefits over the shake flask method in regards to the 
operator time (further benefited by the increased potential for automation), 
space required and the quantity and cost of consumables, including the test 
substance of which there may be very small quantities available in early drug 
development. These microplate tests generally show good correlation in 
regards to sensitivity with the shake flask method and some national guidelines 
now advocate the use of a microplate method over the traditional shake flask 
method (e.g. Environment Canada (2007)). 
Although successfully utilised by some investigators (Churro et al. 2009; Churro 
et al. 2010; Nagai et al. 2013), the optimisation of microplate methods has 
primarily focused upon green algae, with less consideration given to 
cyanobacteria. In order to address the requirement for a cost efficient and 
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medium throughput screen to assess the effects of antibiotics on cyanobacteria, 
here we set out to modify and optimise a microplate approach using eight 
different cyanobacteria species. The selected species were Anabaena flos-
aquae, Synechococcus leopoliensis, Anabaena cylindrica, Synechococcus 
elongates, Synechococcus sp, Synechocystis sp, Cyanobium gracile and 
Geminocystis herdmanii. Species of the genus Anabaena are filamentous, 
nitrogen fixers that occur globally. Considerable focus has been given to this 
genus as a model organism for nitrogen fixation and its role in harmful algal 
blooms. Synechococcus species, of which three are represented here, are 
diverse unicellular picoplankton, that have a wide global distribution and are 
important primary producers, especially in oligotrophic environments (Callieri et 
al. 2007; Palenik et al. 2003). Species belonging to the Synechocystis genus 
are widely distributed in the environment and the strain selected here, 
Synechocystis sp (PCC 6803), was the first fully sequenced photosynthetic 
autotroph (Kaneko et al. 1996) and having biochemical similarities with plant 
chloroplasts it has become an important photosynthesis model organism. 
C. gracile is also a picoplanktonic species (cell length up to approximately 1μm) 
and G. herdmanii has a relatively large cell size (with diameter reaching 
5μm;(Jana et al. 2009). 
The test was designed to provide data that fulfil two objectives: 1) allow the 
direct comparison of the sensitivity to antibiotics across eight species of 
cyanobacteria and 2) ensure results obtained were consistent with that obtained 
for the traditional shake flask test design so that data derived were acceptable 
for informing regulatory testing, although we stress we do not intend for this to 
replace the shake flask test for regulatory purposes. The work included 
performing reference toxicity testing with potassium dichromate to establish the 
sensitivity of each species, ensure valid and consistent performance over time 
and allow for a comparison of results with the shake flask test. Our data derived 
from the microplates show a strong correlation with that from the traditional 
shake flask method for seven of the eight species and is the first protocol to 
allow for the direct comparison of sensitivity of this number of cyanobacteria 





Cyanobacteria strains and maintenance 
Eight cyanobacteria species were selected for testing. These were: Anabaena 
flos-aquae (CCAP 1403/13A), Synechococcus leopoliensis (CCAP 1405/1), 
Anabaena cylindrica (PCC 7122), Synechococcus elongates (PCC 6301), 
Synechococcus sp (PCC 6312), Synechocystis sp (PCC 6803), Cyanobium 
gracile (PCC 6307) and Geminocystis herdmanii (PCC 6308). A. flos-aquae 
(CCAP 1403/13A) and S. leopoliensis (CCAP 1405/1) were both selected 
based on the fact that they are species recommended in the OECD 201 test 
guideline (OECD 2011). The remaining six test species were selected based 
upon the fact that they fulfilled the following criteria: 1) their growth rate was 
sufficient enough to reach exponential growth and achieve measurable 
differences in biomass to enable toxicity testing within a 72 hour period under 
similar laboratory conditions as the other species (media, temperature, shaking 
and light intensity); 2) they are environmentally relevant; and 3) The test 
species also provided a wide range of phylogenetic diversity within those 
species of cyanobacteria with sequenced genomes in Shih et al. (2013). 
Microcystis aeruginosa (PCC 7806) was also considered in some of the early 
analyses due to its high sensitivity to antibiotics (Le Page et al. 2017) and 
importance in harmful algal blooms, but subsequently excluded due to its slow 
and variable growth in this test system. 
Cyanobacteria were maintained as continuous aqueous cultures in 100mL 
conical flasks with approximately 50mL BG-11 medium ((Rippka et al. 1979); 
laboratory grade constituents of >97% purity). In order to provide a continuous 
source of exponentially growing cells, cultures were regularly transferred (twice 
a week) to new medium and incubated in Multitron II incubators (Infors) under 
test conditions. Before their use, cultures were visually examined using an 
inverted light microscope to ensure cells appeared healthy and that there was 
an absence of biological contamination. 
Growth measurements and optimisation 
Cyanobacteria have multiple fluorophores for light harvesting that include 
chlorophyll and the phycobiliproteins: phycoerythrin, phycocyanin and 
allophycocyanin (Glazer 1994). These fluorophores are commonly used as a 
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surrogate for cell biomass along with optical density (absorbance). In 
developing our microplate-based assay we identified the wavelengths for 
phycocyanin fluorescence in the cyanobacteria and compared its fluorescence 
with chlorophyll a and optical density (OD) to determine the most suitable 
surrogate for cell density. After a suitable surrogate was selected we assessed 
the growth of each species under varying temperature, light intensities and 
starting inoculums in order to develop a test design that allowed a direct 
comparison of species sensitivity within 72 hours. 
Spectral scans 
Spectral scans were performed to identify the optimum wavelengths for 
measurement of in vivo phycocyanin fluorescence. Supplementary material A 
gives details on the selection of optimal emission wavelengths for phycocyanin 
in all species. Fluorescence and OD were determined using a Spectromax M5 
with Softmax® Pro software (Molecular Devices). 
Cell density determination 
Optical density and in vivo fluorescence of phycocyanin and chlorophyll a were 
assessed to establish the most suitable surrogate for cell density in order to 
calculate population growth inhibition. For each species a dense culture of cells 
in the stationary phase of the growth curve was serial diluted (50% dilutions) 
and three 200μL replicates of each dilution were pipetted into a microplate. OD 
(at 750nm), phycocyanin and chlorophyll A fluorescence (excitation and 
emission wavelengths of 590 & 650 nm and 420 & 681 nm respectively) were 
determined. Direct cell counts were conducted in a haemocytometer for A. flos-
aquae, A. cylindrical, Synechocystis sp and G. herdmanii. Species with very a 
small cell size (S. leopoliensis, S. elongates, Synechococcus sp, and C. gracile) 
could not be accurately counted in the haemocytometer. 
Calculation of limits of detection for phycocyanin fluorescence 
The limit of detection for phycocyanin fluorescence in this system was 
determined to be 1.1 arbitrary fluorescence units (AFU) and the limit of 




Optimising test conditions 
In order to establish optimal test conditions for obtaining exponential growth 
rates the effects of temperature, starting inoculum and light intensity on the 
growth rate of each species were investigated over 72 hours (with exception of 
light intensity on C. gracile). Temperature ranges tested were between 20 and 
30°C; starting inoculum levels between 2 – 10 AFU (phycocyanin fluorescence); 
and light intensity between 4000 – 12000 lux. Testing was carried out in 
microplates as described below. 
Growth curves 
Growth curves, based upon phycocyanin fluorescence, for cultures in the 
exponential growth phase were determined in microplates under the test 
conditions selected for the exposure (28°C, 2AFU starting inoculum 
(phycocyanin fluorescence) and 4000 lux) over 96 hours in BG-11. 
Reference toxicity testing 
Reference toxicity testing was performed using potassium dichromate (Sigma-
Aldrich, product no P5271, CAS 7778-50-9, purity ≥99.5%). Potassium 
dichromate was selected due to i) having been previously and regularly used 
reference toxicant, ii) being stable in solution and unlikely to absorb to the 
plastic microplates or glass flasks, thus not requiring chemical analysis and, iii) 
have a large body of literature regarding toxic effects to a variety of organisms. 
Seven microplate assays, performed in three groups (a, b and c) were used to 
assess the performance and repeatability of the assay with each species of 
cyanobacteria. Assays were performed as described below. 
Microplate assays in each group (a, b or c) shared the same batch of medium 
and parent inoculum, i.e. the same parent culture was used to prepare the 
starting inoculum stock in all plates within a group (Table 1). To compare how 
the microplate performed with the shake flask test design, A. flos-aquae, 
S. leopoliensis, Synechocystis sp., C. gracile and G. herdmanii were tested 
using a shake flask test (as described below) and these ran concurrently with 
the microplate groups and shared the same batch of medium and parent 












SF A. flos-aquae B 
SF S. leopoliensis C 
SF Synechocystis sp B 
SF C. gracile A 
SF G. herdmanii A 
Table 1. Table of assay groupings indicating which assays were performed at the same time using 
the same medium and parent inoculation culture. MP = Microplates (all species were tested in each 
MP assay); SF = Shake flask. Control pH for each group was as follows: A = 8.1, B = 8.0, C= 8.4. 
Microplate toxicity assay 
To ensure cells entering our tests were growing exponentially a pre-culture 
(50mL) for each species was prepared 3-4 days prior to the start of the test in 
100mL Erlenmeyer flasks. These were grown under exposure conditions and 
growth rate was determined, using phycocyanin fluorescence as a surrogate for 
cell desnity, to verify cells inoculated into the test had been growing 
exponentially. 
A geometric series of test concentrations were prepared in BG-11 medium at 
twice the nominal test concentrations. For each replicate, 100μL of the relevant 
test solution was then added to 100μL of cyanobacteria inoculum in BG-11 
medium at 4AFU (twice the nominal starting inoculum) to achieve a final 
cyanobacteria concentration at 2AFU at the nominal test concentration in each 
well. Inoculums were based upon phycocyanin fluorescence measurement 
rather than cell density. 
When fluorescence is used as an end measure black plates are generally 
adopted to prevent cross-over of fluorescence (the detection of fluorescence 
from neighbouring wells). However in this work, non-transparent, rather than 
black, 96 well plates were used (Greiner Bio-one item no. 650201) to allow 
sufficient light penetration to enable cyanobacteria growth. As found by Nagai et 
al. (2013) in a similar experimental design, cross-over was not observed in our 
assays. Plates were sealed with AMPLIsealTM sealer (Greiner Bio-one item no. 
676040) to prevent water loss due to evaporation over the test period and to 
decrease the risk of possible contamination between wells. The seal prevented 
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gaseous exchange, including for CO2 and O2, between the wells and exterior 
atmosphere. The sealant had no effect on growth of all test species within the 
exposure period (between 24 and 72 hours depending on the species). pH 
fluctuations of the controls ranged between acceptable limits of ±0.2 as defined 
by most standardised test guidelines ((OECD 2011). 
The plate layout for the incubations described is provided in supplementary 
material B (Figure S.B1). All exterior wells on the outer edge of the plate consist 
of cyanobacteria blanks (test solution only with an absence of cyanobacteria) in 
order to i) identify any fluorescent signal from a test compound and provide, if 
required, test concentration specific blanks to subtract from the exposure wells 
with cyanobacteria to obtain cyanobacteria fluorescence only and ii) the 
analytical determination of the test compound concentration in order to compare 
with the exposure well and thus allow the assessment of loss due to the 
presence of cells. 
Cell density in each well was measured by phycocyanin fluorescence (excitation 
= 590nm, emission = 650n, cut-off = 635nm) daily from the start to end of the 
test. pH was determined in the test solution stocks at the beginning of the test 
and in one replicate of each test concentration for each species at the end of 
the exposure. 
In some replicates, the starting inoculum was determined to be <LOQ of 3.6 
AFU. This is because in our test system we prepared a cyanobacteria inoculum 
stock at a nominal 4 AFU which was then 50% diluted by the addition of the test 
solution, thus starting the test at a nominal 2 AFU. As such, some replicates 
had a starting fluorescence of below the LOQ (3.6 AFU). 
Shake flask test procedure 
In order to assess the performance of the microplate test in relation to more 
traditional growth inhibition assays used in regulatory testing, reference toxicity 
testing was performed upon A. flos-aquae, S. leopoliensis, Synechocystis sp., 
C. gracile and G. herdmanii using a shake flask test procedure according to the 
OECD 201 test guideline (OECD 2011). All test conditions were as conducted 
for the microplate test. Cell density was measured by sampling 200μl from each 
replicate flask in triplicate and placing these into a microplate to measure 
phycocyanin fluorescence as described previously. pH was determined in the 
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test solution stocks at the beginning of the test and in one replicate of each test 
concentration for each species at the end of the exposure. 
Statistical analysis 
Growth rate calculations 







X = cell density at time i and j 
t = time at time i and j 
Yield or biomass integral were not calculated as growth rate is more appropriate 
for comparing the sensitivity across organisms. This is because the effects of 
different test durations and absolute growth are taken into account within the 
growth rate calculation and differences in species growth rate do not affect 
‘apparent’ sensitivity (Eberius et al. 2002; Ratte et al. 1998). Additionally, growth 
rate tends to be the endpoint utilised within ERA (EM(E)A 2006). 
In this assay, growth rate reflects the increase in phycocyanin fluorescence over 
time, which is used as a surrogate for cell density. This allows for the rapid 
measurement required of a medium-high throughput assay.  There are some 
limitations and considerations associated with this approach, such as the loss of 
proportionality of phycocyanin fluorescence with cell density at the lowest cell 
numbers or the potential for some chemicals to inhibit phycocyanin 
fluorescence but not affect cell density depending on the mode of action.  
These concerns are described further in the discussion. 
Test condition selection 
To identify the effect of temperature, light intensity and starting inoculum a 
generalised least squares model was constructed using the ‘nlme’ package (J 
Pinheiro et al. 2017) with the restricted maximum likelihood method (Bates et al. 
2015) in R (version 3.3.0; R Project for Statistical Computing, Vienna, Austria). 
Where the data was not homoscedastic the model was weighted by the 
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variance structure in the fixed variable (temperature/light intensity or starting 
inoculum) to account for the variance structure in the data. Models were 
compared using the Akaike information criterion and the best fitting model used. 
Pairwise comparisons were performed using the lsmeans package (Lenth 
2016). 
Dose-response modelling 
Dose-response curves were fitted in r (version 3.3.0; R Project for Statistical 
Computing, Vienna, Austria) using the drc package (Ritz et al. 2015). The data 
handing and standard code used for each species are presented in 
supplementary material C. Several known distributions (3, 4 and 5 parameter 
log-logistic distributions and 4 and 5 parameter Weibull 1 and 2 distributions) 
were fitted to the growth rate data and the optimal distribution selected based 
on log-likelihood score. From this fitted distribution estimates of the effective 
concentrations 10 and 50 (ECx) and associated confidence limits were 
determined and compared to assess the repeatability of the microplate assay 
and to compare results with the traditional shake flask test design. Coefficient of 
variations were also calculated to assess variability in assay performance. 
Results 
Cell density determination 
With the exception of A. flos-aquae phycocyanin and chlorophyll a fluorescence 
were highly positively correlated with cell density at fluorescent values of more 
that 2 AFU for all species (Fig 1 - r2 for phycocyanin fluorescence = 0.97 - 0.99; 
Supplementary material D). OD correlated less well at the lowest cell densities 
tested (Fig S.D1). Direct cell counting by haemocytometer was not possible for 
the smallest sized cells (S. elongates, Synechococcus sp., S. leopoliensis and 
C. gracile), but where they were obtained, for Synechocystis sp., A. flos-aque, 
A. cylindrical and G. herdmanii, they showed a similar linear relationship to the 
fluorescence measurements. It should be noted that in the lowest cell densities 
the reliability of direct counting was lower and this is demonstrated by the 




The reason for the non-linear relationship between phycocyanin fluorescence 
and cell density in A. flos-aque is unknown, however the fluorescence over the 
highest eight cell densities tested was consistent with the other species before 
taking a second linear relationship with a shallower slope over the lower cell 
densities (Figure 1). This change in relationship between phycocyanin 
fluorescence and cell density was also observed in the chlorophyll a 
fluorescence in A. flos-aque and in the OD of all species. 
 
 
Figure 1. Relationship between phycocyanin fluorescence and cell density. Dilution of the 
culture is considered to be a surrogate for cell density (see supplementary material X). A. flos-
aquae does not show a linear relationship over all cell densities and has been split into 2 (one 
each for the lower and higher cell densities). Regression equations and r2 values for each 
species are as follows: A. flos-aquae (lower cell densities) - Y = 1.33 + 0.191x; r2 = 0.047; A. 
flos-aquae (higher cell densities) - Y = 1.03 + 0.908x; r2 = 0.989; A. cylindrical - Y = 0.757 + 
0.937x; r2 = 0.968; S. leopoliensis - Y = 0.956 + 0.968x; r2 = 0.994; S. elongates Y = 1.12 + 
0.869x; r2 = 0.995; Synechococcus sp, Y = 0.983 + 0.872x; r2 = 0.981; Synechocystis sp Y = 
0.526 + 0.934x; r2 = 0.995; C. gracile - Y = 1.04 + 0.961x; r2 = 0.999; and G. herdmanii.- Y = 




Test condition optimisation 
Temperature 
Figure 2 shows the relationship between temperature and growth rate (further 
analysis including a table of all pairwise comparisons can be found in 
supplementary material E). Temperature generally had a significant positive 
relationship with growth rate over 72 hours, with maximum growth rates 
occurring at 28 or 30°C (Figure 2; Table S.E1; Supplementary material E). In 
the case of A. cylindrica there was no significant difference in growth rate for 
temperatures at and above 25°C. The growth rate of G. herdmanii did not 
significantly differ for incubation temperatures between 20 and 30°C. Data for 
C. gracile was not obtained at 28 and 30°C due to problems in the growth of the 
pre-culture. In all species except Synechocystis sp. higher temperatures 
resulted in increased variability in growth rates. This could negatively affect the 
ability of the growth inhibition assay to identify statistical differences between 
test concentrations (e.g. no observed effect concentrations) and increase 
uncertainty around estimates derived from the dose-response curve (ECxs). The 
growth rate of some species (including C. gracile and Synechocystis sp.) at 
temperatures of 20 and 22°C was too slow to establish a reliable dose-response 
over 72 hours. Since the primary aim of the microplate assay is to provide a 
medium to high throughput test, priority was given to a high growth rate that 
enabled a full test in 72 hours or under, as in shake flask assays used for 
regulatory studies. Based upon these results, therefore, a test temperature for 
the growth inhibition assay of 28°C was selected for all species as it 





Figure 2. Effect of temperature on daily growth rate of cyanobacteria over 72 hours with a 
starting inoculum of phycocyanin fluorescence at 2AFU and light intensity of 4000 lux. NS – not 
significant; * - p = <0.05; ** - p = <0.01; *** - p = <0.001; **** - p = <0.0001.  
Light intensity 
Light intensity did not show any major effect on growth rate over 72 hours for 
any of the cyanobacteria (Figure 3; Table S.E2). For the slower growing species 
in these tests, however, including A. flos-aque, A. cylindrical and G. herdmanii, 
growth rate tended to be higher at a light intensity of around 4000 lux. Data for 
C. gracile was not obtained and were therefore not available for analysis due to 
problems in the growth of the pre-culture. As such, 4000 lux was selected as 
the light intensity for the assay across all species. Additionally, the use of a 
lower light intensity is advantageous to reduce any potential photo degradation 





Figure 3. Effect of light intensity on daily growth rate of cyanobacteria over 72 hours with a 
starting inoculum of phycocyanin fluorescence at 2AFU and at a temperature of 28°C. NS – not 
significant; * - p = <0.05; ** - p = <0.01; *** - p = <0.001; **** - p = <0.0001.  
Inoculum cell density: 
With exception of G. herdmanii, increasing the cell density, based upon 
phycocyanin fluorescence, of the starting inoculum had a significant negative 
effect on daily growth rate over the 72 hour period (Figure 4; Table S.E1). Data 
for C. gracile was not obtained and were therefore not available for analysis due 
to problems in the growth of the pre-culture. From these results a starting cell 
density equivalent to a phycocyanin fluorescence measurement of 2 AFU was 





Figure 4. Effect of starting inoculum, measured by phycocyanin fluorescence, on daily growth 
rate of cyanobacteria over 72 hours at a temperature of 28°C and light intensity of 4000 lux. NS 
– not significant; * - p = <0.05; ** - p = <0.01; *** - p = <0.001; **** - p = <0.0001.  
Growth curves 
Figure 5 presents the growth curves for each species, under the selected test 
conditions of 28°C, 4000 lux, 140 rpm (shaking speed was not investigated 
here) and a starting cell density of 2 AFU based on phycocyanin fluorescence. 
To obtain a dose-response curve based upon the exponential growth of each 
species the following exposure periods were selected for toxicity testing: i) for 
the fastest growing cyanobacteria, S. leopoliensis, S. elongates and 
Synechococcus sp, that reached stationary growth phase rapidly (within 
approximately 24 hours) an exposure period of 24 hours was adopted; ii) for 
A. flos-aque and Synechocystis sp. an exposure period of 48 hours was 
selected where they reach the stationary phase of the growth curve; iii) for the 
slower growing species (A. cylindrical, C. gracile and G. herdmanii) that had a 
lag phase over the first 24 hours that was followed by an increase in growth 
rate, reaching exponential growth between 48 and 96 hours, a 72 hour 




Figure 5. Growth curves of cyanobacteria species in microplates over 4 days with a starting 
inoculum of 2 AFU, temperature of 28°C, light intensity of 4000 lux and shaking the plates at 
140rpm. Each replicate represents growth in one well of a microplate. 
 
Reference toxicity testing 
The EC10 and EC50s after exposure to the reference toxicant, potassium 
dichromate, for each microplate and shake flask test are presented in Figure 6. 
The dose-response curves for each species obtained from both test designs are 
presented in supplementary material F along with the percentage growth 
inhibition across all assays for each species. Synechocystis sp. and C. gracile 
were the most sensitive species to potassium dichromate, followed by 
G. herdmanii. A. flos-aque was an order of magnitude less sensitive than these 
whilst the three species in the Synechococcus genera (S. leopoliensis, 
S. elongates and Synechococcus sp.) were the least sensitive overall. 
Variability in A. cylindrical growth rate was high in all concentrations and thus 
dose-response curves were not very reliable and estimates of effective 
concentrations spanned a wide range (e.g. EC50s of 0.96 to 154 mg/L). 
Synechococcus sp. also had high variability in growth rate in control conditions 
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that was reflected in the relatively wide confidence limits around the ECx 
estimates, but this did not appear to result in high variability between ECx 
estimates as seen in A. cylindrical. 
The results in Figure 6 show that, in most cases, the cyanobacteria show a 
consistent response to potassium dichromate in the microtitre well format and 
the results between assays were repeatable with ECx estimates within the 95% 
confidence limits of the other assays. Table 2 provides the coefficient of 
variation (CoV) in EC10 and EC50 estimates across all microplate assays and for 
assay groups that shared medium and parent inoculum cultures (Table 1). Most 
variability in responses occurred between assay groups whilst those that shared 
the same medium and parent inoculum had considerably less variability 
between assays. 
The pH of the controls of the different batches of media ranged between 8.2 ± 
0.2 and the pH of the highest test concentrations of potassium dichromate (100 
and 200 mg/L) decreased the pH to approximately 7.8 ± 0.2. 
Microplate assays were consistent with the traditional shake flask test design for 
A. flos-aque, S. leopoliensis, Synechocystis sp. and G. herdmanii with ECx 
estimates determined to be within the confidence limits calculated from the 
shake flask data (Figure 6). This was not the case in only C. gracile where the 
microplate assays estimated ECxs that were an order of magnitude higher than 
for the shake flask test. For G. herdmanii and S. leopoliensis wide confidence 





Figure 6 – Effective concentrations for growth inhibition of 50 and 10% of the population (EC50 
and EC10) and the associated 95% confidence intervals for eight cyanobacteria species in 
microplate and shake flask test designs exposed to potassium dichromate. Seven microplate 
assays and one shake flask test were run for each species (excluding a shake flask test for S. 
elongates and Synechococcus sp.). Assays run using the same media batch and parent starting 
inoculum: microplates 1 and 2 (circular symbols) with shake flask tests for C. gracile and G. 
herdmanii; microplates 3 and 4 (triangular symbols) with shake flask tests for A. flos-aque and 







Coefficients of variation 
Species 
 
MP 1 & 2 MP 3 & 4 MP 5, 6 & 7 All MPs 
A. cylindrical 
EC10 50.2 69.8 89.2 106.4 
EC50 139.7 22.9 51.4 96.5 
A. flos-aque 
EC10 10.3 11.3 134.9 64.6 
EC50 59.9 1.3 36.3 55.3 
C. gracile 
EC10 22.0 4.4 7.5 27.4 
EC50 8.6 1.3 2.7 5.4 
G. herdmanii 
EC10 9.7 2.0 0.7 73.9 
EC50 1.8 0.8 1.8 38.9 
S. elongates 
EC10 4.4 6.4 3.0 12.9 
EC50 1.3 0.0 1.3 11.0 
S. leopoliensis 
EC10 3.3 4.6 15.0 14.0 
EC50 1.6 13.3 3.2 9.0 
Synechococcus 
sp. 
EC10 0.03 2.9 4.8 19.5 
EC50 3.4 0.2 10.6 8.5 
Synechocystis sp. 
EC10 1.9 30.7 22.1 59.6 
EC50 6.5 3.4 9.4 59.5 
Table 2 – Coefficients of variation of the effective concentrations for growth inhibition 50 and 
10% of the population (EC50 and EC10) obtained from the microplate assays. MP=microplate. 





Bacteria, including cyanobacteria, play key roles in a variety of ecological 
functions on which ecosystems rely upon (Falkowski et al. 2008), but there is 
concern that protection limits determined in ERA are not protective of 
environmental bacteria populations and therefore neither the functional roles 
that they play. We developed a microplate assay for eight species of 
cyanobacteria, using the same environmental conditions to allow for the 
comparison of species sensitivity. After examining the performance with the 
reference toxicant potassium dichromate, the assay proved to be repeatable 
and consistent with a shake flask test design for seven out of the eight species. 
Cell density determination 
Both phycocyanin and chlorophyll a fluorescence were identified to be a 
suitable surrogate for quantifying biomass in the experimental design 
developed. Cyanobacteria have higher levels of phycocyanin than chlorophyll a 
(Nagai et al. 2013; Watras and Baker 1988) and phycocyanin fluorescence 
showed higher sensitivity and less variability in measured fluorescence at the 
lowest cell densities (Fig S.D1). The direct counting of Synechocystis sp., 
A. flos-aque, A. cylindrical and G. herdmanii, showed a similar linear 
relationship to the fluorescence measurements with the percentage dilution of 
the cultures, further supporting fluorescence as a suitable surrogate for cell 
density. These results are consistent with that reported by other authors 
showing that fluorescence of a phytochrome (chlorophyll or phycobiliproteins) 
has higher detection sensitivity than OD, allowing quantification at lower cell 
densities (Eisentraeger et al. 2003; Van Wagenen et al. 2014). Cyanobacteria 
cell density however, has not always been well correlated with phycocyanin 
fluorescence in environmental samples (Beutler et al. 2002; Kasinak et al. 
2014). It is possible that the poor correlation observed in these environmental 
samples is due to mixed phytoplankton communities being measured where cell 
size and morphology varies within and between species thus affecting 
estimation accuracy in cell density determinants. This is in contrast with our 
assay that uses single species cultures and controlled laboratory conditions 
encouraging more uniform growth. It is noteworthy that, in some instances, such 
as when assessing compounds that target or indirectly affect the light 
harvesting pigments, phycocyanin fluorescence may not always be a suitable 
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surrogate for cell density and care should therefore be taken when interpreting 
results from such assays (Debelius et al. 2009; Hadjoudja et al. 2009). 
In the case of A. flos-aque, there appeared to be two separate linear 
relationships between cell density and each surrogate measure (fluorescence of 
phycocyanin and chlorophyll A and OD). At higher cell densities the linear 
relationship had a similar gradient of slope, and thus appeared consistent with 
the other cyanobacteria. Whilst at lower cell densities (equivalent to 8AFU and 
below for phycocyanin fluorescence) a second linear relationship took a 
shallower slope (Fig 1). The reason for this is unknown and requires further 
investigation. If phycocyanin fluorescence in lower cell densities does indeed 
have a different linear relationship than at high cell densities, this measure may 
overestimate cell numbers below 8 AFU for A. flos-aque and effect the growth 
rate determined. These levels of fluorescence (≤8 AFU) are considerably lower 
than the fluorescence readings in control growth that range from 30 to over 100 
AFU over a 48 hour test period. The starting inoculum fluorescence is 
proportionately higher to the final fluorescence in wells that have had less 
growth and it might therefore be expected that this will have a disproportionate 
effect on the growth rate calculations in the highest test concentrations where 
growth is slowest. In this case, the uncertainty and potential overestimation 
caused by this is likely to affect the lower end of the dose-response curve whilst 
the higher end is less likely to be less affected. Any ECx calculations that are 
based on concentrations at which there is a fluorescence of 8 AFU or less (e.g. 
EC80) will therefore be less reliable whilst those based on concentrations with 
higher fluorescence (e.g. EC10 and EC20) more likely to be reliable. This should 
be carefully considered when interpreting the results. 
Test condition selection 
Growth rates and toxicity are influenced by many factors, including the 
metabolic state of the cells in the starting inoculum, the cell density of the 
starting inoculum, temperature and light intensity (Franklin et al. 2002; Yu et al. 
2007). In the development of this assay each of these were investigated in 
order to optimise the experimental conditions such that each species grew 
exponentially over a 24 to 72 hour period. The results showing the effects of 
temperature, light intensity and starting inoculum on growth rate all supported 
the ability to adopt the same test conditions across the eight species. This is of 
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importance because the primary objective of this microplate assay was to 
compare cyanobacteria sensitivity to test chemicals and consistent test 
conditions allow for a more robust species comparison which include eliminating 
the potential for differences in chemical behaviour in the test system (e.g. photo 
degradation rates can be assumed consistent if light intensity is the same 
across all species). 
A low starting inoculum was selected primarily in order to maximise the growth 
rate over the exposure. However there are additional benefits to using a low 
starting cell density; i) higher cell densities could lower toxicity estimation due to 
the dilution of compound relative to the total cell surface area (Franklin et al. 
2002); ii) higher cell densities can result in cell aggregation and/or higher 
quantities of extracellular polymeric substance that, in turn, is likely to affect the 
bioavailability and integrity of the test substance (Khunjar and Love 2011); iii) 
rapid pH changes that may affect bioavailability or test substance speciation are 
more likely to occur in closed systems, such as in this test design, when you 
have higher cell densities (Franklin et al. 2002); and iv) test assays with lower 
cell densities than those used in traditional ecotoxicity testing are more 
environmentally realistic. These examples are likely to be even more 
pronounced for chemicals such as antibiotics where the toxicity is observed at 
very low concentrations. 
For studies assessing growth inhibition, it is important that the population is in 
balanced growth (exponential growth phase) and indeed this is a pre-requisite 
of many standardised test regimes (Environment Canada 2007; ISO 2004; 
OECD 2011). Balanced growth is where the cells are replicating at the 
maximum growth rate possible given the environmental conditions that they are 
in with the assumption that reproducing cells are equally distributed across of all 
stages of the cell cycle and thus, at any given time interval the cell density 
increases at the same rate including the cellular components (ribosomes, 
proteins etc) (Campbell 1957; Schaechter 2015). This is of particular 
importance for growth inhibition studies as only a population in balanced growth 
can ensure reproducible results over time (Schaechter 2015) because cells are 
replicating at a constant rate defined by the environmental conditions, removing 
variation between assays. Populations in other phases of the growth cycle (lag 
and stationary phases) on the other hand, have cells that vary in metabolic 
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states and replication rates, leading to variability between one lag or stationary 
phase and the next. For example, in the lag phase cells are preparing 
themselves for exponential growth by synthesising all the cellular components 
required (RNA, proteins, enzymes) (Rolfe et al. 2012) and the lag phase will 
differ depending on the environmental conditions the cells were in previously 
and their metabolic state on inoculation. This is of even more importance in 
growth assays when using a surrogate such as phytochrome fluorescence for 
cell density because the energy invested in light harvesting pigments may vary 
depending on the metabolic state of the cells and their recent lighting 
environment (MacIntyre and Cullen 2005; Van Wagenen et al. 2014). 
If the toxicity assay is performed on cultures that are not in exponential 
balanced growth there may thus be some variation observed in assays 
performed over time. It isn’t however always possible to avoid initiating a lag 
phase. Indeed, in the case of our microplate assay, in order to obtain a single 
culture of cyanobacteria with a high enough cell density to inoculate the entire 
test the parent culture needs to be grown in a volume larger than what a 
microplate well will allow. As such, the transfer from (in this case) 50mL volume 
in 100mL conical flask to a 200uL microplate well, will initiate a lag phase as the 
cells readjust to the new environment and enter balanced growth. Some 
species will require more readjustment to the new conditions (longer lag phase) 
than others and of the species tested in our assay (and under our sampling 
regime) cyanobacteria in the Synechococcus genera to showed no evidence of 
a lag phase after inoculation whilst C. gracile had a lag phase that lasted 
between 24 and 48 hours. This is unavoidable and as such consideration must 
be given to how this may affect the dose-response curve and any calculations 
derived from it. For example, a lag phase at the beginning of the test may 
increase the apparent affect if exposed replicates take proportionately longer 
than the controls to exit the lag phase and enter balanced growth. Whereas if 
no lag phase was initiated and cells were continuously in balanced growth for 
the whole test the affect observed can be entirely attributed to the test chemical. 
Conversely, if the exposure period is long enough that the growth rate of the 
controls reaches stationary phase before the end of the test, the toxically 
affected (and slower growing) replicates may ‘catch up’, skewing the data and 
driving toxicity endpoints calculated to higher concentrations (smaller apparent 
affect). It is therefore important to both report the maximal growth rate and run 
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regular reference toxicity tests over time to be able to quantify the variability that 
may be expected and identify if a population is in balanced growth at a rate 
within expected norms. 
To best ensure toxicity testing was carried out during balanced growth for each 
species whilst avoiding the lag or stationary phase, two approaches could have 
been adopted. The first was to adopt exactly the same exposure conditions for 
all species and adjust the exposure time. The alternative was to adjust the 
exposure conditions (temperature, light intensity etc) to slow/increase the 
growth rate for each species and have the same length of exposure. This 
compromise reflects the biology of the species and is thus unavoidable. In 
these studies it was decided to keep test conditions the same and adjust the 
exposure period for reasons outlined previously given the objectives of the test 
to examine interspecies sensitivity. Since the exposure period changes 
between species, consideration must therefore be given to the properties of the 
test chemical, especially in regards to degradation. Where degradation occurs 
rapidly in <24-48 hours, it is crucial to base the dose-response on measured, 
rather than nominal, chemical concentrations. 
Reference toxicity testing 
The reference toxicity results showed that there was a very wide range of 
cyanobacteria sensitivity to potassium dichromate (based on EC50s there was 
over 2 orders of magnitude difference in sensitivity between the most sensitive 
species (C. gracile and Synechocystis sp.) and the least sensitive (S. 
leopoliensis and S. elongates)). These results are in accordance with published 
data for cyanobacteria. For example, Gupta et al. (2013) obtained 9 day EC50s 
for S. elongates and Synechocystis sp. of 44.1 and 3.53 mg/L respectively 
which are comparable with our EC50s of 56 - 76 mg/L for S. elongates and 0.14 
– 1.5 mg/L for Synechocystis sp. Microcystis sp., which was found to have 
generally high sensitivities to antibiotics compared to other cyanobacteria (Le 
Page et al. 2017), was found to have an EC50 of 0.211 mg/L (Halling-Sørensen 
2000) which is comparable with the two most sensitive species tested here, 
Synechocystis sp. and C. gracile. Yamagishi et al. (2016) determined an EC50 
for a marine Cyanobium sp. of 4.61 mg/L that was around and order of 
magnitude higher than our EC50s that ranged from 0.31 to 0.60 mg/L, although 
this may be expected since marine algae have been suggested to be more 
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tolerant to metals than freshwater species (Ebenezer and Ki 2013; Yamagishi et 
al. 2016). 
Chromium (VI) (the oxidation state of dichromate) is stable, highly soluble and 
enters bacterial cells via the sulphate uptake pathway (Mishra and Bharagava 
2016). Once in the cell chromium (VI) has several toxic effects due to its 
reduction into other, less stable, forms. For example, chromium (V) is genotoxic 
and chromium (III) binds to phosphates in the DNA (Labra et al. 2007; Mishra 
and Bharagava 2016; Plaper et al. 2002). Changes in morphology such as cell 
elongation and enlargement have been recorded in bacteria following exposure 
to chromium (VI) that may be due to effects upon membrane ligands (Mishra 
and Bharagava 2016). Combined, these various modes of action inhibit normal 
cell functioning, cell division and thus growth (Mishra and Bharagava 2016; 
Yamini Shrivastava et al. 2004). Although the mode of action once in the cell 
has been well investigated across many organisms, none have focused upon 
cyanobacteria and what drives the differences in interspecies sensitivity 
observed in in these results is therefore unknown. 
Some ECx estimates had wide confidence intervals due to increased uncertainty 
due to either i) not having enough test concentrations placed between the EC5 
and EC90 of the dose-response curve; and/or ii) due to one or two replicates that 
have a disproportionate influence on the dose-response model (i.e. some 
replicates having a much higher or lower growth rate compared to the others in 
that test solution). In many instances these data with a ‘disproportionate 
influence’ could be considered a statistical outlier and removed from analysis 
based upon a statistical test, however due to relatively high replication (10 for 
controls and five for exposure wells) it was considered more informative to 
include this variability in the calculations. 
The microplate assay results may be cause for concern in ERA because both 
species recommended for use in regulatory testing (A. flos-aquae and S. 
leopoliensis) were more than an order of magnitude less sensitive to potassium 
dichromate than the most sensitive species. Even with an assessment factor of 
10 applied to determine the predicted no effect concentration (PNEC) in ERA, 
employed to account for interspecies sensitivity and differences between 
laboratory and field environments, PNEC would not be protective of the two 
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most sensitive species here. Indeed, C. gracile was on average 50 times more 
sensitive than A. flos-aquae and 104 times more sensitive than S. leopoliensis. 
The microplate assays proved to be consistent across time with interassay 
variation, as determined by CoV, for five of the eight species was generally low, 
giving comparable ECx estimates between plate runs (CoV = 5 to 39% based 
on EC50s). For A. flos-aque, Synechocystis sp. and A. cylindrical however, 
variation was higher with CoVs based on interassay EC50s of 55, 60 and 97% 
respectively. When considering the CoVs, much variability was accounted for by 
the group in which the assay was run (groups a, b or c). Thus, either the 
different batches of media, test solution preparation and/or the different parent 
starting inoculum cultures are likely to be the main cause of the variability 
observed. One possible explanation could be due to differing pH between 
media batches since the pH of the different batches of media did differ slightly 
with a range of 8.2 ± 0.2. Furthermore, the pH of the highest test concentrations 
of 100 and 200 mg/L were approximately 7.8 ± 0.2 and there is therefore the 
potential for the pH to i) affect the toxicity of potassium dichromate and ii) affect 
the growth rate of the cells across treatments. This however, is not considered 
to explain the observed variation between assays here because where the 
EC50s differed between microplate runs (Figure 6), the difference was not 
consistent across species within the same assay grouping that shared the same 
media and starting pH. For example, the group in which ECxs were lower/higher 
than the remaining assays for G. herdmanii, C. gracile and Synechocystis sp 
were C, A and B respectively and if media pH was the cause of this we would 
expect to see the same effect in all species. Neither is there evidence from the 
published literature that suggests that differences in media pH would affect the 
toxicity. On the contrary, pH did not affect the toxicity of potassium dichromate 
on the green algae Raphidocelis subcapitata (Mayer et al. 1998), although the 
effects of pH on the cyanobacteria growth rate cannot be ruled out. 
It is much more likely therefore that the EC50 variability will be due to differences 
in the parent inoculum culture and the subsequent affects on the lag phase and 
balanced growth as discussed earlier. It is possible that a difference in cellular 
metabolic state in the parent culture when inoculating the assay and thus 
affecting the lag phase and time to balanced growth is responsible for this 
variability. Indeed, other authors have also identified the importance of cellular 
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metabolic state on growth assays (MacIntyre and Cullen 2005; Van Wagenen et 
al. 2014). 
Even with this potential source of variability, we consider that these results are 
adequate for the objectives of this assay: to provide a rapid screen to allow the 
comparison of cyanobacteria sensitivity. But if the data was to be used for 
regulatory purposes, further investigation is required to examine the affects the 
lag phase of these species, how to further optimise the tests to reduce any 
impact and if these species can even be considered suitable for regulatory 
testing within this test system. 
The reference toxicity testing showed that the microplate test produced 
comparable results to the shake flask test design for all species except 
C. gracile. The reason for the difference in performance in test designs 
observed for C. gracile here is unknown, but it may be due to differences in the 
lag phase and maximal growth rate (once in balanced growth) caused by the 
different environments in the shake flask and microplate test designs. Similar 
microplate assays using the green algae Desmodesmus subspicatus 
(Eisentraeger et al. 2003) and five periphytic riverine species (the green alga 
(Desmodesmus sp.), three diatoms (Achnanthidium sp., Nitzschia sp., Navicula 
sp.) and the cyanobacteria (Pseudanabaena sp.) (Nagai et al. 2013) also found 
that there was no significant difference in sensitivity between the 96 well 
microplate assay and their shake flask test designs. 
There are some instances where a microplate assay is either not applicable or 
is perhaps less appropriate than the shake flask test as an approach to 
determining toxicity to growth rate. These are mainly circumstances when 
plastic microplates are not suitable for the physical-chemical properties of the 
test chemical, where bioavailability is compromised due to the compound 
sticking to the plastic plate or alternatively due to loss by volatility. Riedl and 
Altenburger (2007) concluded that microplate test systems shouldn’t be used for 
chemicals with a log KOW higher than three or a Henry coefficient log KAW higher 
than −4. There are ways, however, to mitigate some of the problems caused by 
test chemical properties including glass coated plates, airtight seals and 
obtaining measured exposure concentrations by analytical assessment of the 
test compound at the start and end of the test. 
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Overall, these results demonstrate that the microplate assay we present would 
be suitable for the screening of toxic effects of chemicals on the growth rate of 
cyanobacteria. Compared to the shake flask test, the approach developed 
offers numerous advantages that include the use of less resources (time, 
substance, space and media etc.) and the ability to automate the majority of the 
test protocol. These advantages are particularly important in regards to the 
need for environmental data early in antibiotic development and in the 
screening of legacy chemicals registered previous to 2006 with little 
environmental data in order to prioritise compounds that may pose a risk to 
bacterial populations. 
We stress however, that we don’t advocate this assay as a replacement to the 
shake flask method for regulatory testing, although the results from these 
screens would be able to inform and guide such testing. We also highlight that 
although we consider the data from all species examined here to be useful in 
the context of examining cyanobacteria sensitivity, some species, including 
A. cylindrical and potentially Synechocystis sp. (due to their higher variability) 
and A. flos-aque (due to the non-linear relationship between cell density and 
fluorescence) may not be as suitable as the others. 
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Supplementary material A   
Phycocyanin spectral analysis 
 
 
Figure S.A1. Emission spectra for eight species of cyanobacteria and blank BG-11 media 
following excitation at 590nm. The dotted line indicates 652nm. 
A spectral scan of each species was undertaken on a Spectromax 
M5 microplate reader (Molecular Device Inc., USA) using the SoftmaxPro 3.0 
software (Molecular Devices). Briefly, to identify the optimal emission 
wavelength for phycocyanin, using an excitation wavelength of 590nm 
(Sobiechowska-Sasim et al. 2014) an emission scan was obtained for each 
species between the wavelengths of 620 and 700nm with an interval of 2nm. All 
species had emission spectra that peaked between 650 – 655nm with an 
average of approximate 652nm (Figure S1). As such they confirm the suitability 
of using excitation and emission wavelengths for phycocyanin at 590nm and 
650nm respectively. However, it is likely that measuring the fluorescence at 
these wavelengths will capture both phycocyanin and allophycocyanin to 
different degrees due to the spectra overlap for these pigments (Beutler et al. 
2002; Sobiechowska-Sasim et al. 2014). Since our primary aim is to develop a 
simple, medium throughput assay, attempts to correct for this overlap and relate 
cell density to just one pigment was not deemed necessary in this instance as; 
i) fluorescence at these wavelengths was found to be proportional to cell 




It should be noted however that wavelengths can change between species and 
may differ between measurements on extracted vs in vivo methods due the 
effects of membranes and proteins in the cell (Sobiechowska-Sasim et al 2014). 
Thus, further optimisation would be required if introducing extra species for use 
in this microtitre assay. 
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T1 BL T2 BL T3 BL T4 BL T5 BL T6 BL T7 BL T8 BL T9 BL T10 BL 
Control 
BL 
Figure S.B1. A schematic plate map of the layout of replicates in the mirotitre plate. 
 
The ten control replicates run along the centre of the plate in parallel to the 
concentration gradient where a significant directional effect, caused by uneven 
environmental conditions across the plate (e.g. light intensity) or by the 
contamination from surrounding wells (e.g. volatile compounds) can be 
identified. Five replicates of each test concentration run from column 2 to 11. 
The outer cells of the 96 well microplate will have no addition of algal inoculum, 
creating 16 control blanks and two blanks per concentration. 




Supplementary material C   
Dose-Response model code 
Dose-response models were established using the using the drc package (Ritz 
et al. 2015) in r (version 3.3.0; R Project for Statistical Computing, Vienna, 
Austria). 
Before establishing the model, the data was examined to identify replicates 
where growth rates that could not be calculated. The three reasons for this and 
our rules for the handling of them are given below: 
1. The fluorescent signal at the start of the test is a negative number 
because the background/blank value is higher than the exposure well. 
The log of the negative value cannot be calculated and therefore neither 
could the growth rate. 
a. In these cases the replicate was excluded from further analysis as 
a reliable starting value could not be established in which to 
calculate growth rate 
2. The growth rate is negative as the fluorescence at the end of the test is 
less than that at the beginning. Although the population size decreased 
(grew negatively) it is unknown from this fluorescence data if cells were 
alive or dead (with phycocyanin still fluorescing). 
a. In these cases the growth rate was fixed at 0. 
3. The fluorescent signal at the end of the test is a negative number 
because the background/blank value is higher than the exposure well. 
The log of the negative value could not be calculated and therefore 
neither could the growth rate. 
a. In these cases the replicate considered to have zero growth since 






The data were then examined and the optimal distribution was selected for the 
data based on log-likelihood score (distributions examined were 3, 4 or 5 
parameter log-logistic distributions and 4, or 5 parameter weibull 1 or 2 
distributions). Model residuals were examined for normality and 
heteroscedasticity and residuals with a disproportionate effect on the model 
were identified using cooks distance (>0.5 is considered to have a 
disproportionate effect). Any outliers were individually examined and excluded if 
biologically justified and the dose-response model re-run. Replicates that did 
have a disproportionate effect on the model but without any reason to suggest 
an experimental error (e.g. not inoculated correctly) were included in the 
analysis rather than excluded as an outlier, even if statistically justifiable, in 
order to include the inherent variability of the species and test designs. This 
may result in wider confidence intervals and/or less statistical power. 








# Make starter model 
SpeciesX.m1<-drm(GR~Conc,  
 data=Data,  
 fct=LL.3(), 
 na.action = na.omit) 
# Identify best distribution of data for dose response curve: 
mselect(CYAN.m1, list(LL.3(), LL.4(), LL.5(), W1.3(), W1.4(), W2.4())) 
# Make best fitting model 
SpeciesX.m1<-drm(GR~Conc,  
 data= Data,  
 fct=LL.4(), 
 na.action = na.omit) 
# Plot model 
plot(SpeciesX.m1, xlab = bquote('Concentration ('*mu~'g/L)'), ylab = "Growth rate (per day)", 
 main = "SpeciesX", 
 broken = TRUE, type = "all", 
 col = TRUE, legendPos = c(10,2), cex.legend = 0.5) 
# Estimate EC50, EC20 and EC10 
ED(SpeciesX.m1, c(10, 20, 50), interval = "delta") 
# Summarise the model parameters: 
summary(CYAN.m1) 
# Graphical analysis of residuals – check for heteroscedasticity 
plot(residuals(CYAN.m1) ~ fitted(CYAN.m1), main="Residuals vs Fitted") + 
 abline(h=0) 
# Graphical analysis of residuals – check for heteroscedasticity 
qqnorm(residuals(CYAN.m1)) 
qqline(residuals(CYAN.m1)) 
# Identification of outliers – cooks distance of > 0.5 indicates data had a disproportionate




Supplementary material D   
Cell density validation 
For each species a dense culture of cells was serial diluted 15 times by 50% 
with the assumption that with each 50% dilution the cell density was also 
halved. The percentage dilution, therefore, was considered to be proportional to 
cell density. 
In three replicates for each dilution optical density (at 750nm), phycocyanin and 
chlorophyll A fluorescence (determined at excitation and emissions wavelengths 
of 590 & 650nm and 420 & 681nm respectively) were measured. Where the cell 
size and density allowed reliable results, cell density was also counted in a 
haemocytometer. The correlation between the different cell density 
measurements with the percentage dilution was determined to assess which 
was the most suitable surrogate for cell density. 
The species that had cell sizes that enabled reliable direct counts were A. flos-
aque, A. cylindrical, Synechocystis sp. and G. herdmanii. The optical density 





Figure S.D1. The relationship between cell density and phycocyanin florescence, chlorophyll A 
fluorescence, optical density and direct counting in a haemocytometer (where cell size and 
density allowed) in cyanobacteria. Solid lines show the general linear model and dashed lines 
showing the 95% confident limits 
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Supplementary material E   
Effects of temperature, starting inoculum and light intensity on growth 
rate 
The effects of temperature, starting inoculum and light intensity on the growth 
rate of the cyanobacteria species was investigated to provide data that allowed 
the selection of suitable growth conditions for each species in the microplate 
assay. 
Temperature (ranging from 20 to 30°C) and starting inoculum (ranging from 2 to 
10 AFU of phycocyanin fluorescence at excitation and emission wavelengths of 
590nm and 650nm respectively) was assessed at the same time under a 
constant light intensity of 6000 Lux and with shaking at 140rpm. The growth 
rate of 15 replicates (quarter of a 96 well microplate with dilution water control 
(DWC) blanks in rows A and G) of each species at each combination of 
temperature and starting inoculum was determined over 72 hours. 
The effect of light intensity (4000 – 12000 lux) on growth rate was assessed at 
28°C and with a nominal starting inoculum of 2 AFU and shaking at 140 rpm. 
The growth rate 42 replicates (half a plate with DWC blanks in all outside wells) 
were determined at each light intensity over 72 hours. 
The effects of temperature and starting inoculum were investigated by 
establishing a generalised least squares model using the ‘nlme’ package (J 
Pinheiro et al. 2017) with the restricted maximum likelihood method (Bates et al. 
2015) in R (version 3.3.0; R Project for Statistical Computing, Vienna, Austria). 
Where the data was not homoscedastic the model was weighted by the 
variance structure in the fixed variable. The two models were compared using 
the Akaike information criterion and the best fitting model used. Pairwise 
comparisons were performed to establish significant differences on growth rate 
caused by temperature (using data from a starting inoculum of 2 AFU only) and 
significant differences in growth rate caused by starting inoculum (using data 
from 28°C only) using the ‘lsmeans’ package (Lenth 2016). The effects of light 




The results showing the effect on growth rate of temperature and starting 
inoculum are both presented in figure S.E1 and the results of the pairwise 
comparisons are presented in table S.E1. 
The results showing the effect on growth rate of light intensity are presented in 










Significance level (p) 
Temperature comparison (°C) ANA1 ANA2 SYNch 1 SYNch 2 SYNch 3 SYNcy CYAN GEM 
20 – 22 < 0.001 NS < 0.001 < 0.001 < 0.01 NS < 0.001 NS 
20 – 25 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 NS 
20 – 28 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 N/A NS 
20 – 30 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 N/A NS 
22 – 25 < 0.001 < 0.01 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 NS 
22 – 28 < 0.001 < 0.05 < 0.001 < 0.001 < 0.001 < 0.001 N/A NS 
22 – 30 < 0.001 NS < 0.001 < 0.001 < 0.001 < 0.001 N/A NS 
25 – 28 NS NS < 0.05 < 0.001 < 0.001 < 0.001 N/A NS 
25 – 30 < 0.05 NS < 0.001 NS < 0.001 < 0.001 N/A NS 
28 – 30 NS NS < 0.01 NS NS < 0.001 N/A NS 
Starting inoculum comparison 
(AFU)         
2 – 5 < 0.05 NS < 0.05 < 0.001 < 0.01 NS N/A NS 
2 – 8 < 0.001 NS < 0.01 < 0.001 < 0.001 NS N/A NS 
2 – 10 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 N/A < 0.05 
5 – 8 NS NS NS NS NS NS N/A NS 
5 – 10 < 0.01 < 0.01 < 0.01 NS < 0.001 < 0.001 N/A < 0.001 
8 – 10 NS < 0.05 NS NS < 0.05 < 0.001 N/A NS 
Table S.E1 Table showing results of the pairwise comparisons (p values) of the effect of temperature and starting inoculum on the growth rate of eight 
cyanobacteria species. NS – Not Significant (P >0.05); N/A – Not Applicable; ANA1 - A. flos-aque; ANA2 - A. cylindrical; SYNch 1 - S. leopoliensis; 








Significance level (p) 
Light intensity comparison (Lux) ANA1 ANA2 SYNch 1 SYNch 2 SYNch 3 SYNcy CYAN GEM 
4000 – 6000 < 0.01 < 0.01 NS < 0.001 < 0.01 NS N/A < 0.001 
4000 – 8000 < 0.0001 < 0.05 < 0.05 NS NS < 0.0001 N/A NS 
4000 – 10000 < 0.05 < 0.0001 < 0.01 < 0.0001 < 0.01 < 0.05 N/A < 0.05 
4000 – 12000 NS < 0.0001 < 0.05 NS NS NS N/A < 0.001 
6000 – 8000 < 0.05 NS < 0.05 < 0.01 < 0.001 < 0.001 N/A NS 
6000 – 10000 NS < 0.001 < 0.01 < 0.0001 < 0.0001 NS N/A NS 
6000 – 12000 NS < 0.01 < 0.05 NS NS NS N/A NS 
8000 – 10000 NS < 0.001 NS < 0.0001 < 0.05 < 0.05 N/A NS 
8000 – 12000 < 0.01 < 0.001 NS NS < 0.05 < 0.01 N/A < 0.05 
10000 – 12000 NS NS NS < 0.0001 < 0.001 NS N/A NS 
Table S.E2 Table showing results of the pairwise comparisons (p values) of the effect of light intensity on the growth rate of eight cyanobacteria 
species. NS – Not Significant (P >0.05); N/A – Not Applicable; ANA1 - A. flos-aque; ANA2 - A. cylindrical; SYNch 1 - S. leopoliensis; SYNch 2 - S. 




Supplementary material F  
Reference toxicity with potassium dichromate 
Dose-response curves 
 




































Percentage growth inhibition of microplate assays 
 
Figure S.F9 – Percentage inhibition of growth rate for eight species of cyanobacteria exposed to potassium dichromate. Blue lines represent the 
microplate assay test results (7 assays) and the red line represents the shake flask test (one assay). Assays run using the same media batch and 
parent starting inoculum: microplates 1 and 2 with shake flask tests for C. gracile and G. herdmanii; microplates 3 and 4 with shake flask tests for A. 
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Once released into the environment antibiotics can kill or inhibit the growth of 
bacteria, leading to affects upon community structure and ecosystem function. It 
is the role of environmental risk assessment (ERA) to establish protection limits 
at which adverse effects are of an acceptable level, but recent evidence 
suggests that the current approach may not be adequate to do so. In this study 
we assess the differences in interspecies sensitivity of eight species of 
cyanobacteria to seven antibiotics across three different modes of action 
(cefazolin, cefotaxime, ampicillin, sufamethazine, sulfadiazine, azithromycin and 
erythromycin). We used a microplate assay to measure growth rate inhibition 
that was specifically designed to allow for direct assessment of interspecies 
sensitivity across equivalent culturing conditions. For these species and 
antibiotics, we found that interspecies variability is dependent on the mode of 
action and can vary by up to 70 fold for β-lactams. As a consequence, a 
protection limit based on one of the regulatory approved cyanobacteria species 
was not protective for cefazolin. We also found that cyanobacteria may be 
inappropriate organisms for the setting of protection limits for sulfonamides due 
to their relative insensitivity. Our findings support calls for additional and more 





Antibiotics are designed to kill or inhibit the growth of bacteria and are 
fundamental in the treatment of pathogens in human and veterinary healthcare. 
Following the release of antibiotics into the environment however, non-target 
bacteria may be affected and the vital ecosystem services they facilitate may be 
at risk from being disrupted (Grenni et al. 2018; Kümmerer 2009). Aquatic 
ecosystems may be especially at risk due to antibiotic inputs received from 
manufacturing plant and hospital effluents, wastewater treatment plants 
(WWTP), and run-off from agriculture. Indeed, effluents from manufacturing 
plants and hospitals can be sources of very high environmental inputs of 
antibiotics, where they have been measured in milligrams per litre 
concentrations (Batt et al. 2007; Brown et al. 2006; Jaimes-Correa et al. 2015; 
Larsson 2014; Larsson et al. 2007; Li et al. 2008; Watkinson et al. 2009). 
The purpose of environmental risk assessment (ERA) is to assess the risk 
chemicals pose to organisms and populations; and from this to establish 
suitable protection limits for environmental communities and the ecological 
functions they perform. For bacterial communities, ecosystem functions 
potentially at risk include primary productivity, nutrient cycling and the 
immobilisation and transformation of contaminants (Dopheide et al. 2015). The 
ability of ERA to establish adequate protection limits for antibiotics has recently 
been questioned because of the limited focus on relevant bacteria species that 
provide these ecosystem services (Agerstrand et al. 2015; Brandt et al. 2015; 
Le Page et al. 2017). This is because ERA relies upon just two prokaryotic 
toxicity tests; the activated sludge respiration inhibition test (ASRIT) and a 
cyanobacteria growth inhibition test. The ASRIT however, is not sensitive to 
antibiotics (Kümmerer 2009; Le Page et al. 2017), and consequently just a 
single species of cyanobacteria is used to represent all bacterial diversity in an 
assay that only concerns a single functional endpoint conveyed by bacteria; 
primary productivity. 
The predicted no effect concentration (PNEC) in ERA is derived to protect 
wildlife populations, ecosystem structure and function. This is calculated by 
taking the no observed effect concentration (NOEC) from the most sensitive 
species in the ERA test battery (likely to be cyanobacteria in the case of most 
antibiotics) and applying an assessment factor of 10 to account for differences 
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in species sensitivity and extrapolation from the laboratory to field 
environments. Tests on other species, including an invertebrate and fish, are 
also included within the antibiotic ERA, but these tend not to be sensitive to 
antibiotics (antibiotics are designed not to be toxic to vertebrates at therapeutic 
levels; (Le Page et al. 2017)). 
In this study we focus on cyanobacteria due to their current key role within ERA 
and because they are a very diverse bacterial clade of photoautotrophs that are 
ubiquitous in both aquatic and terrestrial environments, play key roles in many 
bacterial communities, and they have a range of important ecological functions 
such as primary production and nitrogen fixation (Falkowski 1997). 
In a recent meta-analysis of all publicly available literature we identified that the 
sensitivity of different species of cyanobacteria may vary by up to five orders of 
magnitude, far exceeding the assessment factor of 10 used when establishing 
the PNEC used in risk assessment frameworks (Le Page et al. 2017). The afore 
mentioned meta-analysis was based on an assessment of published data and 
although it adopted best practice in the prioritisation of these data in 
accordance with the ‘Criteria for reporting and evaluating ecotoxicity data’ 
system (Moermond et al. 2016), ultimately it was reliant upon studies performed 
using different methodologies and test conditions in different laboratories by 
different study personnel. Accurate numeration and confidence in relative 
sensitivities to antibiotic exposure in cyanobacteria species are best derived 
through comparative experiments conducted under the same test design 
without inter-laboratory variation. 
To this end we optimised a microplate growth inhibition assay to assess the 
effects of antibiotic on population growth for eight species of phylogeneticaly 
diverse cyanobacteria (as assessed by their genome sequences (Shih et al. 
2013)) culturable under laboratory conditions that are of environmental 
relevance, namely, Anabaena flos-aquae, Synechococcus leopoliensis, 
Anabaena cylindrica, Synechococcus elongates, Synechococcus sp., 
Synechocystis sp., Cyanobium gracile and Geminocystis herdmanii. 
Seven antibiotics were selected that spanned both a range of antibiotic classes 
across the main antibiotic modes of action (MoA). These included three cell 
envelope synthesis inhibiting antibiotics, namely cefazolin and cefotaxime (1st 
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and 3rd generation cephalosporins respectively) and ampicillin (penicillin); the 
DNA synthesis inhibitors, sulfadiazine and sulfamethazine (sulfonamides); and 
the protein synthesis inhibitors erythromycin and azithromycin (macrolides). The 
macrolides, azithromycin and erythromycin are priority compounds in both the 
EU watch list (Carvalho et al. 2015) and US EPA contaminate list 3 (US EPA 
2009). Cefazolin and sulfamethazine also have no ecotoxicological data 
available for cyanobacteria in the open literature. Sulfadiazine, cefotaxime and 
azithromycin have very limited ERA relevant ecotoxicological data (Le Page et 
al. 2017). 
Cephalosporins and penicillins, that are β-lactams, target penicillin binding 
proteins that catalyse the building of the peptidoglycan cell membrane of 
bacteria. They normally enter the environment in their parent form after 
excretion from humans (80% and 40-60% of cefazolin and cefotaxime 
respectively, are unchanged after excretion in urine (El-Shaboury et al. 2007)). 
They are therefore most commonly found in WWTP effluents (Mutiyar and Mittal 
2014; Ribeiro et al. 2018). Ampicilin, on the other hand is largely removed in 
WWTPs through adsorption to the sewerage sludge (Li and Zhang 2010). Once 
released in the environment cefazolin, cefotaxime and ampicilin are considered 
to be relatively stable and to undergo relatively slow rates of hydrolysis under 
natural conditions, but they can be rapidly degraded via photolysis or β-
lactamase enzymes released from environmental bacteria (Arsand et al. 2018; 
Fabbri et al. 2015; Jiang et al. 2010; Li and Zhang 2010; Wang and Lin 2012). 
Sulphonamides inhibit DNA synthesis by preventing the production of folic acid, 
a key precursor in the DNA synthesis pathway. They do this by acting as a 
structural analogue of para-aminobenzoic acid and competitively inhibit the 
enzyme dihydropteroate synthase that catalyses the reaction between para-
aminobenzoic acid and dihydropteroate diphosphate to create dihydropteroic 
acid (Bermingham and Derrick 2002). As with the β-lactams, sulphonamides 
also tend to be resistant to hydrolysis and environmentally persistent, although 
they too are reported to be light sensitive (Kümmerer 2009). Sorption to 
sewerage sludge is an important removal mechanism in WWTPs for 
sulphonamides (Kümmerer 2009; Tolls 2001). 
The drug target for the macrolide antibiotics is the 50S subunit of the ribosome, 
which is reported to be evolutionarily conserved across bacterial species 
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(Lecompte et al. 2002; Yutin et al. 2012). Macrolides work by binding to a 
section of the nascent peptide exit tunnel of the ribosome from which the 
protein being synthesised emerges. When a specific amino acid sequence, 
termed a macrolide arrest motif, reaches the peptidyl transferase centre of the 
ribosome (where amino acids are bound together to build the protein), the 
presence of the macrolide prevents the ribosome from catalysing the reaction 
and thus stalls the ribosome and stops the protein from being formed (Vázquez-
Laslop and Mankin 2018). Both azithromycin and erythromycin are considered 
to be fairly persistent in nature and enter the environment largely via WWTP 
effluents (Leung et al. 2012; Schafhauser et al. 2018; Xu et al. 2007). 
We have previously established a microtitre plate assay to assess toxicity for 
population growth effects in cyanobacteria with equivalence to the traditional 
shake flask approach used in regulatory studies for ERA (Chapter 4). Using this 
assay we compared the effects of seven antibiotics (with a range of MoAs) on 
the growth rate of eight species of cyanobacteria and consider the implications 
of our findings for ERA. 
Materials and methods 
Test organisms and maintenance 
We selected eight cyanobacteria species: Anabaena flos-aquae (CCAP 
1403/13A), Synechococcus leopoliensis (CCAP 1405/1), Anabaena cylindrica 
(PCC 7122), Synechococcus elongatus (PCC 6301), Synechococcus sp (PCC 
6312), Synechocystis sp (PCC 6803), Cyanobium gracile (PCC 6307) and 
Geminocystis herdmanii (PCC 6308). A. flos-aquae and S. leopoliensis were 
both obtained from the Culture Collection of Algae and Protozoa (CCAP) and 
are recommended species in the OECD 201 test guideline and as such 
represent species that may drive an ERA. The remaining species were obtained 
from the Pasteur Culture collection of Cyanobacteria (PCC) and were selected 
based on the following: i) there was an exponential growth rate of a magnitude 
to achieve measurable differences in biomass within 72 hours using the same 
laboratory conditions as the other selected species (media, temperature, 
shaking and light intensity); 2) environmental relevance; and 3) a wide range of 
phylogenetic diversity within the genome sequenced cyanobacteria in (Shih et 
al. 2013). Anabaena, more generally, are filamentous, nitrogen fixers that are 
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found globally and are important species in harmful algal blooms. 
Cyanobacteria from the genus Synechococcus are diverse unicellular 
picoplankton, with a large global distribution and represent important primary 
producers, especially in oligotrophic environments (Callieri et al. 2007; Palenik 
et al. 2003). Species belonging to the Synechocystis genus are also widely 
distributed and Synechocystis sp (PCC 6803), the strain utilised in this study, 
was the first fully sequenced photosynthetic autotroph (Kaneko et al. 1996) and 
is an important model organism for photosynthesis. As with the Synechococcus, 
C. gracile, is also a picoplanktonic species and G. herdmanii has a much larger 
cell size with a diameter reaching up to 5μm (Jana et al. 2009). 
Continuous cultures of exponentially growing cyanobacteria were maintained in 
50mL BG-11 medium (Rippka et al. 1979); laboratory grade constituents of 
>97% purity). Cultures were incubated in Multitron II incubators (Infors) under 
test conditions. Cultures were visually examined using an inverted light 
microscope to ensure cells appeared healthy before testing. 
Antibiotics 
Seven antibiotics were selected: cefozolin sodium salt (CAS: 27164-46-1; purity 
≥98%; Tokyo Chemical Industry UK Ltd (TCI)), cefotaxime sodium salt (CAS: 
64485-93-4; purity ≥ 91.6%; Sigma-Aldrich), ampicillin trihydrate (CAS: 7177-
48-2; purity ≥98%; TCI), sulfadiazine (CAS: 68-35-9; purity ≥99%; Sigma-
Aldrich), sulfamethazine (CAS: 57-68-1; purity ≥98%; TCI), azithromycin 
dihydrate (CAS: 117772-70-0; purity ≥98%; TCI) and erythromycin (CAS: 114-
07-8; purity ≥98%; TCI). A summary of the chemical properties is given in table 
1. 
Growth inhibition assays 
Growth rate inhibition assays were performed in 96 well microplates that 
followed a procedure adapted from the (Environment Canada 2007) and 
(OECD 2011) test guidelines. Biomass was measured using phycocyanin 
fluorescence as a surrogate (excitation = 590nm, emission = 650nm, cut-off = 
635nm; bottom read mode; Spectromax M5 with Softmax® Pro software 
(Molecular Devices)). This has been previously demonstrated to have a linear 
relationship with cell density for all species except A. flos-aquae that had a 
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shallower gradient at cell densities below eight artificial fluorescence units 
(AFU; chapter 4). 
A pre-culture for each species was prepared three to four days prior to the start 
of the test in 50 mL of BG-11 and under exposure conditions (and in the 
absence of the antibiotic) in order to obtain exponentially growing cells. A 
cyanobacteria inoculum was prepared in BG-11 medium at a phycocyanin 
fluorescence of 4 AFU (twice the nominal starting inoculum). Following this a 
geometric series of stock solutions for each test concentration were prepared in 
BG-11 medium at twice the nominal test concentrations. 
The test solution (100μL) was added to 100 μL of cyanobacteria inoculum to 
achieve a final cyanobacteria concentration at 2 AFU at the nominal test 
concentration in each well. Assays were conducted in non-transparent, 96 well 
plates (Greiner Bio-one item no. 650201), sealed with AMPLIsealTM sealer 
(Greiner Bio-one item no. 676040) to prevent water loss due to evaporation 
over the test period. The plate layout for the incubations described is provided 
in Figure S.A1. 
The assays were run in Multitron II incubators (Infors) under the following test 
conditions: light intensity = 4000 lux, temperature = 28 +/- 1°C and shaking = 
140 rpm. The test lengths were optimised to best ensure toxicity testing was 
carried out during exponential growth for each species whilst avoiding the lag or 
stationary phase and as such the following exposure lengths were selected for 
each species: i) 24 hours for the fastest growing species, S. leopoliensis, 
S. elongates and Synechococcus sp; ii) 48 hours for A. flos-aque and 
Synechocystis sp, with the exception for the exposure of the Synechocystis sp. 
to sulfadiazine where the exposure period adopted was 72 hours (rather than 
48 hours due to a slower growth rate than expected in all replicates); iii) 72 
hours for the slower growing species, A. cylindrical, C. gracile and G. herdmanii. 
Daily cell density determinations were obtained for each culture well via 
measurement of phycocyanin fluorescence (excitation = 590nm, emission = 
650nm, cut-off = 635nm). 
pH was measured in the stocks and in a replicate of each test concentration for 
each species at the end of the test using micro pH meter (Jenco 6230N; pH 
probe: Hanna instruments HI1083) to ensure fluctuations did not exceed the 
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acceptable limits of ±0.2 as defined by most standardised test guidelines 
(OECD 2011). 
For the azithromycin exposure, dimethyl sulfoxide (DMSO) was used as a 
solvent carrier at a concentration of 10 μl/L. Ten solvent control replicates were 
employed and comparisons of the dilution water control and solvent control 
replicates for all species are provided in Supplementary material A. Growth rate 
was found not to be significantly different from the dilution water control for any 
cyanobacteria with exception of A. flos-aquae and S. elongates where small but 
significant decreases in growth rate (p = 0.01; Supplementary Material A, Figure 
S.A2) were observed in the solvent control (t.test in R, version 3.3.0; R Project 
for Statistical Computing, Vienna, Austria). All dose-response curves and 
subsequent statistical comparisons with antibiotic exposures were performed 
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12.45 (acid)   
9 (base) 
1.55 43.3 
Table 1 – Chemical properties of antibiotics.a according to drugbank (www.drugbank.ca). 
b predicted by ChemAxon (www.chemicalize.org) 
Chemical analysis 
The concentrations of antibiotics in the stocks and in three exposure replicates 
for each species at the end of the tests were measured using LC-MS (method 
supplied in Supplementary material A). Following the final cell density 
determination of the assay, microplates were centrifuged at 4000 rpm for 30 
minutes. 150μL of supernatant was carefully removed and transferred to a deep 
well microplate (96-well, 2ml; Porvair Sciences) with acetonitrile (50% volume). 
Where necessary samples were further diluted to within the calibration range. 
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All chemical concentrations are reported as free acids and bases. 
In the instances where analytical data was <LOQ or where an extraction error 
occurred (see Supplementary material B and Table S.B1) these 
samples/replicates were excluded from further analysis (detailed in Table S.B1) 
Limits of quantification (LOQ) for each antibiotic are given in Table S.B2. 
Statistical analysis 
Growth rate calculations 
Growth rate of cyanobacteria was calculated according to equation 1. 




where  X = cell density at time i and j 
t = time at time i and j 
 
Dose-response modelling and ECx determination 
Dose-response curves were fitted in r (version 3.3.0; R Project for Statistical 
Computing, Vienna, Austria) using the drc package (Ritz et al. 2015). The 
known distributions; 3, 4 and 5 parameter log-logistic distributions and 4 and 5 
parameter Weibull 1 and 2 distributions were fitted to the growth rate data for 
each antibiotic and each species and the optimal distribution selected based on 
log-likelihood score. From this fitted distribution estimates of the 10% and 50% 
effective concentrations (ECx) and associated confidence limits were 
determined. The growth rate data handing and standard code used for each 
species is presented in Supplementary material A. 
Results 
The dose-response curves for growth inhibition for each antibiotic on the eight 
species of cyanobacteria are presented in Figure 1 based upon geometric 
mean measured test concentrations. The data in Figure 1 also shows the 
maximum measured environmental concentration (MEC; derived from the UBA 
‘Pharmaceuticals in the environment database’, (Umwelt bundesamt 2018)). 
The measured concentrations of the antibiotics in each microplate assay are 
provided in the Supplementary material B (graphs S.B1 – S.B14). Reductions in 
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antibiotic concentrations due to the presence of the cyanobacteria in the 
replicates, determined as the difference in percentage between exposure 
replicates (cyanobacteria present) and blank replicates (without cyanobacteria) 
are also illustrated in the Supplementary material (graphs S.B15 – S.B21). 
The EC10s, EC50s and NOECs for the experimental data are given in Table 2 
(raw data are provided, and shown graphically in Supplementary material C). All 
dose-response analyses (ECx’s) are based upon geometric mean measured 
test concentrations. The pHs at the start and the end of the tests are given in 
Supplementary material D. 
Exposure concentrations 
Cefazolin: Measured cefazolin concentrations were consistently low also across 
all stocks (17 to 42% of nominal) indicating low stability. Mean measured 
concentrations (calculated using a geometric mean of the concentrations at the 
start (stocks) and end (exposure replicates)) of cefazolin in the exposure 
replicates ranged between 14 to 32 % of the nominal concentrations (Fig S.B1). 
The greatest losses of cefazolin (Fig S.B1, S.B2 and S.B17) occurred in the 
exposure replicates of S. elongates and Synechococcus sp. (that were lower 
than in the blank replicates (no cyanobacteria) by an additional 10 to 36% 
respectively). Reductions in antibiotic concentration in the presence of 
cyanobacteria also occurred for A. flos-aquae (10 to 25% further reduction) and 
A. cylindrical (between 6 and 12% further reduction S.B15). 
Cefotaxime: Measured concentrations of cefotaxime in the stock solutions were 
between 25 and 52% of nominal in the stock solutions, indicating low stability. 
Mean measured concentrations of cefotaxime in the exposure replicates ranged 
between 18 and 44% of nominal (Fig S.B3). The presence of the cyanobacteria 
had variable effects on the levels of cefotaxime with the greatest reductions in 
the exposure replicates for the three species from the Synechococcus genus 
(particularly at the higher exposure concentrations of cefotaxime (Fig S.B16)). 
Ampicillin: Measured ampicillin concentrations in the stocks were between 78 
and 102% with exception of the lowest concentration (0.83 μg/L) that was 124% 
of nominal. Mean measured concentrations of ampicillin in the exposure 
replicates ranged between 44 and 95% of nominal (Fig S.B5). In the presence 
of all species of cyanobacteria there were between 10 and 30% reductions in 
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the level of measured ampicillin compared with in the blank replicates without 
bacteria. This was most pronounced in A. cylindrical exposure replicates where 
ampicillin was reduced by 35 and 68% compared to the blanks (S.B17). 
Sulfadiazine: Stock solutions at the start the test were between 88 and 142% of 
nominal, with the exceptions for the nominal concentrations of 6.6 and 407 μg/L 
that were 41 and 71% of nominal, respectively. Mean measured concentrations 
of sulfadiazine in the blanks were between 101 and 142% of nominal 
(Fig S.B7). Additional reductions in sulfadiazine due to the presence of the 
cyanobacteria varied across tests concentrations (S.B18). 
Sulfamethazine: Solutions at the test outset were between 81 and 118% of 
nominal, with exception of the highest concentration (nominal 100,000 μg/L; 
136% of nominal). Mean measured concentrations of sulfamethazine in the 
exposure replicates ranged between 87 to and 134% of nominal (Fig S.B9). 
There were extraction errors for nominal 907 and 1633 μg/L in the S. elongates 
exposure and these were not included in the analyses. Additional reductions of 
sulfamethazine in the tests due to the presence of cyanobacteria were variable 
(between 13 to 23%, S.B19). The exceptions to this were for A. flos-aquae and 
Synechocystis sp. 
Erythromycin: Stock solutions at the start of the test were between 54% and 
109% of nominal. Mean measured concentrations of erythromycin in the 
exposure replicates were between 71 and 100% of nominal (Fig S.B11) with 
exception of the nominal 3.77 μg/L test concentration (53% of nominal). 
Erythromycin exposure concentrations were further decreased by up to 50% 
over the exposure period in the exposure and blank replicates and the presence 
of the cyanobacteria in the exposure replicates caused additional erythromycin 
losses of on average of 10 and 20% (but up to 60%) compared to the blank 
replicates (Fig S.B20). 
Azithromycin: Measured stock solutions at the start the test were between 
108% and 156% of nominal. Mean measured concentrations of azithromycin in 
the exposure replicates ranged between 23 and 79% of nominal (Fig S.B13). 
Azithromycin concentrations in the exposure and blank replicates at the end of 
the exposures were considerably lower, by up to 96%. The presence of all 
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species of cyanobacteria had an effect of reducing the test concentrations 
further compared to the banks (by between 10 and 15%; Fig S.B21). 
Growth inhibition for cell membrane inhibitors: 
Cefazolin: Across the different cyanobacteria species, the EC10s for cefazolin 
ranged between 2.4 and 124 μg/L and the EC50s ranged between 4.1 to 283 
μg/L (Table 2). Based upon both EC10 and EC50 A. flos-aquae and G. herdmanii 
were the most sensitive species to cefazolin (Figure 1) and the three species in 
the Synechococcus genera (S. leopoliensis, S. elongates and Synechococcus 
sp.) along with Synechocystis sp. were the least sensitive. Synechococcus sp. 
was up to 70 times less sensitive than the most sensitive species based on the 
EC50. 
Cefotaxime: EC10s across cyanobacteria exposed to cefotaxime ranged 
between 1.2 and 39.8 μg/L and the EC50s ranged between 2.2 and 98 μg/L for 
the different bacteria species. The maximum difference in sensitivity was 45 
times between the most sensitive (A. flos-aquae) and least sensitive species 
(Synechococcus sp). The four least sensitive species, S. leopoliensis, 
Synechocystis sp., S. elongates and Synechococcus sp., were also the least 
sensitive species to cefazolin, the other cephalosporin tested, with the same 
order of relative sensitivity. 
Ampicillin: EC10s for the different cyanobacteria exposure to ampicillin ranged 
between 5.9 and 44.6 μg/L and EC50s ranged between 8.4 and 81.4 μg/L. 
Based on the EC50, there was a difference in sensitivity of approximately 10-fold 
(9.7) between the most sensitive and least sensitive species (C. gracile and A. 
cylindrical respectively). C. gracile was particularly sensitive compared with the 
other species tested (3 times more sensitive than the next most sensitive 
species, S. leopoliensis). The remaining cyanobacteria all had similar 
sensitivities with EC50s of between 52 and 81.4 μg/L. 
Growth inhibition for DNA synthesis inhibitors: 
Sulfadiazine: Sulfadiazine caused partial inhibition only of growth of the 
cyanobacteria tested. It was possible to fit log-logistic or weibul distributions to 
the growth data but as growth inhibition was incomplete (growth rate stopped 
decreasing before the point of 50% growth inhibition) EC10 or EC50 values could 
not be calculated. 
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Sufamethazine: As for sulfadiazine, sulfamethazine did not induce full growth 
inhibition for any of the cyanobacteria tested and it was thus not possible to 
calculate EC10 or EC50 values. C. gracile was the most sensitive species to the 
growth inhibition effects of sulfamethazine (a 50% reduction in growth rate was 
observed down to an exposure concentration of 1465 μg/L). At the highest 
tested sulfamethazine exposure concentration (10,000 μg/L) there was between 
a 30% to 40% decrease in growth rate in A. flos-aquae, A. cylindrical, 
S. leopoliensis, S. elongates, Synechococcus sp., and G. herdmanii. 
Synechocystis sp was far less affected with only a 4% inhibition of growth at the 
highest tested concentration. 
Growth inhibition for protein synthesis inhibitors: 
Erythromycin: EC10s across the different cyanobacteria species exposed to 
erythromycin ranged from 21.1 and 58.8 μg/L and the EC50s were between 43.4 
and 135.1 μg/L. Based upon the EC50, there was only a small difference in 
sensitivity, of 3.1-fold, between the most sensitive (A. cylindrical) and least 
sensitive species (A. flos-aquae). 
Azithromycin: EC10s for the different cyanobacteria exposure to azithromycin 
ranged between 3.2 and 17.7 μg/L and EC50s ranged between 5.4 and 33.8 
μg/L. Based upon the EC50, there was difference in sensitivity of 6.3 times only 







Figure 1 – Concentration- response curves showing the effects of antibiotics on the growth rate 
of cyanobacteria. Antibiotics are arranged vertical panels related to their mode of action. Red 
dotted line indicates the highest measured environmental concentration (MEC) in UBA 
database (Umwelt bundesamt 2018). Median MEC values sit below the lowest concentration on 
the x-axis. Raw data plots are presented in Supplementary material C. 







































A. flos-aquae 2.4 1.7 3.0 4.1 3.7 4.5 1.5 
70 
A. cylindrical 7.9 2.9 12.8 17.8 15.4 20.2 6.4 
C. gracile 32.2 24.8 39.5 51.3 47.5 55.1 44.0 
G. herdmanii 3.1 2.6 3.5 5.1 4.8 5.3 4.5 
S. elongates 111.3 97.3 125.3 238.0 217.6 258.3 66.4 
S. leopoliensis 51.6 41.4 61.9 134.1 122.5 145.6 45.3 
Synechococcus 
sp 
124.1 101.5 146.8 283.2 263.6 302.8 93.4 
Synechocystis 
sp 
104.5 80.9 128.1 191.3 170.0 212.5 157.0 
Cefotaxime 
A. flos-aquae 1.4 1.0 1.8 2.2 2.0 2.4 1.9 
45 
A. cylindrical 1.2 0.3 2.2 3.1 2.2 4.1 1.7 
C. gracile 8.3 7.5 9.2 15.4 14.8 16.0 9.6 
G. herdmanii 15.1 8.9 21.4 17.7 14.7 20.6 9.9 
S. elongates 20.8 16.2 25.4 75.4 56.3 94.4 12.7 
S. leopoliensis 8.7 7.0 10.3 31.0 28.7 33.3 7.0 
Synechococcus 
sp 
16.2 11.5 20.8 97.9 74.2 121.6 12.1 
Synechocystis 
sp 
39.8 28.3 51.3 62.3 53.7 71.0 46.3 
Ampicillin 
A. flos-aquae 18.7 11.6 25.9 52.4 45.2 59.7 30.2 
9.7 
A. cylindrical 44.6 40.0 49.3 81.4 73.5 89.2 37.1 
C. gracile 5.9 5.1 6.7 8.4 7.4 9.4 4.9 
G. herdmanii 34.3 27.2 41.4 64.4 60.5 68.3 12.2 
S. elongates 38.8 35.0 42.7 54.0 50.4 57.6 36.4 
S. leopoliensis 16.2 11.8 20.6 27.5 25.1 29.9 11.5 
Synechococcus 
sp 
38.0 30.1 45.9 66.6 63.0 70.1 31.5 
Synechocystis 
sp 
36.5 25.8 47.2 57.1 50.7 63.5 34.2 







































A. flos-aquae N/A N/A N/A N/A N/A N/A N/A 
N/A 
A. cylindrical N/A N/A N/A N/A N/A N/A N/A 
C. gracile N/A N/A N/A N/A N/A N/A N/A 
G. herdmanii N/A N/A N/A N/A N/A N/A N/A 
S. elongates N/A N/A N/A N/A N/A N/A N/A 
S. leopoliensis N/A N/A N/A N/A N/A N/A N/A 
Synechococcus 
sp 
N/A N/A N/A N/A N/A N/A N/A 
Synechocystis 
sp 
N/A N/A N/A 1275 1058 1493 380 
Sulfamethazine 
A. flos-aquae N/A N/A N/A N/A N/A N/A N/A 
N/A 
A. cylindrical N/A N/A N/A N/A N/A N/A N/A 
C. gracile N/A N/A N/A N/A N/A N/A N/A 
G. herdmanii N/A N/A N/A N/A N/A N/A N/A 
S. elongates N/A N/A N/A N/A N/A N/A N/A 
S. leopoliensis N/A N/A N/A N/A N/A N/A N/A 
Synechococcus 
sp 
N/A N/A N/A N/A N/A N/A N/A 
Synechocystis 
sp 





A. flos-aquae 10.5 7.1 14.0 25.8 22.4 29.3 10.2 
6.3 
A. cylindrical 5.0 3.8 6.2 5.4 0.6 10.1 4.9 
C. gracile 4.8 3.8 5.7 12.5 10.3 14.6 9.5 
G. herdmanii 3.2 2.2 4.3 13.8 11.8 15.8 1.5 
S. elongates 4.4 2.7 6.0 17.4 14.9 19.9 3.3 
S. leopoliensis 8.7 6.7 10.6 23.5 21.6 25.4 1.9 
Synechococcus 
sp 
17.7 13.5 21.9 33.8 31.5 36.1 2.6 
Synechocystis 
sp 
8.6 5.7 11.4 18.1 12.9 23.4 9.6 



































A. flos-aquae 58.8 41.5 76.1 135.1 121.9 148.3 28.8 
3.1 
A. cylindrical 22.3 16.5 28.2 43.9 40.2 47.6 12.2 
C. gracile 44.5 15.5 73.5 57.3 56.0 58.6 31.2 
G. herdmanii 50.7 42.6 58.7 104.8 98.1 111.5 11.5 
S. elongates 30.1 26.4 33.9 63.3 57.7 68.9 <6.2 
S. leopoliensis 35.0 28.6 41.3 63.9 53.6 74.1 31 
Synechococcus 
sp 
29.1 23.8 34.4 59.8 55.6 64.0 13.4 
Synechocystis 
sp 
21.2 12.3 30.1 55.7 49.5 61.8 <7.2 
Table 2 – 10 and 50% effective concentrations (ECx) and no observed effect concentrations (NOEC) of antibiotics for exposure to eight cyanobacteria. 
All concentrations reported in μg/L. CL = Confidence Limit. a Times difference calculated by largest ECx/smallest ECx – reported value is based on largest range of 




The data we present includes, to our knowledge, the first ecotoxicological data 
available on cefazolin and sulfamethazine for MoA and environmentally relevant 
species. We show that for the eight species of cyanobacteria, tested under 
equivalent culture conditions, the interspecies sensitivity based on growth 
inhibition following exposure to antibiotics can vary widely and is influenced 
strongly by the MoA of the antibiotic. For the β-lactam antibiotics in particular, 
the sensitivity between the different cyanobacteria species varied by up to 70-
fold. This far exceeds the assessment factor of 10 applied to the NOEC for a 
single cyanobacteria species currently used in ERA. We show also that 
cyanobacteria were not sensitive to sulphonamides with neither species 
showing complete inhibition of growth for sulfamethazine nor sulfadiazine. This 
work illustrates that to be most effective, ERA requires the adoption of 
additional bacteria species relevant to the antibiotic MoA in order to ensure 
protection limits are suitable for bacteria populations and the ecosystem 
functions they provide. 
Chemical analysis, fate and behaviour in the cultures 
Our analytical results showed considerable variation in the fate of the antibiotics 
in our assays. Generally speaking, reductions in the measured concentrations 
over exposure period were high in the β-lactams and macrolides whilst the 
sulphonamides were more stable. Losses of these antibiotics during the 
cultures may be due to i) abiotic degradation by hydrolysis or photolysis, ii) 
absorption to the polypropylene microplate, AmpliSeal membrane and/or the 
bacteria (or extracellular matter) in the well, iii) biodegradation by the 
cyanobacteria and/or iv) uptake into the cells. Generally, the presence of the 
cyanobacteria resulted in reduced amount of antibiotic (measured at the end of 
the exposure) that may have resulted from antibiotic biodegradation by the 
cyanobacteria and/or adsorption to the bacterial cells. Biodegradation is 
considered the most likely factor as the outer membranes of cyanobacteria 
species are similar and therefore surface binding of the antibiotic to the bacteria 





β-lactams: The loss of the cephalosporins, cefazolin and cefotaxime in our 
cultures may in part be explained by photodegradation. Cefazolin and 
cefotaxime have been shown to have half-lives of just 1.1 and 6.6 hours 
respectively, attributed to photolysis in synthetic river water (Wang and Lin 
2012). Ampicillin too is rapidly degraded by photolysis (Arsand et al. 2018). 
Additionally, bicarbonate and nitrate, both at relatively high levels in the BG-11 
media used in this study (Na2CO3 = 20 mg/L and NaNO3 = 1500 mg/L), have 
been indicated to affect (reduce) the half-life of cefotaxime (Wang and Lin 
2012). 
In all the species of cyanobacteria tested the levels of the β lactams were 
considerably lower in the exposure replicates compared with the blank 
replicates without the bacteria, suggesting biodegradation. In activated sewage 
sludge the main removal mechanism for cefalexin (a 1st generation 
cephalosporin like cefazolin) and amoxicillin (a penicillin closely related to 
ampicillin) is via biodegradation (≥90%) (Andreozzi et al. 2004; Li and Zhang 
2010). The considerable variability in the rates of biotransformation of β-lactams 
reported in the literature is likely attributable to the variable side chains in the 
chemical structures (Li and Zhang 2010). 
Sulfonamides: Although both sulfonamides, sulfamethazine and sulfadiazine, 
were relatively stable in the microplate assays, some reductions in levels due to 
the presence of the bacteria in our assays occurred for both antibiotics. 
Sulphonamides are hydrophilic with a Kow of -2.09 and -2.13 for sulfamethazine 
and sulfadiazine, respectively (assuming a negative charge in at the tested pH 
of approximately 8.2) and thus are unlikely to be absorbed strongly to the 
bacteria. Photolysis has been reported as a key degradation mechanism for 
sulfamethazine and sulfadiazine (Biošić et al. 2017), with half-life’s reported of 
28-72 days and 28 to 69 days respectively depending on the season (summer 
or winter, at 30° latitude (Boreen et al. 2005) (Baran et al. 2006; Biošić et al. 
2017; Pan et al. 2014; Yu et al. 2011). 
Macrolides: The relatively limited (20%) loss of erythromycin in our assays 
over the course of the test period is in accordance with its known persistent 
nature (including in effluents, freshwater, seawater, soils, sediments and 
organisms (Schafhauser et al. 2018)). The persistence and potential for 
bioaccumulation of erythromycin are major reasons for its inclusion in the 
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European Unions watch list of priority substances and in the United States 
Environmental Protection Agency contaminate candidate list 3 (Carvalho et al. 
2015; US EPA 2009). 
Azithromycin too is also considered ‘very persistent’ (also included in the 
European Unions watch list of priority substances (Carvalho et al. 2015)), but in 
our assays azithromycin levels were heavily reduced in both exposure and 
blank replicates. The partition-coefficient (LogP) and adsorption coefficient (Kd) 
of 4.02 and 3100 respectively (National Centre for Biotechnology Information 
2018) suggests that azithromycin could have been bound to the either the 
microplate, membrane and/or any cellular or extracellular matter. This is 
supported by the higher losses in the lowest tested concentrations (i.e. more 
cells and thus higher surface area) and no losses in the highest concentrations. 
Cyanobacteria sensitivity 
β-lactams: There was a large difference in sensitivity to β-lactams (and in 
particular the cephalosporins) observed between the different species of 
cyanobacteria in our study of up to 70-fold. The reason for this difference in 
sensitivity is unknown but it may reflect differences in the quantity and type of 
porins they contain that in turn affect antibiotic uptake rtes. The bilayered outer 
membrane of cyanobacteria (and in Gram-negative bacteria) is comprised of a 
hydrophobic lipopolysaccharide and acts as an effective barrier to most drugs. 
Antibiotics must therefore permeate through the membrane or use porin 
channels that mediate a size-selective diffusion of molecules into the periplasm. 
Porins tend to let small and non-lipophilic molecules pass through with ease 
and this includes the β-lactams (as well as fluoroquinolones, tetracycline, 
chloramphenicol, cycloserine, and aminoglycosides antibiotics) (Delcour 2009; 
Li et al. 2015). The rate at which porin channels allow the diffusion of an 
antibiotic through the outer membrane may be a key determinate to the 
sensitivity of the species (Li et al. 2015; Sugawara et al. 2016). 
In cyanobacteria and Gram-negative bacteria, β-lactams need only pass 
through the outer membrane into the periplasm to reach the penicillin binding 
protein drug target. For cefazolin and ampicillin that have relatively small 
chemical structures, we might expect therefore that the porin channels are likely 
to be the main routes through the outer membrane. Cefotaxime however, a 
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larger 3rd generation cephalosporin, may not pass in as easily depending on 
the size of the porin channels. Indeed, it has been shown that the susceptibility 
of the Gram-negative bacteria K. pneumoniae was 4-8 times higher when the 
strain expressed a larger porin channel (OmpK35) compared to those 
expressing the smaller OmpK36 (García-Sureda et al. 2011). If cefotaxime is 
too large to easily enter the cells through the porin channels, diffusion through 
the outer membrane, although slow, may be more important in cellular uptake. 
It is possible therefore that uptake via porins is might be a driving factor in the 
interspecies sensitivity differences observed between our cyanobacteria, at this 
time we cannot directly equate porins and the relative sensitivity to β-lactams 
for the species cultured in this study. More is known about porins in clinically 
relevant Gram-negative bacteria that have a thinner peptidoglycan layer and 
different protein families to cyanobacteria. Indeed, porins in the outer 
membrane differ between bacterial clades and cyanobacteria specifically do not 
appear to have the same porin families as those typically found in other bacteria 
(Flores et al. 2006). Gram-negative bacteria, for example, generally have 
smaller outer membrane porins but with higher channel conductance than 
cyanobacteria and thus allow more molecules to enter into the cell (Hoiczyk and 
Hansel 2000). It is hypothesised cyanobacteria synthesise the large organic 
molecules they need due to their autotrophic nature and thus only require 
smaller molecules from outside the cell (Hoiczyk and Hansel 2000; Kowata et 
al. 2017). Conversely, non-autotrophic bacteria need to uptake all molecules 
from outside of the cell. It is therefore reasonable to hypothesise that 
cyanobacteria may not be as susceptible as Gram-negative bacteria to larger 
antibiotics (such as macrolides) that require larger porin channels. Since ERA 
only uses one species of cyanobacteria to represent all primary producer 
diversity, if sensitivity is, at least in part, driven by uptake due to their outer 
membrane porins, other bacterial clades such as Gram-negative bacteria that 
differ in their membrane structure and porins may show even more variability as 
compared to cyanobacteria and thus may not be well represented. 
In addition to uptake, efflux and β-lactamase enzymes may have key roles in 
determining the sensitivity of bacteria to antibiotics. Efflux rates of the antibiotics 
in cyanobacteria studied are not known, but our data do indicate biodegradation 
for all the β-lactams tested. For cefazolin this (potential) biodegradation was 
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greatest for S. elongates and Synechococcus sp. These species were also the 
least sensitive species tested based on growth inhibition. There was no 
apparent relationship observed however between the level of biodegradation 
and sensitivity rankings for either cefotaxime or ampicillin. Further investigation 
quantifying β-lactamase in the different bacteria might help determine if 
biodegradation might, at least partly, explain the differences in sensitivity 
observed between cyanobacteria exposed to β-lactams. Studies on the Gram-
negative bacteria Kluyvera ascorbata and Kluyvera cryocrescens (from the 
family Enterobacteriaceae), Stock (2005) have shown natural variability to β-
lactams within species (for 58 strains of K. ascorbata and 24 strains of K. 
cryocrescens ) ranged by between one and two orders of magnitude (based 
upon minimum inhibitory concentrations (MIC)) and these differences were 
attributed to differences in chromosomal β-lactamases. 
Reductions of porins in the outer membrane over the exposure period could 
also help explain the differences in variability observed between the 
cyanobacteria cultures. This is a well reported β-lactam resistance mechanism 
in Gram-negative bacteria (Delcour 2009). Charrel et al. (1996) found that the 
MIC in 80 Enterobacteriaceae increased after exposure to four β-lactams, 
including for exposure to cefotaxime, and this was associated with a decrease 
in porins. Whether this resistance mechanism is present and could explain the 
high interspecies variability in cyanobacteria is currently unknown. 
It should also be noted that the photolysis product of cefotaxime, attributed to its 
5-methyl-1,3,4-thiadiazole-2-thiol moiety may have increased toxicity (Wang 
and Lin 2012) and has been predicted to have potential chronic toxicity to algae 
and daphnids in the high μg/L range (Fabbri et al. 2015). It is therefore possible 
that the toxicity observed could be due to this rather than the parent compound 
and further investigation is required for clarification. 
Sulphonamides: Growth inhibition of cyanobacteria for exposure to the 
sulphonamides was generally limited and in some species the inhibitory effect 
stabilised with increasing antibiotic concentration suggesting the development 
or initiation of a possible resistance mechanism. The results are in accordance 
with a recent meta-analysis where cyanobacteria were found to be less 
sensitive to sulphonamides compared to microalgae and macrophytes (Le Page 
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et al. 2017). A possible explanation for the insensitivity could be that 
cyanobacteria contain a protein (slr0642 identified in Synechocystis) that may 
act as a folate transporter and which allows the uptake of folates from the 
environment. This in turn overcomes the effect of the targeting of this drug on 
the folate synthesis pathway (de Crécy-Lagard et al. 2007; Klaus et al. 2005). 
The small differences in sensitivity across the species observed in our assays 
may include differences in the ability to activate the folate transporter resistance 
mechanism. It should be highlighted that the growth rate was lower than the 
controls and thus there appears to be some fitness consequence to this 
resistance mechanism. 
Macrolides: Responses to the macrolides were more consistent across the 
cyanobacteria compared with the β-lactam antibiotics; the EC10s and EC50s for 
the eight species differed by less than an order of magnitude (6.3 and 3.1 times 
difference between the most and least sensitive species for azithromycin and 
erythromycin respectively). The similar levels of efficacy of the macrolides 
across the different cyanobacteria may, in part, be explained by the highly 
conserved ribosome drug target (Lecompte et al. 2002; Yutin et al. 2012). R-
proteins however, which make up the ribosome, do vary between broader 
bacterial taxonomic clades and because the MoA of macrolide antibiotics is 
highly dependent on the positioning and interaction with the ribosome, 
differences in r-proteins between bacterial taxa could feasibly affect antibiotic 
efficacy/action. 
The uptake of macrolides may be a key driver of the small difference in 
cyanobacteria sensitivity. Due to the large size of macrolides their uptake is 
generally thought to be restricted by the outer membrane (Delcour 2009; Stock 
2005). Although there is some evidence that porin-like uptake maybe present 
(Hahn et al. 2012), erythromycin is both large and hydrophobic and is likely to 
permeate slowly via diffusion through the outer membrane. Azithromycin on the 
other hand, is dicationic and less hydrophobic, and will therefore pass through 
the outer membrane more easily (Farmer et al. 1992; Stock 2005). Indeed, 
Stock (2005) hypothesized that Gram-negative bacteria species specific 
differences are at least partially, driven by outer membrane hydrophobicity 
differences. Because little is understood regarding the outer membranes of 
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cyanobacteria, we can only hypothesise that differences in uptake could explain 
the relatively small interspecies sensitivity observed in our results. 
The molecular mechanisms for protein secretion in cyanobacteria are not well 
understood, but there is evidence to suggest cyanobacteria do have some 
porin-like proteins that are associated with the efflux of antibiotics and 
secondary metabolites, although they could also be part of an uptake 
mechanism. For example, HgdD, a TolC-like protein (an outer membrane efflux 
protein found in Gram-negative bacteria) is responsible for the efflux of 
erythromycinin in Anabaena sp. PCC 7120 and may have a multidrug 
resistance function more generally (Hahn et al. 2013; Hahn et al. 2012). 
Another TolC-like protein, Slr1270, has been identified in Synechocystis sp. 
PCC 6803 which also provides resistance to antibiotics (Oliveira et al. 2016). 
Based on the literature therefore, the differences in in cyanobacterial sensitivity 
to macrolides are more likely to driven by differences in uptake or efflux than 
differences in the drug target given that their ribosomes are likely evolutionarily 
well conserved. In addition to decreased uptake/increased efflux, other 
mechanisms of resistance to macrolides in Gram-negative bacteria comprise of 
target mutations, methylation, pseudouridylation and modification of the 
macrolide (Gomes et al. 2017), but such resistance mechanisms have not yet 
been considered in cyanobacteria. 
In our assays azithromycin had a greater potency than erythromycin across all 
cyanobacteria. Interestingly, azithromycin is reported to have modes of action in 
addition to the ribosomal drug target that may help to explain this enhanced 
potency. It is dicationic and in a similar MoA as aminoglycosides, may disrupt 
the outer bacterial membrane through the displacement of divalent cations from 
their binding sites on adjacent lipopolysaccharide molecules in Gram-negative 
bacteria (Farmer et al. 1992; Imamura et al. 2005). Azithromycin has also been 
shown to reduce the ability of P. aeruginosa to form fully polymerised alginate 







Sensitivity comparisons with other bacteria 
When comparing our β-lactam effects with the MICs of clinically relevant 
bacteria in the EUCAST database, the most sensitive cyanobacteria in our 
assay study were 3-6 times more sensitive to cefozolin than Streptococcus 
pneumoniae and Staphylococcus aureus (most sensitive pathogens with MICs 
of 32 and 64 μg/L respectively (EUCAST)). Several of the clinically relevant 
bacteria appeared to be more sensitive to cefotaxime than our cyanobacteria 
with MICs at the lowest tested concentration of 2 μg/L (EUCAST). The effects of 
ampicillin upon the cyanobacteria were similar to those observed by Ando et al. 
(2007) and within the ranges seen in clinically relevant bacteria in the EUCAST 
database (EUCAST). It should be noted that due to the limited data available 
we have compared the MIC for clinically relevant bacteria with the data obtained 
in our assays, but these values represent different parts of the dose-response 
curve (the MIC represents the concentration with complete inhibition and the 
EC10 the concentration that inhibits growth rate by 10%) (Bengtsson-Palme and 
Larsson 2018; Le Page et al. 2018). 
There are limited data available in the literature for sulfadiazine and 
sulfamethazine and being veterinary antibiotics neither have EUCAST data, 
thus their ecotoxicological profile is rather less well understood than that of their 
fate and behaviour. Investigators have found however that sulfamethazine MICs 
tend to be relatively high in comparison to other antibiotics, for example, an MIC 
of >512 mg/L for both Gram-negative and gram positive bacterial strains 
(Salmon and Watts 2000; Salmon et al. 1995). The MIC reflects only the 
concentration with complete inhibition of growth and thus it is not known 
whether the incomplete growth inhibition observed in our results is mirrored and 
further research is required to establish the effects of sulphonamides on a more 
diverse range of bacterial taxa. A 7 day EC50 of 0.14 mg/L was reported for the 
effects of sulfadiazine on the cyanobacteria Microcystis aeruginosa (Lützhøft et 
al. 1999), which is lower than in this study, although it may be a reflection of the 
longer exposure length and it is unknown if there was complete inhibition and a 




There is also only limited data on azithromycin in the literature for traditional 
ecotoxicologically relevant species and methods, but our results are in 
accordance with those reported in Vestel et al. (2015) where cyanobacteria 
have a EC50 of 1.8 μg/L (species not provided). The MICs of clinically relevant 
bacteria in the EUCAST database suggest the most sensitive bacteria have 
complete growth inhibition at 16 μg/L, which is consistent the more sensitive 
cyanobacteria in this study potentially indicating limited sensitivity differences 
across bacterial clades due to drug target conservation. For the second 
macrolide, erythromycin, EC50s were generally similar to those obtained by 
Ando et al. (2007) for eight species of cyanobacteria and although the most 
sensitive species they tested was the same as ours, A. cylindrical, they 
calculated it to be over an order of magnitude lower than in this study (3.5 
compared to 44 μg/L respectively), possibly due to differences in test period (3 
days in this study compared to 6 days in (Ando et al. 2007)). The most sensitive 
clinically relevant bacteria in the EUCAST database to erythromycin have MICs 
from 8 μg/L (EUCAST), suggesting that for this antibiotic they may be more 
sensitive than cyanobacteria. 
It should be noted that the MIC is equivalent to the EC100, at which there is 
100% growth inhibition and thus isn’t directly comparable to the EC10 used in 
this study (Bengtsson-Palme and Larsson 2018; Le Page et al. 2018). 
Additionally, the EUCAST data is not based upon measured concentrations and 
is determined in the dark and we might thus expect less degradation from 
photolysis. 
Implications for ERA 
Our data show that for some antibiotics, especially β-lactams, there may be 
differences in sensitivity that exceed an order of magnitude, thus indicating that 
a PNEC in some instances will not be protective of all cyanobacteria 
populations. Comparing our results, with the two species of cyanobacteria 
recommended in the OECD 201 guideline (A. flos-aquae and S. leopoliensis), 
we found S. leopoliensis was between 1.6 to 21.8 times less sensitive (based 
upon EC10) than the most sensitive species of the eight we tested. Thus a 
PNEC for cefazolin based upon S. leopoliensis would be not be protective of 
A. flos-aquae nor G. herdmanii, even with the given assessment factor of 10. 
A. flos-aquae was overall the most sensitive to the β-lactam antibiotics tested. A 
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PNEC based upon A. flos-aquae would have been protective of all the other 
species tested for cephalosporin and macrolide antibiotics, even though it was 
one of the least sensitive species to the macrolide antibiotics. Careful selection 
of a cyanobacteria species is therefore of importance to ensure ERA remains 
protective of bacterial species more widely and the MoA can be an important 
factor in this consideration. 
Our results indicate that we require a more comprehensive understanding of the 
effects of antibiotics upon prokaryotic diversity. We argue that this should 
include consideration of microbes that are known to play key roles in 
ecosystems function/services, such as nitrifying bacteria or sulphate-reducing 
bacteria as some of the organisms we may wish most to protect. Additionally, 
the effects on community structure and diversity should also be considered 
given that if a specific group of bacteria in a community increased or decreased 
in abundance due to antibiotic exposure, there may be significant 
consequences for the normal functioning of that community. 
The limited sensitivity of cyanobacteria tested here to sulphonamide antibiotics 
confirmed the conclusions from the previous meta-analysis (Le Page et al. 
2017) that cyanobacteria may not be suitable for the estimating protection limits. 
Furthermore, in some cases microalgae and macrophytes may be more 
sensitive than cyanobacteria to this class of antibiotics (Le Page et al. 2017) but 
under current ERA framework for pharmaceuticals neither microalgae nor 
macrophytes would be tested. 
Finally, there is some evidence in the literature that the degradation products of 
at least some β-lactams may have increased toxicity (Fabbri et al. 2015; Wang 
and Lin 2012). It is therefore possible that these products could be influencing, 
or driving, the toxicity observed in these results. Further research is thus 






In this study we have used a microplate assay to assess the relative 
interspecies sensitivity of a range of cyanobacteria to the effects of seven 
antibiotics spanning three different MoAs. Our experimental data experimentally 
verify the findings of a meta-analysis of published literature (Le Page et al. 
2017) where interspecies sensitivity spanned by more than an order of 
magnitude depending on the MoA; including that not all species in the meta-
analysis were able to be tested in our assays, including the most sensitive 
species in the meta-analysis, Microcystis aeruginosa. To our knowledge, we 
present the first environmentally relevant bacterial data for cefazolin, cefotaxime 
and sulfamethazine and we show that for the β-lactam antibiotics, the 
interspecies sensitivity exceeds the assessment factor of 10 currently used in 
ERA to account for such variability. These results therefore support previous 
recommendations by Le Page et al. (2017) and Brandt et al (2016) to widen the 
number of bacterial and cyanobacteria species tested. We show also that 
cyanobacteria may not be a suitable group of bacteria for determining 
environmental risk to sulphonamides due to their insensitivity relative to other 
environmentally important taxa. Furthermore, when comparing these data with 
clinically relevant bacteria MICs there was evidence that an ERA based on just 
one cyanobacteria may not be protective of other clades of environmental 
bacteria. We conclude that the ERA of antibiotics should include additional 
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Supplementary material A  
Material and methods 
Analytical method 
Details of chromatographic separation and mass spectrometry analysis for each 
antibiotic are summarised below: 
Analytical Chemistry: LC-MSMS Methods 
Analyses of exposure media samples were performed using a TSQ Vantage 
triple quadrupole mass spectrometer. The mass spectrometer was equipped 
with a heated electrospray (HESI II) source (ThermoFisher Scientific, Hemel 
Hempstead, UK).  The HESI probe was operating in positive mode; an ion-
spray voltage of 4.0 kV, heated capillary temperature was set at 270 °C and the 
vaporizer temperature was 350 °C. Nitrogen was employed as a sheath and 
auxiliary gas at a pressure of 60 and 2 arbitrary units, respectively.  
The argon CID gas was used at a pressure of 1.5 mTorr and the optimum 
collision energy (CE) for each transition was selected. Quantification of the 
target compounds was performed by monitoring two characteristic multiple 
reaction monitoring (MRM) transitions (Table below). 
Analyte Parent ion (m/z) Product ion (m/z) CE (eV) 































Chromatographic separation was achieved using a reversed-phase, 3 µm 
particle size, C18 Hypersil GOLD column (50 mm × 2.1 mm i.d., Thermo 
Scientific, San Jose CA, USA). 
All analytes were separated using a linear gradient with a flow rate was 
500µL/min. The autosampler temperature was maintained at 6˚C, while column 
was kept at a room temperature. Several variations of mobile phase and 
gradient were required and these are summarised in the following tables: 
Analyte Gradient (A) 0.1% Formic Acid 
in Water 


















    
Analyte Gradient (A) 0.1% Formic Acid 
in Water 


































     
Analyte Gradient (A) 0.1% 
Ammonium 





(B) 0.1% Formic 




















































































T1 BL T2 BL T3 BL T4 BL T5 BL T6 BL T7 BL T8 BL T9 BL T10 BL 
Control 
BL 
Figure S.A1. A schematic plate map of the layout of replicates in a mirotitre plate. BL = blank 
(sterile medium only) 
The concentration gradient runs across the length of the plate from columns 2 
to 11, with cyanobacteria blanks in columns 1 and 12. The 10 control replicates 
also run across the length of the plate from D2 to D11 so that any effect in 
growth across the plate, caused by uneven environmental conditions in the 
incubator (e.g. light intensity) or by the contamination from surrounding wells 
(e.g. volatile compounds) can be identified and render the test invalid. 
Five replicates of each antibiotic test concentration run in columns 2 to 11. The 
outer cells of the 96 well microplate had no cyanobacteria inoculum, creating 
sixteen control blanks and two blanks per concentration. 
If a solvent control was required this was run in the blank wells in row H. 
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Dilution water control and solvent control comparisons 
The growth rates of the bacteria in the dilution water control (DWC) and solvent 
control (SC) replicates (10 replicates each) were compared using a t test in R 
(version 3.3.0; R Project for Statistical Computing, Vienna, Austria; (Figure 
S.A1)). 
 
Figure S.A2 – Cyanobacteria growth rates in dilution water control (DWC) and solvent control 
(SC) medium. SC comprised of BG-11 with 10 μl/L of dimethyl sulfoxide (DMSO). ns = not 
significant. ** = p < 0.01.  
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Data handling and dose-response modelling 
Dose response models were established using the using the drc package (Ritz 
et al. 2015) in r (version 3.3.0; R Project for Statistical Computing, Vienna, 
Austria). 
Before establishing the model, the data was examined to identify poor 
replicates and exclude data where necessary according to the following criteria: 
1. Where the growth rate cannot be calculated because the fluorescent 
signal at the start of the test (day 0) was a negative number due to the 
background/blank value being higher than the exposure well value; the 
replicates were excluded from further analysis. 
2. Where the growth rate is negative because the fluorescence at the end 
of the test is less than that at the beginning; the growth rate was fixed at 
0. N.B. Although the population size decreased (grew negatively) it is 
unknown from this fluorescence data if cells were alive or dead (with 
phycocyanin still fluorescing). 
3. Where the growth rate cannot be calculated because the fluorescent 
signal at the end of the test was a negative number due to the 
background/blank value being higher than the exposure well value; the 
replicate was considered to have zero growth. 
The optimal distributions for the data were selected based on log-likelihood 
score (distributions examined were 3, 4 or 5 parameter log-logistic distributions 
and 4, or 5 parameter weibull 1 or 2 distributions). Model residuals were 
examined for normality and heteroscedasticity and residuals with a 
disproportionate effect on the model were identified using cooks distance (>0.5 
is considered to have a disproportionate effect). Any outliers were individually 
examined and excluded if biologically justifiable and the dose response model 
was then re-run. Replicates that did have a disproportionate effect on the model 
but without any reason to suggest an experimental error (e.g. not inoculated 
correctly) were included in the analysis rather than excluded as an outlier, even 
if statistically justifiable. This approach may result in wider confidence intervals 
and/or less statistical power but ensured inclusion of the inherent variability of 
the species and test designs 
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# Make starter model 5 
SpeciesX.m1<-drm(GR~Conc,  6 
 data=Data,  7 
 fct=LL.3(), 8 
 na.action = na.omit) 9 
# Identify best distribution of data for dose response curve: 10 
mselect(CYAN.m1, list(LL.3(), LL.4(), LL.5(), W1.3(), W1.4(), W2.4())) 11 
# Make best fitting model 12 
SpeciesX.m1<-drm(GR~Conc,  13 
 data= Data,  14 
 fct=LL.4(), 15 
 na.action = na.omit) 16 
# Plot model 17 
plot(SpeciesX.m1, xlab = bquote('Concentration ('*mu~'g/L)'), ylab = "Growth rate (per day)", 18 
 main = "SpeciesX", 19 
 broken = TRUE, type = "all", 20 
 col = TRUE, legendPos = c(10,2), cex.legend = 0.5) 21 
# Estimate EC50, EC20 and EC10 22 
ED(SpeciesX.m1, c(10, 20, 50), interval = "delta") 23 
# Summarise the model parameters: 24 
summary(CYAN.m1) 25 
# Graphical analysis of residuals – check for heteroscedasticity 26 
plot(residuals(CYAN.m1) ~ fitted(CYAN.m1), main="Residuals vs Fitted") + 27 
 abline(h=0) 28 
# Graphical analysis of residuals – check for heteroscedasticity 29 
qqnorm(residuals(CYAN.m1)) 30 
qqline(residuals(CYAN.m1)) 31 
# Identification of outliers – cooks distance of > 0.5 indicates data had a disproportionate32 




Supplementary material B  
Analytical results 
Analytical results are presented as i) geometric means as a percentage of 
nominal and ii) the measured concentrations at the end of the exposure as a 
percentage of the stock solutions. Species are represented as follows: ANA 
CCAP = A. flos-aquae, ANA PCC = A. cylindrical, CYAN = C. gracile, GEM = G. 
herdmanii, SYNch CCAP = S. leopoliensis, SYNch PCC1 = S. elongates, 
SYNch PCC2 = Synechococcus sp. and SYNcy = Synechocystis sp. 
 
Antibiotics measured in the dilution water control solutions at the end of the test: 
Antibiotics were measured at >LOQ in some of the control solutions sampled at 
the end of the exposures (both cyanobacteria blank and exposure replicates). 
Since the stock solutions from which all microplates were prepared did not have 
measurable quantities of antibiotics this contamination is considered to be 
caused by operator error in the extraction process or from carryover in the mass 
spectrometer. 
The numbers of replicates excluded across all eight species were as follows: 
 For azithromycin one blank replicate 
 For erythromycin one stock; five blank and six exposure replicates 
 For ampicillin seven blank and seven exposure replicates 
 
Analytical comments 
In some cases the analytical data did not allow the accurate determination of 
the exposure concentrations and as such these concentrations were excluded 
from further analysis in order not to adversely affect the dose response curves. 









Azithromycin ANA PCC 0.43 and 0.77 
Stock preparation error 






Measured concentrations at the end of 
the exposure were below the LOQ 








Measured concentrations at the end of 
the exposure were below the LOQ 










Measured concentrations at the end of 
the exposure were below the LOQ 
- removed from further dose response 
analysis 
Erythromycin All 1.7 
Sampling/extraction error 
- removed from further dose response 
analysis 
Erythromycin All 6.6 and 407 
Sampling/extraction error 













Many replicates measured as <LOQ 
- Where this occurred in blanks or in all 
3 exposure replicates they removed 
from further dose response analysis 
- Where only 1 replicate of 3 was 
<LOQ the average of the remaining 2 
replicates was used for dose response 
analysis. 
- For SYNcy nominal concentration of 
165 μg/L there was high variability 
replicates was used for dose response 
analysis 
Cefotaxime All 
 0.46, 0.82 and 
1.5 
Measured concentrations at the end of 
the exposure were below the LOQ 
- removed from further dose response 
analysis 
Table S.B1 - Analytical comments and concentrations excluded from further analysis. LOQ = 





















Figure S.B1 – Geometric mean measured concentrations of cefazolin as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. 
 
Figure S.B2 – Measured concentrations at the end of the exposure of cefazolin as a percentage 
of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median average of 
three replicates. Blanks (red – without cyanobacteria) calculated by median average of up to 





Figure S.B3 – Geometric mean measured concentrations of cefotaxime as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate replicates that were removed 
(see table S.B2). 
 
Figure S.B4 – Measured concentrations at the end of the exposure of cefotaxime as a 
percentage of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median 
average of three replicates. Blanks (red – without cyanobacteria) calculated by median average 
of up to three replicates. Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate 





Figure S.B5 – Geometric mean measured concentrations of ampicillin as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate replicates that were removed 
(see table S.B2). 
 
Figure S.B6 – Measured concentrations at the end of the exposure of ampicillin as a percentage 
of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median average of 
three replicates. Blanks (red – without cyanobacteria) calculated by median average of up to 
three replicates. Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate replicates 





Figure S.B7 – Geometric mean measured concentrations of sulfadiazine as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. 
 
Figure S.B8 – Measured concentrations at the end of the exposure of sulfadiazine as a 
percentage of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median 
average of three replicates. Blanks (red – without cyanobacteria) calculated by median average 






Figure S.B9 – Geometric mean measured concentrations of sulfamethazine as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. 
 
Figure S.B10 – Measured concentrations at the end of the exposure of sulfamethazine as a 
percentage of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median 
average of three replicates. Blanks (red – without cyanobacteria) calculated by median average 
of up to three replicates. Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate 





Figure S.B11 – Geometric mean measured concentrations of erythromycin as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. 
 
Figure S.B12 – Measured concentrations at the end of the exposure of erythromycin as a 
percentage of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median 
average of three replicates. Blanks (red – without cyanobacteria) calculated by median average 






Figure S.B13 – Geometric mean measured concentrations of azithromycin as a percentage of 
nominal. Exposure (blue - with cyanobacteria) calculated by median average of three replicates. 
Blanks (red – without cyanobacteria) calculated by median average of up to three replicates. 
Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate replicates that were removed 
(see table S.B2). 
 
Figure S.B14 – Measured concentrations at the end of the exposure of azithromycin as a 
percentage of the stock solutions. Exposure (blue - with cyanobacteria) calculated by median 
average of three replicates. Blanks (red – without cyanobacteria) calculated by median average 
of up to three replicates. Dotted lines indicate 100 ± 20% of nominal. Missing bars indicate 
replicates that were removed (see table S.B2). 
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Graphs showing the percentage loss due to the presence of cyanobacteria 
 
Figure S.B15 – Percentage loss of cefazolin due the presence of cyanobacteria. Y-axis 
calculated as the difference in percentages of the blank replicates (sterile culture medium with 
no cyanobacteria) and exposure replicates (with cyanobacteria). 
 
Figure S.B16 –Percentage loss of cefotaxime due the presence of cyanobacteria. Y-axis 
calculated as the difference in percentages of the blank replicates (sterile culture medium with 




Figure S.B17 –Percentage loss of ampicillin due the presence of cyanobacteria. Y-axis 
calculated as the difference in percentages of the blank replicates (sterile culture medium with 
no cyanobacteria) and exposure replicates (with cyanobacteria). 
 
Figure S.B18 –Percentage loss of sulfadiazine due the presence of cyanobacteria. Y-axis calculated 
as the difference in percentages of the blank replicates (sterile culture medium with no 




Figure S.B19 – Percentage loss of sulfamethazine due the presence of cyanobacteria. Y-axis 
calculated as the difference in percentages of the blank replicates (sterile culture medium with 
no cyanobacteria) and exposure replicates (with cyanobacteria). 
 
 
Figure S.B20 –Percentage loss of erythromycin due the presence of cyanobacteria. Y-axis 
calculated as the difference in percentages of the blank replicates (sterile culture medium with 




Figure S.B21 –Percentage loss of azithromycin due the presence of cyanobacteria. Y-axis 
calculated as the difference in percentages of the blank replicates (sterile culture medium with 
no cyanobacteria) and exposure replicates (with cyanobacteria). 
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Supplementary material C  
Growth inhibition raw data 
 









































Figure S.C7 - Growth inhibition of cyanobacteria exposed to azithromycin including the raw data for each replicate.  
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Starting pH Final pH pH change 
Ampicillin 
A. flos-aquae 
DWC 8.0 8.0 0.0 
0.96 8.0 7.9 -0.1 
0.53 8.0 7.9 -0.1 
0.30 8.0 7.9 -0.1 
0.16 8.0 7.9 -0.1 
0.091 8.0 7.9 -0.1 
0.051 8.0 7.9 -0.1 
0.028 8.0 8.0 0.0 
0.016 8.0 8.0 0.0 
0.0087 8.0 8.0 0.0 
0.0048 8.0 8.0 0.0 
A. cylindrica 
DWC 8.0 8.1 0.1 
5.60 8.0 8.0 0.0 
3.11 8.0 7.9 -0.1 
1.73 8.0 7.9 -0.1 
0.96 8.0 7.9 -0.1 
0.533 8.0 8.0 0.0 
0.296 8.0 8.0 0.0 
0.165 8.0 8.0 0.0 
0.091 8.0 8.1 0.1 
0.0508 8.0 8.1 0.1 
0.0282 8.0 8.1 0.1 
S. leopoliensis    
DWC 8.0 8.1 0.1 
1.73 8.0 8.0 0.0 
0.96 8.0 8.0 0.0 
0.53 8.0 8.0 0.0 
0.30 8.0 8.0 0.0 
0.165 8.0 8.0 0.0 
0.091 8.0 8.0 0.0 
0.051 8.0 8.0 0.0 
0.028 8.0 8.0 0.0 
0.0157 8.0 8.0 0.0 
0.0087 8.0 8.0 0.0 
S. elongates 
DWC 8.0 8.1 0.1 
1.73 8.0 8.0 0.0 
0.96 8.0 8.0 0.0 
0.53 8.0 8.0 0.0 
0.30 8.0 8.0 0.0 
0.165 8.0 8.0 0.0 
0.091 8.0 8.0 0.0 
0.051 8.0 8.0 0.0 
0.028 8.0 8.0 0.0 
0.0157 8.0 8.0 0.0 








Starting pH Final pH pH change 
Ampicillin 
Synechococcus sp.    
DWC 8.0 8.1 0.1 
1.73 8.0 8.0 0.0 
0.96 8.0 8.0 0.0 
0.53 8.0 8.0 0.0 
0.30 8.0 8.0 0.0 
0.165 8.0 8.0 0.0 
0.091 8.0 8.0 0.0 
0.051 8.0 8.0 0.0 
0.028 8.0 8.0 0.0 
0.0157 8.0 8.0 0.0 
0.0087 8.0 8.0 0.0 
Synechocystis sp. 
DWC 8.0 8.1 0.1 
1.73 8.0 7.9 -0.1 
0.96 8.0 7.9 -0.1 
0.53 8.0 7.9 -0.1 
0.30 8.0 7.9 -0.1 
0.165 8.0 7.9 -0.1 
0.091 8.0 7.9 -0.1 
0.051 8.0 8.0 0.0 
0.028 8.0 8.1 0.1 
0.0157 8.0 8.1 0.1 
0.0087 8.0 8.1 0.1 
C. gracile  
DWC 8.0 8.2 0.2 
0.53 8.0 8.0 0.0 
0.30 8.0 8.0 0.0 
0.16 8.0 8.0 0.0 
0.09 8.0 8.0 0.0 
0.051 8.0 8.0 0.0 
0.028 8.0 8.0 0.0 
0.016 8.0 8.0 0.0 
0.009 8.0 8.1 0.1 
0.0048 8.0 8.1 0.1 
0.0027 8.0 8.1 0.1 
G. herdmanii 
DWC 8.0 8.1 0.1 
0.16 8.0 8.0 0.0 
0.09 8.0 8.0 0.0 
0.05 8.0 8.1 0.1 
0.03 8.0 8.1 0.1 
0.016 8.0 8.1 0.1 
0.009 8.0 8.1 0.1 
0.005 8.0 8.1 0.1 
0.003 8.0 8.1 0.1 
0.0015 8.0 8.1 0.1 








Starting pH Final pH pH change 
Cefotaxime 
A. flos-aquae 
DWC 8.3 8.3 0.0 
0.09 8.3 8.1 -0.2 
0.05 8.3 8.0 -0.3 
0.03 8.3 8.1 -0.2 
0.02 8.3 8.1 -0.2 
0.009 8.3 8.2 -0.1 
0.005 8.3 8.3 0.0 
0.003 8.3 8.3 0.0 
0.001 8.3 8.3 0.0 
0.0008 8.3 8.3 0.0 
0.0005 8.3 8.3 0.0 
A. cylindrica 
DWC 8.3 8.2 -0.1 
0.09 8.3 8.1 -0.2 
0.05 8.3 8.1 -0.2 
0.03 8.3 8.1 -0.2 
0.02 8.3 8.1 -0.2 
0.009 8.3 8.1 -0.2 
0.005 8.3 8.2 -0.1 
0.003 8.3 8.2 -0.1 
0.001 8.3 8.1 -0.2 
0.0008 8.3 8.1 -0.2 
0.0005 8.3 8.2 -0.1 
S. leopoliensis    
DWC 8.3 8.4 0.1 
0.95 8.3 8.2 -0.1 
0.53 8.3 8.2 -0.1 
0.29 8.3 8.3 0.0 
0.16 8.3 8.2 -0.1 
0.091 8.3 8.2 -0.1 
0.050 8.3 8.3 0.0 
0.028 8.3 8.4 0.1 
0.016 8.3 8.5 0.2 
0.0086 8.3 8.4 0.1 
0.0048 8.3 8.5 0.2 
S. elongates 
DWC 8.3 8.4 0.1 
1.71 8.3 8.0 -0.3 
0.95 8.3 8.1 -0.2 
0.53 8.3 8.1 -0.2 
0.29 8.3 8.1 -0.2 
0.163 8.3 8.0 -0.3 
0.091 8.3 8.1 -0.2 
0.050 8.3 8.3 0.0 
0.028 8.3 8.4 0.1 
0.0156 8.3 8.4 0.1 








Starting pH Final pH pH change 
Cefotaxime 
Synechococcus sp.    
DWC 8.3 8.5 0.2 
1.71 8.3 8.0 -0.3 
0.95 8.3 8.1 -0.2 
0.53 8.3 8.2 -0.1 
0.29 8.3 8.2 -0.1 
0.163 8.3 8.2 -0.1 
0.091 8.3 8.2 -0.1 
0.050 8.3 8.4 0.1 
0.028 8.3 8.4 0.1 
0.0156 8.3 8.5 0.2 
0.0086 8.3 8.5 0.2 
Synechocystis sp. 
DWC 8.3 8.4 0.1 
10.00 8.3 8.1 -0.2 
5.56 8.3 8.2 -0.1 
3.09 8.3 8.2 -0.1 
1.71 8.3 8.1 -0.2 
0.953 8.3 8.1 -0.2 
0.529 8.3 8.1 -0.2 
0.294 8.3 8.1 -0.2 
0.163 8.3 8.2 -0.1 
0.0907 8.3 8.3 0.0 
0.0504 8.3 8.4 0.1 
C. gracile  
DWC 8.3 8.5 0.2 
0.29 8.3 8.1 -0.2 
0.16 8.3 8.1 -0.2 
0.09 8.3 8.2 -0.1 
0.05 8.3 8.4 0.1 
0.028 8.3 8.2 -0.1 
0.016 8.3 8.5 0.2 
0.009 8.3 8.5 0.2 
0.005 8.3 8.5 0.2 
0.0027 8.3 8.6 0.3 
0.0015 8.3 8.5 0.2 
G. herdmanii 
DWC 8.3 8.4 0.1 
0.09 8.3 8.1 -0.2 
0.05 8.3 8.5 0.2 
0.03 8.3 8.5 0.2 
0.02 8.3 8.5 0.2 
0.009 8.3 8.5 0.2 
0.005 8.3 8.5 0.2 
0.003 8.3 8.5 0.2 
0.001 8.3 8.5 0.2 
0.0008 8.3 8.5 0.2 








Starting pH Final pH pH change 
Cefazolin 
A. flos-aquae 
DWC 8.1 8.1 0.0 
0.27 8.1 8.1 0.0 
0.18 8.1 8.2 0.1 
0.12 8.1 8.1 0.0 
0.08 8.1 8.2 0.1 
0.054 8.1 8.2 0.1 
0.036 8.1 8.2 0.1 
0.024 8.1 8.2 0.1 
0.016 8.1 8.2 0.1 
0.0106 8.1 8.2 0.1 
0.0071 8.1 8.1 0.0 
A. cylindrica 
DWC 8.1 8.1 0.0 
0.27 8.1 8.2 0.1 
0.18 8.1 8.2 0.1 
0.12 8.1 8.2 0.1 
0.08 8.1 8.2 0.1 
0.054 8.1 8.2 0.1 
0.036 8.1 8.1 0.0 
0.024 8.1 8.1 0.0 
0.016 8.1 8.1 0.0 
0.0106 8.1 8.1 0.0 
0.0071 8.1 8.1 0.0 
S. leopoliensis    
DWC 8.1 8.4 0.3 
2.07 8.1 8.4 0.3 
1.38 8.1 8.4 0.3 
0.92 8.1 8.4 0.3 
0.61 8.1 8.4 0.3 
0.409 8.1 8.4 0.3 
0.273 8.1 8.4 0.3 
0.182 8.1 8.4 0.3 
0.121 8.1 8.4 0.3 
0.0808 8.1 8.4 0.3 
0.0538 8.1 8.4 0.3 
S. elongates 
DWC 8.1 8.3 0.2 
3.11 8.1 8.3 0.2 
2.07 8.1 8.3 0.2 
1.38 8.1 8.3 0.2 
0.92 8.1 8.3 0.2 
0.613 8.1 8.3 0.2 
0.409 8.1 8.3 0.2 
0.273 8.1 8.3 0.2 
0.182 8.1 8.3 0.2 
0.1212 8.1 8.3 0.2 






Starting pH Final pH pH change 
Cefazolin 
Synechococcus sp.    
DWC 8.1 8.3 0.2 
10.48 8.1 8.3 0.2 
6.99 8.1 8.2 0.1 
4.66 8.1 8.3 0.2 
3.11 8.1 8.3 0.2 
2.070 8.1 8.3 0.2 
1.380 8.1 8.3 0.2 
0.920 8.1 8.3 0.2 
0.613 8.1 8.3 0.2 
0.4089 8.1 8.3 0.2 
0.2726 8.1 8.3 0.2 
Synechocystis sp. 
DWC 8.1 8.3 0.2 
6.99 8.1 8.3 0.2 
4.66 8.1 8.3 0.2 
3.11 8.1 8.3 0.2 
2.07 8.1 8.3 0.2 
1.380 8.1 8.3 0.2 
0.920 8.1 8.3 0.2 
0.613 8.1 8.3 0.2 
0.409 8.1 8.3 0.2 
0.2726 8.1 8.3 0.2 
0.1817 8.1 8.3 0.2 
C. gracile  
DWC 8.1 8.4 0.3 
0.92 8.1 8.1 0.0 
0.61 8.1 8.2 0.1 
0.41 8.1 8.2 0.1 
0.27 8.1 8.2 0.1 
0.182 8.1 8.2 0.1 
0.121 8.1 8.3 0.2 
0.081 8.1 8.3 0.2 
0.054 8.1 8.3 0.2 
0.0359 8.1 8.4 0.3 
0.0239 8.1 8.4 0.3 
G. herdmanii 
DWC 8.1 8.3 0.2 
0.92 8.1 8.2 0.1 
0.61 8.1 8.2 0.1 
0.41 8.1 8.2 0.1 
0.27 8.1 8.2 0.1 
0.182 8.1 8.2 0.1 
0.121 8.1 8.3 0.2 
0.081 8.1 8.2 0.1 
0.054 8.1 8.3 0.2 
0.0359 8.1 8.3 0.2 








Starting pH Final pH pH change 
Sufadiazine 
A. flos-aquae 
DWC 8.2 8.3 0.1 
25.00 8.2 8.3 0.1 
8.93 8.2 8.3 0.1 
3.19 8.2 8.3 0.1 
1.14 8.2 8.3 0.1 
0.407 8.2 8.3 0.1 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 
0.0024 8.2 8.3 0.1 
A. cylindrica 
DWC 8.2 8.3 0.1 
25.00 8.2 8.3 0.1 
8.93 8.2 8.3 0.1 
3.19 8.2 8.3 0.1 
1.14 8.2 8.3 0.1 
0.407 8.2 8.3 0.1 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 
0.0024 8.2 8.3 0.1 
S. leopoliensis    
DWC 8.2 8.3 0.1 
25.00 8.2 8.3 0.1 
8.93 8.2 8.3 0.1 
3.19 8.2 8.3 0.1 
1.14 8.2 8.3 0.1 
0.407 8.2 8.3 0.1 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 
0.0024 8.2 8.3 0.1 
S. elongates 
DWC 8.2 8.3 0.1 
25.00 8.2 8.3 0.1 
8.93 8.2 8.3 0.1 
3.19 8.2 8.3 0.1 
1.14 8.2 8.3 0.1 
0.407 8.2 8.3 0.1 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 








Starting pH Final pH pH change 
Sulfadiazine 
Synechococcus sp.    
DWC 8.2 8.3 0.1 
25.00 8.2 8.3 0.1 
8.93 8.2 8.3 0.1 
3.19 8.2 8.3 0.1 
1.14 8.2 8.3 0.1 
0.407 8.2 8.3 0.1 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 
0.0024 8.2 8.3 0.1 
Synechocystis sp. 
DWC 8.2 8.3 0.1 
25.00 8.2 8.2 0.0 
8.93 8.2 8.2 0.0 
3.19 8.2 8.2 0.0 
1.14 8.2 8.2 0.0 
0.407 8.2 8.2 0.0 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 
0.0024 8.2 8.3 0.1 
C. gracile  
DWC 8.2 8.3 0.1 
25.00 8.2 8.2 0.0 
8.93 8.2 8.2 0.0 
3.19 8.2 8.2 0.0 
1.14 8.2 8.2 0.0 
0.407 8.2 8.3 0.1 
0.145 8.2 8.3 0.1 
0.052 8.2 8.3 0.1 
0.019 8.2 8.3 0.1 
0.0066 8.2 8.3 0.1 
0.0024 8.2 8.3 0.1 
G. herdmanii 
DWC 8.2 8.3 0.1 
25.00 8.2 8.2 0.0 
8.93 8.2 8.2 0.0 
3.19 8.2 8.2 0.0 
1.14 8.2 8.2 0.0 
0.407 8.2 8.2 0.0 
0.145 8.2 8.2 0.0 
0.052 8.2 8.2 0.0 
0.019 8.2 8.2 0.0 
0.0066 8.2 8.2 0.0 








Starting pH Final pH pH change 
Sufamethazine 
A. flos-aquae 
DWC 8.2 8.1 -0.1 
100.00 8.2 8.1 -0.1 
55.56 8.2 8.1 -0.1 
30.86 8.2 8.2 0.0 
17.15 8.2 8.1 -0.1 
9.526 8.2 8.1 -0.1 
5.292 8.2 8.1 -0.1 
2.940 8.2 8.2 0.0 
1.633 8.2 8.1 -0.1 
0.9074 8.2 8.1 -0.1 
0.5041 8.2 8.1 -0.1 
A. cylindrica 
DWC 8.2 8.4 0.2 
100.00 8.2 8.2 0.0 
55.56 8.2 8.3 0.1 
30.86 8.2 8.2 0.0 
17.15 8.2 8.3 0.1 
9.526 8.2 8.3 0.1 
5.292 8.2 8.3 0.1 
2.940 8.2 8.2 0.0 
1.633 8.2 8.3 0.1 
0.9074 8.2 8.3 0.1 
0.5041 8.2 8.3 0.1 
S. leopoliensis    
DWC 8.2 8.3 0.1 
100.00 8.2 8.2 0.0 
55.56 8.2 8.2 0.0 
30.86 8.2 8.2 0.0 
17.15 8.2 8.2 0.0 
9.526 8.2 8.2 0.0 
5.292 8.2 8.2 0.0 
2.940 8.2 8.2 0.0 
1.633 8.2 8.2 0.0 
0.9074 8.2 8.2 0.0 
0.5041 8.2 8.2 0.0 
S. elongates 
DWC 8.2 8.3 0.1 
100.00 8.2 8.1 -0.1 
55.56 8.2 8.1 -0.1 
30.86 8.2 8.1 -0.1 
17.15 8.2 8.1 -0.1 
9.526 8.2 8.1 -0.1 
5.292 8.2 8.2 0.0 
2.940 8.2 8.2 0.0 
1.633 8.2 8.2 0.0 
0.9074 8.2 8.2 0.0 








Starting pH Final pH pH change 
Sulfamethazine 
Synechococcus sp.    
DWC 8.2 8.2 0.0 
100.00 8.2 8.2 0.0 
55.56 8.2 8.2 0.0 
30.86 8.2 8.2 0.0 
17.15 8.2 8.2 0.0 
9.526 8.2 8.2 0.0 
5.292 8.2 8.2 0.0 
2.940 8.2 8.2 0.0 
1.633 8.2 8.2 0.0 
0.9074 8.2 8.2 0.0 
0.5041 8.2 8.2 0.0 
Synechocystis sp. 
DWC 8.2 8.4 0.2 
100.00 8.2 8.3 0.1 
55.56 8.2 8.3 0.1 
30.86 8.2 8.3 0.1 
17.15 8.2 8.3 0.1 
9.526 8.2 8.4 0.2 
5.292 8.2 8.4 0.2 
2.940 8.2 8.4 0.2 
1.633 8.2 8.4 0.2 
0.9074 8.2 8.4 0.2 
0.5041 8.2 8.4 0.2 
C. gracile  
DWC 8.2 8.3 0.1 
100.00 8.2 8.1 -0.1 
55.56 8.2 8.2 0.0 
30.86 8.2 8.2 0.0 
17.15 8.2 8.2 0.0 
9.526 8.2 8.2 0.0 
5.292 8.2 8.2 0.0 
2.940 8.2 8.2 0.0 
1.633 8.2 8.2 0.0 
0.9074 8.2 8.2 0.0 
0.5041 8.2 8.2 0.0 
G. herdmanii 
DWC 8.2 8.3 0.1 
100.00 8.2 8.3 0.1 
55.56 8.2 8.3 0.1 
30.86 8.2 8.3 0.1 
17.15 8.2 8.4 0.2 
9.526 8.2 8.4 0.2 
5.292 8.2 8.4 0.2 
2.940 8.2 8.4 0.2 
1.633 8.2 8.4 0.2 
0.9074 8.2 8.4 0.2 








Starting pH Final pH pH change 
Azithromycin 
A. flos-aquae 
DWC 8.2 8.3 0.1 
SC 8.2 8.3 0.1 
0.50 8.2 8.1 -0.1 
0.28 8.2 8.1 -0.1 
0.15 8.2 8.1 -0.1 
0.09 8.2 8.1 -0.1 
0.048 8.2 8.1 -0.1 
0.026 8.2 8.1 -0.1 
0.015 8.2 8.1 -0.1 
0.008 8.2 8.1 -0.1 
0.0045 8.2 8.1 -0.1 
0.0025 8.2 8.1 -0.1 
A. cylindrica 
DWC 8.2 8.3 0.1 
SC 8.2 8.3 0.1 
0.09 8.2 8.1 -0.1 
0.05 8.2 8.1 -0.1 
0.03 8.2 8.1 -0.1 
0.01 8.2 8.1 -0.1 
0.008 8.2 8.1 -0.1 
0.005 8.2 8.1 -0.1 
0.003 8.2 8.3 0.1 
0.001 8.2 8.2 0.0 
0.0008 8.2 8.3 0.1 
0.0004 8.2 8.3 0.1 
S. leopoliensis    
DWC 8.2 8.3 0.1 
SC 8.2 8.3 0.1 
0.50 8.2 8.2 0.0 
0.28 8.2 8.2 0.0 
0.15 8.2 8.3 0.1 
0.09 8.2 8.2 0.0 
0.048 8.2 8.2 0.0 
0.026 8.2 8.2 0.0 
0.015 8.2 8.3 0.1 
0.008 8.2 8.3 0.1 
0.0045 8.2 8.3 0.1 












Starting pH Final pH pH change 
Azithromycin 
S. elongates 
DWC 8.2 8.3 0.1 
SC 8.2 8.3 0.1 
0.50 8.2 8.3 0.1 
0.28 8.2 8.3 0.1 
0.15 8.2 8.2 0.0 
0.09 8.2 8.2 0.0 
0.048 8.2 8.2 0.0 
0.026 8.2 8.2 0.0 
0.015 8.2 8.3 0.1 
0.008 8.2 8.3 0.1 
0.0045 8.2 8.3 0.1 
0.0025 8.2 8.3 0.1 
Synechococcus sp.    
DWC 8.2 8.2 0.0 
SC 8.2 8.2 0.0 
0.50 8.2 8.3 0.1 
0.28 8.2 8.2 0.0 
0.15 8.2 8.2 0.0 
0.09 8.2 8.2 0.0 
0.048 8.2 8.2 0.0 
0.026 8.2 8.2 0.0 
0.015 8.2 8.2 0.0 
0.008 8.2 8.2 0.0 
0.0045 8.2 8.3 0.1 
0.0025 8.2 8.3 0.1 
Synechocystis sp. 
DWC 8.2 8.3 0.1 
SC 8.2 8.3 0.1 
0.50 8.2 8.2 0.0 
0.28 8.2 8.1 -0.1 
0.15 8.2 8.1 -0.1 
0.09 8.2 8.1 -0.1 
0.048 8.2 8.2 0.0 
0.026 8.2 8.2 0.0 
0.015 8.2 8.2 0.0 
0.008 8.2 8.2 0.0 
0.0045 8.2 8.3 0.1 












Starting pH Final pH pH change 
Azithromycin 
C. gracile  
DWC 8.2 8.3 0.1 
SC 8.2 8.3 0.1 
0.28 8.2 8.1 -0.1 
0.15 8.2 8.1 -0.1 
0.09 8.2 8.1 -0.1 
0.05 8.2 8.1 -0.1 
0.026 8.2 8.1 -0.1 
0.015 8.2 8.1 -0.1 
0.008 8.2 8.2 0.0 
0.005 8.2 8.3 0.1 
0.0025 8.2 8.3 0.1 
0.0014 8.2 8.3 0.1 
G. herdmanii 
DWC 8.2 8.3 0.1 
SC 8.2 8.2 0.0 
0.28 8.2 8.2 0.0 
0.15 8.2 8.1 -0.1 
0.09 8.2 8.1 -0.1 
0.05 8.2 8.1 -0.1 
0.026 8.2 8.1 -0.1 
0.015 8.2 8.1 -0.1 
0.008 8.2 8.2 0.0 
0.005 8.2 8.2 0.0 
0.0025 8.2 8.3 0.1 


















Starting pH Final pH pH change 
Erythromycin 
A. flos-aquae 
DWC 8.1 8.1 0.0 
0.50 8.1 7.8 -0.3 
0.28 8.1 7.8 -0.3 
0.15 8.1 7.9 -0.2 
0.09 8.1 7.9 -0.2 
0.048 8.1 8.0 -0.1 
0.026 8.1 8.0 -0.1 
0.015 8.1 8.0 -0.1 
0.008 8.1 8.0 -0.1 
0.0045 8.1 8.0 -0.1 
0.0025 8.1 8.0 -0.1 
A. cylindrica 
DWC 8.1 8.0 -0.1 
0.09 8.1 7.9 -0.2 
0.05 8.1 7.9 -0.2 
0.03 8.1 7.9 -0.2 
0.01 8.1 7.9 -0.2 
0.008 8.1 7.9 -0.2 
0.005 8.1 7.9 -0.2 
0.003 8.1 8.0 -0.1 
0.001 8.1 8.0 -0.1 
0.0008 8.1 8.0 -0.1 
0.0004 8.1 8.0 -0.1 
S. leopoliensis    
DWC 8.1 8.0 -0.1 
0.50 8.1 7.9 -0.2 
0.28 8.1 7.9 -0.2 
0.15 8.1 7.9 -0.2 
0.09 8.1 7.9 -0.2 
0.048 8.1 8.0 -0.1 
0.026 8.1 7.9 -0.2 
0.015 8.1 7.9 -0.2 
0.008 8.1 7.9 -0.2 
0.0045 8.1 8.0 -0.1 
0.0025 8.1 8.0 -0.1 
S. elongates 
DWC 8.1 8.0 -0.1 
0.50 8.1 8.0 -0.1 
0.28 8.1 7.9 -0.2 
0.15 8.1 7.9 -0.2 
0.09 8.1 8.0 -0.1 
0.048 8.1 8.0 -0.1 
0.026 8.1 7.9 -0.2 
0.015 8.1 7.9 -0.2 
0.008 8.1 8.0 -0.1 
0.0045 8.1 8.0 -0.1 







Starting pH Final pH pH change 
Erythromycin 
Synechococcus sp.    
DWC 8.1 8.0 -0.1 
0.50 8.1 8.0 -0.1 
0.28 8.1 7.9 -0.2 
0.15 8.1 7.9 -0.2 
0.09 8.1 8.0 -0.1 
0.048 8.1 8.0 -0.1 
0.026 8.1 7.9 -0.2 
0.015 8.1 7.9 -0.2 
0.008 8.1 8.0 -0.1 
0.0045 8.1 8.0 -0.1 
0.0025 8.1 8.0 -0.1 
Synechocystis sp. 
DWC 8.1 8.1 0.0 
0.50 8.1 7.9 -0.2 
0.28 8.1 7.8 -0.3 
0.15 8.1 7.9 -0.2 
0.09 8.1 7.9 -0.2 
0.048 8.1 7.9 -0.2 
0.026 8.1 7.8 -0.3 
0.015 8.1 7.9 -0.2 
0.008 8.1 8.0 -0.1 
0.0045 8.1 8.1 0.0 
0.0025 8.1 8.1 0.0 
C. gracile  
DWC 8.1 8.0 -0.1 
0.28 8.1 7.9 -0.2 
0.15 8.1 7.9 -0.2 
0.09 8.1 7.9 -0.2 
0.05 8.1 7.9 -0.2 
0.026 8.1 8.0 -0.1 
0.015 8.1 8.0 -0.1 
0.008 8.1 8.0 -0.1 
0.005 8.1 8.0 -0.1 
0.0025 8.1 8.0 -0.1 
0.0014 8.1 8.0 -0.1 
G. herdmanii 
DWC 8.1 8.0 -0.1 
0.28 8.1 7.9 -0.2 
0.15 8.1 7.9 -0.2 
0.09 8.1 7.9 -0.2 
0.05 8.1 7.9 -0.2 
0.026 8.1 8.0 -0.1 
0.015 8.1 8.0 -0.1 
0.008 8.1 8.0 -0.1 
0.005 8.1 8.0 -0.1 
0.0025 8.1 8.0 -0.1 
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This article is in preparation for submission as a short communication for 
publication at the time of submitting this thesis. It is a paper that uses the dose 
response curves from chapter 5 to construct species sensitivity distributions and 
from these evaluate the protection limits derived under current environmental 
risk assessment guidelines.   
I performed all statistical analysis, modelling and first drafting of the paper. All 
authors were actively involved in later discussions on the work and in the 





Protection limits for antibiotics 
are enhanced via the 
incorporation of species 




Limits established for the protection of the environment from the adverse effects 
of antibiotics have been criticised due to the lack of bacterial representation. 
Probabilistic analysis using species sensitivity distributions (SSD) for a wider 
and more diverse selection of bacteria may provide for more accurate and 
statistically robust protection limits compared with the single cyanobacteria 
species growth inhibition test currently used in environmental risk assessment. 
Here we used the dose-response data for eight cyanobacteria species to create 
SSDs for cefazolin, cefotaxime, ampicillin, erythromycin and azithromycin. From 
this we determined the 5% hazardous concentrations (concentration at which 
5% of species will be effected) to compare with the predicted no effect 
concentration (PNEC) used in the traditional approach for determining the 
protection limit. We show that the current PNEC may be either over or under 
protective of cyanobacteria species dependent on the species choice and mode 
of action of the antibiotic. For instance, the PNEC for macrolides was over 
protective but generally under protective for β-lactams. We also used measured 
environmental concentrations of selected antibiotics to conduct an expected 
total risk assessment and this indicates that in some locations of high antibiotic 
concentrations there is a significant risk to cyanobacteria populations. We 
conclude that protection limits using SSDs and a wider range of bacteria would 






The environmental risk assessment (ERA) of antibiotics aims to establish 
protection limits that prevent “risk of undesirable effects on the environment” 
(EC 2001). But how effective the current approach to ERA is for antibiotics has 
recently been questioned (Brandt et al. 2015; Le Page et al. 2017). Thus, there 
is an urgent need to identify if the protection limits currently derived by ERA are 
able to protect against adverse effects upon environmental populations and 
ecosystem functions and how they compare with protection limits for 
antimicrobial resistance (AMR). 
The approach currently taken to determine a protection limit for pharmaceuticals 
in surface water, including for antibiotics, is to calculate a predicted no effect 
concentration (PNEC) by applying an assessment factor of 10 to the lowest no 
observed effect concentration (NOEC) following testing upon a cyanobacteria 
(green algae when not an antibiotic), an invertebrate, a fish and an activated 
sludge respiration inhibition test. The assessment factor is applied to account 
for uncertainty caused by interspecies variability and the extrapolation from 
controlled laboratory studies to the field. But a factor of 10 is unsupported by 
experimental data and recent evidence shows that in some cases interspecies 
sensitivity may exceed this by several orders of magnitude (Chapman et al. 
1998; Le Page et al. 2017) (Chapter 5). This suggests that there may be cases 
where the PNEC is likely not to be protective of the most sensitive species. 
Moreover, a PNEC uses a NOEC, which has two potential drawbacks i) the 
NOEC has been heavily criticised due to its dependence on experimental 
design (both for replication for statistical power to detect differences from the 
controls and for the choice in test concentration range) (Green et al. 2013) and 
ii) because it uses only a single effect value (e.g. the NOEC) so that there can 
be no quantification of the uncertainty around the PNEC (Chapman et al. 1998). 
A second approach for establishing protection limits is to construct a species 
sensitivity distribution (SSD), which is a probability model of interspecies 
variability across a toxicity endpoint following chemical exposure (e.g. NOEC or 
ECx) allowing the prediction of the proportion of species affected at any 
concentration for the species group modelled (Aldenberg et al. 2001; Belanger 
et al. 2017; Wheeler et al. 2002). SSDs are more commonly used for higher tier 
ERA such as in plant protection product regulations (EFSA 2013) and in the 
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Water Framework Directive (European Commission Joint Research Centre 
2003). The protection limit most often derived from a SSD is the hazardous 
concentration that affects 5% of species (HC5), although it has been suggested 
that the lower 95% confidence limit of the HC5 (HC52.5%) should be used to 
ensure a truly protective limit (Verdonck et al. 2001; Wheeler et al. 2002). An 
assessment factor of less than 10 is sometimes applied depending on the 
specific regulations and quality/quantity of the data on which the SSD is based 
(EFSA 2013). 
Although SSDs have been criticised in the past for being ecologically unrealistic 
and for lack of statistical robustness (equally, no more so than single species 
testing with an assessment factor), there have been recent advances that allow 
for the mitigation of some of these concerns (Forbes and Calow 2002; Kon Kam 
King et al. 2015; Kon Kam King et al. 2014). Importantly, SSDs are influenced 
by the quality and number of data included. Where previously a sample size of 
10-15 species was required for a robust analysis (TGD 2003), newer protocols 
that use bootstrap regression and the incorporation of censored data now allow 
for the reliable use of a more limited dataset (<10 data points) (Kon Kam King et 
al. 2014; Wheeler et al. 2002). Furthermore, less species are arguably required 
if they are all known to be sensitive to the mode of action (MoA) of the chemical. 
This is because data from non-sensitive species or taxonomic clades will not be 
impacting the distribution and thus allowing a SSD that focuses upon the lower 
tail of the SSD from which a protection limit is derived and allowing for a more 
reliable estimate (Schmitt-Jansen et al. 2008; Segner 2011). 
It is not uncommon for the measured environmental concentrations (MECs) of 
antibiotics to surpass the PNEC in the environment, especially in sewerage 
treatment plants, hospital and manufacturing effluents (Batt et al. 2007; Brown 
et al. 2006; Jaimes-Correa et al. 2015; Larsson 2014; Larsson et al. 2007; Li et 
al. 2008; Watkinson et al. 2009). In these cases it is likely that there is a 
significant risk to bacterial communities and the ecosystem functions that they 
provide. By considering these MECs in relation to the SSD it is possible to 
obtain an indication of the potential fraction of species that may be at risk under 
that toxic pressure. Moreover, by integrating the frequency probability 
distribution of MECs with the SSD it is possible to perform probabilistic 
ecological risk assessments (PERA) to determine the likelihood of adverse 
 
 273 
effects. One such PERA is the expected total risk (ETR), which gives the 
probability that a randomly selected species will be affected given the 
distribution of measured concentrations and is equivalent to the risk determined 
by the area under the curve of a joint probability plot (Aldenberg et al. 2001). 
Interspecies differences in sensitivity to antibiotics, ranging by several orders of 
magnitude, mean that current ERA procedures that rely upon a single species 
of cyanobacteria to represent all bacterial diversity could underestimate the 
PNEC (Le Page et al. 2017) (Chapter 5). Thus, in order to improve the ERA for 
antibiotics there have been calls to increase the bacterial diversity tested 
(Brandt et al. 2015; Le Page et al. 2017). In Chapter 5 we attempted to address 
this by performing growth inhibition assays on eight species of cyanobacteria 
and found up to two orders of magnitude difference in interspecies sensitivity 
following exposure to β-lactams and approximately one order of magnitude 
difference to macrolides. This supported the findings of the meta-analysis (Le 
Page et al. 2017) where large differences in sensitivity were shown between 
cyanobacteria species. We therefore hypothesise that when calculating 
protection limits for antibiotics using the current approach to ERA there may be 
cases where the PNEC for surface water (PNECSW) is not fully protective of all 
cyanobacteria populations. Using the data for eight species of cyanobacteria 
exposed to five antibiotics in Chapter 5, SSDs were established and how 
protective a PNEC derived using a NOEC and assessment factor of 10 for 
cyanobacteria populations was explored. We then establish the fraction of 
cyanobacteria species affected (based on our SSDs) by published MECs and 
consider the risk posed to cyanobacteria in the environment through the 
determination of the ETR. 
Methods 
Data collection 
For this analysis two datasets were used. The first was the effect data from for 
eight species of cyanobacteria exposed to the antibiotics cefazolin, cefotaxime, 
ampicillin, azithromycin and erythromycin in Chapter 5. The cyanobacteria were 
Anabaena flos-aquae (CCAP 1403/13A), Synechococcus leopoliensis (CCAP 
1405/1), Anabaena cylindrica (PCC 7122), Synechococcus elongates (PCC 
6301), Synechococcus sp (PCC 6312), Synechocystis sp (PCC 6803), 
Cyanobium gracile (PCC 6307) and Geminocystis herdmanii (PCC 6308). 
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Further information on the choice of species, experimental design and statistical 
analysis can be found in Chapter 5. The second dataset used for these 
analyses were the MECs for each antibiotic in Umweltbundesamt's (UBA) 
'Pharmacuiticals in the environment' database (Umwelt bundesamt 2018). 
MECs from all matrices that were measured in, or able to be converted into μg/L 
were extracted for use. Results that were recorded as 0 μg/L were removed, as 
they represent either no antibiotic presence or below the limit of detection and 
their inclusion would prevent the fitting of a parametric distribution. 
SSDs 
SSDs were constructed in r (version 3.3.0; R Project for Statistical Computing, 
Vienna, Austria) using the fitdistrplus package (Delignette-Muller and Dutang 
2015) following procedure outlined in the MOSAIC SSD platform (Kon Kam 
King et al. 2014). Briefly, the 95% confidence intervals of the EC10 for each 
species (Chapter 5) were used as interval-censored data (i.e. not a single fixed 
value but a range between the 95% confidence limits). This allowed for the 
incorporation of the uncertainty around the EC10 into the SSD and thus increase 
confidence in the SSD output (Kon Kam King et al. 2014). Six parametric 
distributions were fitted to the data; i) normal, ii) log-normal, iii) weibull, iv) log-
logistic, v) gamma and vi) exponential. The best fitting distribution was selected 
based upon a combination of the Akaike Information Criterion (AIC) score and 
the goodness of fit tests; Kolmogorov-Smirnov statistic, Cramer von Mises 
statistic and Anderson-Darling statistic. It has been shown that the distribution 
selection can have large effects on the SSD outputs and that this is a key factor 
in the construction of the SSD (Obiakor et al. 2017). 
The HC5 and associated confidence intervals were determined from 
bootstrapping the data (5000 iterations) based on the parameters of the fitted 
distribution. A similar protocol was followed to derive the SSD, HC5 and 
confidence intervals from the NOEC data (Chapter 5) but for this the NOEC 
values were used as non-censored data. 
ETR 
The MEC data were fitted to the selection of distributions as for the SSD 
analysis and the best fitting selected using the AIC score. The ETR was 
calculated in r by integrating the product of the MEC probability distribution 
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function and the SSD in respect to concentration. Due to the limited number of 
MECs available all matrices from all locations globally were analysed together. 
An example script of code for the construction of the SSD and calculation of the 
ETR can be found in the supplementary material. 
Results 
The SSDs, based upon cyanobacteria EC10’s for each antibiotic, are presented 
in figure 1 together with the PNECs, based upon the NOEC of the most 
sensitive species tested in the microplate assays (PNEClowest), and the PNECs, 
based upon the two Organisation for Economic Co-operation and Development 
(OECD) test guideline recommended species (from which all PNECs derived for 
regulatory purposes are likely derived from) A. flos-aquae (PNECA. flos-aquae) and 
S. leopoldensis (PNECS.leopoldensis). Figure 1 also illustrates the PNECs for AMR 
(PNECR) as calculated by (Bengtsson-Palme and Larsson 2016). SSDs based 
upon cyanobacteria NOECs are presented in supplementary material (figure 
S1). 
Table 1 provides values for the HC5, PNECs and the fraction of cyanobacteria 
affected predicted from the SSD (based on the EC10s) for each antibiotic whilst 
Table 2 gives the ETR for each antibiotic, the highest and median MECs and 
the fraction of cyanobacteria affected predicted from the SSD (based on EC10s). 
Tables S1 and S2 in the supplementary material provide the same information 
as tables 1 and 2 but using the SSD based upon NOEC data. Table S3 in the 
supplementary material provides the best fitting distributions used for 
establishing the SSD and for the MECs used to the calculate the ETR. 
Cefazolin 
The HC5 for cefazolin, based upon EC10s, was 1.13 μg/L, which was 7.5 times 
higher than the lowest PNEC (for A. flos-aquae) but four times lower than that 
based upon S. leopoldensis (Figure 1 and Table 1). 
The fraction of cyanobacteria affected at the PNECs ranged between 0.95 and 
13.3% depending on which species was used to derive the PNEC (Table 1). 
The HC5 based upon the NOEC data was twice this when based on the EC10 
(Table S1). The HC5 was approximately the same concentration as the PNEC 
for resistance (1.1 and 1.0 μg/L, respectively) (Table 1). 
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An ETR of 6.75% was determined for cefazolin and whilst the median MEC 
showed little effect upon cyanobacteria (<1%) based on the SSD, the highest 
recorded MEC of 42.9 μg/L was predicted to affect 60.2% of cyanobacteria 
(Table 2 and Figure S1). 
Cefotaxime 
The HC5 for cefotaxime, based upon EC10s, was 0.67 μg/L, which was four 
times higher than the lowest PNEC (for A. cylindrica) and approximately the 
same value as for the PNEC based upon S. leopoldensis (Figure 1 and Table 
1). 
The fraction of cyanobacteria affected at the PNECs ranged between 1.3 and 
5.2% depending on which species was used to derive the PNEC (Table 1). The 
HC5 based upon the NOEC data was approximately the same as when based 
on the EC10 (Table S1). The PNEC for resistance was lower than the HC5 and 
all of the PNECs for ecotoxicity based on the EC10s (Table 1). 
There was an ETR of 2.2% for cefotaxime and whilst the median MEC showed 
little effect upon cyanobacteria based on the SSD, the highest recorded MEC of 





Figure 1. Species sensitivity distributions of cyanobacteria exposed to five antibiotics. Cefazolin and cefotaxime (cephalosporin), ampicillin (penicillin), 
azithromycin and erythromycin (macrolide). Red line indicates the modelled species sensitivity distribution. Dashed black lines represent upper and lower 95% 
confidence limits. Blue shaded area indicates results of bootstrapped distributions. Orange vertical lines indicate predicted no effect concentrations (PNEC): Dot-dash 





The HC5 for ampicillin, based upon EC10s, was 8.6 μg/L, which was 17.5 times 
higher than the lowest PNEC (for C. gracile) and 2.9 and 7.4 times higher than 
the PNECs based upon A. flos-aquae and S. leopoldensis, respectively (Figure 
1 and Table 1). 
The fraction of cyanobacteria affected at the PNECs ranged between 0.9 and 
1.6% depending on which species was used to derive the PNEC (Table 1). The 
HC5 based upon the NOEC data was approximately the same as when based 
on the EC10 (Table S1). The PNEC for resistance was lower than the HC5 and 
all PNECs for ecotoxicity based on the EC10s (Table 1). 
The ETR for ampicillin was 6.3% and whilst the median MEC indicated little 
effect upon cyanobacteria based on the SSD, the highest recorded MEC of 
263 μg/L was predicted to affect 100% of the cyanobacteria (Table 2 and Figure 
S1). 
Azithromycin 
The HC5 for azithromycin, based upon EC10s, was 3.2 μg/L, which was 21 
times higher than the lowest PNEC (for G. herdmanii) and 3.1 and 16.6 times 
higher than the PNECs based upon A. flos-aquae and S. leopoldensis, 
respectively (Figure 1 and Table 1). 
The proportion of cyanobacteria affected at the PNECs was <1% for all PNECs 
irrespective of which species was used to derive it (Table 1). The HC5 based 
upon the NOEC data was approximately half as much as when based on the 
EC10. The PNEC for resistance was lower than the HC5. This was not the case 
however for the PNEC for ecotoxicity based on the EC10s of the most sensitive 
species and S. leopoldensis (Table S1). PNECR was however lower than the 
PNEC based on A. flos-aquae (Table 1). 
An ETR of 1.5% was determined for azithromycin and whilst the median MEC 
showed no effect upon cyanobacteria based on the SSD, the highest recorded 






The HC5 for erythromycin, based upon EC10s, was 21.3 μg/L, which was 34.4 
times higher than the lowest PNEC (for S. elongatus) and 7.3 and 6.9 times 
higher than the PNECs based upon A. flos-aquae and S. leopoldensis 
respectively (Figure 1 and Table 1). 
The fraction of cyanobacteria affected at the PNECs was <1% for all PNECs 
irrespective of which species was used to derive it (Table 1). The HC5 based 
upon the NOEC data was 3.5 times lower than when based on the EC10. The 
PNEC for resistance was lower than the HC5 but not for the PNEC for 
ecotoxicity based on the EC10s of the most sensitive species (Table S1). 
PNECR was however lower than the PNEC based on both OECD 
recommended species A. flos-aquae and S. leopoldensis (Table 1). 
An ETR of 0.1% was determined for erythromycin and no species of 
cyanobacteria are predicted to be affected by the MECs based on the SSD 

















HC5 1.13 0.13 19.88 5.00 
PNECLowest 0.15 - - 0.95 
PNECA. flos-aquae 0.15 - - 0.95 
PNECS. 
leopoldensis 
4.53 - - 13.26 
PNECR 1.00 - - 4.16 
Cefotaxime 
HC5 0.67 0.32 1.13 5.00 
PNECLowest 0.17 - - 1.29 
PNECA. flos-aquae 0.19 - - 1.44 
PNECS. 
leopoldensis 
0.70 - - 5.20 
PNECR 0.13 - - 0.99 
Ampicillin 
HC5 8.56 0** 26.47 5.00 
PNECLowest 0.49 - - 0.91 
PNECA. flos-aquae 3.00 - - 1.56 
PNECS. 
leopoldensis 
1.15 - - 1.05 
PNECR 0.25 - - 0.86 
Erythromycin 
HC5 21.30 16.18 28.76 5.00 
PNECLowest 0.62 * - - 0.00 
PNECA. flos-aquae 2.90 - - 0.00 
PNECS. 
leopoldensis 
3.10 - - 0.00 
PNECR 1.00 - - 0.00 
Azithromycin 
HC5 3.15 2.11 5.03 5.00 
PNECLowest 0.15 * - - 0.00 
PNECA. flos-aquae 1.02 - - 0.00 
PNECS. 
leopoldensis 
0.19 - - 0.00 
PNECR 0.25 - - 0.00 
Table 1. Protection limits; 5% hazardous concentration (HC5) based upon a species sensitivity 
distribution (SSD) using 10% effective concentrations (EC10), predicted no effect concentrations 
(PNECs) and the fraction of cyanobacteria affected based upon the cyanobacteria SSD. PNECs 
determined as specified in current environmental risk assessment. PNECLowest represents the 
PNEC based on the most sensitive cyanobacteria in the microplate assays. PNECA. flos-aquae and 
PNECS. leopoldensis are based on the data of species recommended in the OECD 201 test 
guideline (OECD 2011). PNECR is the PNEC for resistance as described by the Antimicrobial 
Resistance Industry Alliance. * PNECLowest for erythromycin is < 0.62 and < 0.15 for 

















Median 0.15 0.95 
Highest 42.93 60.23 
Cefotaxime 2.21 
Median 0.04 0.29 
Highest 41.90 95.91 
Ampicillin 6.33 
Median 0.10 0.83 
Highest 263.30 100.00 
Erythromycin 0.13 
Median 0.06 0.00 
Highest 7.84 0.00 
Azithromycin 1.53 
Median 0.09 0.00 
Highest 9.70 80.06 
Table 2. Expected total risk, measured environmental concentrations (MEC) and the fraction of 
cyanobacteria affected based upon the cyanobacteria species sensitivity distributions using 
10% effective concentrations and MECs obtained from Umweltbundesamt's 'Pharmacuiticals in 
the environment' database (Umwelt bundesamt 2018).    
Discussion 
The analysis conducted shows that the PNEC, as determined under the current 
approach to ERA using a NOEC and assessment factor of 10, was protective of 
>98% of cyanobacteria populations but with the exceptions of the PNECs for 
cefazolin and cefotaxime, based upon S. leopoldensis, which would adversely 
affect the growth of 13% and 5% of cyanobacteria respectively. We also show 
that based on published MECs the ETR for cyanobacteria was 6.8, 2.2 and 
6.3% for cefazolin, cefotaxime and ampicillin respectively whilst there was a 
<1% and 1.5% risk from erythromycin and azithromycin, respectively. 
PNECs with an assessment factor of 10 are not always protective 
Examining how protective a PNEC was, calculated using a NOEC and 
assessment factor of 10, when based on the two OECD recommended species 
A. flos-aquae and S. leopoldensis it was found that whilst PNECA. flos-aquae 
provided adequate protection for >98% of cyanobacteria, the EC10s, 
PNECS. leopoldensis was not always protective and failed to protect >95% 
cyanobacteria EC10s for the two cephalosporins; cefazolin and cefotaxime. 
These data indicate that under current ERA procedures (of using a single test 
species) the choice of species is critical in establishing a protection limit. For the 
two macrolides however, the PNEC was protective of all cyanobacteria 
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regardless of the species from which the PNEC was derived. This can be 
explained by the MoA of the antibiotic classes. 
Due to the larger interspecies variability observed between cyanobacteria 
exposed to cell membrane synthesis inhibitors, the PNEC has a higher 
probability of being under protective compared with other MoAs (Chapter 2 and 
5). This relates to the fact that the assessment factor of 10 is inadequate to 
account for the large differences in sensitivity between the tested species (on 
which the PNEC is based) and the more sensitive species. For other MoAs, 
such as the macrolides, the smaller interspecies variability (Chapter 5) means 
an assessment factor of 10 is sufficient to cover the entire SSD no matter which 
species is selected on which to base the PNEC. Indeed an assessment factor of 
10 arguably may be seen as somewhat over protective for these antibiotics. 
This is clearly observed by the slopes of the SSDs (Figure 1) that have a 
shallower gradient for the cell membrane synthesis inhibiting antibiotics 
compared with that for the protein synthesis inhibitors. 
In addition, the variability observed between cells following exposure to cell 
membrane synthesis inhibiting antibiotics (reflected by the larger confidence 
limits around the ECxs compared to other MoAs) is propagated in the SSDs that 
show higher uncertainty (larger confidence limits) compared with that for the 
macrolides. In Chapter 5 we concluded that the magnitude of species sensitivity 
might, at least in part, be explained by the conservation of the drug target 
between species and by the bioavailability/uptake of the antibiotic. As such, it 
may be possible to extrapolate these results to hypothesise that PNECs using 
an assessment factor of 10 may be protective for other classes of antibiotics 
that have a relatively well conserved drug target across bacteria and less 
difference in interspecies sensitivity (such as some DNA synthesis inhibitors 
(e.g. fluoroquinolones)) (Chapter 5). 
These results are in accordance with the conclusions of other investigators that 
have found that the parameters of SSDs are consistent across MoAs. For 
example, SSDs were comparable across primary producers exposed to 
herbicides (Chèvre et al. 2006; Nagai and Taya 2015) and invertebrates and 
fish exposed to organophosphorus insecticides (Sala et al. 2012). It has been 
suggested that this consistent relationship between MoA and SSD parameters 
may allow for the extrapolation between chemicals of the same MoA (Nagai and 
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Taya 2015). But this assumes that the relative species sensitivity is also 
consistent across MoAs. This was not the case for the cyanobacteria in our 
assays, where there was an order of species sensitivity difference between 
antibiotics with the same MoA (Chapter 5). Relative species sensitivity did 
however, show a general trend; although the order of sensitivity varied, 
individual species did not show large differences in relative sensitivity between 
antibiotics of the same class. Thus, with further investigation, it may be possible 
to extrapolate SSDs across antibiotic classes to help inform prioritisation 
schemes for antibiotics. It is of importance to note that although SSD 
parameters are consistent across MoAs in the literature, our SSDs for the 
cephalosporins and for ampicillin (a penicillin) indicate somewhat different 
shapes in the line slopes. This suggests that for antibiotics it may be possible to 
extrapolate within an antibiotic class but not between classes, even if the MoA 
is similar. 
The analysis conducted here shows that the PNECR was lower than the HC5(2.5) 
for the two macrolides and cefotaxime whilst the HC5(2.5) was lower than the 
PNECR for cefazolin (the negative HC5(2.5) prevents interpretation for ampicillin). 
This indicates that a protection limit derived for environmental health based 
upon a HC5 or HC5(2.5) would not be protective of resistance for 80% of these 
antibiotics, but that a PNECR maybe protective of 95% of cyanobacteria EC10’s. 
In the case of cefotaxime, a recently experimentally derived PNECR was derived 
(0.4 μg/L; Murray et al. 2018), which compares to the theoretically derived 
PNECR of 0.13 μg/L, obtained from the AMR Industry Alliance (AMR Industry 
alliance 2018; Bengtsson-Palme and Larsson 2016). In this case the HC5(2.5) 
would have been 1.2 times lower than the PNECR. The HC5 (i.e. not the lower 
confidence limit) however, is still a slightly higher value. These results add 
support to the conclusions in Chapter 2 and 3 (Le Page et al. 2017; Le Page et 
al. 2018) that using current methodologies neither the protection limit for 
environmental health nor for AMR is protective of each other and that both 




The HC5 may provide a better protection limit than the traditional PNEC 
Results from this analysis show that for the cephalosporins, the HC5 was 
generally 4 - 8 times higher than the PNEClowest but that the HC5(2.5%) was more 
similar at 0.9 - 2 times higher. For the macrolides the HC5 far exceeded this 
and was up to 34 times higher than the PNEClowest, further highlighting how the 
PNEC and assessment factor of 10 might be highly conservative as a protective 
factor for this antibiotic class/MoA. The HC5s were more similar to the NOECs 
than the PNECs, with the HC5(2.5%) being just 0.1 – 2.6 times the value for the 
lowest NOECs for all antibiotics. These results therefore support the suggestion 
that the HC5(2.5%) could be used to ensure an empirically based protection limit 
that is a more accurate and is truly protective of 95% of species (Wheeler et al. 
2002) without being over protective in for some MoAs as appears to be the 
case for the PNECs for macrolides. 
The 95% confidence intervals of the HC5s for cefotaxime, azithromycin and 
erythromycin suggest some uncertainty (although this is relatively small) 
surrounding the HC5 for these antibiotics. But given that these estimates 
include the error around the original EC10 via the use of the 95% confidence 
limits as censored data, this might be expected. The wider confidence limits 
around the HC5 for cefazolin shows that there is more uncertainty in this 
estimate and this may be due to higher variability observed between replicates 
in the microplate assay. 
The HC5 has been suggested as a protection limit under the premise that 
functional redundancy (where multiple species are capable of performing the 
same ecological functions) in the ecosystem will compensate for some small 
effects on the most sensitive species (Solomon and Sibley 2002). However, the 
magnitude of functional redundancy is not clear, especially in bacterial 
communities (Antwis et al. 2017). Although our results suggest that the 
HC5(2.5%) (based upon the EC10) may be suitable for setting protection limits, 
further investigation is required to explore the hypothesis that 5% of species 
can be affected beyond their EC10 without adverse effects upon environmental 
communities and ecosystem function. 
The use of SSDs and the HC5(2.5%) may be a suitable way to address 
uncertainties in interspecies differences in sensitivity and the extrapolation from 
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a few single species studies to reflect all species within a taxonomic group. But 
the selection of species is of clear importance (Verdonck et al. 2003). Our 
analysis may be a suitable reflection of cyanobacteria sensitivity, but in the case 
of antibiotics a more diverse range of bacteria are required since sensitivity 
differences between taxonomic clades could be large, even spanning several 
orders of magnitude (Chapters 2 and 5). Furthermore, a protection limit also 
needs to consider the extrapolation from the laboratory to the field. Previous 
authors have concluded that large safety factors are not considered necessary 
for extrapolation between the laboratory and field (Chapman et al. 1998). 
Indeed, bacteria associated with biofilms in the field may be more resilient to 
chemical toxicity than cells in laboratory testing due to the protective nature of 
complex biofilm communities and extracellular substances (Harrison et al. 
2007). On the other hand, there may still be considerable unknowns regarding 
the effect of antibiotics in the environment that may significantly increase the 
sensitivity of bacteria to antibiotics. These include an increase in sensitivity in 
chemical mixtures or as a result of different biotic and abiotic factors (e.g. 
competition, predation, temperature, pH (Rohr et al. 2016)). As such, in the 
absence of conclusive evidence demonstrating the safe concentrations in 
mixtures or in a variety of environmental conditions, it may be prudent to take a 
protective approach and continue to include an assessment factor to 
compensate for this, as is required in some regulatory guidance (EFSA 2013; 
TGD 2003). Further investigation is required to determine the suitable size of 
such an assessment factor, as these are still largely arbitrary. Using an 
assessment factor with the HC5 or HC5(2.5) to establish a protection limit may 
appear to undermine the benefits of conducting a more accurate, reliable and 
robust SSD, which requires multiple experiments and will thus be more costly 
and experimentally time consuming compared to a single species test (as is 
currently used in antibiotic ERA). However, more confidence can be applied to 
an empirically derived HC5/ HC5(2.5) with a small assessment factor (of  less 
than 10) and for which error can be quantified. Furthermore, a HC5 has less 
chance of underestimating the PNEC where interspecies variability is high and 
overestimating the PNEC where interspecies variability is low. Additionally, the 
SSD based on an ECx avoids the criticisms of the NOEC that is flawed and 




Measured environmental concentrations and expected total risk 
The SSDs highlight that for the majority of MECs there is a very limited effect on 
cyanobacteria in the field (potentially affected fractions of <1%) from all 
antibiotics based on the median MEC. However, with exception of erythromycin, 
between 60 and 100% of cyanobacteria may be affected when exposed to the 
highest antibiotic MECs recorded in the UBA database (Umwelt bundesamt 
2018) for all antibiotics tested here. Our analysis therefore suggests that 
bacterial populations in these communities for the higher measured 
concentrations may be severely affected with potential consequences on the 
ecosystem functions that they provide. 
The expected total risk (ETR) determined for the antibiotics indicated a 
relatively high risk (of up to 6%) for the cell membrane synthesis inhibiting 
antibiotic classes compared with the macrolides that had an ETR of 0.1 and 
0.5% for erythromycin and azithromycin, respectively. This was not expected 
given that the macrolides are on the priority contaminant watch list, in part 
because of their persistent nature (Carvalho et al. 2015). One explanation for 
this may be that there were considerably more MEC data for the macrolides, 
reflecting their priority status as chemicals of concern. This additional MEC data 
may have resulted in a more environmentally realistic distribution with more 
samples consisting of low levels in surface waters and effluents. The 
cephalosporins and ampicillin on the other hand, have far fewer MECs (<30) of 
which sampling bias may have resulted in higher concentrations having a 
disproportionate effect on the distribution. This was unavoidable given the 
limited MEC data available. 
The interpretation of the ETR therefore requires careful consideration of what 
the MEC and SSD distributions represent (Verdonck et al. 2003). The ETRs 
calculated here use the limited MEC data available on the literature, but 
whether each individual sample is truly representative of the concentrations 
found in the environment is unknown. For example, does it reflect a temporal or 
spatial average concentration? Or could it represent a peak (or low point) in 
concentration? As such, with a limited dataset such as those available for this 
analysis caution must be employed in the interpretation of the calculated risk. 
Additionally, interpretation of the risk from a PERA also needs to consider the 
data on which the species sensitive distribution was based. In this instance it 
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reflects the EC10 and thus the expected risk here is that of a random measured 
concentration exceeding a random species’ EC10, which may or may not lead to 
adverse ecological consequences. Furthermore, the effect level modelled 
needs to be considered in relation to the MEC data used to ensure it is relevant 
(Verdonck et al. 2003). For example, effect data from a chronic 72 hour 
cyanobacteria study as utilised in this analysis, would not be suitable in a PERA 
using MEC data that represent short <24h peaks in environmental 
concentrations such as following irregular surface runoff of antibiotics following 
agricultural use. 
Our analysis represents the expected risk that the growth rate of a random 
species of cyanobacteria will be adversely affected by 10% in the presence of 
the antibiotic based upon MECs globally in a wide range of matrices. It is thus a 
useful indication of which antibiotics may be of a higher concern than others 
(based on the available MECs) but is not suitable for drawing specific 
conclusions about the risk of each individual antibiotic in the environment. 
Further investigation of antibiotic MECs that are spatially or temporally discrete 
in a single matrix is required to perform precise and reliable ETR assessments. 
Conclusion 
Our analysis shows that the choice of species from which a PNEC is derived, as 
currently determined in ERA, is of critical importance in order to ensure a 
suitable protection limit. We also show that an assessment factor of 10 may be 
protective of other cyanobacteria populations in some cases but may be over 
conservative for the protection in others and that this depends on the MoA of 
the antibiotic and the interspecies differences in sensitivity to it. The ETR 
analysis suggests that the risk to cyanobacteria populations in the environment 
is currently low, although the highest recorded MECs in the literature pose a 
significant threat to cyanobacteria populations. Finally, the data used in the 
analyses undertaken do not allow for the extrapolation to other bacterial taxa 
and thus the examination of additional bacterial diversity is required to fully 
assess the effectiveness of the PNEC to protect against the detrimental effects 
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Supplementary material A  
Data handling and distribution modelling 
Example code for modelling MEC and SSDs and integration of the curves to 
determine the ETR 
# Create distribution of MEC 
MEC_CFZ <- read.csv("")  
MEC_CFZ # show data 
MEC_Fit_CFZ_Gamma <- fitdist(MEC_CFZ$MEC, "gamma") # fit gamma distribution  
          over MEC data  
plot(MEC_Fit_CFZ_Gamma) # plot distribution 
 
MEC_Fit_CFZ_lnorm <- b(MEC_CFZ$MEC, "lnorm") # fit log normal distribution  
          over MEC data 
plot(MEC_Fit_CFZ_lnorm) # plot distribution 
 
MEC_Fit_CFZ_norm <- fitdist(MEC_CFZ$MEC, "norm") # fit normal distribution   
  over MEC data  
plot(MEC_Fit_CFZ_norm) # plot distribution 
 
MEC_Fit_CFZ_exp <- fitdist(MEC_CFZ$MEC, "exp") # fit exponential distribution  
          over MEC data 
plot(MEC_Fit_CFZ_exp) # plot distribution 
 
MEC_Fit_CFZ_logis <- fitdist(MEC_CFZ$MEC, "logis") # fit logistic distribution  
             over MEC data  
plot(MEC_Fit_CFZ_logis) # plot distribution 
 
MEC_Fit_CFZ_weibull <- b(MEC_CFZ$MEC, "weibull") # fit weibull distribution  
 over MEC data  
plot(MEC_Fit_CFZ_weibull) # plot distribution 
 
# Establish best fitting distribution 
cdfcomp(list(MEC_Fit_CFZ_Gamma, MEC_Fit_CFZ_lnorm, MEC_Fit_CFZ_norm, MEC_Fit_CF
Z_exp, MEC_Fit_CFZ_logis, MEC_Fit_CFZ_weibull), legendtext=c("Gamma", "Lognorm", "nor
m", "exponential", "logis", "Weibull")) ") # compare empirical cumulative distributions  
       against fitted distributions 
 
denscomp(list(MEC_Fit_CFZ_Gamma, MEC_Fit_CFZ_lnorm, MEC_Fit_CFZ_norm, MEC_Fit_
CFZ_exp, MEC_Fit_CFZ_logis, MEC_Fit_CFZ_weibull), legendtext=c("Gamma", "Lognorm", "n
orm", "exponential", "logis", "Weibull # compare histograms against fitted distributions 
 
qqcomp(list(MEC_Fit_CFZ_Gamma, MEC_Fit_CFZ_lnorm, MEC_Fit_CFZ_norm, MEC_Fit_CF
Z_exp, MEC_Fit_CFZ_logis, MEC_Fit_CFZ_weibull), legendtext=c("Gamma", "Lognorm", "nor
m", "exponential", "logis", "Weibull")) # compare empirical and theoretical quantiles 
 
ppcomp(list(MEC_Fit_CFZ_Gamma, MEC_Fit_CFZ_lnorm, MEC_Fit_CFZ_norm, MEC_Fit_CF
Z_exp, MEC_Fit_CFZ_logis, MEC_Fit_CFZ_weibull), legendtext=c("Gamma", "Lognorm", "nor
m", "exponential", "logis", "Weibull"))")) # compare empirical and theoretical probabilities 
 
gofstat(list(MEC_Fit_CFZ_Gamma, MEC_Fit_CFZ_lnorm, MEC_Fit_CFZ_norm, MEC_Fit_CFZ
_exp, MEC_Fit_CFZ_logis, MEC_Fit_CFZ_weibull), fitnames=c("Gamma", "Lognorm", "norm", "




# Create modelled distribution and data frame for plotting 
x_vector <- seq(0.01,1000, length.out = 100000) # vector for concentrations 
MEC_CFZ <- dlnorm(x_vector, MEC_Fit_CFZ_lnorm$estimate[1], MEC_Fit_CFZ_lnorm$estima
te[2]) # Create density distribution 
plot(x_vector, MEC_CFZ, type = "l", log="x", ylim = c(0, 1)) # Plot distributions to x vector 
MECdata_CFZ <- data.frame(MEC_CFZ) # make into a dataframe 
MECdata_CFZ$x_vector <- x_vector # add x-values 
# Make SSD using EC10 
Use 95% CI as censored data to create a cumulative distribution for SSD 
df_CFZ <- read.csv("")  
df_CFZ <- df_CFZ[order(df_CFZ$Conc), ] # Order EC10s 
df_CFZ$frac <- ppoints(df_CFZ$Conc, 0.5) # Probability  
df_CFZ_cens <- data.frame(left = df_CFZ$Low.CL, right = df_CFZ$High.CL)  
# create dataframe of censored data 
 
fit2_CFZ_lnorm <- fitdistcens(df_CFZ_cens, 'lnorm') # fit the censored data  
using log normal distribution 
 
fit2_CFZ_norm <- fitdistcens(df_CFZ_cens, 'norm') # fit the censored data  
using normal distribution 
 
fit2_CFZ_exp <- fitdistcens(df_CFZ_cens, 'exp') # fit the censored data  
using exponential distribution 
 
fit2_CFZ_logis <- fitdistcens(df_CFZ_cens, 'logis') # fit the censored data using  
logistic distribution 
 
fit2_CFZ_weibull <- fitdistcens(df_CFZ_cens, 'weibull') # fit the censored data using  
weibull distribution 
 
fit2_CFZ_Gamma <- fitdistcens(df_CFZ_cens, 'gamma') # fit the censored data using  
gamma distribution 
 
# compare models 
 
cdfcompcens(list(fit2_CFZ_lnorm, fit2_CFZ_norm, fit2_CFZ_exp,  
                 fit2_CFZ_logis,fit2_CFZ_weibull, fit2_CFZ_Gamma),  
            legendtext=c("Lognorm", "norm", "exponential", "logis", "Weibull", "Gamma"))  
 
# create AIC and LogLik tables for distribution comparison 
AICtable <- matrix(c(fit2_CFZ_lnorm$aic,fit2_CFZ_norm$aic,fit2_CFZ_exp$aic, 
                     fit2_CFZ_logis$aic,fit2_CFZ_weibull$aic, fit2_CFZ_Gamma$aic),ncol=6,byrow=FA
LSE) 
colnames(AICtable) <- c("Lognorm", "norm", "exponential", "logis", "Weibull", "Gamma") 
rownames(AICtable) <- c("AIC") 
AICtable <- as.table(AICtable) 
AICtable 
Logliktable <- matrix(c(fit2_CFZ_lnorm$loglik,fit2_CFZ_norm$loglik,fit2_CFZ_exp$loglik, 
                     fit2_CFZ_logis$loglik,fit2_CFZ_weibull$loglik,fit2_CFZ_Gamma$loglik),ncol=6,byr
ow=FALSE) 
colnames(Logliktable) <- c("Lognorm", "norm", "exponential", "logis", "Weibull", "Gamma") 
rownames(Logliktable) <- c("Loglik") 





# Run bootstraps and obtain new distribution parameters 
fit2_boot_CFZ <- bootdistcens(fit2_CFZ_Gamma, niter = 5000) # bootstrap the distribution 
quantile(fit2_boot_CFZ, probs = 0.05) # Extract 5th percentile and credible intervals 
summary(fit2_boot_CFZ) # summarise the distribution parameters 
# Build dataframes for graph from distributions 
x_Conc <- 10^(seq(log10(0.01), log10(1000), length.out = 1000)) # create x vector  
pp_CFZ <- apply(fit2_boot_CFZ$estim, 1, function(x) pgamma(x_Conc, x[1], x[2]))  
# fit bootstrapped distribution to x vector 
bootdat_CFZ <- data.frame(pp_CFZ)  # convert into dataframe 
bootdat_CFZ$x_Conc <- x_Conc # add x-values 
bootdat_CFZ <- melt(bootdat_CFZ, id.vars = 'x_Conc') # bring to long format 
cis_CFZ <- apply(pp_CFZ, 1, quantile, c(0.025, 0.975), na.rm = TRUE) # get CI from  
bootstraps 
 
rownames(cis_CFZ) <- c('lwr' ,'upr') 
pdat_CFZ <- apply(pp_CFZ, 1, median, na.rm = TRUE) # get CI from bootstraps 
pdat_CFZ <- data.frame(pdat_CFZ)  
pdat_CFZ$x_Conc <- x_Conc # add x-values 
pdat_CFZ <- melt(pdat_CFZ, id.vars = 'x_Conc') # bring to long format 
 
pdat_CFZ <- cbind(pdat_CFZ, t(cis_CFZ)) # add CI 
df_CFZ$fit <- 10^(log10(df_CFZ$Conc) + 0.2) # add x coordinates for species names from fitted
       values 
# Solve CDF in respect to concentration to get fraction affected at particular 
concentrations 
T<-function(x) {b(x, fit2_boot_CFZ$CI[1,1],fit2_boot_CFZ$CI[2,1])} 
Create values for PNECs and MECs 
PNECL_CFZ <- 0.15 # PNEC lowest 
PNECA_CFZ <- 0.15 # PNEC A. flos-aquae 
PNECS_CFZ <- 4.53 # PNEC S. leopoldensis  
PNECR_CFZ <- 1 # PNEC resistance 
MECm_CFZ <- 0.15 # MEC median 

















# Plot of SSD and relevant data (PNECs and MECs) 
CFZ_Plot <-  
  ggplot()+ 
  geom_line(data = bootdat_CFZ, aes(x = x_Conc, y = value, group = variable), col = '#e0f3f8', a
lpha = 0.05) + # bootstraps 
  geom_point(data = df_CFZ, aes(x = Conc, y = frac)) + # data points 
  geom_line(data = pdat_CFZ, aes(x = x_Conc, y = value), col = 'red') + # SSD/CDF 
  geom_line(data = pdat_CFZ, aes(x = x_Conc, y = lwr), linetype = 'dashed') + # Lower CI 
  geom_line(data = pdat_CFZ, aes(x = x_Conc, y = upr), linetype = 'dashed') + # Higher CI 
  geom_text(data = df_CFZ, aes(x = fit, y = frac, label = Species), hjust = 0, size = 3) + # data la
bels 
  theme_bw() + 
  scale_x_log10(breaks = c(0.01, 0.01, 0.1, 1, 10, 100, 1000), limits = c(0.01, 3000)) + 
  scale_y_continuous(limits = c(0,1)) + 
  labs(x = expression(paste('Concentration of cefazolin (', mu, 'g ', L^-1,')')),  
       y = 'Fraction of species affected') + 
  theme_bw() + 
  theme(panel.grid.major = element_blank(), panel.grid.minor = element_blank()) + 
  theme(text=element_text(family="Arial")) + 
  #geom_vline(xintercept = PNECL_CFZ, linetype = 4, colour = "#fc8d59") + # Lowest PNEC fro
m my results 
  geom_vline(xintercept = PNECA_CFZ, linetype = 2, colour = "#fc8d59") + # ANA1 PNEC from 
my results 
  geom_vline(xintercept = PNECS_CFZ, linetype = 3, colour = "#fc8d59") + # SYN1 PNEC from 
my results 
  geom_vline(xintercept = PNECR_CFZ, linetype = 2, colour = "#2c7bb6")  # Resistance PNEC f
rom AMR industry alliance 
CFZ_Plot 
# Integrate the distributions to get ETR 
F <- function(x) {dlnorm(x, meanlog = MEC_Fit_CFZ_lnorm$estimate[1], sdlog = MEC_Fit_CFZ
_lnorm$estimate[2]) * pgamma(x, fit2_boot_CFZ$CI[1,1], fit2_boot_CFZ$CI[2,1])} 
c <- integrate( F, lower = 0, upper = 1000000) 
c 
 
This code was partially adapted from both the MOSAIC SSD platform 
(http://pbil.univ-lyon1.fr/software/mosaic/ssd) and from Eduard Szoecs 
(https://edild.github.io/ssd/). 
Kon Kam King, G., et al. (2014). "MOSAIC_SSD: A new web tool for species 
sensitivity distribution to include censored data by maximum likelihood." 
Environmental Toxicology and Chemistry 33(9): 2133-2139. 
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Species sensitivity distributions based upon NOEC data 
 
Figure S1. Species sensitivity distributions of cyanobacteria based upon no observed effect concentrations exposed to five 
antibiotics. Cefazolin and cefotaxime (cephalosporin), ampicillin (penicillin), azithromycin and erythromycin (macrolide). Red 
line indicates the modelled species sensitivity distribution. Dashed black lines represent upper and lower 95% confidence 
limits. Blue shaded area indicates results of bootstrapped distributions. Orange vertical lines indicate predicted no effect 
concentrations (PNEC): Dot-dash orange line= PNEClowest; Dashed orange line = PNECA. flos-aquae; Dotted orange line = 















a affected (%) 
Cefazolin 
HC5 2.33 0.41 10.62 5.00 
PNECLowest 0.15 - - 0.01 
PNECA. flos-aquae 0.15 - - 0.01 
PNECS. 
leopoldensis 
4.53 - - 11.94 
PNECR 1.00 - - 1.17 
Cefotaxime 
HC5 0.63 0.28 1.17 5.00 
PNECLowest 0.17 - - 1.38 
PNECA. flos-aquae 0.19 - - 1.55 
PNECS. 
leopoldensis 
0.70 - - 5.58 
PNECR 0.40 - - 1.06 
Ampicillin 
HC5 7.05 -6.62 19.08 5.00 
PNECLowest 0.49 - - 1.18 
PNECA. flos-aquae 3.00 - - 2.11 
PNECS. 
leopoldensis 
1.15 - - 1.38 
PNECR 0.25 - - 1.11 
Erythromycin 
HC5 6.02 3.15 11.13 5.00 
PNECLowest 0.62 * - - 0.00 
PNECA. flos-aquae 2.90 - - 0.13 
PNECS. 
leopoldensis 
3.10 - - 0.19 
PNECR 1.00 - - 0.00 
Azithromycin 
HC5 1.50 0.66 3.04 5.00 
PNECLowest 0.15 * - - 0.00 
PNECA. flos-aquae 1.02 - - 1.26 
PNECS. 
leopoldensis 
0.19 - - 0.00 
PNECR 0.25 - - 0.00 
Table S1. Protection limits; 5% hazardous concentration (HC5) based upon a species sensitivity 
distribution (SSD) using no observed effect concentrations (NOEC), predicted no effect 
concentrations (PNECs) and the fraction of cyanobacteria affected based upon the 
cyanobacteria SSD. PNECs determined as specified in current environmental risk assessment. 
PNECLowest represents the PNEC based on the most sensitive cyanobacteria in the microplate 
assays. PNECA. flos-aquae and PNECS. leopoldensis are based on the data of species recommended in 
the OECD 201 test guideline (OECD 2011). PNECR is the PNEC for resistance as described by 
the Antimicrobial Resistance Industry Alliance. * PNECLowest for erythromycin is < 0.62 and < 

















Median 0.15 0.01 
Highest 42.93 67.11 
Cefotaxime 2.21 
Median 0.04 0.31 
Highest 41.90 96.78 
Ampicillin 6.33 
Median 0.10 1.07 
Highest 263.30 100.00 
Erythromycin 0.13 
Median 0.06 0.00 
Highest 7.84 11.89 
Azithromycin 1.53 
Median 0.09 0.00 
Highest 9.70 90.00 
Table S2. Expected total risk, measured environmental concentrations (MEC) and the fraction 
of cyanobacteria affected based upon the cyanobacteria species sensitivity distributions using 
no observed effect concentrations and MECs obtained from Umweltbundesamt's 
'Pharmacuiticals in the environment' database (Umwelt bundesamt 2018).  
  
 
Table of distributions used for species sensitivity and measured 







Cefazolin Log normal Gamma Log normal 
Cefotaxime Exponential Exponential Log normal 
Ampicillin Normal Normal Log normal 
Erythromycin Log normal Log normal Log normal 
Azithromycin Log normal Log normal Log normal 
Table S3. Distributions used in the probabilistic modelling of the measured environmental 
concentrations (MEC) and species sensitivity distributions (SSD) based upon the no observed 




Chapter 7  
Discussion 
As a result of antibiotic use in human and veterinary medicine antibiotics are 
regularly found in aquatic environments, including surface waters, ground 
waters, rivers, estuaries, marine waters and sediments (Carvalho and Santos 
2016; Gaw et al. 2014; Kümmerer 2009; Pei et al. 2006). They are also found 
across terrestrial matrices, especially soils (Kinney et al. 2006; Tolls 2001). 
Antibiotics are designed/selected to target pathogenic bacteria but they may 
also adversely affect non-pathogenic bacteria that perform a wide range of roles 
in the normal functioning of healthy ecosystems. Despite this, our knowledge of 
how antibiotics may affect microbial communities is limited. Furthermore, 
microbial representation in environmental risk assessment (ERA) is severely 
lacking, bringing into question the ability of ERA to establish adequate 
protection limits for these hugely important organisms (Agerstrand et al. 2015; 
Brandt et al. 2015; Le Page et al. 2017). 
The work presented in this thesis demonstrates that the current ERA of 
antibiotics may not always be protective of bacterial populations in the 
environment and highlights the knowledge gaps and uncertainties in the current 
regulatory practice. In chapters 2, 5 and 6 it is shown that reliance upon a single 
cyanobacteria species in the ERA to represent all prokaryotic diversity means 
that protection limits can fall short of protecting sensitive bacterial taxa, even 
when an assessment factor of 10 is applied to account for interspecies 
sensitivity. We demonstrate that including a wider range of cyanobacteria 
assays would go some way to improving ERA, but that additional testing on 
different bacterial clades may be necessary to ensure truly effective protective 
limits. In this work, I suggest that this could include the use of pre-clinical 
minimum inhibitory concentrations (MIC) data. 
In chapters 2 and 3 it is demonstrated that antimicrobial (AMR) protection limits 
need to be considered equally to that of ecotoxicological limits because neither 
are always been protective of the other using currently available methods. The 
findings from this research have already been used whereby the ‘AMR Industry 
Alliance’ have now proposed to use both ecotoxicological and AMR data for 
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establishing antibiotic manufacturing discharge limits (AMR Industry alliance 
2018). 
In the last empirical data chapter (chapter 6) we provide further evidence that a 
protection limit (in this case a predicted no effect concentration (PNEC)) based 
upon the no observed effect concentration (NOEC) and an assessment factor of 
10 may be over or under protective depending on the species selected for 
testing, the class of antibiotic and the magnitude of interspecies variability in 
sensitivity. Finally, the expected total risk from antibiotics on environmental 
cyanobacteria populations was explored. In this work it was found that for the 
five antibiotics analysed, there is a limited risk based on the species sensitivity 
distributions of the eight species of cyanobacteria tested in the microplate 
assays conducted in chapter 5. However, for those environments with high 
antibiotic concentrations, such as hospital and waste water treatment effluents, 
there is likely to be adverse effects on cyanobacteria populations. It is important 
to highlight however, that the risk calculated in chapter 6 reflects a limited 
dataset of MECs that represent a wide variety of matrices and geographic 
locations. Thus, although the expected total risk and fraction of affected species 
at higher MECs are useful for comparing between antibiotics and getting a 
snapshot of antibiotics/potential locations or discharge sources for further 
investigation, they can not be interpreted in the context of ERA or 
environmental management. 
Screening assays and their application 
In order to experimentally examine the findings of our meta-analysis that testing 
on a single species of cyanobacteria may not allow for adequate estimation of a 
protection limit, we needed to develop an assay that allowed for the direct 
comparison of growth rate inhibition across a range of cyanobacteria (chapter 
4). Growth inhibition studies on cyanobacteria are generally lacking in the 
literature (chapter 2) and there are even less examining interspecies differences 
in sensitivity. The notable exceptions to this were the studies by (Ando et al. 
2007; Dias et al. 2015; Guo et al. 2016). The former tested eight species of 
cyanobacteria and, as we found in chapter 5, also recorded large variability 
between species of over 2 orders of magnitude. A limit in the work of Ando et al 
however, was the fact that no chemical analysis was conducted to confirm the 
exposure concentrations. The study by (Guo et al. 2016) on the other hand had 
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supporting chemistry but only tested two cyanobacteria species alongside other 
primary producers. (Dias et al. 2015) also showed high interspecies variability 
but based their results upon minimum inhibitory concentrations that aren’t 
directly comparable to the endpoints used for ERA due to being at different 
ends of the dose-response curve. 
The microplate assay was designed (and validated against the reference 
toxicant potassium dichromate) with the aim for it to be i) comparable to 
traditional shake flask methods and ii) to enable a faster throughput compared 
with the more cumbersome shake flask system. We also adjusted the exposure 
period for each individual species so that the assay was conducted, as far as 
possible, during the balanced growth phase and under the same environmental 
conditions. This allowed for a direct interspecies comparison that was both 
environmentally relevant (all species are exposed to the same environmental 
conditions rather than a range optimised for laboratory growth) and in line with 
internationally recognised test guidelines (OECD 2011). Adopting this assay 
approach however required performing the assays under a constant light 
regime and at a temperature of 28°C, thus lacking direct environmental realism. 
This however was seen as an acceptable trade-off to achieve balanced growth 
in a timeframe comparable to the more traditional 72 hour shake flask test. 
The exposure studies conducted in this thesis were limited in duration and to 
only one part of the growth cycle (balanced growth). It cannot be excluded 
therefore that longer-term effects might arise from exposure to the antibiotics 
that were not detected here or whether other phases of the growth cycle are 
affected. Imamura et al. (2005) found that the pathogen Pseudomonas 
aeruginosa was not as sensitive to azithromycin in the exponential growth 
phase when compared with in the stationary growth phase; in the stationary 
growth phase the minimum bactericidal concentration was over two orders of 
magnitude lower compared with the growth phase; 1 μg/mL versus 128 μg/mL, 
respectively. This finding may have serious consequences for ERA where, as 
discussed in chapters 1 and 4, although there is a clear advantage in terms of 
reliability and reproducibility for running assays with cultures in balanced 
growth, the results may not always reflect well the most sensitive parts of the 
growth cycle. This requires further research that may identify more suitable test 
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methodologies or the need to incorporate additional assessment factors in 
establishing protection limits in order to compensate for this uncertainty. 
Although consideration of the limitations of the assay systems is important, they 
are likely to be much less significant compared with the limitations any 
laboratory based, single species study has when used to extrapolate the assay 
results to microbial communities in the field. In this case there are the additional 
complexities to be considered including resource limiting conditions, biological 
and ecological processes (predation, competition etc) and multiple 
environmental stressors (temperature changes, toxic mixtures, disturbance etc). 
The assessment factor of 10 used in establishing a protection limit is intended 
to acknowledge this uncertainty but, as demonstrated in chapters 2 and 5, it 
may be insufficient to protect against interspecies sensitivity alone, before 
considering these additional differences in sensitivity that might arise due to the 
complexities of what may be occurring within real life microbial communities. 
The implications of the thesis findings for ERA 
The work in this thesis, coming from both the meta-analysis and the 
experimental testing of the selected antibiotics (chapters 2 and 5), clearly 
demonstrates shortcomings of current ERA for the protection of cyanobacteria 
populations (and most likely other bacterial taxa). 
The experimental work in chapter 5 found that it was the case that the large 
difference observed in species sensitivity through the meta-analysis (chapter 2) 
was not seen of the same level (up to and over 5 orders of magnitude) with the 
species assayed. This may be a reflection of the variety of methodologies 
adopted in the meta-analysis compared to our assays used in chapter 5 that 
may have been superior in terms of consistency (and species run under the 
same conditions, by a single experimenter, in the same laboratory). 
Nevertheless, this does not mean that the greater variation in responses in 
cyanobacteria than found in our laboratory based analysis doesn’t actually 
occur because the meta-analysis included a wider range of species. To 
illustrate this, in the meta-analysis the most sensitive species tended to be 
Microcystis aeruginosa but we were unable to get this species into balanced 
growth in the microplate assay within 72 hours and thus it was not tested. 
Furthermore, some of the least sensitive cyanobacteria in the meta-analysis 
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were from the Nostoc genus and this genus was not represented at all in our 
assays (Ando et al. 2007; Le Page et al. 2017). This difference across chapters 
2 and 5 prompted the investigation in to species sensitivity distributions (SSD) 
in chapter 6. From this work, it was concluded that using an SSD based on 
mode of action (MoA) relevant species offers a valuable approach in ERA for 
seeking to obtain more reliable protection limits that don’t under or over 
estimate the effect level. An SSD approach incorporating more bacterial species 
therefore has a better chance of setting adequate protection limits compared 
with the current approach of calculating a NOEC (with the limitations associated 
with it (Green et al. 2013)) and adding what is essentially an arbitrary 
assessment factor. 
My thesis work compared the NOEC, 10% and 50% effective concentrations 
(ECx) with the MIC of clinically relevant bacteria as found in the EUCAST 
database (EUCAST). The rationale for this work was that ERA would be better 
served via the addition of more bacterial diversity, but very little has been 
published regarding the effect of antibiotics on environmental bacteria that is 
useful in the context of ERA (chapter 2). The clinical data from the EUCAST 
database provides an extensive source of effect data upon a wide range of 
bacteria, but does have the limitation that a direct comparison is not possible 
given that the endpoints (NOEC and MIC) represent different ends of the dose-
response curve and this must be taken into consideration (chapter 3). It was 
hypothesised that for some antibiotics the clinically relevant Gram-positive and 
negative bacteria would have been more sensitive than cyanobacteria species 
(chapters 2, 5 and 6). Assuming these pathogenic bacteria may be 
representative of other Gram-positive and negative bacteria we concluded that 
cyanobacteria may not adequately represent the bacterial taxa as a whole and 
an increase in bacterial diversity to incorporate other bacterial taxonomic clades 
is required. Further work in identifying suitable bacteria with a wide diversity 
would be hugely beneficial. Additionally, it would be of great value if the data for 
clinically relevant bacteria (CRB) in the EUCAST database included the whole 
dose-response curve rather than just the MIC, allowing for more sophisticated 
analysis for ecotoxicological testing and AMR. 
In pesticide regulations, if the active ingredient is a herbicide multiple MoA 
relevant algal species must be tested from across broader sensitive taxonomic 
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clades, including green algae, a diatom and a macrophyte (EFSA 2013; US 
EPA 2017), although they do not necessarily require an SSD to be modelled 
based on the data. An approach such as this, where testing is performed using 
a variety of MoA relevant species, ideally from a variety of bacterial taxonomic 
clades, for the ERA of antibiotics would be a significant step forwards to gaining 
more confidence around the protection limits established currently. 
The need for an increase in bacterial diversity in the ERA of antibiotics can be 
exemplified using the differences in cell wall structure between bacterial clades. 
The permeability, or lack of permeability, of the cell wall is likely to be a key 
determinate in the sensitivity of a bacterial species to an antibiotic (chapter 5). 
For example, sensitivity may be driven by the species-specific constitutional 
makeup of the outer membrane of Gram-negative bacteria and cyanobacteria 
that restricts hydrophobic molecules such as most macrolides (Delcour 2009; 
Stock 2005); or due to the presence of porins that allow the passage of smaller 
molecules such as β-lactums across the membranes. Indeed, it has been 
demonstrated that the cyanobacteria, Synechocystis sp., had an outer 
membrane that was 20 times less permeable than that of E.coli (Kowata et al. 
2017). The difference in the outer membrane of Gram-negative and 
cyanobacteria is of particular importance when considering the effectiveness of 
the approach of ERA to protect prokaryotic populations, communities and their 
functions. If cyanobacteria have intrinsically less permeable membranes than 
Gram-negative bacteria, a protection limit based upon a single cyanobacteria 
growth inhibition test may be unlikely protect Gram-negative bacteria, at least 
for antibiotics that would normally cross Gram-negative membranes through 
porins. This could potentially lead to the disproportionate loss of more sensitive 
Gram-negative bacteria in a community and the selection of more resistant 
Gram-negative species and cyanobacteria. This will be further complicated 
since bacterial communities are comprised of other bacteria clades with variable 
cell envelopes that have different structures and properties. For example, 
Gram-positive bacteria, lack an outer membrane in their cell envelope structure 
and it is therefore reasonable to assume that there may be even greater 
differences in uptake and thus antibiotic sensitivity between Gram-positive 
bacteria and those that have an outer membrane such as cyanobacteria and 
Gram-negative bacteria. It is of critical importance to understand the 
implications of these different bacterial features to identify if particular 
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species/clades are likely to be particularly sensitive and thus confidently protect 
prokaryotic species in the environment. Further research is urgently required to 
examine if it is reasonable to base a protection limit that aims to be protective of 
all bacteria on a single cyanobacteria growth inhibition test where the bacteria it 
should represent may have considerable morphological and physiological 
differences. 
Further differences in sensitivity may occur due to the various morphological 
forms of bacteria, such as filamentous compared to single celled bacteria. 
Some investigators have shown that the outer membrane of filamentous 
cyanobacteria, specifically those with heterocysts, is both continuous 
(surrounding all cells and producing a shared periplasm) and has decreased 
permeability in order to prevent the loss of metabolites, such as sucrose, that 
are to be shared between cells (Flores et al. 2006; Nicolaisen et al. 2009a; 
Nicolaisen et al. 2009b). As such, it is plausible that uptake of antibiotics into 
these species may be more restrictive than for single cells for which the outer 
membrane maybe less restrictive. I don’t however see any strong evidence to 
support this hypothesis within our data in chapter 5, where of the eight 
cyanobacteria the two Anabaena species were filamentous but also some of the 
more sensitive species to some antibiotics. 
In chapter 5 we also found that the MoA might explain the interspecies 
differences in sensitivity observed and, with further investigation, may also allow 
the identification of particular bacterial clade(s) that will be particularly sensitive. 
Further research such as genome analysis on the presence and similarity of 
drug targets of this kind may potentially allow for a more intelligent testing 
approach in ERA in the future that targets the most vulnerable species. 
Finally, this thesis also shows that the requirement to test antibiotics on MoA 
irrelevant fish and invertebrate species is unnecessary and that, in accordance 
with the 3Rs (Hutchinson et al. 2016), the environment would be better served 





Protection from antibiotics in the environment–the wider picture on what 
is still lacking? 
The many assumptions required in testing a single species of bacteria is hugely 
limiting in the current ERA for antibiotics. The suggestions in this thesis for 
increasing bacterial diversity in the toxicity testing and establishing a SSD will 
go some way to increasing confidence for establishing protection limits, but I 
now attempt to consider how this extrapolates to real world microbial 
communities. For example, whether the ecological functions served by these 
bacteria are protected in the current ERA process. 
At this point it is perhaps worth highlighting that protection goals in chemical 
regulations tend to be vague and it is difficult to ascertain whether we should 
aim to for the protection of ecosystem function or biodiversity more generally 
(Brown et al. 2017). This is an important distinction because if the aim is for the 
protection of function it is theoretically possible to lose species providing there is 
sufficient functional redundancy in the community to continue normal 
functioning of the ecosystem. If however, the aim is to protect biodiversity or 
community structure, or a given percentage of them (e.g. 95%), the protection 
of function may be inherently included (Backhaus et al. 2012), although this 
hypothesis will be examined further below. In chapter 3 it was argued that in the 
absence of knowledge regarding functional redundancy in communities, 
together with huge uncertainty regarding the consequences of chronic exposure 
to multiple stressors, that a conservative approach that aims to protect 
biodiversity is preferable to best ensure the protection of function. The 
protection of biodiversity rather than function is also in line with recent initiatives 
such as the European commissions biodiversity strategy (European 
Commission 2011). This would mean however, that in some circumstances the 
protection limit will be overprotective where sensitive species are not present 
due to the location being an unsuitable habitat (Brown et al. 2017). 
Due to recent technological advances in genomics and phylogenetics, the 
effects of chemicals on microbial community diversity and structure can be 
assessed more easily than ever before. It is clear that antibiotics generally have 
a negative effect on microbial diversity and can affect community structure in 
most matrices: for example soil (Cui et al. 2014), aquatic biofilms (Proia et al. 
2013) and sediment (Laverman et al. 2015). But due to the inherent complexity 
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involved, few studies have been able to unpick the effects that antibiotics have 
on ecosystem functions and biogeochemical processes. There is however, an 
increasing body of evidence suggesting links between antibiotic exposure, 
community structure and ecosystem function with recent reviews of the 
literature showing that antibiotic effects on ecological functions have been often 
observed, albeit much of this research has been directed towards soil 
communities and parts of the nitrogen cycle, in laboratory controlled conditions 
(anaerobic ammonium oxidation, nitrification and denitrification) (Ding and He 
2010; Grenni et al. 2018; Roose-Amsaleg and Laverman 2016). To illustrate 
some of these findings, exposure to ciprofloxacin has been shown to affect soil 
microbial communities by decreasing the bacteria to fungal ratio and increasing 
the ratio of Gram-positive versus Gram-negative bacteria, in turn leading to a 
decrease in denitrification rates at high antibiotic concentrations and an 
increase at lower concentrations (Cui et al. 2014). In a statistical analysis of 82 
datasets Graham et al. (2016) found that incorporating community structure into 
models explaining environmental carbon and nitrogen processes increased the 
explanatory power of the model. Studies on the human gut have shown that two 
antibiotic courses of ciprofloxacin over a ten month period caused a loss of 
diversity and changed the microbial community structure in the human gut after 
the initiation of each course (Dethlefsen and Relman 2011). This was 
subsequently followed by a partial, but incomplete recovery to the original 
community following completion of the course. Thus, repeated antibiotic 
exposure here led to an alternative stable community, the functional 
consequences of which, however, are not known (Dethlefsen and Relman 
2011). Given the vast number of clinical studies on the effects of antibiotics on 
microbial communities perhaps more of this knowledge can be used to 
supplement the limited environmental evidence on how antibiotic exposure 
might affect microbial communities and their functions. It should be emphasised 
that most studies investigating the effects of antibiotics on ecosystem functions 
have adopted concentrations that are environmentally unrealistic and closer to 
known therapeutic doses and there is a need for future investigations on 
chronic exposures at environmentally realistic concentrations (Roose-Amsaleg 
and Laverman 2016). There are a few cases however where investigators have 
demonstrated functional affects for antibiotics exposure at environmentally 
relevant concentrations. Examples of this include the negative affects on 
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microbial denitrification rates (47% inhibition at 1.2μg/L of sulfamethoxazole 
(Underwood et al. 2011) and 17% inhibition at 10μg/L of sulfamethazine 
(Ahmad et al. 2014)). These affects on denitrification, however, do not appear 
to occur for all antibiotics, or at least not in all microbial communities or 
environmental scenarios (Laverman et al. 2015). 
The magnitude of an antibiotic effect upon ecosystem function will depend on 
the level of functional redundancy in the community, but this is not well 
understood in microbial communities and may vary over time and space (Antwis 
et al. 2017). Some investigators have indicated high functional redundancy 
(Dopheide et al. 2015; Frossard et al. 2011) whilst others report lower levels of 
functional redundancy (Galand et al. 2018; Strickland et al. 2009; Wang et al. 
2011). Indeed, it is likely that the levels of functional redundancy will depend, in 
part, on which functions are measured, and including the type of ecosystem and 
the local environmental conditions (biotic and abiotic). Broad functional 
endpoints, such as oxygen respiration, that are performed by many taxa will 
have greater redundancy than for more specialised functions, such as the 
transformation of specific contaminants (Louca et al. 2018). If the protection 
goal of ERA is to protect ecosystem function, the challenge is to identify and 
protect those functional groups that may have more limited redundancy, with 
the additional complexity of the heterogeneous nature of ecosystems. 
Above, I state that that the protection of diversity would inherently protect 
function and would thus be a more conservative approach given the uncertainty 
involved. Although this true, it is more complicated than simply protecting an 
arbitrary proportion of the overall diversity (e.g. 95%) after which functional 
redundancy will compensate and ensure normal ecological functioning. Louca 
et al. (2018) concluded that the taxonomic and functional composition of 
microbial communities are de-coupled and that the factors that shape 
taxonomic diversity are different compared with those that may shape functional 
diversity. This means that there will not always be a link, and certainly not a 
consistent link across all microbial communities between taxonomic diversity 
and ecological function, possibly explaining the broad range of results observed 
in the literature trying to examine this. Protection of diversity in ERA may 
therefore be insufficient by itself and should be complemented, or perhaps 
replaced, by functional and community structure endpoints. However, it is 
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impractical for ERA to consider the vast number of bacterial metabolic functions 
that contribute to overall ecosystem functioning. Future research is required to 
establish which ecological functions are representative and applicable in most 
ecosystems, which functional endpoints are particularly sensitive due to more 
limited redundancy and, if possible, what proportion of microbial diversity should 
be protected to ensure no (or minimal) degradation of these ecological 
functions. This is likely to lead to the requirement of additional functional and 
community based assays to be incorporated in ERA that are able to address 
these concerns (Brandt et al. 2015; Le Page et al. 2017). Furthermore, many 
bacterial communities in the environment will already be impacted by 
anthropogenic activities and may already have lost some proportion of 
biodiversity. It may be that these partially degraded communities will have less 
functional redundancy than a healthy community in pristine conditions. For 
example, bacterial communities in agricultural soil, where nutrients have been 
eroded and replaced with fertilisers may have lower functional redundancy than 
a forest soil that has less anthropogenic disturbance and much higher organic 
nutrient content. An open question that needs to be addressed is whether ERA 
should consider the impact of antibiotics on healthy or compromised 
communities. 
A further consideration that is neglected in the ERA of chemicals (although not 
always within pesticide ERA) is how a community or ecosystem may recover (or 
not), which may be driven by redundancy or immigration from outside the 
affected ecosystem. Using wetland mesocosms Weber et al. (2011) showed 
that although ciprofloxacin reduced bacterial diversity and catabolic activity over 
the exposure period the microbial communities recovered after a period of 2 to 
5 weeks. Interestingly, there was a negative effect on plant health and 
hydrological parameters in the mesocoms that did not recover within the 
timescale of the study. Although this study was carried out at a relatively high 
(but not entirely environmentally unrealistic) concentration of 2mg/L at which it 
is bactericidal (Silva et al. 2011), it demonstrates that both the recovery of the 
microbial community and wider ecological indirect effects might be important to 
consider in establishing risk. Furthermore, it is not possible to identify these 
potential affects within the current approach to ERA that only assesses the 
growth rate of bacteria in short term single species tests as in our microplate 
assays (chapter 5). Further research is required to identify the wider 
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environmental consequences of antibiotic exposure and to assess whether the 
current protection limits established in ERA are suitably protective of 
environmental health. 
Laboratory based growth inhibition tests on a single bacteria species (as in 
chapter 5) or even probabilistic modelling of multiple species (chapter 6) fail to 
address the heterogeneous nature of environmental microbial communities 
whom experience a multitude of stressors over space and time (chemical 
mixtures, biological pressures, changes in physical conditions; temperature, 
hydrological parameters etc). More research is urgently required to identify the 
long-term risks of persistent, pseudo-persistent and repeated-dose exposure to 
microbial communities and their ecological functions, especially in the presence 
of multiple stressors. The bacteriostatic or bactericidal nature of an antibiotic 
may be of importance in the outcome of such exposures and both should be 
carefully considered. Additionally, if functional redundancy, in some cases, can 
mitigate the loss of some of the more sensitive species, we need to identify if 
this loss of diversity reduces the community and functional resilience to 
additional stressors that may occur alongside of following antibiotic exposure. 
The complexity of unravelling these relationships makes such research very 
challenging, but recent scientific advances in genomics, metagenomics and 
statistical modelling provide the tools in which to begin addressing these 
questions (Faust et al. 2015; Li et al. 2016; Muller et al. 2018). 
A final consideration when assessing the impacts of antibiotics on microbial 
communities is that these communities are also comprised of non-bacterial 
species and that there will also be indirect effects upon these non-bacterial 
species and thus the structure, diversity and potential ecological functioning of 
the community as a whole. This again is not considered in current ERA except 
for the justification of the arbitrary assessment factor of 10. For example, 
exposure to tetracycline, sulfamonomethoxine and an antibiotic mixture were 
shown to increase the proportion of fungi in soil communities relative to bacteria 
(Lin et al. 2016). Changes in this ratio can have significant functional effects on 
microbial communities such as carbon sequestration, decomposition and 
available nitrogen (in the form of ammonium or nitrates) (Strickland and Rousk 
2010). Archaea are another significant part of microbial communities and 
although little is known regarding their functional roles beyond key processes 
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such as methanogenesis (Moissl-Eichinger et al. 2018), any evaluation of the 
effects of antibiotics upon microbial communities would be incomplete without 
their consideration. Archaea tend not to be sensitive to antibiotics and those 
that do show some sensitivity do so at environmentally unrealistic 
concentrations (Khelaifia and Drancourt 2012). As such, there seems to be 
limited evidence that antibiotics may directly affect archaeal populations, but 
disruption to bacteria within these communities by antibiotics may have indirect 
effects upon them (Khelaifia and Drancourt 2012). Archaea are the only 
microbes that perform methanogenesis and recent evidence shows that there is 
little functional redundancy in methanogens and thus disruption to these 
communities directly or indirectly, could potentially have environmental 
consequences (Sierocinski et al.). This further exemplifies the complex nature 
of microbial communities and strengthens the need to consider antibiotic effects 
on microbial communities more broadly, including the associated changes in 
diversity and structure that may lead to effects on ecosystem functions. The 
chapters within thesis go some way to examine the role of single species testing 
for setting protection limits, but it is clear that there are considerable unknowns 
regarding the extrapolation from these tests to communities in the field. 
The incorporation of antimicrobial resistance in ERA 
How antimicrobial resistance (AMR) is incorporated into ERA is problematic, 
with one of the key issues being the lack of empirical methodology from which 
to be able to assess the concentration at which resistance determinates are 
selected for. In chapters 2 and 3, PNECs for resistance, as determined by 
(Bengtsson-Palme and Larsson 2016) and other available experimental data, 
were compared with PNECs in surface water and we found that neither 
protection limit was fully protective of the other. From this we concluded that 
whilst using the current available methodologies both protection limits for 
ecotoxicology and AMR should be determined within ERA. This approach has 
since been taken up by the ‘AMR Industry Alliance’ (AMR Industry alliance 
2018). 
Since publishing chapters 2 and 3, some investigators have published 
methodologies that may help to fill the lack of empirical data on AMR and 
further inform the discussion of how to integrate AMR into ERA. For example 
(Murray et al. 2018) measured resistance alleles in a complex bacterial 
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community and determined a minimum selective concentration (MSC; minimum 
concentration that selects for AMR) of 0.4 μg/L for cefotaxime. This is 
comparable to the HC5 obtained from our SSD in chapter 6 of 0.67 μg/L with 
95% confidence limits of 0.3 to 1.1 μg/L, although our data in the SSD was 
based on measured concentrations whilst the MSC was based on nominal 
concentrations and may be lower in reality. A PNEC for cefotaxime, derived 
from the most sensitive cyanobacteria in our microplate assays (chapter 5) 
using the NOEC and assessment factor of 10 would have been 0.17 μg/L and 
the PNEC for AMR predicted by (Bengtsson-Palme and Larsson 2016) was 
0.13 μg/L. These results are thus comparable in terms of effect levels (0.13 – 
0.67 μg/L). 
The link between AMR and ecological function is unclear, although some 
investigators have suggested that the promotion of resistance genes have less 
of an effect on function than changes in community structure (Wu et al. 2017). If 
this is the case, from an ecological perspective, the ecotoxicological 
consequences of antibiotic exposure maybe a greater concern, although any 
increase in AMR genes could be a significant concern for human health. 
Next steps 
There are several key steps that can be taken In order to further develop and 
expand upon the conclusions drawn throughout this thesis and these are briefly 
considered below: 
 Additional bacterial testing – This thesis focused upon cyanobacteria as 
it is this bacterial clade that is used in current regulatory procedures. We 
showed however, using the MICs of Gram-positive and Gram-negative 
bacteria in the EUCAST database (EUCAST) and findings from other 
investigators in the literature that there is likely to be vast differences in 
bacteria sensitivity across bacterial clades.  Future testing is required to 
experimentally confirm this, using methodologies that allow for the direct 
comparison (comparable endpoints and test conditions) of a much more 
diverse selection of bacteria.  Such testing should also consider how 
sensitivity differences between bacterial clades may be affected by the 
antibiotic mode of action. For example, delmanid inhibits mycobacterial 
cell membranes by preventing the synthesis of methoxy mycolic acid and 
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ketomycolic acid, two components that are not found in the 
cyanobacteria or Gram-negative bacteria cell membrane.  For this 
antibiotic, it is likely mycobacterial species will be most suitable for 
establishing protection limits rather than other bacteria such as 
cyanobacteria. 
 Mixtures – Bacterial communities in the environment are not exposed to 
just one antibiotic, but rather they are more typically exposed to a 
cocktail of chemical contaminants. As such, future work needs to 
consider how mixtures of antibiotics may interact to cause toxicity and 
whether synergism or antagonism can be predicted. Furthermore, how 
the toxicity of antibiotics may influence, or be influenced, by other 
classes of chemical compounds or other additional stressors (both biotic 
and abiotic) needs to be established.  
 Recovery – Current ERA employs tests that tend to have relatively short 
term, and where possible, consistent dosing of a chemical (i.e. the test 
concentrations are kept stable over the test period). This is not realistic of 
the exposure profile organisms have in the environment where chemical 
concentrations are likely to fluctuate over short time scales 
(hours/days/weeks) and longer timescales (months/seasons/years), 
possibly allowing for the recovery of populations.  Future work should 
consider how different dosing regimes might affect the risk posed by 
antibiotics when their concentrations are in flux. 
 Functional redundancy – In this thesis I discuss how protection limits 
might be impacted by functional redundancy, but as previously 
mentioned the relationship between redundancy and biodiversity is not 
well understood.  A key future step is to consider this further and to 
establish which ecological functions may have more limited redundancy 
in the presence of antibiotics.  Following this, assays that reflect these 
findings are required that can be incorporated into ERA to establish 





Final thoughts and future perspectives 
This thesis has critically analysed the current ERA of antibiotics and found it to 
be lacking in its assessment for toxic effects on bacteria, their communities and 
the functions they perform.  The work in this thesis includes the development of 
a simple, medium to high throughput and cost efficient screen that allows for a 
more effective assessment of cyanobacteria sensitivity to antibiotics with 
benefits for support in prioritising legacy compounds for further research and 
enabling environmental assessment earlier within the drug discovery process, 
with potentially major cost benefits. This thesis work highlights that the impact of 
antibiotics on environmental communities remains are poorly understood and 
greater efforts are required to establish how protective ERA is of diversity and 
ecosystem function. It is also the case that ERA based on the effects of 
individual species and populations will not necessarily provide a high level 
confidence for setting protection limits relevant to real life microbial 
communities. 
This thesis work highlights the need for a greater diversity of bacteria taxa in 
ERA and that this is clearly necessary even before the cumulative effects of 
antibiotic mixtures and multiple stressors can be truly accounted. Links between 
effects on bacterial populations to effects on ecosystem functions that they 
perform is poorly understood and in such extrapolations and assessments 
careful consideration of functional redundancy within bacterial communities is 
needed. But here too, the relevant information to do so is generally lacking. It is 
becoming increasingly obvious that future ERA needs to develop to consider 
both taxonomic diversity and ecological functions. This will likely involve studies 
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A B S T R A C T
Antibiotics are vital in the treatment of bacterial infectious diseases but when released into the environment they
may impact non-target organisms that perform vital ecosystem services and enhance antimicrobial resistance
development with significant consequences for human health. We evaluate whether the current environmental
risk assessment regulatory guidance is protective of antibiotic impacts on the environment, protective of anti-
microbial resistance, and propose science-based protection goals for antibiotic manufacturing discharges. A
review and meta-analysis was conducted of aquatic ecotoxicity data for antibiotics and for minimum selective
concentration data derived from clinically relevant bacteria. Relative species sensitivity was investigated ap-
plying general linear models, and predicted no effect concentrations were generated for toxicity to aquatic
organisms and compared with predicted no effect concentrations for resistance development. Prokaryotes were
most sensitive to antibiotics but the range of sensitivities spanned up to several orders of magnitude. We show
reliance on one species of (cyano)bacteria and the ‘activated sludge respiration inhibition test’ is not sufficient to
set protection levels for the environment. Individually, neither traditional aquatic predicted no effect con-
centrations nor predicted no effect concentrations suggested to safeguard for antimicrobial resistance, protect
against environmental or human health effects (via antimicrobial resistance development). Including data from
clinically relevant bacteria and also more species of environmentally relevant bacteria in the regulatory fra-
mework would help in defining safe discharge concentrations for antibiotics for patient use and manufacturing
that would protect environmental and human health. It would also support ending unnecessary testing on
metazoan species.
1. Introduction
Antibiotics are crucial in human healthcare. They are used in the
treatment of bacterial infectious diseases, supporting surgical inter-
ventions, and in cancer and prophylactic treatment. Antibiotics are also
used widely in livestock and domestic animal veterinary treatments and
as growth promoters in aquaculture. Global production of antibiotics
for human use is valued at $40 billion a year (O'Neill, 2015) illustrating
their societal and economic importance. Antibiotic consumption is on
the rise and between the years 2000 and 2010 there was an estimated
36% increase in use globally for human healthcare (Van Boeckel et al.,
2014).
Antibiotics, as other pharmaceuticals, enter the environment via
patient and animal use, through manufacturing plants and/or improper
disposal. Common points of entry into the environment from human
therapeutic use are via effluents from hospitals, domestic sewerage
treatment plants, as well as via leachates from landfill sites. Antibiotics
can enter into surface waters from sewerage treatment plants directly or
they can be transferred via surface run off. Ground waters can be ex-
posed from agricultural land treated with sewage sludge biosolids as a
source of fertiliser (Kümmerer, 2009). Veterinary antibiotics enter the
aquatic environment either directly, if treated animals are poorly
managed and have access to surface water, or via groundwater from the
manure of treated livestock (Davies, 2012; Kümmerer, 2009). Anti-
biotics in surface waters and sewerage treatment plant effluents/was-
tewaters are generally measured at concentrations ranging between
0.01 and 1.0 μg/L (Batt et al., 2007; Miao et al., 2004; Monteiro and
Boxall, 2010; Watkinson et al., 2009). The highest levels of antibiotic
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residues in effluents - in the milligram per litre range, with records in
excess of 1000 mg/L - are reported from manufacturing plants in China
and India (Larsson, 2014; Larsson et al., 2007; Li et al., 2008; O'Neill,
2015). Hospital effluents too can contain antibiotic residues in the
milligram per litre concentration range (Brown et al., 2006; Watkinson
et al., 2009).
Antibiotics affect prokaryotic cells via a number of distinct me-
chanisms of action, including the inhibition of cell envelope synthesis,
inhibition of protein synthesis or inhibition of nucleic acid (DNA/RNA)
synthesis. Antibiotics are designed for use in the treatment of bacterial
infection in humans and livestock and are thus developed to avoid, or
limit, effects on mammalian cells. It is, therefore, reasonable to assume
that environmental bacteria are more likely to be adversely affected as
a result of non-therapeutic exposure compared with aquatic verte-
brates, such as fish.
Within Europe, an environmental risk assessment (ERA) is required
for a medicine if the predicted environmental concentration exceeds
10 ng/L (EMA, 2006). In the USA effect studies are triggered if the
expected environmental concentration exceeds 100 ng/L (US Food and
Drug Administration, 1998). The ERA aims to establish the safe con-
centrations for the protection of wildlife populations, ecosystem struc-
ture and function and includes the calculation of three predicted no
effect concentrations (PNEC) for aquatic organisms, namely
PNECsurfacewater (PNECSW), PNECmicroorganism, and PNECgroundwater (EMA,
2006). These are determined by establishing a no observed effect con-
centration (NOEC, the test concentration at which there is no statisti-
cally significant effect in the response being tested, such as on growth
rate or reproduction) for a range of aquatic taxa and applying an as-
sessment factor of ten to account for variability in species sensitivity
and extrapolation from laboratory data to the field. PNECmicroorganism is
based on the ‘activated sludge respiration inhibition test’ (ASRIT,
OECD, 2010) and is primarily used to establish risk to microorganisms
in (and the function of) sewerage treatment plants. The PNECgroundwater
is based on a chronic test with Daphnia magna (e.g. OECD 211 test
guideline, (OECD, 2012)) and PNECSW is calculated from the toxicity to
three eukaryotic species – a green algae, invertebrate and fish. For
antibiotics, in Europe the ERA guidance encourages ecotoxicity testing
with prokaryotes rather than a green algae “as they are [a] more sensitive
indicator organisms than green algae” (EMA, 2006), and this is conducted
in one species of cyanobacteria only.
There is concern that the ERA for antibiotics is biased towards
testing on metazoan species (invertebrates and fish in this instance),
and does not consider fully the possible impacts of antibiotics on mi-
crobial community structure, function and resilience (Agerstrand et al.,
2015; Brandt et al., 2015). This is a major shortfall considering the
fundamental ecosystem services microbial communities provide (e.g.
primary production, nutrient cycling, metabolism and degradation of
organic, inorganic and synthetic compounds). A major aim of this meta-
analysis therefore was to test if current ERA is protective of vulnerable
populations in the environment.
Microorganisms exposed to antibiotics at low, sub-lethal or sub-in-
hibitory exposure concentrations can develop, or acquire, antimicrobial
resistance (AMR) and this has been identified as a major threat to public
health (Smith and Coast, 2002; World Health Organization, 2014).
AMR is likely to persist and disseminate in diverse environments, in-
cluding in aquatic ecosystems (Laxminarayan et al., 2013; Taylor et al.,
2011). Where the benefit of possessing and expressing the resistance
gene outweighs the fitness costs of carriage, antibiotics in the en-
vironment may select for and enrich resistance genes in bacterial po-
pulations/communities which can then harbour these resistance de-
terminants and transfer them to human pathogens (Ashbolt et al.,
2013).
To ensure clinical efficacy and protection of human health,
minimum inhibitory (growth) concentrations (MICs, the lowest con-
centration at which there is no observable growth) are monitored in
clinically relevant bacteria (CRB) and recorded in the European
Committee on Antimicrobial Susceptibility Testing database (http://
www.eucast.org). In addition to monitoring MICs in clinically relevant
species, studies with clinical isolates have also identified the lowest
concentration that will select for AMR, called minimum selective con-
centrations (MSCs). MSCs are the minimum concentration at which the
presence and expression of resistance gene(s) give bacteria a fitness
advantage over non-resistant cells of the same species/strain. This can
occur at concentrations considerably below the MIC of the non-resistant
cells (Gullberg et al., 2011). Indeed, selection may occur at exposures
up to two orders of magnitude lower than the MIC for growth (Gullberg
et al., 2011; Hughes and Andersson, 2012; Lundström et al., 2016).
From both human and environmental health perspectives, it is im-
portant that risk assessment frameworks incorporate the risk of AMR
selection. An approach to establish a surrogate PNEC for AMR (PNECR)
has been suggested adopting MICs from CRB, which are available
through the European Committee on Antimicrobial Susceptibility
Testing database (Bengtsson-Palme and Larsson, 2016). This is the most
comprehensive dataset available where theoretical PNECs (PNECR(T))
have been calculated for 111 antibiotics. This approach uses growth
(via the MIC) to predict upper boundaries for resistance, although there
has been no verification of an increase in resistance determinants. The
approach also assumes that the CRB are representative of the diversity
of bacteria in nature. Furthermore, whilst AMR maybe enriched at
concentrations well below the MIC of clinical bacteria, the AMR en-
richment could potentially occur at concentrations below the effects
determined in traditional ERA ecotoxicity growth tests on cyano-
bacteria. This meta-analysis therefore also sought to determine the re-
lationship between protection goals proposed to protect against re-
sistance development and the traditional aquatic protection goals; i.e.
establish if the proposed methods used to derive a PNEC for AMR de-
velopment (PNECR) are protective of those currently used for aquatic
ecosystem function (PNECsw) and vice versa.
Recognising that antibiotic releases from drug production and for-
mulation facilities represent ‘hot spots’ for the development of AMR it is
critical that these discharges are minimised and managed effectively
across the whole supply chain. To address this concern, the pharma-
ceutical industry recently established an AMR Road map which in-
cluded a commitment to “establish science-driven, risk-based targets for
discharge concentrations for antibiotics and good practice methods to
reduce environmental impact of manufacturing discharges, by 2020”
{IFPMA, 2016 #415}.
To improve the testing paradigm for antibiotics for use in pro-
spective regulatory frameworks and to establish safe discharge con-
centrations for antibiotic production, we conducted a meta-analysis
based on a systematic review of the publically available aquatic eco-
toxicity data and clinically relevant MICs for antibiotics. Specifically
we; 1) assess the relative sensitivity of commonly used taxa in aquatic
ecotoxicity, with a MOA perspective, to evaluate the reliability of the
current ERA of antibiotics to identify risk to vulnerable populations; 2)
assess the value of extending the toxicity testing for bacteria through an
assessment on the relative sensitivity of several cyanobacterial species,
the marine bacteria Vibrio fischeri and the CRB MICs; 3) critically
evaluate the current proposed approaches for determining the risk of
AMR and its incorporation into risk assessment for the protection of
human health; i.e. whether a PNECR is more or less protective than
PNECSW calculated using traditional ecotoxicity testing; 4) test the as-
sumption that CRB adequately represent environmental bacteria and
evaluate the use of pre-clinical MIC data for the protection of other
bacterial species through a comparison of the NOECs for cyanobacteria
with the adjusted MIC, calculated by Bengtsson-Palme and Larsson
(2016) from CRB and; 5) use the empirical data collected in these
analysis to help establish science-driven, risk-based targets for manu-
facturing discharge concentrations for antibiotics.
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2. Methods
2.1. Data search strategy
A comprehensive literature search was carried out to identify stu-
dies reporting toxicological effects of antibiotics on aquatic taxa com-
monly used in ERA. These taxa included cyanobacteria, green algae,
macrophytes (the latter currently used in ERA for agrochemicals, but
not pharmaceuticals), invertebrates and fish. Data were also collected
for the effects of antibiotics on Vibro fischeri, for the ASRIT test and
Pseudomonas putida (where available). Data were used in our analyses
only if they met the following criteria: 1) the endpoint calculated was a
NOEC, 50% effective concentration (EC50) or 50% inhibition con-
centration (IC50), the concentration at which 50% of the population are
effected or inhibited respectively; 2) the methodology adopted was
according to (or with minor deviations from) currently accepted reg-
ulatory protocols (e.g. Organisation for Economic Co-operation and
Development (OECD) or International Organisation for Standardisation
(ISO) test guidelines); 3) the aquatic species belong to the taxa de-
scribed above; 4) exposures were for single species not multiple spe-
cies/community exposures (with exception of the ASRIT which is a
community based exposure) and; 5) organisms were exposed to a single
antibiotic (not a chemical mixture).
The aim of this paper was to conduct a meta-analysis of available
data in the context of current regulatory guidance that uses population-
relevant endpoints to establish PNECs. Therefore NOECs and EC/IC50s
for growth, reproduction or mortality only (or accepted surrogates e.g.
luminescence in V. fischeri or respiration in the ASRIT) were collected
and analysed. Moreover, interpretation of biomarker endpoints in re-
lation to population-based NOECs and EC/IC50s are not well estab-
lished.
Searches and data collections were conducted for the following
public databases and literature:
• Environmental data on antibiotics from the trade organisation for
the research-based pharmaceutical industry in Sweden (LIF), ob-
tained from the Swedish fass.se database (www.fass.se accessed Jan
2016).
• Environmental data for antibiotics from the ‘European public as-
sessment report’ database (www.ema.europa.eu, accessed Jan
2016).
• All published data in the Wikipharma database (http://www.
wikipharma.org, accessed Jan 2016).
• All relevant data in the study by Vestel et al. (2015) which included
the antibiotics azithromycin, bedaquiline, ceftobiprole, doripenem,
linezolid, meropenem, sulfamethoxazole and trimethoprim.
• Data for sulfadiazine, neomycin and gentamycin, kindly provided by
Merck Sharp & Dohme (MSD) through the ‘Innovative Medicines
Initiative’ iPIE project (https://www.imi.europa.eu/content/ipie).
• A GoogleScholar search focused on cyanobacteria with the following
search criteria for the 111 antibiotics listed in the paper by
Bengtsson-Palme and Larsson (2016): Antibiotic cyanobacteria
“OECD 201” OR “ISO8962” OR “ISO 8962” OR “850.4500” OR
“E1440-91”
• The theoretical PNECR (PNECR(T)) and the size-adjusted MIC (MICaj)
for antibiotics were collected from Bengtsson-Palme and Larsson
(2016). For antibiotics where< 40 species have been tested in the
European Committee on Antimicrobial Susceptibility Testing data-
base, Bengtsson-Palme and Larsson (2016) calculated a size-ad-
justed MIC. This is a theoretical adjustment to the MIC to include
99% of CRB. The number derived from that calculation was rounded
down to the nearest concentration in the range operated in the
European Committee on Antimicrobial Susceptibility Testing pro-
tocol. PNECR(T)s were calculated by applying an assessment factor of
10 to account for differences between inhibitory concentrations and
selective concentrations of the antibiotics. Experimentally derived
MSCs were identified from literature following a GoogleScholar
search with search criteria: “Minimum selective concentration” MSC
AND “antibiotic resistance”. We highlight here that currently there
is no internationally standardized test method for MSC and that
extrapolation to the environment is poorly understood due to the
complex nature of resistance enrichment, the complex nature of
communities and a range of environmental factors that may influ-
ence the MSC (Khan et al., 2017; Quinlan et al., 2011).
• Antifungal and antiviral drugs obtained through our search criteria
were excluded from this assessment.
All data derived from these searches are provided in the supple-
mental material, Table S1 and a flowchart to illustrate the data col-
lection and statistical processes for these analyses is provided in Fig. S1.
2.2. Assessment of data reliability
Assessments on data reliability were undertaken using the ‘Criteria
for reporting and evaluating ecotoxicity data’ (CRED) system that is
specifically designed for the evaluation of ecotoxicity data for reg-
ulatory use (Moermond et al., 2016). In this system reliability is defined
as “the inherent quality of a test report or publication relating to
(preferably) standardized methodology and the way the experimental
procedure and results are described to give evidence of the clarity and
plausibility of the findings”. The CRED system categorises the reliability
of studies into one of four scores; R1 (reliable without constraints), R2
(reliable with constraints), R3 (unreliable) or R4 (not assignable).
Studies identified as R3 are considered unsuitable for use in regulatory
decision-making; whereas caution needs to be applied on a study-by-
study basis for studies categorised as R2 or R4. The CRED evaluation
method also provides guidance on the evaluation of the relevance of
data (Moermond et al., 2016). This, however, was not applied as the
data were considered relevant for this meta-analysis having fulfilled the
selection criteria outlined in Section 2.1. The CRED reliability score for
each study is given in Table S1.
2.3. Relative taxa sensitivity data
The lowest ‘reliable’ NOEC and EC50 for each taxa were identified
for each antibiotic. Data from studies that had CRED reliability scores of
R1 and R2 were prioritised, without bias between R1 and R2, over those
in the categories of R3 or R4. R4 data were selected over R3 data as the
majority of R4 studies were assigned R4 due to unpublished/missing
information in an otherwise (apparently) reliable study compared with
R3, which were assigned unreliable for defined reason. The lowest
‘reliable’ NOEC and EC50 were applied in the analysis of relative taxa
sensitivity and are presented in the Table S2. This conservative ap-
proach was deemed more appropriate rather than taking an average of
all available data that has imbalanced taxa representation and varying
data reliability.
An analysis of the relative sensitivity of cyanobacterial species
adopted the same CRED criteria as described above to establish the
lowest ‘reliable’ EC50. EC50s were used rather than NOECs as there was
a larger dataset for cyanobacterial EC50s. These data are presented in
Table S3.
2.4. Censored data
For some antibiotics the data was either left or right censored,
meaning that the value was not a precise number and was given as
greater than (>) or less than (<) the value reported (i.e. no effect at
the highest test concentration or an observed effect at the lowest tested
concentration, respectively). Censored data values were used when no
other data were available (> than numbers would represent con-
servative values and< numbers were included only when they re-
presented the lowest ‘reliable’ data value). Where data were censored,
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this is indicated in Table S1.
2.5. Establishing relative taxa sensitivity to antibiotics
A sensitivity ratio (SR) was calculated between the different taxa
and cyanobacteria for each antibiotic, where data were available. The
SR was calculated using the lowest NOEC (or NOEC and MICaj in the
case of CRB) or EC50 using the following equation:
= −Log SR logE logE10 cyanobacteria taxa
where E is the endpoint (NOEC, EC50 or MICaj).
A SR > 0 indicates that the cyanobacteria are more sensitive than
the other taxa and less sensitive when SR< 0. Each unit of SR is
equivalent to an order of magnitude difference in sensitivity.
The difference between a SR calculated from NOECs compared with
those calculated from EC50s was examined to identify how the end-
point used might impact the sensitivity ratio. Briefly, a generalised
linear model (GLM) (Gaussian error family with identity link function)
was constructed using the ‘lmer’ package with the restricted maximum
likelihood method (Bates et al., 2015) in R (version 3.3.0; R Project for
Statistical Computing, Vienna, Austria). The model residuals were
normally distributed and significant differences identified using the
“lmerTest” package in R (Kuznetsova et al., 2013). SRs were used only
where a NOEC and EC50 were from the same species and publication in
order to exclude effects of different methodologies. The SRs calculated
from EC50s were significantly higher by 0.5 (p = 0.05) than those
calculated from NOECs i.e. cyanobacteria were less sensitive as mea-
sured by EC50s. As such, SRs calculated from EC50s were only included
in subsequent analyses comparing taxa sensitivities where NOEC SRs
were not available. We acknowledge that this will have a small effect on
the output of the models. However, because of the sparse dataset and
the relatively small difference in SR between EC50s and NOECs com-
pared with the differences between taxa, the inclusion of the EC50 SRs
where NOEC SRs are not available increases the number of SRs for
comparison and robustness of the models.
We established a GLM in R (version 3.3.0; R Project for Statistical
Computing, Vienna, Austria) to determine the effects of exposure
duration on the EC50 for V. fischeri, as EC50 are often reported for 5, 15
and 30 min and for 24 h. Censored data were removed and the re-
maining EC50s were log10 transformed before use in the GLM (Gaussian
error family with inverse link function) that was constructed as de-
scribed for comparing NOEC and EC50 SRs above. Significant differ-
ences were identified by applying a TukeyHSD post hoc test. Twenty
four hour EC50s were significantly lower (p ≤0.001) than those fol-
lowing shorter exposure periods and data for this time point only were
therefore used in subsequent analyses on relative taxa sensitivities.
Differences in SR across all taxa for all antibiotics were analysed
using a GLM. The aim of the analysis was to compare the sensitivity of
all taxa to cyanobacteria. Cyanobacteria were chosen as the comparator
because they are assumed to be the most mode-of-action relevant taxa
(therefore, most sensitive species) in current ERA, and thus expected to
drive the PNECSW. Briefly, to assess for statistical differences in SR the
GLM was constructed forcing the intercept through 0 (the SR value of
cyanobacteria). Therefore, the statistical differences identified by
“lmerTest” (Bates et al., 2015) represent the statistical difference from 0
and thus the statistical difference between the taxa and cyanobacteria.
This allowed for the exclusion of cyanobacterial SRs in the GLM as the
sensitivity of cyanobacteria were already accounted for in the calcula-
tion of the SRs. TukeyHSD post hoc tests were applied to identify any
further differences between the taxa groups. Details on model con-
struction and validation are provided in the Supplemental Material.
Adopting the same process and validation steps, further GLMs were
established for analyses of antibiotics with different mechanisms of
actions and, where sufficient data were available, for antibiotic classes
(a more detailed methodology for this is presented in Supplementary
Material).
Antibiotics were classified into three groups based on their broad
mode of action, specifically, cell envelope inhibitors (Anatomical
Therapeutic Chemical (ATC) classification system codes J01C and
J01D), Nucleic acid synthesis inhibitors (ATC codes J01E and J01 M)
and protein synthesis inhibitors (ATC codes J01A, J01B, J01F, J01G,
J01XC, J01XX08, J01XX11 and QJ01XQ).
It is important to note that in addition to comparing different end-
points and methodologies, representation of antibiotics - in both po-
tency and number of antibiotics with data - varied between and within
taxa and antibiotic classes. We acknowledge this may introduce some
uncertainty and potential bias in our analysis and have thus avoided the
use of more complex model designs that might otherwise have in-
troduced random factors and interactions. However, the biases men-
tioned above are unlikely to have an impact on the overall conclusions
drawn from these analyses.
2.6. Calculation of PNECs
Where a full set of ecotoxicity data for an European Medicines
Agency Phase 2 ERA was available (cyanobacteria, invertebrate and
fish tests) a PNECSW was calculated by taking the lowest NOEC of the
three studies and applying an assessment factor of 10, as described in
the regulatory guidance (EMA, 2006). A theoretical PNECR (PNECR(T))
was taken directly from (Bengtsson-Palme and Larsson, 2016). An ex-
perimental PNECR (PNECR(Exp)) was calculated from the lowest ex-
perimental selective concentration and applying an assessment factor of
10.
There was not enough data to conduct species sensitivity distribu-
tion analysis and calculate 95% percentile protective limits, as this
requires a minimum of 10 species and preferably> 15 (Echa, 2008).
2.7. 5th Percentile determination
The calculated 5th percentiles for the NOEC and MIC data subsets
were not normally distributed or fitting to other known distributions
(e.g. gamma and weibull) before or following transformations (log,
log10 or boxcox). The 5th percentile therefore was established using the
non-parametric Harrell-Davis quantile estimator method. Analysis was
conducted in R (version 3.3.0; R Project for Statistical Computing,
Vienna, Austria) using the hdquantile function in the ‘Hmisc’ package
(Harrell, 2016).
3. Results
Ecotoxicity data were collected for 79 antibiotics (Table S1) re-
presenting 48% of the 164 approved antibiotics identified in www.
drugbank.ca and (Santos et al., 2017). Information on the ecotoxicity in
cyanobacteria was available for 41 of these 79 antibiotics, but with
NOECs for only 27 (16%). Antibiotics with NOECs for cyanobacteria
were well distributed across all ATC sub-classes under J01, with ex-
ception of J01XX (‘other antibacterials’; Fig. S2).
A complete Phase 2, ERA dataset that included the full range of taxa
for calculating a PNECSW (EMA, 2006) was available for only seven of
these antibiotics. This may reflect the lack of pharmaceutical ERA da-
tasets placed in the public domain and/or that few antibiotics have
been approved since the existing European Medicines Agency guideline
came into force in 2006 requiring full chronic toxicity testing on cya-
nobacteria/microalgae, invertebrates and fish and consequently lack a
full ecotoxicity data set.
3.1. Relative species sensitivities
Overall, cyanobacteria were the most sensitive taxa of those cur-
rently recommended in the ERA of human pharmaceuticals (EMA,
2006; US Food and Drug Administration, 1998) (p≤0.001, Fig. 1A)
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and they were equally sensitive as other bacteria (CRB and V. fischeri)
and more sensitive than macrophytes (that are not currently required in
ERA of pharmaceuticals; p≤0.001).
The sensitivity of cyanobacteria and CRB were not significantly
different for any of the three broad antibiotic mechanisms of actions
(Figs. 1B-D); NOECs in cyanobacteria were lower than CRB MICaj for
half (12 out of 24 antibiotics; Fig. 2A). If we were to adopt the lowest
MIC, instead of the modelled MICaj, in this meta-analysis there would be
more cases (18, rather than 12, out of 24) where the cyanobacteria were
the most sensitive. Although there was no clear relationship between
the CRB MICaj and cyanobacterial NOECs the difference in sensitivity
was up to two orders of magnitude for specific individual antibiotics
(Fig. 2A and 6C).
There were no significant differences in sensitivity to DNA or pro-
tein synthesis inhibiting antibiotics between V. fischeri and cyano-
bacteria (Fig. 1; there were no data for cell-envelope inhibiting anti-
biotics). Of the seven antibiotics where SRs could be determined five
were for quinolones giving an antibiotic class bias for the V. fischeri
data. EC50s for V. fischeri were lower than those for the cyanobacteria
on six occasions (Fig. 2B), three of these were almost an order of
magnitude lower (flumequine, lomefloxacin and oxolinic acid). V.
fischeri was also the most sensitive organism to olfoxacin, with a NOEC
one order of magnitude lower than the CRB MICaj (Fig. 2A) and an
EC50 half that for the cyanobacteria (Fig. S3).
Pseudomonas putida, a model (soil) gram-negative bacteria used in
standard growth inhibition test guideline (ISO, 1995) was more sensi-
tive than cyanobacteria for one out of five antibiotics (meropenem;
Fig. 2A and B).
The ASRIT (OECD, 2010) was consistently between two and four
orders of magnitude less sensitive than cyanobacteria, with the excep-
tion of trimethoprim (Figs. 1 and 2 p ≤0.001).
There were large differences in sensitivity between cyanobacterial
genera and species, with between two and three orders of magnitude
difference in EC50s for 10 out of the 16 antibiotics, and approximately
five orders of magnitude difference in response to the β-lactams
amoxicillin and ampicillin (Fig. 3). Overall, Microcystis aeruginosa was
the most sensitive species (in half of the 16 antibiotics). Anabaena cy-
lindrical, Synechococcus leopoliensis andMicrocystis wesenbergii were each
the most sensitive cyanobacterium for 2 of 16 antibiotics for which
there were data on multiple species. A. flos-aquae, one of the cyano-
bacterial species recommended for testing in the OECD 201 test
guideline, was the most sensitive species for only 1 of the 13 antibiotics
Fig. 1. Boxplots of Log10 sensitivity ratio (SR) between cyanobacteria and other species/phyla for A) all antibiotics (n = 37), B) cell envelope inhibitors (n = 8), C) Nucleic acid synthesis
inhibitors (n = 12) and D) protein synthesis inhibitors (n = 16). SR calculated based on log10cyanobacteria NOEC or EC50 – log10taxa NOEC or EC50. Where SR = 0 the sensitivity of the
taxa is equal to cyanobacteria, represented by horizontal line, where SR > 0 taxa had a lower sensitivity and< 0 indicates higher comparative taxa sensitivity. Significant differences of
SR from cyanobacteria in the generalised linear mixed models are indicated by: * p < 0.05; ** p < 0.01; *** p < 0.001. Statistical tests were not performed on macrophytes in cell
envelope inhibitors as there was only one antibiotic tested in macrophytes.
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in which it was tested. When considering antibiotic sensitivity based on
their mechanisms of action, Microcystis species appeared to be more
sensitive to nucleic acid synthesis inhibitors (7 out of 9 antibiotics).
Microcystis and Synechococcus species were the most sensitive to cell
envelope inhibiting antibiotics. Anabaena genera were the most sensi-
tive to the protein synthesis inhibitors (3 out of 6) and in two cases by
more than an order of magnitude.
Overall, macrophytes were generally less sensitive to antibiotics
compared with cyanobacteria with a wide range of SRs (Fig. 1,
p ≤0.001). However, they showed equal sensitivity with cyanobacteria
to nucleic acid synthesis inhibitors (average SR = 0.42; p = 0.3). The
NOECs for trimethoprim and sulfadimethoxine were lower for macro-
phytes than for cyanobacteria (Fig. 4A). A comparison of macrophyte
and environmental bacteria EC50s is provided in Fig. S3.
Microalgae were also generally less sensitive to antibiotics than
cyanobacteria (Fig. 1, p≤0.001). However, for sulfadiazine and sul-
fadimethoxine the NOECs in microalgae (0.135 and 0.529 mg/L, re-
spectively) were over an order of magnitude lower than for the lowest
in the cyanobacteria (Fig. 4A). We interpret these data with caution,
however, as the results for the cyanobacteria were derived from a study
based on nominal (i.e. not measured) test exposure concentrations
(Ando et al., 2007). A comparison of the EC50s for microalgae with
environmental bacteria is shown in Fig. S3.
Metazoans (fish and invertebrates) were significantly less sensitive
across all antibiotics compared with cyanobacteria and often by be-
tween two and four orders of magnitude (with exception of tedlizolid
phosphate, Figs. 1 and 4, p ≤ 0.001, for both fish and invertebrates).
There was substantial variation in SR between cyanobacteria and the
metazoan taxa (as illustrated by the standard errors in the data; Fig. 1).
In the case of tedlizoid phosphate, a pro-drug, fish appeared more
sensitive than cyanobacteria (NOECs of 0.032 versus 0.063 mg/L, re-
spectively; Fig. 4B). A MICaj for tedozolid (the active pharmaceutical
ingredient) was not available from the Bengtsson-Palme and Larsson
(2016) study, but a MIC of 0.016 mg/L (based on 12 species), corre-
sponding to a MICaj < 0.008 mg/L was recently (January 2017) re-
ported the European Committee on Antimicrobial Susceptibility Testing
database. This suggests that CRB are substantially more sensitive to
tedozolid compared with fish and cyanobacteria. The fact that tedizolid
phosphate (pro-drug) requires activation by phosphatases in the blood
to convert it into the active ingredient (tedizolid), and the ecotoxicity
assessments in cyanobacteria appear to be based on the pro-drug only,
may explain why cyanobacteria were relatively insensitive. In no cases
were the chronic NOECs for invertebrates lower than the NOECs for
cyanobacteria (Fig. 4). The daphnid EC50 for the antifolate trimetho-
prim, however, was lower than the EC50 for cyanobacteria (8.21 and
91.68 mg/L, respectively. Fig. S3). This was not the case for the NOECs
Fig. 2. Chronic exposure effects of antibiotics on A) en-
vironmental bacteria and clinically relevant bacteria (no
observed effect concentrations (NOEC) and adjusted
minimum inhibitory concentrations respectively) and B)
environmental bacteria 50% effective concentrations.
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for the same compound, indicating differences in the shape of the dose-
response curve. Importantly, in this case cyanobacteria would still drive
the PNECSW.
3.2. PNEC comparisons
For the limited number of antibiotics where a definitive PNECSW
could be calculated (n= 7) an analysis of the relationship between
traditional ERA PNECs and those for AMR was conducted. Within this
meta-analysis the theoretically determined PNEC for resistance devel-
opment PNECR(T)) obtained from Bengtsson-Palme and Larsson (2016)
for the different antibiotics was not always protective of (lower than)
the PNECSW (Fig. 5A). The PNECR(T) was lower than PNECSW for cef-
taroline, ciprofloxacin and tobramycin. However, the PNECSW was ap-
proximately ten-fold lower than PNECR(T) for ceftobiprole, sulfa-
methoxazole and azithromycin.
Where experimentally derived MSCs existed, the PNECR(Exp) was
lower than PNECR(T) for three out of five antibiotics with available data
(Fig. 5B). However, PNECR(T) overestimated the risk of resistance de-
velopment for streptomycin by an order of magnitude. PNECR(T) and
PNECR(Exp) were similar for trimethoprim (Fig. 5B; trimethoprim PNE-
CR(Exp) was< 0.2 μg/L). The PNECSW for erythromycin and strepto-
mycin were lower than their PNECR(T) and PNECR(Exp) (Fig. 5B). The
PNECR(Exp) for erythromycin however, did not have a definitive value,
(i.e. < 0.2 mg/L) and as such we assign caution to this comparison.
3.3. Establishing 5th percentiles
We determined the 5th percentile for growth inhibition data for
cyanobacteria and environmental bacteria and MICs for CRB (See table
S4). The rationale for this was to establish an environmental protection
goal for antibiotic production discharges that would be protective of
bacterial NOECs with 95% confidence. The 5th percentiles ranged from
225 to 2028 ng/L, depending on the bacteria and endpoints used. The
lowest NOECs for environmentally relevant bacteria (cyanobacteria, P.
putida and V. fischeri) gave the lowest value (225 ± 71 ng/L, Fig. 6A).
4. Discussion
In our evaluation of the current regulatory ERA guidance we show
that of the taxa tested, as expected based on the mechanisms of action,
prokaryotes were most sensitive to antibiotics. However, we also show
that reliance on one species of (cyano)bacteria to set protection levels
(e.g. PNECs), as operates currently, is unlikely to be protective of en-
vironmental and human health (through AMR). Individually, neither
traditional aquatic PNECs nor the AMR based PNECs protect fully
against the effects of antibiotics. We thus recommend the inclusion of
both clinically important bacteria and a wider range of species of en-
vironmentally relevant bacteria to improve the prospective regulatory
framework for human and ERA. This approach will help also in defining
more appropriate safe discharge concentrations for antibiotic produc-
tion, and help to exclude unnecessary ERA testing on metazoan species.
4.1. Species relative sensitivity: The need for more bacteria
During their development, the efficacy and safety of new antibiotics
are assessed in preclinical and clinical studies before market approval.
It is therefore unlikely that toxic effects will occur in an aquatic ver-
tebrate (such as fish) at water concentrations lower than those affecting
prokaryotic species (target or non-target). As expected, in our analyses,
those species evolutionarily more distant to pathogenic bacteria were
generally less sensitive to antibiotics compared with clinically relevant
and environmental bacteria. Our results also indicate that neither cy-
anobacteria, CRB nor other environmental bacteria (V. fischeri and P.
putida) provide a single organism/test that is fully protective of the
diversity of bacteria in the environment. Thus, a PNECSW determined
Fig. 3. Chronic exposure effects (EC50s) of antibiotics on different cyanobacteria species.
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according to the current ERA guidance (EMA, 2006; US Food and Drug
Administration, 1998) will not always be protective of the environ-
ment.
Sensitivity to any one antibiotic differed by up to five orders of
magnitude across different species of cyanobacteria. Patterns of sensi-
tivity for the different genera were observed across the different anti-
biotic mechanisms of actions, but no one species was consistently the
most sensitive. Cyanobacteria are one of the most diverse phyla on the
planet (Shih et al., 2013; Whitton, 2012) and this large range in sen-
sitivity to antibiotics might therefore be expected. In ERA A. flos-aquae
is the most regularly used of the two OECD test guideline recommended
cyanobacterial species (the other being S. leopoliensis; (OECD, 2011))
but A. flos-aquae was the most sensitive cyanobacteria for only one of
the 13 antibiotics for which data were available for multiple genera and
species. In the cases of ampicillin, erythromycin, norfloxacin, oxyte-
tracycline, sulfdiazine and trimethoprim (35% of antibiotics with
multiple cyanobacterial EC50s) the difference in sensitivity between A.
flos-aquae and the most sensitive taxon was greater than the assessment
factor (×10) used to generate a PNEC for the risk assessment. For
ampicillin, reliance on A. flos-aquae could underestimate the PNECSW
by more than three orders of magnitude. This questions the current over
reliance on a single cyanobacteria test species within ERA frameworks
and we propose at least three cyanobacteria genera should be included
within these risk assessment frameworks. The case above for ampicillin
highlights a further important issue relating to the relevance of high
sensitivity for some cyanobacteria. Ampicillin is not persistent in the
environment and undergoes partial degradation by bacteria; indeed,
primary degradation is the resistance mechanism. If degradation were
factored in, from an ecotoxicological point of view, exposure and en-
vironmental effects would be low, although community structure
changes could impact resilience. Furthermore, since the resistance
mechanism partially degrades the antibiotic resulting in a lower con-
centration of ampicillin in the environment care needs to be taken not
to assume a low measured concentration of ampicillin necessarily
equates with an absence of selection for AMR development and human
health risk.
The cyanobacteria adopted for toxicity testing has been based lar-
gely on experimental convenience (e.g. the ability to grow them and
measure cell density in the laboratory) with little knowledge on how
representative they are of other cyanobacteria. No consideration has
been given to how they grow and function in non-pelagic habitats, e.g.
biofilms. From our analyses, M. aeruginosa would potentially provide a
relatively high sensitivity to most antibiotics. This species however, has
a slower growth rate and the current test with this species may there-
fore have to be extended to make the test comparable in terms of the
growth and replication dynamics with that for A. flos-aquae and S.
Fig. 4. Chronic exposure effects of antibiotics on cyano-
bacteria and clinically relevant bacteria (no observed effect
concentrations (NOEC) and adjusted minimum inhibitory
concentrations respectively) compared with A) NOECs for
microalgae and macrophytes and B) NOECs in invertebrates
and fish.
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leopoliensis. We highlight that the requirement for optimized conditions
for culturing a species and variation in life history components across
species (e.g. growth rates and lag time) create further challenges for
interspecies substance effects analyses. For example, exposure time can
have a direct impact on the perceived sensitivity. In this meta-analysis
we have used data that are based on regulatory approved guidelines in
which exposure time and exposure conditions have been optimized for
the different organisms to ensure that growth in the controls do not
reach the plateau phase, thus maximizing the ability to detect for any
effects against treatment groups. Longer exposure periods could po-
tentially result in lower effective exposure concentrations, as we de-
monstrate for the EC50 in V. fischeri (for a 24 h exposure compared with
shorter test periods) and as has been shown for the ASRIT (Kümmerer
et al., 2004). Extending exposure periods in growth tests however needs
to ensure that this does not compromise the ability to distinguish for
effects i.e. additional time does not result in the controls being limited
in their growth dynamics by the available resources and thus affect the
comparison with the treated groups. It needs to be recognized, how-
ever, that differences between test conditions optimized for different
species (e.g. chemical constituents of the culture media, pH, tempera-
ture, light intensity and test length, to name just a few) could all impact
the fate and behavior of the antibiotic and its bioavailability, dis-
tribution, metabolism and excretion in test organisms, which in turn
may influence the perceived relative sensitivity. Distinction needs to be
made on whether the exposure adopted is optimized for assessment of
effects relative to controls (as is the case in the OECD 201 test guideline
for green algae and cyanobacteria) or focused more on environmental
relevance (for example in the ASRIT analyzing for impacts within hy-
draulic residence time in sewerage treatment works). Species sensitivity
analyses and /or functional impacts are arguably better addressed
under context specific conditions that consider the microbial commu-
nity structure(s) and physicochemical conditions that occur in those
natural systems.
Available study information was not sufficiently comprehensive to
allow for consideration of these variables within our meta-analysis and
we were thus restricted to endpoint data (EC50 and NOEC) that we
derived from reliable studies. Further investigation is warranted into
the physiological basis for the differences in sensitivity to antibiotics to
help identify species, or groups of species, that best represent the
phylum for their protection and the critical ecosystem services (e.g.
primary productivity and food source) they provide.
V. fischeri and Pseudomonads were more sensitive than cyano-
bacteria to some antibiotics and may potentially provide valuable ad-
ditional species for inclusion within the ERA. Furthermore, they already
have internationally recognized test guidelines (ISO, 1995, 2007). V.
fischeri, is a marine bacterium that would not normally be considered in
ERA for freshwaters, but is sometimes used in whole effluent assess-
ments (ECETOC, 2004). It is, nevertheless, a prokaryotic species and
antibiotics and antibiotic resistant bacteria have been detected in es-
tuaries and marine environments emanating from sewerage treatment
plant discharges and manufacturing effluents (Schaefer et al., 2009;
Webster et al., 2004; Zheng et al., 2011; Zou et al., 2011). The compiled
data show that V. fischeri was more sensitive than cyanobacteria for six
antibiotics, and for half of these by nearly an order of magnitude (flu-
mequine, lomefloxacin and oxolinic acid). The inclusion of this test
could therefore be of value to ERA if performed with an exposure time
of 24 h (results based on exposure lengths of< 24 h showed sig-
nificantly less sensitivity). Pseudomonads have been shown to be less
sensitive than the other soil bacteria to tetracycline, chlortetracycline,
and oxytetracycline and in some instances by over an order of magni-
tude (Halling-Sørensen et al., 2002). The low sensitivity observed in
Pseudomonas species has been attributed to their apparent high natural
resistance to some antibiotics (Halling-Sørensen et al., 2002; Kittinger
et al., 2016). Thus, our findings suggest that additional testing with P.
putida could be of value to the ERA, but it may still not be protective of
other soil bacteria. Any consideration to incorporate the test with P.
putida in antibiotic ERA would need to first characterise the strain in
terms of its chromosomal and plasmid resistance to help prevent biasing
any function or growth based assessment (Brandt et al., 2015).
The ASRIT (OECD, 2010) was several orders of magnitude less
sensitive to antibiotics than cyanobacteria and other bacterial species,
confirming reports that this test is largely insensitive to antibiotics
(Kümmerer et al., 2004). As such, the ASRIT would not influence the
outcome of the ERA. This lack of sensitivity may be due to several
factors, including the short exposure time (3 h) of the test (Kümmerer
et al., 2004), the lack of antibiotic bioavailability due to adsorption to
the sludge solids (e.g. Golet et al., 2002) or that the microbial com-
munity in the activated sludge has an innate resistance having been
exposed previously to the antibiotic (Davies, 2012). It was not possible
to assess the effect of extending the ASRIT test duration due to a lack of
Fig. 5. Comparisons of predicted no effect concentrations (PNEC) for antimicrobial resistance and ecotoxicity for aquatic taxa in surface water. A) Comparison of theoretically derived
PNEC for resistance development (PNECR(T)) based on clinically relevant bacteria (Bengtsson-Palme and Larsson, 2016) and PNEC for ecotoxicity in surface water (PNECSW). (B)
Comparison of PNECR(T), PNECR based on experimentally derived minimum selective concentrations (PNECR(EXP)) and PNECSW. In A) data are presented for antibiotics only where a full
data set including cyanobacteria, invertebrate and fish tests were available and calculated from no observed effect concentrations as described in (EMA, 2006). PNECSW in B) are
calculated from cyanobacteria NOECs regardless of a complete ecotoxicity data set where a PNECR(EXP) was available. PNECR(EXP) is a less than (<) value in erythromycin and
trimethoprim. PNECR(EXP) based on strain specific MSC in ciprofloxacin, erythromycin, streptomycin and trimethoprim. PNECR(EXP) based on community based MSC in tetracycline. EC50
for cyanobacteria was used because NOEC were not available for PNECSW in streptomycin and tetracycline therefore NOEC may be up to an order of magnitude lower.
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available data and because most ASRIT results are reported as censored
data of> 100 mg/L. Furthermore, the endpoint of respiration, may not
be suitable for all mechanisms of actions (Brandt et al., 2015) and it
does not equate with changes in bacterial diversity or community
structure. We thus support the need to replace and/or complement the
ASRIT with other assays (Brandt et al., 2015), which are relevant for all
pharmaceuticals.
In order to build greater confidence in the ERA for antibiotics we
sought to gain a better understanding on the differences observed in
sensitivity between the species and to establish both how often and for
which antibiotic classes these differences exceed the assessment factor
of 10. Overall, across all the antibiotics assessed, cyanobacteria and
CRB were equally sensitive to antibiotics (fig. 1). Thus, neither CRB nor
cyanobacteria were consistently more sensitive than the other. In this
meta-analysis, the inclusion of CRB in ERA would drive the PNEC in
40% of cases further supporting a more holistic ‘one health’ approach
that uses clinical and environmental data. There were, however, sub-
stantial differences in sensitivity to antifolates observed between the
cyanobacterial species and CRB. The folate synthesis pathway that
antifolates inhibit is present in cyanobacteria and so the reason for the
apparent lack of sensitivity in some cyanobacteria is unknown. How-
ever, de Crécy-Lagard et al. (2007) reported that cyanobacteria possess
a protein that may act as a folate transporter allowing the bypassing of
some of the folate synthesis pathway. Our analysis suggests therefore
that cyanobacteria may not always be a suitable representative for
bacteria for full protection against antifolate antibiotics.
Macrophytes appear especially sensitive to antifolates and quino-
lones. The folate synthesis pathway in bacteria, algae and plants is
fundamentally the same (Basset et al., 2005) and they are, therefore, all
potentially susceptible to antifolates. Indeed, sulfamethoxazole has
been reported to act as a competitive agonist to p-aminobenzoic acid in
both Lemna gibba (Brain et al., 2008b) and Arabidopsis thaliana (Zhang
et al., 2012). Macrophytes were also more sensitive than cyanobacteria
to five quinolones. Quinolones cause toxicity by forming complexes
with DNA gyrase or topoisomerase IV resulting in the inhibition of DNA
replication and transcription (Aldred et al., 2014). Chloroplasts are
descended from cyanobacteria (Falcon et al., 2010) and some plants
and red algae have been shown to contain DNA gyrases in their plastids
(including chloroplasts) and mitochondria (Moriyama and Sato, 2014;
Wall et al., 2004). Quinolone antibiotics are reported to have anti-
chloroplastic activity (Brain et al., 2008a; Brain et al., 2004; Ebert et al.,
2011) which can affect photosynthesis in plants (Brain et al., 2008a).
Indeed, organellar DNA gyrase has been shown to be the primary target
of ciprofloxacin in Arabidopsis thaliana (Evans-Roberts et al., 2016).
Thus, our findings indicate that for some antibiotics in these classes,
macrophytes could potentially drive the protection goal. Consequently,
these species should be considered for inclusion within risk assessment
frameworks for antibiotics.
The metazoan taxa were never found to be the most sensitive
compared with all bacterial taxa. This questions the necessity of re-
source intensive metazoan testing of antibiotics, as required by
European Medicines Agency and Food and Drugs Administration gui-
dance (EMA, 2006). Inclusion of appropriate (and additional) bacterial
testing in the ERA for antibiotics would potentially allow for the ex-
clusion of some unnecessary testing on metazoan species, acknowl-
edging the principles of the 3R's to replace, reduce and refine studies
that use ‘protected’ animals, such as fish (Hutchinson et al., 2016;
Scholz et al., 2013).
We performed this meta-analysis based on data that was deemed
most reliable according to the CRED system (Moermond et al., 2016).
The conclusions however, are still drawn upon data that were con-
ducted in different labs, with different procedures and of varying
quantity (in terms of test performance and meta-data) and quality of
reporting. We strongly emphasise the need to collect and report suitable
control data, chemical analysis and meta-data in order to assist in re-
liable comparisons of studies.
An analysis of appropriate additional bacterial species for inclusion
in the ERA needs to consider potential differences in sensitivity due to
pharmacokinetic considerations including bioavailability, charge, up-
take, elimination, metabolism, degradation rates or binding affinities,
Fig. 6. A) Cumulative density plot of the NOECs for environmental bacteria for 27 an-
tibiotics, showing the 5th percentile. B) Cumulative density plot of PNECs for AMR for
103 antibiotics, as calculated by Bengtsson-Palme and Larsson (2016). The vertical solid
line represents the 5th percentile of the bacteria NOECs, dashed lines represent the
standard error and dotted line indicates the proposed discharge limit. Note each point can
represent up to 17 antibiotics. C) Comparison of NOECs for environmental bacteria and
clinically relevant bacteria minimum inhibitory concentrations.
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or a combination of them. Differences in bacterial morphologies and
innate resistance may also account for some of the differences in sen-
sitivity between species. Some bacteria have several different growth
forms depending on the environmental conditions. As an example, in-
creased temperature and light intensity causes aggregation of
Synechococcus elongates cells (Koblížek et al., 2000) and this aggrega-
tion may have an impact on the sensitivity of the cells to antibiotic
exposure. Several studies have demonstrated that cells in biofilms are
less sensitive/more protected from chemical exposure (Balcázar et al.,
2015). A better understanding of how physiological and morphological
differences in cells and community structure affect the toxicity of che-
micals to bacteria is required to fully understand the risk posed by
antibiotics in the environment.
Bacteria are fundamental to many vital ecosystem services, but little
is understood regarding species loss and functional redundancy and
thus, the resilience of ecosystem function. Some investigators, however,
have begun to address this. For example, Lundström et al. (2016) found
no change in the overall taxonomic diversity when biofilms were ex-
posed to tetracycline, however, the community composition was altered
and the functional diversity, as measured by utilization of carbon
sources, decreased with increasing tetracycline concentrations. Cipro-
floxacin exposure altered the bacterial community structure in marine
sediments at 0.2 mg/L, resulting in a decrease in the community ability
to degrade pyrene (Näslund et al., 2008). It was also found to increase
overall biomass in salt marsh microbial communities, favouring gram
negative and sulfate-reducing bacteria (Cordova-Kreylos and Scow,
2007). Several studies have shown that bacterial diversity has a positive
relationship with ecosystem function (Bell et al., 2005; Langenheder
et al., 2010). Delgado-Baquerizo et al. (2016) demonstrated that loss of
diversity in aquatic bacterial communities caused a decrease in both
broad (microbial respiration) and specialized (toxin degradation; of
mycrocystin-LR and triclosan degradation) endpoints and the commu-
nities showed little or no functional redundancy. These studies indicate
that a small drop in bacterial diversity may potentially impact nega-
tively on the ecosystem services they provide.
From this, we conclude that the ERA framework for antibiotics
needs to be based upon a suitable range of bacteria. This should include
CRB and capture a wider range of ecologically important functional
groups. Previous investigators have identified standard studies that may
fulfill some of these data gaps e.g. nitrifying bacteria, methanogens and
sulfate-reducing bacteria (Brandt et al., 2015) although more research
is required to identify if these tests will be protective of all functional
bacterial groups or if further standard tests will need to be developed.
The effect of antibiotics on these functional groups is currently outside
risk assessment frameworks and environmental and non-therapeutic
human impacts are considered in isolation. Furthermore, a measure of
the change in community structure would add value, especially looking
at diversity in terms of clinical and environmental relevance, and un-
derstanding to changes in functional endpoints in bacterial multi-
species/community tests to determine whether ecological resilience is
being compromised.
4.2. PNECs for AMR verses traditional ecotoxicological effects
AMR is a serious risk to human health globally and currently sits
outside the ERA regulations. Both theoretical methodologies and em-
pirical data available for assessing AMR selection and transfer in the
environment are limited. Consequentially, evidence is lacking to assess
the best approach for the risk of AMR development, how resistance in
the environment may lead to enrichment of resistance in human pa-
thogens and how the risk posed by antibiotics by AMR development
compares to their effects upon ecosystem function and services.
Previous investigators have explored resistance selection using a variety
of approaches, for example, comparing predicted environmental con-
centrations with MICs (Kümmerer and Henninger, 2003), using MICs to
calculate potentially affected fractions of communities (Singer et al.,
2011) and using growth and competition experiments to demonstrate
resistance selection (Negri et al., 2000) and calculate MSCs (Gullberg
et al., 2011). The theoretical approach proposed by Bengtsson-Palme
and Larsson (2016) is a recent contribution and provides a good basis
for this discussion, using MIC data to assess reduction in antibiotic ef-
ficacy due to erosion by resistance. However, it is important to note that
this approach assumes growth can be used to predict resistance and is
not verified through direct testing of resistance markers and as such any
conclusions drawn from this analysis must therefore be considered with
this in mind.
Our findings suggest that the PNECR(T) defined by Bengtsson-Palme
and Larsson (2016) is not always lower than the PNECSW; for 7 anti-
biotics PNECSW was lower in four cases (fig. 5). This may be due to
either the PNECR(T) underestimating the risk or cyanobacteria being
more sensitive to some antibiotics compared with the CRB. Experi-
mentally determined MSCs were derived largely from laboratory strain
competition experiments (four of the five cases; Fig. 5B), where strains
that differ in only the presence/absence of the resistance genes under
investigation are compared (Gullberg et al., 2014; Gullberg et al.,
2011). These strain competition experiments have limitations in scaling
up to more complex microbial communities (Bengtsson-Palme et al.,
2014). There are very few cases where analyses have been conducted
for more complex communities but it is hypothesised that the combined
effects of changes in community structure (due to loss of the most
sensitive species), protective morphological forms (e.g. bacteria maybe
less susceptible in biofilms compared to those within the water column
(Balcázar et al., 2015)), difficulty in defining the ‘true’ antibiotic ex-
posure concentration, and alternative selection pressures (e.g. nutrient
limitation, predation and other chemical/physical stressors) may ne-
gate the fitness benefit of the resistance (Bengtsson-Palme and Larsson,
2016; Brosche and Backhaus, 2010; Day et al., 2015; Gullberg et al.,
2014; Lundström et al., 2016; Quinlan et al., 2011). Most studies that
have considered effects of antibiotics on complex communities have
been taxon independent, assessing AMR gene copy number relative to
16SrRNA, rather than providing species specific information. In-
vestigations into AMR following tetracycline exposure, however, have
found that resistance was increased in periphyton at the lowest test
concentration of 0.5 μg/L (Quinlan et al., 2011), horizontal gene
transfer (HGT) was promoted at 10 μg/L (Jutkina et al., 2016) and re-
sistant bacteria and resistance genes was increased in biofilms at con-
centrations below 1 μg/L (Lundström et al., 2016). Assuming an as-
sessment factor of 10, from this data a PNECR(Exp) would be 0.05 μg/L,
which is 20 times lower than PNECR(T) of 1 μg/L (Bengtsson-Palme and
Larsson, 2016). There is no NOEC data for tetracycline in cyano-
bacteria, but in Microcystis aeruginosa a EC50 is reported at 90 μg/L
(Halling-Sørensen, 2000) and in Anabaena sp. an EC10 of 2.5 mg/L
(González-Pleiter et al., 2013), suggesting that resistance for tetra-
cycline may occur at concentrations nearly 100-fold lower than effects
on growth inhibition in cyanobacteria. This again emphasizes the need
for a more holistic approach to the setting of protection goals for an-
tibiotics and the development of validated assays to assess MSCs in
complex and simple systems, as well as generating toxicity data for
cyanobacteria and other environmental and/or clinical bacteria.
It should be recognized that although studies that are used to guide
regulatory decision-making require standardized test methodologies to
help ensure reliable and repeatable results, the link between these
single species studies and those operating in the complex systems in the
field is largely unknown and, as mentioned previously, the link to
ecosystem services is not made. The application of mesocosm studies
that enable community response and effects upon ecosystem functions
to be assessed have good utility here to help provide insights into the
development of AMR in environmentally realistic scenarios (Knapp
et al., 2008; Knapp et al., 2010; Quinlan et al., 2011). In addition to
living in complex communities in the environment, it is important to
note that organisms are also likely to be exposed to antibiotic mixtures
and the relationship between single exposure laboratory testing and
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mixtures toxicity is unknown and requires further research (Backhaus
et al., 2000; Brosche and Backhaus, 2010; González-Pleiter et al., 2013;
Liu et al., 2014).
In the context of current regulatory guidance, MSCs derived from
experimental data, albeit they are limited, in some cases supported the
theoretically derived PNECR(T). There were cases also where PNECR(T)
was not necessarily appropriate (optimal) for risk assessment for AMR.
Nevertheless, until there is an internationally accepted method for the
experimental determination of PNECR - which may require further
knowledge on resistance mechanisms, model variability and the ap-
plication to mixed communities that vary over time and space - the
theoretical approach advocated by Bengtsson-Palme and Larsson
(2016), based on MIC data in the European Committee on Anti-
microbial Susceptibility Testing database, provides a valuable alter-
native as part of a broader evidence-based approach to ERA. Moreover,
it provides an efficient and cost effective method to address concerns
and prioritise legacy antibiotics that have already been registered and
are present in the environment. It should be noted, however, that there
are clear limitations to this approach (as identified by the paper's au-
thors). These include the test conditions for determining the MIC in
CRB, that are largely environmentally irrelevant, the assumptions that
growth inhibition can be used to predict selection for resistance. There
is also an assumption that an assessment factor of 10 will provide a
suitable safety margin to account for selection below the MIC and
conversely that adjusting the MIC down to account for species numbers
and then applying a further assessment factor of 10 isn't overprotective.
Finally, MIC-derived protection goals will change over time, as MICs
are determined for more species with variable sensitivity and as a
consequence periodic updates will be required.
Our analysis suggests that the susceptibility of species in European
Committee on Antimicrobial Susceptibility Testing is not always pro-
tective of environmental bacteria, such as cyanobacteria and therefore a
PNECR(T) using CRB MIC data as a surrogate for resistance may not be
protective of the risk of AMR development in environmental bacteria.
Furthermore, we show that a PNECR(T) may not be protective of eco-
system function traditionally determined using the growth inhibition
test with cyanobacteria. From this we conclude that despite evidence
that resistance will occur at lower concentrations than the effects on
population density (Gullberg et al., 2011; Hughes and Andersson,
2012), both a PNECR and a PNECSW are needed to establish safe con-
centrations for the protection of ecosystem function and against the
development of resistance.
It is noteworthy that from an environmental health perspective
(rather than human health), AMR can provide an ecosystem service or
benefit. For example, bacteria expressing beta-lactamase enzyme ac-
tivity degrade and reduce the environmental burden of beta-lactam
antibiotics and this in turn could contribute positively in sewerage
treatment plants where high antibiotic concentration might otherwise
compromise functional efficiency.
4.3. Production discharge limits
In addressing the impact of antibiotic pollution on ecosystem
function, AMR development and human health, safe discharge limits for
antibiotic production facilities need to be established (Agerstrand et al.,
2015; Larsson, 2014; Pruden et al., 2013). However, there are few data
available in the public domain to support the development of such
limits and this is especially so for experimental data on AMR develop-
ment. Most data that are available are based on growth inhibition tests
and we have therefore identified the lowest NOEC values for 27 anti-
biotics representing sensitive phyla (cyanobacteria, V. fischeri and P.
putida) and using these data we estimate the 5th percentile to be
225 ± 71 ng/L. Thus, a conservative limit of 154 ng/L would account
for uncertainty. Provided that these 27 antibiotics are representative of
all antibiotics, the cyanobacterial NOECs are, with 95% confidence,
likely to be higher than 154 ng/L.
The lowest MSC reported in the literature is 100 ng/L with many
others between 10 and 1000 times higher (Brosche and Backhaus,
2010; Gullberg et al., 2014; Gullberg et al., 2011; Lundström et al.,
2016). Setting a threshold limit of 100 ng/L for antibiotic discharges
would, therefore, appear to be protective of environmental bacterial
populations (with 95% confidence) and match the lowest empirical
evidence of AMR development. However, it would not be protective for
16% of the theoretical PNECR(T)s, described by Bengtsson-Palme and
Larsson (2016) (Fig. 6B) highlighting that safe discharge limits may
need to be lower than this for some antibiotics in order to consider the
potential to select for resistance in clinical and environmental isolates.
It should be noted, however, that the PNECR(T) incorporates a correc-
tion factor that adjusts the MIC according to the number of species it is
based upon and a further assessment factor of 10 to account for AMR. In
turn, the corrections could cause the PNECR(T) to be over protective (as
shown for some antibiotics in Fig. 5B).
A single, protective threshold limit that could be applied as an in-
terim measure in the absence of other reliable empirical clinical and or
environmental data (and standardized methodologies for AMR), which
is based on empirical data would be of great value. Based on the anti-
biotic compounds for which we were able to obtain NOECs from en-
vironmentally relevant bacteria and from the available MSCs in the
literature, we suggest a production discharge limit of 100 ng/L for each
antibiotic, applied in the mixing zone downstream of the point source
discharge for protection of ecosystem function and the risk of AMR
development. The use of a single protection goal rather than a range,
for production facilities offers pragmatic benefits to industry and sup-
pliers. Compliance with a single protection value provides simplicity
and ease of implementation compared with the 111 values advocated
for the different antibiotics suggested by Bengtsson-Palme and Larsson
(2016), of which some would not be protective of the environment or
the MSC. Consideration is required for how this limit would apply in the
case of antibiotic mixtures, although this falls out of scope of this meta-
analysis.
This approach could also help prevent the use of conflicting values
for a single antibiotic. However, it is important to ensure that this value
proves to be protective. So where other data are available (e.g. em-
pirical or PNECR(T)) that suggest a lower limit is required to be pro-
tective, the 100 ng/L should be adjusted accordingly to provide the
required protection. Equally, a higher limit may be applicable where
there are substantive data to support its increase. We advocate this as
an interim measure only until more data are obtained to support the
risk analysis for antibiotics. Furthermore, as methodologies for the as-
sessment of AMR are developed these values should also be in-
corporated and protection goals updated.
5. Concluding remarks and considerations for ERA
Our analysis shows that frameworks for ERA and human health
protection (through protection for the risk of AMR) for antibiotics need
to consider the impact of antibiotics on relevant vulnerable species and
the essential ecosystem services they provide. The current framework
for ERA based on just one cyanobacterial species is, in many cases,
inadequate and it does not address risk to critical ecosystem services.
There is also an urgent need to better establish the effects of antibiotics
on bacterial diversity, community structure, ecosystem function and
resilience in order to better understand the effects of antibiotics in the
environment.
We emphasise that the presence of antibiotics in the environment
does not necessarily lead to the development of AMR in bacterial
communities and studies are required that better establish the toxic
effects of antibiotics, AMR and the relationship between them in en-
vironmentally relevant contexts. In the environment other selection
pressures (e.g. nutrient availability and predation) may be more sig-
nificant than that posed by exposure to low levels of antibiotics. As a
consequence AMR may not be observed at the same concentrations as in
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the laboratory studies. However, it is also the case that the fitness cost
of carrying some resistance genes may be very low or even neutral and
therefore the genes coding for resistance could remain in the bacterial
communities after only a short exposure. Understanding these com-
plexities in AMR development in the environment is crucial for estab-
lishing interrelationships with human pathogens and in turn managing
and mitigating the risk of antibiotics in the environment for the pro-
tection of human health.
From our analyses on relative species sensitivity we highlight the
following as key considerations for the use, and development of human
and ERA frameworks for antibiotics.
1. The need for inclusion of a larger selection of bacterial species for
testing to account for the variability in sensitivity between species
and for greater confidence in the protection of bacterial commu-
nities and the ecosystem services they provide.
a. Brandt et al. (2015) have identified a number of suitable estab-
lished standard tests for other bacteria (including P. putida) and
for ecosystem services (e.g. nitrification and carbon transforma-
tion) and these should be considered as additional tests in the
ERA of antibiotics.
b. We show that pre-clinical MIC data of CRB could be used to in-
crease the diversity of bacterial species represented in ERA at
little cost. The use of pre-clinical and clinical data is often ad-
vocated to identify environmental risk (Boxall et al., 2012) but
the realisation of this is limited with ‘bridging’ studies and
methods still being developed.
c. We reaffirm that the only required community test, the ASRIT, is
not sensitive to antibiotics and thus its suitability for determining
the effect of antibiotics to environmental bacteria and sewerage
treatment plant microorganism communities is questionable.
Consideration for its replacement by tests to assess the effects on
bacterial community function or impacts on population growth
are warranted.
2. Testing of antibiotics on metazoans may not be required.
a. Metazoans were generally 2 to 4 orders of magnitude less sensi-
tive to antibiotics than cyanobacteria. Further investigation is
required to assess and confirm these results on a wider series of
empirical in vivo exposures, however this meta-analysis provides
a starting point for this discussion and the possible reduction in
the use of metazoans in antibiotic testing.
3. Our meta-analysis highlights that the relative high sensitivity of
microalgae and macrophytes to some antifolate and quinolone an-
tibiotics (compared with cyanobacteria) supporting their inclusion
in risk assessment frameworks for these compound classes. Further
research into the relative sensitivity of macrophytes and microalgae
to these classes of antibiotics is warranted.
4. Test systems to determine PNEC or MSC for AMR development are
urgently required for clinical and environmental species. Our ana-
lysis, suggests that the CRB in the European Committee on
Antimicrobial Susceptibility Testing database are not always re-
presentative of the diversity of sensitive bacteria in nature. This il-
lustrates that ERA needs to incorporate both PNECSW and PNECR.
There is a need to develop a standardized method to experimentally
determine an MSC in environmental and clinical bacteria, ex-
emplified by three out of five experimental values being lower than
the theoretical value.
5. A discharge limit of 100 ng/L maybe a protective and pragmatic
approach to address environmental concerns around antibiotic
production in the absence of sufficient reliable clinical and en-
vironmental data, whilst urgently needed methodologies and em-
pirical data are obtained to draw firmer conclusions. Where data
exists that suggest a higher or lower concentration is required to be
protective that value should be used instead.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.envint.2017.09.013.
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Antibiotic risk assessment needs to protect both environmental and human health
In our recent meta-analysis on antibiotic ecotoxicity data published
in Environment International (Le Page et al., 2017) we suggest that be-
cause of the great diversity in species sensitivity, environmental risk
assessment (ERA) would be improved by testing a more diverse range of
bacteria (including both environmental bacteria and clinically relevant
bacteria (CRB)). We also conclude that tests on antibiotics should
consider endpoints of relevance to ecosystem function. Comparing the
protection goals for environmental heath with those for human health
(protection against antimicrobial resistance (AMR) development) we,
furthermore, identify that neither protection goal is always protective
of the other whilst using current methodologies (with surrogate end-
points for each goal and very limited bacterial biodiversity tested);
supporting the need for both in any comprehensive health protection
system for antibiotics.
In a correspondence to our paper Bengtsson-Palme and Larsson
(2018) point out a bias in our sensitivity analysis favouring environ-
mental bacteria (including cyanobacteria). We acknowledge this, but
equally in this correspondence we challenge some of their points made
on how this impacts on the significance of our data. We also address
points relating to the lack of clarity on protection goals for antibiotics in
the discussion of our paper and discuss what data are most suitable for
establishing those protection goals. We emphasise that the main con-
clusion drawn from our original paper has not changed and we main-
tain that a holistic approach including both environmental health and
resistance selection is required to drive an effective overall protection
limit for antibiotics.
1. Sensitivity analyses skews
Bengtsson-Palme and Larsson (2018) rightfully point out that our
analysis skews the apparent sensitivity in favour of the environmental
bacteria because the endpoints compared for CRB (minimum inhibitory
concentrations, MIC) and environmental bacteria (no observed effect
concentrations, NOEC) for growth inhibition are derived from different
ends of the dose response curve; MICs are derived from the top of the
dose-response curve (full inhibitory effect on growth) and the NOECs
for environmental bacteria from the bottom of the response curve
(concentration with no inhibition). In some cases therefore CRB may be
more sensitive than environmental bacteria than our analysis suggests.
However, it should be highlighted that this doesn't necessarily mean
that environmental bacteria will not represent the most sensitive taxa
for individual antibiotics. This is because, in the first instance, in the
cases where environmental bacteria were more sensitive by an order of
magnitude or more compared with CRB in our analysis, environmental
bacteria are likely to be comparable, if not more sensitive to those
antibiotics. In our meta-analysis this would be the case for 6 out of 24
antibiotics (including azithromycin and ampicillin). Secondly, very
large differences in sensitivity can occur between different species of
bacteria (our meta-analysis showed sensitivity spanned five orders of
magnitude in 8 species cyanobacteria exposed to ampicillin) and be-
cause of the far greater species number and diversity tested in CRB
compared with environmental bacteria there is likely to be a sensitivity
bias in favour of CRB. The size-adjusted MIC value used as our com-
parative endpoint for CRB was calculated from the MICs of up to 70
species in up to 5 families (Bengtsson-Palme and Larsson, 2016). In
stark contrast to CRB, cyanobacteria antibiotic test data were generally
derived from only one or two species giving far greater uncertainty in
the sensitivity calculation for this group.
2. Uncertainty in protection targets
ERA for antibiotics in the European Union is legislated by the
Medicinal Products for Human Use directive (EC, 2001) where the
protection goal is to prevent “any risk of undesirable effects on the
environment”. Current practice is to calculate a PNEC using chronic
growth and/or reproduction data on single species, which for anti-
biotics is normally based on the PNECSW driven by a cyanobacterium.
The relationship however, between individual species sensitivity, eco-
system function and functional redundancy is not well understood
(Antwis et al., 2017) and what constitutes an “undesirable effect” is
unclear. As Bengtsson-Palme and Larsson (2018) point out, clarity is,
therefore, required in the definition and objectives of these protection
goals. The issue of functional redundancy, and to what extent it is
possible to eradicate or lose a microbial species without compromising
that ecosystem function is a hugely important consideration for en-
vironmental protection. There is some evidence that microbial com-
munities may be less functionally redundant than macroorganism
communities (Delgado-Baquerizo et al., 2016). Thus, although we re-
iterate our support of the inclusion of ecosystem function based tests,
given the uncertainties relating to functional redundancy, at this time
ecosystem level protection may be best served by a conservative pro-
tection goal based upon bacterial biodiversity (and therefore inherently
ecosystem function).
Bengtsson-Palme and Larsson (2018), highlight that the risk of AMR
and human health concerns are generally the main driving force for
antibiotic protection goals but they also agree with our conclusions that
a holistic approach that considers both environmental health and AMR
should be taken. The meta-analysis shows that for some antibiotics the
environmental protection limits may be lower than the protection limits
predicted for AMR (using current methodologies and surrogate end-
points for biodiversity and AMR). To illustrate this, here (Fig. 1) we
compare the PNECr determined using the size-adjusted MIC data
(Bengtsson-Palme and Larsson, 2016) and PNECsw calculated from the
lowest NOEC in our meta-analysis with the PNECfw (PNEC in fresh-
water) determined for the 5 antibiotics in the European commission
environmental quality standards watch list (Carvalho et al., 2015). In
each case the PNECr represents the highest PNEC for each antibiotic
(i.e. is least protective as a whole).
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As Bengtsson-Palme and Larsson (2018) point out, protection
against antibiotic pollution for environmental health is more of a lo-
calised impact, whereas AMR has a wider and more pervasive global
significance, directing stakeholders towards the need for two different
protection targets determined from appropriate data and methodolo-
gies. We still maintain however, that an overall protection limit should
protect both environmental and human health. Environmental protec-
tion and associated legislation differs across countries, but equally there
is a social responsibility to ensure that product provenance is conducted
to the highest possible levels.
3. Discharge limit
In response to stakeholder calls to address the risk of antibiotics
released from manufacturing operations, which currently sits outside of
the regulatory ERA framework, in our original paper we proposed an
interim production discharge limit of 100 ng/L for each antibiotic, to be
applied in the mixing zone to both protect environmental bacteria po-
pulations and reduce the risk of AMR development. This interim limit
recognised that (i) because most antibiotics were authorised before the
current guidelines came into force, many either lack or have very
limited ecotoxicology data, and (ii) the need to establish science-based
limits in the absence of such data. We were explicit in our paper to
point out, however, that as sufficient data become available for mode of
action relevant species we support the use of higher or lower protection
limits based on these empirical data. Bengtsson-Palme and Larsson
(2018) questioned this conservative limit for antibiotics because it may
incur higher manufacturing costs through the need for infrastructure
investment to reduce discharges and based on the fact that some anti-
biotics have relatively low toxicity and do not exert a strong selection
pressure for antibiotic resistance. These are important points to debate.
A single interim value helps the pharmaceutical industry, many of
whom are currently reviewing their antibiotic manufacturing opera-
tions, to prioritise interventions and actions. These interventions may
include generating relevant environmental toxicology data where em-
pirical data does not exist or when a possible risk is identified at a site.
A single value will also enable the pharmaceutical industry to bench-
mark existing suppliers more effectively to identify best practice in
waste management. The requirement for infrastructure investments, as
highlighted by Bengtsson-Palme and Larsson (2018), represents a last
resort and these would only be required where risks could not be re-
fined and managed through other interventions. Where infrastructure
upgrades are required to meet scientifically robust limits, then the costs
of these upgrades will need to be evaluated and justified as part of a
wider socio-economic assessment into the stewardship of antimicrobial
chemotherapy. In most cases, however, these interventions are not
likely to incur excessive costs; the manual wipe down of equipment
prior to cleaning washes, separation and incineration of the wastewater
from the first wash of equipment, or the installation of inline filters to
remove undissolved material can all significantly reduce environmental
concentrations of APIs, in most cases by> 90% (Hargreaves et al.,
2017). The logistics for antibiotic supply can be extremely complex
with many suppliers manufacturing a whole range of antibiotics for
numerous contractors and there can be language barriers and many
suppliers lack the expertise to determine safe concentrations for
themselves. In this case the use of a single interim limit has practical as
well as scientific value. It may help remove conflicting limits (e.g.
where two contractors provide different safe values or no level of
protection), and minimise confusion amongst the pharmaceutical in-
dustry and their suppliers in the absence of data.
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